Idiopathic erythrocytosis is associated with a risk of thrombosis - a retrospective case series review by Hodson, A. et al.
Idiopathic erythrocytosis is associated with a risk of thrombosis
- a retrospective case series review
Hodson, A., Harrison, C. N., Percy, M., Jones, F., & McMullin, M. F. (2007). Idiopathic erythrocytosis is
associated with a risk of thrombosis - a retrospective case series review. British Journal of Haematology,
137(Suppl 1), 44-45.
Published in:
British Journal of Haematology
Document Version:
Peer reviewed version
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:16. Feb. 2017
Monday 30 April 2007
Free Communications: Lymphoproliferative Disorders
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Karyotype is an independent prognostic factor in
adult acute lymphoblastic leukaemia
AV Moorman, CJ Harrison, GAN Buckw, SM Richardsw,
LM Secker-Walkerw, M Martineauw, GH Vancez, AM Cherryy,
RR Higginsz, AK FieldingJ, L ForoniJ, E Paietta,
MS Tallmanww, PH Wernik, MR Litzowzz, JM Roweyy,
AH Goldstonezz and GW DewaldJJ
Leukaemia Research Cytogenetics Group, Cancer Sciences
Division, University of Southampton, UK, wClinical Trial Service
Unit, University of Oxford, UK, zDepartment of Medical and
Molecular Genetics, Indiana University School of Medicine,
Indianapolis, IN, USA, yDepartment of Pathology, Stanford
University School of Medicine, Stanford, CA, USA, zAllina
Medical Laboratories, Abbott Northwestern Hospital, Min-
neapolis, USA, JDepartment of Haematology, Royal Free and
UCMS, London, UK, Comprehensive Cancer Center, Our
Lady of Mercy Medical Center, New York, NY, USA, wwDivision
of Haematology, Department of Medicine, Northwestern
University Feinberg School of Medicine, Chicago, IL, USA,
zzDivision of Hematology, Mayo Clinic, Rochester, MN, USA,
yyDepartment of Hematology, Rambam Medical Center, Haifa,
Israel, zzDepartment of Haematology, University College
London Hospital, London, UK, JJDivision of Laboratory
Genetics, Mayo Clinic, Rochester, MN, USA
Pre-treatment cytogenetics is a known predictor of outcome in
haematological malignancies. However, its usefulness in adult acute
lymphoblastic leukaemia is generally limited to the presence of the
Philadelphia chromosome (Ph) because of the low incidence of other
recurrent abnormalities and the rarity of the disease in this age
group. We present centrally reviewed cytogenetic data from adult
patients enrolled on the Medical Research Council UKALLXII/
Eastern Cooperative Oncology Group 2993 Trial. Ph-positive patients
(n5 267) had a significantly inferior 5-year overall survival (OS)
compared with Ph-negative patients (n5 1106): 22% (95% CI 17–
27%) vs 41% (38–44%) [P5 0.0001 adjusting for age, gender and
white cell count (WCC)]. Within the Ph-negative cohort, the
following chromosomal abnormalities were associated with a poorer
outcome: t(4;11)(q21;q23), n5 54 (7%), OS 24% (13–36%), Po0.001;
t(8;14)(q24.1;q32), n5 16 (2%), OS 13% (2–33%), Po0.001; complex
karyotype (five or more chromosomal abnormalities), n5 41 (5%),
OS 28% (15–43%), P5 0.027; low hypodiploidy/near triploidy (Ho-
Tr), n5 31 (4%), OS 22% (9–38%), P5 0.001). In contrast, patients
with high hyperdiploidy or del(9p) had a significantly improved
outcome: n5 77, OS 53% (41–64%), P5 0.015 and n5 71, OS 58%
(46–69%), P5 0.032 respectively. We used a Cox proportional
hazards model to assess the prognostic relevance of cytogenetic
variables within the Ph-negative cohort in the context of other
established survival indicators: gender, age, WCC and T-cell status.
The adverse effect of t(8;14), Ho-Tr and complex karyotype was
shown to be independent of these risk factors both within the overall
cohort and a reduced cohort which excluded patients undergoing a
bone marrow transplant. The observation that Ho-Tr and, for the
first time, karyotype complexity confer an increased risk of
treatment failure demonstrates that cytogenetic subgroups other
than the Ph can and should be used to risk stratify adults with ALL in
future trials.
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Deletion of 16q identified by FISH is an independent
adverse prognostic marker in multiple myeloma
MW Jenner, PE Leone, BA Walker, DC Johnson,
L Chiecchiow, E Dachs Cabanasw, GP Dagradaw, M Nightingalew,
RKM Protheroew, D Stockleyw, M Else, NJ Dickens,
FM Rossw, NCP Crossw, FE Davies and GJ Morgan
Section of Haemato-Oncology, Institute of Cancer Research,
Sutton, UK, wLRF UK Myeloma Forum Cytogenetics Group,
Wessex Regional Cytogenetics Laboratory, Salisbury, UK
Deletion of 16q (del(16q)) has been identified in 15% of newly
diagnosed myeloma but the prognostic impact has not been
determined. We performed FISH on CD138 selected plasma cells
from 861 newly diagnosed patients with multiple myeloma from the
LRF UK Myeloma Forum Cytogenetics Database. Del(16q) occurred
in 168/861 cases (19.5%) and was significantly associated with
deletion 13q (54.8% vs 43.5%, P5 0.009), deletion of IgH (19.6% vs
8.7%, Po0.001), deletion 17p (20.7% vs 7.2%, Po0.001) and non-
hyperdiploid status (47.9% vs 40.3%, P5 0.043). Clinical and
survival data was available in 505 patients. Median age was 65 years
(range 33–92) and median follow-up was 19 months. Del(16q) showed
no association with baseline clinical and demographic parameters
but was associated with a significantly worse overall survival (median
survival 36 months vs not reached, P5 0.025). Moreover, del(16q)
conferred additional adverse impact in combination with the known
poor risk cytogenetic factors t(4;14) and deletion 17p (del(17p)).
Median survival for del(16q) and t(4;14) was 13 months, del (16q)
alone 36 months, t(4;14) alone not reached, P5 0.001. Median
survival for del(16q) and del(17p) was 17 months, del(16q) alone 36
months, del(17p) alone not reached, P5 0.003. Multivariate analysis
confirmed that del(16q) retained independence as an adverse
prognostic marker (P5 0.003) along with t(4;14), t(14;16), light chain
isotype, WHO performance status, ISS and age.
Integration of gene mapping with global gene expression data in a
subset of 55 cases identified two potential tumour suppressor genes
located on 16q, CYLD and WWOX. We have shown that loss of CYLD
dysregulates the NFkB pathway and loss of WWOX dysregulates apop-
tosis via p73, both of crucial importance in myeloma biology. WWOX is
also a common fragile site gene and deletions at other common fragile
sites were identified that may also contribute to myeloma pathogenesis.
An update of this mapping and expression data including the NFkB
signature associated with 16q deletion will be presented.
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GCS-100: a novel therapy for myeloma inhibits Mcl-1,
bcl-xL and cell cycle proteins
MJ Streetly,w, B Su, SA Scheyz, M Kazmiw and FE Cotter
Centre for Haematology, Bart’s and the London Queen
Mary’s School of Medicine and Dentistry, London, UK, wGuy’s
Hospital, GSTFT, London, UK, zKing’s College Hospital,
London, UK
Marrow stromal cells in myeloma secrete cytokines that stimulate
anti-apoptosis, drug resistance, cell cycle and metabolic pathways.
Disruption of these networks can lead to myeloma cell death making
them attractive targets for novel therapies. The modified citrus
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pectin, GCS-100 has been used safely in Phase I studies for solid
tumors, induces cell death in lymphoma via blocking galectin-3/Bcl-2
dimerisation and in myeloma cells by mechanisms not fully
understood. This study aimed at further elucidating the mechanism
of action of this novel agent in myeloma. GCS-100 induced apoptosis
in a dose and time dependent manner in myeloma cell lines
RPMI8226, U266 and OPM2 with associated significant increase in
G0/sub-G1 cells. Treatment led to a marked time and dose dependent
reduction of the crucial anti-apoptotic proteins mcl-1 and bcl-xL.
NFkappaB activation in myeloma cells is associated with prolifera-
tion and adhesion molecule upregulation. GCS-100 led to a time-
dependent reduction in activated IkappaBalpha and p65NFkappaB.
Furthermore pre-treatment of myeloma cells with GCS-100 inhibited
IkappaBalpha activation by exogenous TNFalpha. Similarly, treat-
ment with GCS-100 led to a reduction in the amount of activated Akt
(a cell cycle regulator) and inhibited IGF-1 associated activation of
Akt. The effect of GCS-100 on cell cycle regulatory proteins revealed
downregulation of cyclin D1, p16INK4A and CDK6 at 24 hours,
however, there was no change in expression of CDK4 and p15INK4B.
The p21CIP1 was upregulated with a corresponding decrease in protein
levels of cyclin E2 and CDK2 but with no change in p27KIP1. Studies
are currently ongoing for primary cells. In conclusion GCS-100 is a
novel complex carbohydrate that reduces proliferation and induces
apoptosis by down-regulating crucial anti-apoptotic proteins, cell
cycle regulators and signalling proteins and may also act by
interfering with the myeloma cell microenvironment. Phase I studies
in myeloma have been commenced.
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Restricted MHC phenotypes in splenic marginal zone
lymphoma
Z Davis, AM Littlew, F Fowlesw, J Richardsz, D Oscier
and S Devereuxz
Department of Haematology, Royal Bournemouth Hospital,
Bournemouth, UK, wHistocompatibility Laboratories, Anthony
Nolan Trust, London, UK, zDepartment of Haematological
Medicine, King’s College Hospital, London, UK
Immunoglobulin heavy chain variable gene sequencing in splenic
marginal zone lymphoma (SMZL) reveals biased usage of the VH1-02
gene, present in 30% of cases, suggesting that stimulation by a
specific antigen may have a role in the pathogenesis of this disease.
SMZL is thought to arise from normal splenic marginal zone B cells
which in health mediate rapid but short lived immunity to bacterial
antigens. Although these responses are generally thought to be T-
independent both normal and malignant splenic marginal zone B
cells may undergo somatic hypermutation (SHM). To investigate
whether SHM in SMZL occurs through a T-dependent or T-
independent pathway we looked for evidence of MHC restriction.
Medium resolution HLA typing was performed by PCR-SSO and the
phenotypes of 18 cases of SMZL utilising the VH1-02 gene and 18
non-VH1-02 SMZL’s were compared with 1667 normal controls, 17
cases of CLL utilising VH1-02 and 40 VH3-21 CLL’s by Fisher’s exact
test with Bonferronis-correction. Sixty one percent of the VH1-02
SMZL’s had an HLA-DR15 phenotype compared to only 26% of
controls (P5 0.0022). Both VH1-02 SMZL’s that did not express
HLA-DR15 and non-VH1-02 SMZL’s were associated with HLA-DR4
(P5 0.0023). In contrast there was no MHC restriction in cases of
CLL utilising either the VH1-02 gene nor the VH3-21 gene. These
findings support the hypothesis that SMZL derives from a marginal
zone B cell that has responded to a T-dependent antigen.
5
The 13q and 11q B-cell chronic lymphocytic leukaemia
deleted regions derive from a common ancestral
region in the zebrafish on chromosome 9
RL Auer, S Riaz and FE Cotter
Centre for Haematology, Bart’s and The London Queen Mary
School of Medicine, London, UK
Loss of the long arm of chromosomes 11 and 13 are the commonest
cytogenetic abnormalities for patients with B-cell chronic lympho-
cytic leukaemia (B-CLL) and suggest the presence of as yet
unidentified tumour suppressor genes. The use of small vertebrate
organisms, such as the zebrafish, as models of diseases associated
with chromosomal deletions enables the functional analysis of
potential causative genes. In this study, the evolutionary conserva-
tion between the zebrafish and human genome is investigated for the
13q14 and 11q22–23 regions deleted in B-CLL. Zebrafish orthologues
have been identified and radiation hybrid mapping performed to
confirm their chromosomal location and define regions of conserved
synteny. The 13q14 region was syntenic with two main regions in the
zebrafish genome, namely chromosomes 1 and 9. The majority of
zebrafish orthologues to 11q22–23 were found on chromosomes 5, 15
and 21. One region within an area of 22.02 cR on zebrafish
chromosome 9 (approximately 3260 kb) is of potential interest.
Within chromosome 9, five genes and two microRNAs were
identified with shared synteny to the smallest 11q22–23 and 13q14
critically deleted regions (two genes to human chromosome 11, three
to human chromosome 13 and two chromosome 13 microRNAs). The
critical region on zebrafish chromosome 9 maps to the minimal
deleted region for both human chromosomes, suggesting a common
ancestry for the B-CLL tumour suppressor genes. This is further
supported by analysis of the chicken genome where the same 5 genes
from 13q14 and 11q22–23 (C13orf1, RFP2, FLJ11712, FDX1, ARHGAP20)
lie within a 10.04 Mb region on chromosome 1. Target-selected
mutagenesis for knock-outs of genes in this region of zebrafish will
allow analysis of their in vivo potential for lymphoproliferation. Our
study provides an explanation for involvement of both 11q and 13q in
B-CLL and potential to develop animal models for this common
lymphoproliferative disorder.
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Five CCAAT-enhancer-binding-protein gene family
members are deregulated by the immunoglobulin
heavy chain locus in B-cell precursor acute
lymphoblastic leukaemia
LJ Russell, T Akasakaw, T Balasasw, E Chaprioz, O Bernardz,
R Sieberty, MJ Dyerw and CJ Harrison
Cancer Sciences Division, University of Southampton,
Southampton, UK, wMRC Toxicology Unit, Leicester, UK,
zHoˆpital Necker, Paris, France, yInstitute of Human Genetics,
Kiel, Germany
Chromosomal translocations lead to oncogene activation in a
significant number of haematological malignancies. Those involving
the immunoglobulin heavy chain locus, IGH, at chromosome band
14q32 are frequently observed in B-cell malignant proliferation. A
small number have been described in B-cell precursor acute
lymphoblastic leukaemia (BCP-ALL). However, their biological and
clinical significance is currently unknown. Detailed fluorescence in
situ hybridisation (FISH) and molecular studies were carried out on
a series of BCP-ALL patients with chromosomal abnormalities
involving 14q32. Novel and recurrent translocations affecting
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different chromosomes were highlighted. Refined FISH mapping
identified putative IGH partner genes at, or flanking, the transloca-
tion breakpoints. Four translocations: two previously reported,
t(14;19)(q32;q13), t(8;14)(q11;q32), and two novel, t(14;14)(q11;q32)/
inv(14)(q11q32) and t(14;20)(q32;q13), were identified. Molecular
analyses showed that four different members of the CAATT enhancer
binding protein (CEBP) gene family were involved: CEBPA (19q13,
n5 9), CEBPD (8q11, n5 8), CEBPE (14q11, n5 3) and CEBPB (20q13,
n5 2). One patient with a t(14;19)(q32;q13) was observed to involve
the fifth family member CEBPG (19q13, n5 1). Breakpoints were
located within the 30 untranslated region (UTR) of CEBPA and either
30 UTR or 50 of CEBPE, whereas breakpoints in 8q11 were B30 kb
centromeric of CEBPD. Where material was available, over-expres-
sion of target genes was shown by quantitative real-time PCR.
Overall, this study has demonstrated for the first time the
involvement of five members of the same gene family in a single
subtype of haematological disease. It has indicated that transcrip-
tional upregulation of CEBP gene family members, by juxtaposition
to IGH, is important in BCP-ALL: a mechanism in complete contrast
to that involving CEPBA in acute myeloid leukaemia.
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Non-hodgkin’s lymphoma (NHL) cells induce a local
and systemic regulatory T-cell response
S Mittal, NA Marshallw, L Duncanw, PW Johnstonz, JE Tighe,
HG Watson, DJ Culligan, RN Barkerw and MA Vickersw
Department of Haematology, Aberdeen Royal Infirmary,
Aberdeen, UK, wDepartment of Medicine and Therapeutics,
University of Aberdeen, Aberdeen, UK, zDepartment of
Pathology, Aberdeen Royal Infirmary, Aberdeen, UK
T regulatory (Treg) cells, especially CD251 , are a type of
lymphocyte that suppress immune responses and may be important
in mediating escape of malignant cells from immune surveillance. In
order to investigate their importance in NHL, we enumerated Treg
cells in peripheral blood (PBMC) and involved tissues from 30
patients at diagnosis. CD251 FoxP31 CD127low CD41 T reg cells
were increased significantly in PBMC (patients’ median5 20.3% of
CD4T cells [n5 20] vs healthy control median5 3.16% of CD4T cells
[n5 13]; Po0. 001, rank sum test). This proportion is higher than
recorded in any other malignancy and may explain the global
immunosuppression seen in NHL. Furthermore, Treg cells from
PBMC significantly correlated with serum lactate dehydrogenase, a
tumour bulk marker (r25 0.84, Po0.001). Poor T-cell responses to
control stimuli by PBMC from patients with NHL were reversed by
depleting CD251 cells with magnetic beads or by addition of anti-
CTLA-4. As a high percentage of Treg cells were also present in
involved tissues (patients’ median5 38.8% of CD4T cells [n5 15] vs
reactive nodes’ median5 11.6% of CD4T cells [n5 2]; P5 0.02, rank
sum test), we determined if tumour cells could induce a Treg
phenotype. We incubated the CD25 PBMC fraction with tumour
cells in vitro for five days. A dose and time-dependent Treg
phenotype (CD251 FoxP31 ) induction was seen (number5 6,
maximum induction of 86.76%). Less effective induction was seen
when these populations were separated in transwells. These ‘induced
Treg cells’ were FACS sorted and suppressed effector T-cell
proliferation. We conclude that NHL cells are powerful inducers of
Treg cells. These suppressive cells circulate and may induce active
immune tolerance both systemically and within the tumour
microenvironment, thus representing a new therapeutic target in
NHL.
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Report of the UKCLL02 trial: a phase II study of
subcutaneous alemtuzumab and fludarabine in
patients with fludarabine refractory CLL (on behalf
of the NCRI CLL trials sub-group)
HA Sayala, P Moretonw, RA Jones, AC Rawstron,
SJ O’Connor, PE Evans, A Carterz, C Deardeny, E Matutesy,
AR Pettittz, BD Kennedyz and P Hillmen
HMDS, Leeds General Infirmary, Leeds, UK, wDepartment of
Haematology, Pinderfields General Hospital, Wakefield, UK,
zDepartment of Haematology, Royal Liverpool University
Hospital, Liverpool, UK, yDepartment of Haemato-Oncology,
Institute of Cancer Research, London, UK, zDepartment of
Haematology, Leicester Royal Infirmary, Leicester, UK
Fludarabine refractory CLL has a median survival of 10 months.
Intravenous alemtuzumab is approved in fludarabine refractory CLL.
Combined alemtuzumab and fludarabine can induce responses in
CLL refractory to both agents. Infusion reactions and 2-hour
infusions 3 a week are problems with IV alemtuzumab. We report
on the UKCLL02 study to assess the safety and effectiveness of SC
alemtuzumab in fludarabine-refractory CLL. SC alemtuzumab was
given at a dose of 30 mg 3 a week for up to 24 weeks. Patients not
responding to alemtuzumab in the trial could receive oral
fludarabine combined with SC alemtuzumab. 49 patients are
evaluable. Responses to alemtuzumab monotherapy (n5 49) were
7 CR(5 MRD negative, two MRD positive), 15 PR, 25 NR and two
patients died on treatment. Seventeen patients (6 PRs and 11 NRs)
received concurrent fludarabine and SC alemtuzumab. Two non-
responders achieved a PR and one of the partial responders achieved
a CR. Therefore the overall response rate for the whole cohort was
24/49(49%) including 6 MRD negative patients (5CRs and 1 PR). 22/
38 patients (58%) with poor risk deletions (11q- and/or 17p-) and/or
p53 dysfunction responded to treatment. The initial alemtuzumab
dose was associated with localised skin reactions in 26 patients, fever
in eight and rigors in four. All reactions subsided in o48 hour.
Serious infections during alemtuzumab monotherapy were: CMV
reactivation (18); febrile neutropenia (10); invasive fungal infection
(4); pneumonia (7) and septicaemia (2). On the combination, CMV
reactivation in three cases and septicaemia in one case. All CMV
reactivations resolved on antiviral therapy. Grade 31 thrombocy-
topenia and neutropenia was seen in 26 and 41 patients on
alemtuzumab monotherapy as well as in one and five patients on
combined therapy, respectively. The median survival for campath
responders was 25 months compared to 13 months for nonrespon-
ders. We conclude that subcutaneous alemtuzumab is effective in
poor-risk fludarabine-refractory CLL and is well tolerated compared
to IV therapy. The addition of oral fludarabine improves the
response rates with acceptable toxicity.
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Cryopreservation of mature monocyte-derived
dendritic cells (DC) for assessment of alloreactivity
in humans
RE Protheroe,w, KS Nicolson, CG Steward,w and DC Wraith
Department of Cellular and Molecular Medicine, University
of Bristol, Bristol, UK, wDepartment of Paediatric Oncology
and Haematology, Royal Hospital for Children, Bristol, UK
Conventional mixed lymphocyte reactions (MLR) have not been
informative in predicting graft-versus-host disease. Such assays are
made significantly more sensitive through the use of DCs as antigen
presenting cells (APC). Human DCs may be obtained from CD341
bone marrow or blood cells, or from peripheral blood monocytes
stimulated with recombinant human granulocyte macrophage-
colony stimulating factor (rhGM-CSF) and interleukin-4 (rhIL-4).
Methodological difficulties exist in the use of monocyte-derived DCs,
with unstable immunophenotype and reversion to macrophage
characteristics on culturing in the absence of cytokines. This
presents logistical problems in using DCs to assess alloreactivity.
We report a method for in vitro generation and cryopreservation of
mature monocyte-derived DCs. Peripheral blood monocytes, from
healthy volunteers (n5 7), were isolated by plastic adherence and
cultured for six days in RPMI with 1% autologous heat-inactivated
plasma, rhGM-CSF and rhIL-4. The DCs were matured by further
culture for three days with lipopolysaccharide. Phenotypic char-
acterisation demonstrated CD83 and CD1a expression, lack of CD14,
high levels of HLA-DR, and upregulation of CD83, and co-
stimulatory molecules, CD80 and CD86, on maturation. DCs were
significantly more potent APCs than peripheral blood mononuclear
cells in MLRs. Mature DCs were cryopreserved in 50% autologous
heat-inactivated plasma, 40% RPMI and 10% dimethyl sulphoxide.
On thawing, viability was 87.6%7 15.7% (mean7 SD). Following
cryopreservation, CD1a, CD83 and co-stimulatory molecule expres-
sion was downregulated to the level observed in immature DCs. MHC
class II molecule expression was unaffected. Despite the immuno-
phenotypic changes, cryopreservation did not alter DC function, with
no reduction in APC potency in MLRs. The MLR kinetics showed no
significant difference between fresh and cryopreserved DCs. This
may be explained by recovery of co-stimulatory molecule expression
48 hours after thawing. Effective cryopreservation of mature DCs will
facilitate application of DC-driven MLRs in the assessment of
alloreactivity in stem cell transplantation.
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Fourier transform infrared spectroscopic studies of
lymphoma, lymphoid and myeloid leukaemia cell lines
J Babrah, R Lushw, A Ryew, K McCarthyz, C Bessanty and
N Stone
Biophotonics Research Group, Gloucestershire Royal Hospi-
tal, Gloucester, UK, wDepartment of Haematology, Glouces-
tershire Royal Hospital, Gloucester, UK, zDepartment of
Histopathology, Gloucestershire Royal Hospital, Gloucester,
UK, yCranfield Health, Cranfield University, Silsoe, UK
Fourier transform infrared spectroscopy (FT-IR) is sensitive to the
structural and biochemical composition of intact single cells. This
study presents a novel method to characterise differences that
distinguish leukaemia and lymphoma cell lines based on mathema-
tical modelling of objective spectral measurements. Lymphoma
(Karpas), Lymphoid (REH and ACV) and Myeloid (HL60 and
Meg01) cell lines obtained from the Section of Haemato-Oncology, at
the Institute of Cancer Research, Sutton were studied. Cell samples
were washed and diluted in normal saline. 50 microlitre aliquots were
transferred onto calcium fluoride slides by cytospin to yield a
monolayer. These were air dried. Spectral data in transmission mode
were acquired using a Perkin-Elmer Spotlight 300 FT-IR imaging
spectrometer. The data obtained for each cell line were a
combination of point spectra, hyperspectral IR and white light
images. Multivariate statistical techniques incorporating principal
component analysis (PCA) and linear discriminate analysis (LDA)
were used to construct a mathematical model. This model was
validated for reproducibility. Spectra collected at different positions
on the monolayer were averaged for each cell line. Our results show
distinct spectral differences in the 720 to 4000 cm1 spectral region.
Bands in the averaged spectra for each cell line were assigned to
proteins, fatty acids, carbohydrates and nucleic acids. Pseudocolour
maps generated using PCA were used to identify major differences in
the spectra across each image, resulting in the clustering of cell line
populations. LDA was used to maximise the separation in the model
between different cell lines, whilst minimising the separation within
each group. Spectral analysis by PCA and LDA demonstrated subtle
variation within each cell line but revealed significant differences
between cell lines and cell lineage. The FT-IR spectrum produces a
molecular signature that reflects the unique set of molecular
vibrations of bio-molecules present in cells. The cellular spectra
reflect phenotypic differences and offers the potential to serve as a
novel diagnostic technique.
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Functional characterisation of mutations in the
telomerase complex: no evidence of a dominant
negative effect
A Marrone, T Vulliamy, A Walne and I Dokal
Academic Unit of Paediatrics, QueenMary School of Medicine
and Dentistry, London, UK
Heterozygous mutations in the RNA component of telomerase
(TERC) have been identified as causing the autosomal dominant
form of dyskeratosis congenita, a bone marrow failure syndrome.
They have also been detected in a small subset of patients presenting
with aplastic anaemia or myelodysplasia. The majority of these
mutations have been found to reduce telomerase activity but do not
appear to have a dominant negative effect on the activity of wild-type
TERC. Using an in vitro telomerase assay we have investigated the
functional consequences of three recently described TERC mutations:
C79del, which disrupts base pairing in the pseudoknot domain and
A48G and 52-55del, which are the first mutations identified that
disrupt the template region of TERC. All three mutations resulted in
reduced telomerase activity (o10% of wild-type TERC) when
expressed alone. When each of the mutant forms was mixed with
wild-type TERC, we did not observe any reduction in activity of the
wild-type TERC and therefore see no evidence of a dominant
negative effect. The clinical presentation of all three mutations is not
atypical, with a parental generation remaining asymptomatic and for
both template mutations the disease appearing as a sporadic case. It
is therefore of interest that a recent report of the same template
mutations suggests that they do indeed cause a dominant negative
effect on the activity of the wild type enzyme (Xin et al. [2006] Blood,
pre-published DOI 10.1182/blood-2006-07-035089). It is not clear why
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differing results have been obtained in the two laboratories. We can
only point to the fact that our data is consistent with previous reports
from several laboratories indicating that the clinical manifestations
of TERC mutations arise due to haploinsufficiency rather than due to
a dominant negative effect.
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Characterisation of Hox expression signatures during
haemopoietic differentiation of embryonic stem cells
P Mc Crory, G McGoniglew, E Dobbin, R Freeburn,
H Wheadon, T Lappinw and A Thompsonw
School of Biomedical Sciences, University of Ulster,
Coleraine, UK, wHaematology Research Group, CCRCB,
Queen’s University Belfast, UK
The 39 mammalian Class I Homeobox (Hox) genes arranged as
paralogs (A–D) in clusters (1–13) on four separate chromosomes
encode master regulators of embryonic development. Aberrant
expression of Hox genes, reported in several haematological
malignancies, may reflect reactivation of dormant embryonic tissue
remnants. Embryonic stem (ES) cells have the capacity to become
virtually any differentiated tissue of the body and are therefore an
excellent model to study the initiating processes involved in the
development of malignancies. A comprehensive strategy to quantify
the Hox signature in both pluripotent ES cells and during the critical
stages of mesodermal/haemopoietic development was designed. ES
cell lines were differentiated using two rounds of embryoid body
(EB) formation optimised to drive mesodermal (primary EB) and
then haemangioblast formation (secondary EB), followed by specific
conditions to drive both myeloid and erythroid haemopoietic colony
formation. Total RNA isolated from cells of each differentiation stage
was converted to cDNA for Hox profiling by Q-PCR. Transcript copy
numbers were evaluated from standard curve calculations and
expression levels compared to untreated controls. Preliminary data,
focussing on the Hoxa and Hoxb clusters showed that these genes
were well-represented and highly expressed in the pluripotent ES
cells (up to 3 105 copies/50 ng RNA). A marked decrease in
expression (over 70%) for the majority of Hox genes assayed (15/21)
was observed following initiation of haemopoiesis. Only Hoxa11 and
Hoxa13 exhibited a marked increase in expression during mesoder-
mal/haemopoietic development and five genes (Hoxa6, Hoxa7,
Hoxb5, Hoxb7 and Hoxb13) remained unchanged. These data confirm
and extend reports of Hox repression during the early differentiation
of ES cells to committed progenitors. The mechanism of regulation
of Hox genes in ES cells and the significance of maintainance or
upregulation of a subset of genes during early haemopoietic
commitment are topics for future studies.
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Abnormal erythropoietin receptor downregulation
following erythropoietin stimulation of non-small
cell lung carcinoma cells
EA Dunlop, AP Maxwellw and TRJ Lappin
Haematology Research, Centre for Cancer Research and Cell
Biology, Queen’s University Belfast, UK, wRegional Nephrology
Unit, Queen’s University Belfast, UK
Erythropoietin receptor mRNA and protein have been identified in a
variety of cancer cell lines, as well as solid tumours. This has raised
concerns about the use of erythropoiesis stimulating agents in the
treatment of cancer-related anaemia. Previously we demonstrated
expression of functional erythropoietin receptors in a non-small cell
lung carcinoma cell line, H838, which activated key signalling
pathways in response to erythropoietin stimulation. We detected
activation of STAT5, Akt and ERK which are important downstream
signalling proteins in erythroid progenitors, suggesting the EpoRs in
H838 cells function similarly to EpoRs in the erythroid compartment
[Dunlop EA et al. [2006] Neurodegen Dis 3, 94–100.]. Recent analysis
of the downregulation mechanisms operational in this cell line has
highlighted a number of abnormalities. In erythroid progenitors,
EpoR is downregulated by negative regulators such as SOCS3 and
SOCS1 and by ubiquitination and degradation of the receptor by the
ubiquitin-proteasome pathway. By inhibiting protein synthesis and
analysing EpoR levels over time we found that the erythropoietin
receptor is not turned over in either resting or erythropoietin-
stimulated H838 cells. Additionally, we could find little evidence for
ubiquitination of the receptor, although proteasome assays showed
the proteasome was active. Compounding this blunted response was
impaired SOCS3 induction downstream of erythropoietin signalling
pathways and a delayed induction of SOCS1 when compared to the
UT-7 erythroid line. Despite this impaired downregulation, there was
no evidence that erythropoietin treatment increased the proliferation
or invasive potential of the H838 cells. If abnormal erythropoietin
receptor downregulation and degradation is a widespread phenom-
enon in tumour cells it could have clinical implications for those
patients receiving erythropoiesis stimulating agents for cancer-
related anaemia.
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Methylation profiling of myeloid leukaemia cell lines
M Lazenby, AF Gilkes, AK Burnett and KI Mills
Department of Haematology, Cardiff University, Cardiff, UK
Hypermethylation of CpG islands occurs during leukemogenesis
particularly in AML and myelodysplastic syndrome (MDS). One of
the drugs approved for the treatment of MDS is the potent DNA
demethylating agent 5-aza-20 deoxycytidine. About 30% of MDS
patients with an abnormal karyotype have normalization of their
karyotype after receiving the drug. However, to monitor the
effectiveness of the drug, the methylation status of the genome
needs to be measured. This can be done using several methods to
assess the global methylation status or the methylation status of the
promoter regions around candidate genes can be monitored.
Pyrosequencing allows the highly reproducible quantification of
methylation frequencies within individual consecutive CpG sites
allowing reproducible measurement of small changes in methylation
levels. This is due to the analysis of the CpG sites within the context
of the surrounding DNA sequence with integrated internal controls
for bisulphite conversion. In our study, we have used pyrosequen-
cing to monitor the levels of methylation in 17 CpG sites across four
genes (MLH1, p16, MGMT and LINE-1) in a panel of myeloid cell
lines and a series of normal samples with the aim of monitoring
methylation status of AML and MDS patients at diagnostic and
during treatment. The cell lines used in the study represent a range of
cell types, some with recurrent translocations. Similar levels of MLH1
methylation was seen except in Kazumi cells. However, highly
variable levels of p16 and MGMT methylation, particularly U937 cells
with both genes highly methylated whilst MGMT was high in K562
cells. This study will form the basis of using pyrosequencing
methodology for the rapid and sensitive monitoring of clinical
samples particularly to assess the effectiveness of therapeutic
demethylating agents.
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Written responses to some outpatient referrals are
appropriate and time- saving for patients and doctors
S Gooding, R Cowenw and TJ Littlewoodz
Department of Medicine, Oxford Radcliffe Hospital, Oxford,
UK, wDepartment of Medicine, Wycombe General Hospital,
UK, zDepartment of Haematology, Oxford Radcliffe Hospital,
Oxford, UK
We have previously established that written responses (rather than
seeing the patient in clinic) to some outpatient referrals are
appropriate, safe and appreciated by general practitioners (GPs).
An audit published in 2004 (Tso et al. [2004] BMJ, 329, 946–947.)
showed that 103 of 104 GPs found written advice about a range of
haematological problems acceptable and helpful. The audit has been
repeated and included, on this occasion, a survey of patients’
opinions. Eighty-five GPs, to whom a written response had been sent,
were asked whether they found the written response acceptable and
helpful. They were also asked whether they thought the patient was
happy with the written response and whether we could survey the
patient to directly ascertain their views. Of the 85 GPs, 78 responded
and all found the system acceptable and helpful. All said they would
be happy to have referrals dealt with in a similar way in the future.
Not all GPs wanted their patients contacted but we were able to send
questionnaires to 52 patients of whom 32 replied.
Twenty-nine out of thirty-two patients were aware that a referral
letter had been sent. Twenty-one patients were happy with a written
reply to their GP but 10 (31%) said that they would have preferred to
see the haematologist in person. Twenty-five patients (78%) would
have liked to see a copy of the letter sent to their GP. The data show
that this system is widely appreciated by GPs but about a third of
patients felt dissatisfied. We will try to address this by sending
patients a copy of the letter and re-auditing. Written responses have
reduced new referrals at the haematology clinic of TJL by nearly 50%.
GPs are very positive about the benefits but some patients feel that
they should still be seen by a specialist.
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A high rate of ‘CLL phenotype’ lymphocytes in
autoimmune haemolytic anaemia and immune
thrombocytopenic purpura
S Mittal, MG Blaylockw, HG Watson, JE Tighe, DJ Culligan,
RN Barkerw, MA and Vickersw
Department of Haematology, Aberdeen Royal Infirmary,
Aberdeen, UK, wDepartment of Medicine and Therapeutics,
University of Aberdeen, Aberdeen, UK
The causes of autoimmune haemolytic anaemia (AIHA) and immune
thrombocytopenic purpura (ITP) are unknown. About 15% of cases
of AIHA and ITP are associated with underlying CLL. Conversely,
about 10% of cases with CLL are complicated by AIHA or ITP. It has
recently been established that clinically silent, CLL-like monoclonal
B-cell lymphocytosis is considerably more prevalent than true CLL,
being present in about 3.5% of healthy individuals. Together, these
observations suggest the possibility that apparently idiopathic cases
of AIHA and ITP are associated with subclinical CLL clones. To test
this hypothesis, we investigated the presence of ‘CLL phenotype’
lymphocytes in 11 cases of primary AIHA, 18 ITP, two with Evan
Syndrome by FACS analysis and compared with 26 age matched
healthy controls. A discrete population of stronger CD5, weaker
CD20 and CD79b (over 50 events out of total 200 000 leucocytes) was
classified as ‘CLL phenotype’ compared to normal B-lymphocytes.
Six out of total 31 patients showed this subclinical ‘CLL phenotype’
compared to one in healthy control group, which is significant
statistically (chi-square5 3.9; P5 0.05). We speculate that these ‘CLL
phenotype’ cells process antigen differently to conventional antigen
presenting cells, thus revealing ‘cryptic’ epitopes, which fail to
provoke previously established, appropriate tolerance or anergy,
causing autoimmunity.
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Evaluation of pneumococcal conjugate vaccine
(Prevenar) in patients with myeloma and chronic
lymphocytic leukaemia
HM Greenfield, R Borroww, R Warringtonw, P Balmerw,
J Cavetz, J Adams, K Muttonw and JA Liu Yin
University Department of Haematology, Manchester Royal
Infirmary, Manchester, UK, wNorth West Regional Health
Protection Agency, Manchester Royal Infirmary, Manchester,
UK, zDepartment of Haemato-Oncology, Christie Hospital,
Manchester, UK
Infection with Streptococcus pneumoniae is responsible for signifi-
cant mortality in patients with a defective humoral response.
Immunisation with pneumococcal polysaccharide vaccine (PsV) is
not always effective in these individuals. Conjugation of polysac-
charides renders vaccines more immunogenic through T-cell
dependency. Impressive results in children lend themselves to
evaluation in other high-risk groups.
We assessed the immunogenicity of Prevenar in patients with
myeloma and CLL. The schedule followed UK DoH guidance for
vaccination of high-risk children; two doses of Prevenar followed by
a dose of PsV (Group 1). Patients who had previously received PsV
were only offered Prevenar (Group 2).
Data are available on 30 individuals. Twenty-four had myeloma
and six CLL. Median age was 64 years (range 51–75). Six patients had
never required treatment. Median chemotherapeutic treatments was
two (range 0–5). Seventeen patients had undergone a transplant
procedure.
Median time from last treatment was 14.5 months (range 6–69).
Eight patients with myeloma were receiving maintenance thalido-
mide. Two had low baseline IgG levels, 10 low IgM and six low IgA.
We utilised a serotype-specific IgG Bioplex assay for all seven
serotypes in Prevenar, levels greater than 0.35mg/ml are protective.
Prior to vaccination, the median number of serotypes with
protective antibody levels was 0 in Group 1 (n5 20), (range 0–5) and
4 in Group 2 (n5 10), (range 0–7).
Following vaccination the median number of serotypes with
protective antibody levels increased to six in Group 1 (range 1–7) and
a doubling of antibody concentrations was observed for a median of
six serotypes (range 1–7). In Group 2 the median number of
serotypes with protective levels remained at four (range 0–7) and
only doubled for a median of one (range 0–7).
We conclude that the pneumococcal conjugate vaccine Prevenar
appears to be immunogenic in patients naı¨ve to PsV; however it does
not benefit those previously immunised with PsV. Further studies are
required prior to introduction in adult clinical practice.
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Treatment-related morbidity and mortality in
haematology and oncology patients – a prospective
survey in a district general hospital cancer unit
DC Wylie, B Black, P Abram, P Henry, M Bowers, M El Agnaf
and YL Ong
Department of Haematology, Ulster Hospital, Belfast,
UK
An audit was carried out in the haematology department of Ulster
Hospital. The main aims of the study were to determine the risk
factors for the development of neutropenic sepsis so as to derive a
risk score, and audit this information against current anti-microbial
protocol.
This 6-month prospective survey recorded a total of 86 episodes
from February to August 2006. The majority of these episodes
resulted in ward admission (60%, n5 52), approximately half were
due to neutropenic sepsis (48%, n5 25). Among the latter group, the
vast majority were aged 60 years and over (88%, n5 22). Most of
these patients also had significant co-morbidity (72%, n5 18),
abnormal liver function tests (60%, n5 15) and a calculated
creatinine clearance of less than 60 ml/min (20, n5 5).
The most common underlying diagnosis among these patients
was breast cancer (28%, n5 7), B-cell non-Hodgkin’s lymphoma
(24%, n5 6) and chronic lymphocytic leukaemia (20%, n-5). Most of
these patients had been treated with R-CHOP21 (28%, n5 7), FEC
(20%, n5 5) and fludarabine (16%, n5 4). Approximately one-third
despite receiving G-CSF prophylaxis presented with neutropenic
sepsis (36%, n5 9).
Septic screen revealed that almost half were culture positive (48%,
n5 12), either positive blood cultures (36%, n5 9), urine (12%,
n5 3) or sputum cultures (8%, n5 2). Of the positive blood cultures,
the most commonly cultured organisms were coagulase-negative
Staphylococcus (44%), Enterococcus (22%), Klebsiella (11%), Pseudo-
monas (11%) and MRSA (11%). All organisms were sensitive to
Gentamycin and/or Tazocin.
The majority of patients with neutropenic sepsis made a full
recovery (88%, n5 22). The others either commenced palliative
therapy or died.
Patients age 60 or over who have comorbidity and receiving
chemotherapy regimen FEC, R-CHOP 21 and fludarabine (for breast
cancer, NHL and CLL, respectively) are at very high risk of developing
neutropenic sepsis. Hence, primary G-CSF prophylaxis is justifiable
in these patients in order to reduce morbidity and mortality.
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Risk factors for the development of adverse
gastrointestinal events post-chemotherapy
DC Wylie, B Black, P Abram, P Henry, M Bowers, M El Agnaf
and YL Ong
Department of Haematology, Ulster Hospital, Belfast,
UK
The Ulster Hospital delivers BCSH level 2 care for the haematology
patients, and provides oncology cover for the Cancer Centre. A
prospective study was conducted from February to August 2006
which aimed to assess treatment-related morbidity and mortality
among haemato-oncology patients and to ascertain the risk factors
for the development of adverse events.
Eighty-six episodes were recorded during this period. The main
causes of morbidity were severe gastrointestinal symptoms (36%,
n5 31) and neutropenic sepsis (29%, n5 25). Other less frequent
symptoms were suspected thromboembolism, cellulitis, headache,
rash, lethargy and renal failure.
Most cases of gastrointestinal symptoms occurred in oncology
patients (90%, n5 28), including diarrhoea, vomiting, or mucositis.
Most episodes were severe and resulted in ward admission (57%,
n5 16). Many patients (29%, n5 8) had biochemical abnormalities
including hypomagnesaemia, hypokalaemia, hypophosphataemia,
hypercalcaemia and hypoalbuminaemia. Of the patients who were
admitted, the mean duration of admission was 5.8 days (range 1–16
days). Although most patients made a full recovery (79%, n5 22), a
significant number requiredvdose-modification or even discontinua-
tion of their chemotherapy.
The most common underlying diagnoses were bowel cancer (50%,
n5 14) and breast cancer (48%, n5 12). Most episodes occurred in
patients aged 60 years and over (71%, n5 20), and in those who had
received previous treatment with another chemotherapy regime
(61%, n5 17). Many had significant co-morbidity (50%, n5 14). Five
patients (18%) had a creatinine clearance of less than 60 ml/min and
2 (7%) had abnormal liver function tests prior to treatment. The
most common chemotherapy regimen received was FEC (25%,
n5 7), Oxaliplatin1Capecitabine (18%, n5 5), Capecitabine only
(11%, n5 3), Taxatere (11%, n5 3), Irinotecan1MAYO (11%, n5 3)
and MAYO only (11%, n5 3). Other treatment included Irinote-
can1Capecitabine and Vinorelbine.
Following chemotherapy, gastrointestinal adverse events are a
significant cause of morbidity among oncology patients. The main
risk factors are: age 60 years or over, underlying diagnosis of bowel
or breast cancer, treatment with FEC or Capecitabine, co-morbidity
and abnormal liver function tests.
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Survival of patients with haematological malignancy
admitted to the intensive care unit (ICU): prognostic
factors and outcome compared to unselected medical
ICU admissions
QA Hill, A Hill, R Kellyw, C Patalappaw, AM Whittle,
AJ Scallyz, A Hughesy and AJ Ashcroftw
Department of Haematology, Leeds General Infirmary,
Leeds, UK, wDepartment of Haematology, Pinderfields
Hospital, Wakefield, UK, zSchool of Health Studies, Bradford
University, Bradford, UK, yIntensive Care Department,
Bradford Royal Infirmary, Bradford, UK
Historically, cancer patients had a poor outcome following ICU
admission. We assessed survival and factors predicting survival for
patients with haematological malignancy to improve ICU patient
selection. We also assessed the APACHE II scores ability to predict
outcome for these patients. One non-surgical admission within 7 1
week of each hematological admission acted as a control group.
Factors assessed by multivariate regression analysis were age,
diagnosis, time from haematological diagnosis to ICU admission,
degree of prior treatment, remission status, prior stem cell
transplant, documented infection and length of neutropenia. For
haematology patients, predicted hospital mortality was calculated
from the APACHE II score. We identified 111 patients with
haematological malignancy (acute leukemia n5 42, chronic leukemia
n5 11, myeloma n5 19 and lymphoma n5 39) admitted to ICU in
four hospitals (November 2000 to January 2006). Haematological
patients median age was 59 years (range 17–84), M:F ratio 1.22:1.
Control patients (n5 111) were similar: median age 63 years (range
17–86), M:F ratio 1.09:1. For control patients, overall ICU and hospital
survival rates were 70% and 55%, respectively, while survival for
haematology patients was approximately half at 44% and 24%,
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respectively. In multivariate regression analysis, only increasing age
(P5 0.016) and documented infection (P5 0.016) predicted poor
outcome. APACHE scores were significantly higher in haematology
patients (median 27) than controls (median 19) Po0.001 (two-
sample t-test). Haematology patients predicted hospital mortality
(56%) was significantly lower than actual mortality (77%) Po0.001
(one-sample test of proportion). For controls, hospital survival was
slightly reduced if mechanical ventilation (MV) required (risk
ratio5 1.37; 95% CI5 0.91, 2.05). Haematology patients hospital
survival was significantly worse for MV – 5/55 (9%) vs no MV 20/44
(45%) (risk ratio5 5.00; 95% CI5 2.04, 12.50). Most pre-admission
variables assessed did not predict mortality and should not be used
for this purpose. In haematological malignancy, need for MV still
predicts poor outcome but without MV nearly half survive to
hospital discharge.
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A single centre study of the acute pain experienced by
adult patients undergoing a bone marrow procedure
L Lloyd
Department of Haematology, Basingstoke and North
Hampshire NHS Foundation Trust, UK
Background: Bone marrow aspirate/trephine procedures (BMAT)
are performed in a wide variety of patients. Research suggests that
acute pain is an integral part of BMAT despite administration of
Lidocaine pre-procedure. Once diagnosed with a bone marrow
disorder patients are often required to endure multiple BMAT.
Patients who experience severe pain may become anxious and afraid
of having subsequent tests. Provision of; adequate analgesia, sensory
and procedural information and priming patient expectations are
recognised as key factors that positively impact on the patient’s pain
experience. There is, however, a dearth of information regarding the
quantity and quality of pain associated with BMAT.
Aim: The study’s primary aim was to assess the intensity of acute
pain experienced by adult respondents undergoing BMAT in order to
evaluate efficacy of Lidocaine. It’s secondary aim was to identify
sensory and affective words associated with BMAT as a means to
improve future patient’s experience.
Methodology: Fifty-six consecutive patients were recruited over a six
month period (34 men [61%] and 22 [39%] women). The data
collection tool was the Short Form – McGill Pain Questionnaire
incorporating a Visual Analogue Scale [VAS] and a present pain
index. Data analysis was performed using descriptive statistics,
paired t-test, McNemar test, Fischer exact test and logistic regression
techniques.
Results: Twenty-four respondents (43%) reported a VAS pain rating
of 4 or above with 25% of respondents scoring between 5.4–9.9. The
mean VAS pain intensity score was 3.7 cm (range 0–10).
The most frequently selected quality words chosen by respon-
dents to describe the pain experienced during the BMAT procedure
included; sharp (45%), shooting (36%), aching (35%), tiring-
exhausting (17%) and fearful (15%).
Conclusion: Lidocaine did not provide adequate pain relief. Provi-
sion of supplementary analgesia, alongside procedural and sensory
information may help to improve the patient experience. We propose
repeating the study utilising Entonox.
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Interim development report from the UK NEQAS
Haematology Web Based Digital Morphology Pilot
Scheme, registered for continuing professional
development (CPD) with the Institute of Biomedical
Science (IBMS)
F Maringanise,y, ML Brereton, J Ardern, B De la Sallew,
LE Hickman, J Burthem, L Sealz, P McTaggartw, J Harcourt,y,
M Westw, W Akhtar, J Parker-Williamsw and K Hyde,w
Department of Haematology, Manchester Royal Infirmary,
Manchester, UK, wUK National External Quality Assessment
Scheme for General Haematology (UKNEQAS(H)), Watford,
UK, zManchester Metropolitan University, UK, ySalford
University, Manchester, UK
UKNEQAS(H) in collaboration with Manchester Royal Infirmary and
Manchester Universities have introduced a Web based pilot scheme
for Digital Morphology, registered with the IBMS for CPD. In April
2005 participating centres of the conventional Morphology Scheme
were invited to register one individual with UKNEQAS(H). In April
2006 registration was increased from 221 to 412 individuals, from 14
countries (485% UK).
Two Web based cases were released quarterly (seven releases),
consisting of multiple digital images from previous UKNEQAS(H)
morphology surveys with coded comment report sheets and reflec-
tive feedback forms, 1CPD point was awarded per completed case.
Exercise completion by registrants was 51% (43–69%). The
majority of participants (72%) spent o30 mins reviewing cases,
with additional time background reading. Cases included Haemolytic
conditions and Leukaemias. Of those who commented 470% stated
an improved awareness of the clinical conditions, o20% stated that
their knowledge had not changed (variation was associated with the
clinical condition).
Feedback was used to develop the scheme format; optical
magnifications now appear with images and the clinical data stream-
lined. Image quality has improved and criticism of red cell images used
to progress the project. Comments included: raised awareness of Hae-
matology, improved understanding of clinical features and laboratory
results (cell markers, cytogenetics, chemistry) and of specific
morphology (significance of granulation or nuclear appearance).
Participants stressed the usefulness of images for teaching,
particularly for rare haematological cases seen less frequently in
some laboratories. Future development by UKNEQAS(H) include a
revised protocol for reflective reporting, introduction of electronic
reporting and improved access to viewing software for larger images.
The scheme’s aim remains one of education, rather than
assessment, directed at individuals rather than centres. With the
key theme of personal professional development promoting im-
provement to the quality of haematological morphology this scheme
has potential for expansion across the UK and internationally.
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Non adherance to dosing guidelines for LMWHs in
renal impairment leads to a high incidence of
significant bleeding
W Marshall, A Cole, J Smythw and MR El-Agnafw
Renal Unit, Ulster Hospital, Belfast, UK, wDepartment of
Haematology, Ulster Hospital, Belfast, UK
Introduction: Recently Guidelines have been developed for dose
reduction in LMWHs in the treatment of patients with renal
impairment. Following a number of significant bleeding events
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related to LMWH (Enoxaparin) usage in Medical admissions to this
hospital we prospectively audited Enoxaparin usage in patients with
renal impairment and the incidence of adverse events over a three
month period. All patients included were receiving therapeutic doses
of Enoxaparin for the treatment of thromboembolic events or
ischaemic heart disease.
Methods: Estimated GFR (eGFR) was calculated using the four
variable MDRD formula. Twenty patients with an eGFRo30 ml/min/
1.73 m2 who were commenced on a therapeutic dose of Enoxaparin
over the three month period were included. Patients were assessed as
to whether they were weighed prior to commencing treatment and if
Enoxaparin dose was reduced appropriately as per established
guidelines. The number of adverse bleeding events was recorded.
Antifactor Xa levels were measured on each patient. Concurrent
anitplatelet drug usage was also recorded.
Results: The mean age of the 20 patients included (nine male, 11
female) was 75. Fifteen out of twenty (75%) patients were incorrectly
prescribed a higher initial dose than appropriate based on their
weight and renal function. Of these patients 5/15 (33%) developed
significant GI haemorrhage. One patient developed a haematoma at
the injection site. Of the six patients who developed bleeding
complications five had therapeutic Antifactor Xa levels and only one
had an elevated level 4 1 u/ml. Eleven out of twenty (55%) patients
were commenced on initial treatment without a recorded weight.
Conclusions: Failure to record weight and to appreciate renal
impairment can lead to excessively high dosing of LMWHs in
patients admitted to general medical and cardiology wards. Renal
function frequently changes over the duration of medical admissions
and the dose of LMWHs should be reviewed daily and altered
accordingly in order to avoid serious complications. Routine
measurement of Antifactor Xa does not identify patients at risk of
bleeding and should not be routinely measured.
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A funding framework for high cost haematology drugs
in Merseyside and Cheshire Cancer Network (MCCN)
B Woodcock, A Hines, M Stanleyw, P Sneddon and
S Herwitker
Mersey and Cheshire Cancer Network, wCheshire and
Merseyside Specialist Commissioning Team
Introduction: Cancer chemotherapy drug costs are excluded from
the national tariff. There is considerable delay between drug
licensing and National Institute of Clinical Excellence (NICE)
appraisal and not all drugs are appraised. Haematology Services
are funded through the commissioning of local hospital services by
Primary Care Trusts (PCTs). This has meant that some high cost
drugs have not been available to all patients. We describe the
development and operation of a new high cost drug framework
(HCDF) for cost per case funding haematology drug treatments.
Methods: The network haematology group agreed a standard
protocol framework for some high cost therapies. An Effective
Therapies paper, stating the clinical evidence for each treatment, its
place in practise and expected cost per 100,000 population for the
current financial year was approved by the local specialist and
collective commissioning group (LSCCG) and circulated to all
Primary Care Trusts. MCCN also developed a standardised case of
need pro-forma and robust centralised pathways for funding
requests.
Results: During the first 6 months of the framework, MCCN received
35 requests for funding. Thirty (85%) of these were for MCCN cancer
patients. Of these 27 (90%) cases were approved and three (10%)
were not. Twenty-six out of twenty-seven (96%) requests within the
framework were approved. Only one of three (33%) requests outside
the HCDF was approved. Sixteen out of thirty (53%) of all requests
were for Bortezomib. There were two requests each for Alemtuzumab
and Depocyte (Liposomal Cytarabine) and Neulasta (Pegfilgrastim).
Conclusions: A high cost drug framework consisting of selected
effective therapies and robust cancer network pathways is an
effective way of securing funding for previously unfunded high cost
haematology cancer drugs. The cancer network also holds previously
unavailable high cost drug funding data.
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Pseudo-hyperkalaemia and aetiology of thrombocy-
tosis: a six-year retrospective correlation study
R Deore, S Harte, M Bowers, M El-Agnaf and YL Ong
Department of Haematology, Ulster Hospital Dundonald,
Belfast, UK
Pseudohyperkalaemia is a rarely encountered event that causes
unnecessary anxiety among clinicians, and may lead to inappropriate
treatment to lower a spuriously raised potassium level. The
association between pseudohyperkalaemia and aetiology of throm-
bocytosis is unclear. A 6-year retrospective audit was conducted on
90 patients with thrombocytosis referred to the Haematology
Department in Ulster Hospital Dundonald, a large district general
hospital. Over two thirds of this study population had myeloproli-
ferative disorders, and the most common diagnosis was primary
thrombocythaemia (41%, n5 37). In contrast, reactive thrombocy-
tosis was observed in approximately one third of the cases (32.2%,
n5 29). Pseudohyperkalaemia with apparent potassium level above
the upper limit of the normal range was observed in the majority of
patients with thrombocytosis from any aetiology (60%, n5 54). The
likelihood of finding pseudohyperkalaemia was highest among
patients with primary thrombocythaemia (75.7%, n5 28/37), fol-
lowed by polythaemia rubra vera (75%, n5 12/16), and reactive
thrombocytosis (34.5%, n5 10/29). A significant positive correlation
was observed between the platelet counts and the serum potassium
level (Spearman’s correlation coefficient, r5 0.28, P5 0.01).
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Workshop on developing digital images of blood and
bone marrow morphology for external quality assur-
ance led by UK NEQAS for General Haematology
ML Brereton, J Burthem, B De la Sallew, J Ardern,
LE Hickman, L Sealz, P McTaggartw, J Harcourt,y, M Westw,
W Akhtar, D Swirskyz and K Hyde,w
Department of Haematology, Manchester Royal Infirmary,
Manchester, UK, wUK National External Quality Assessment
Scheme for General Haematology (UKNEQAS(H)), Watford,
UK, zManchester Metropolitan University, UK, ySalford
University, Manchester, UK, zDepartment of Haematology,
Leeds General Infirmary, UK
A Web based Scheme for Digital Morphology, registered with the
Institute of Biomedical Science for CPD was successfully introduced
in 2005 by UKNEQAS(H), in collaboration with Manchester Royal
Infirmary and Manchester Universities. A workshop was held for
invited clinicians and scientists to assist in prioritising development
projects in digital morphology.
Delegates were sent two unstained blood smears to be stained
locally, these were returned for imaging at MRI and assessed at the
workshop. Delegates were required to complete a questionnaire and
Poster Presentations: General Haematology
r 2007 The Authors
Journal compilation r 2007 Blackwell Publishing Ltd, British Journal of Haematology, 137, (Suppl. 1), 1–88 9
view two virtual slides, composed of multiple high power images,
depicting a bone marrow smear of acute leukaemia and a blood
smear of plasmodium falciparum.
The workshop formed two focus groups, the Biomedical Scientists
considered the expansion of the digital CPD scheme, the Clinical
Haematologists considered issues around digital morphology for
assessment and teaching.
Review, by the workshop, of images highlighted the variety in
range and quality of staining techniques nationally which requires
addressing before definitive imaging standards can be achieved.
Expectations of image quality and content varied and the need to
standardise image viewing software was highlighted.
Both focus groups identified future roles for images in education
and assessment, for both organisations and individuals, including
the possible use of images in performance monitoring at different
levels.
UKNEQAS(H) has a major role in the assurance of performance
quality. Participants of Schemes must help lead the way in
development by providing critical feedback. The workshop produced
intense debate on how emerging wed based technology should be
used to not only educate but possibly to assess performance in
morphology both for centres and individuals. The promotion of
personal professional development by improvement to the quality of
haematological morphology in different professional groups was
denoted as of immense importance. Workshop feedback will be used
to develop digital morphology in EQA.
27
JAK2 mutation in the diagnosis and management of
myeloproliferative disorders
AC Sikora, A Cader and MN Narayanan
Department of Haematology, George Eliot Hospital,
Nuneaton, UK
According to the World Health Organisation classification, myelo-
proliferative diseases encompass polycythaemia vera (PV), essential
thrombocythaemia (ET), myelofibrosis (MF), and other less well-
known disorders.
In 2005, several papers were published which reported an
association between the myeloproliferative disorders and an
acquired, single-point mutation (valine to phenylalanine) in the
JAK2 gene. In one published series the mutation was detected in 65–
97% PV patients, 23–57% ET patients, and 35–57% MF patients.
This study was undertaken to investigate these findings in our
own patient population. Case notes were examined for haematolo-
gical profile at diagnosis, haemorrhagic and thrombotic episodes,
venesection frequency, hydroxycarbamide use, and spleen size. Bone
marrow trephine biopsies, along with haematological parameters,
were reviewed to confirm the diagnosis. A PCR method was utilised
to detect the presence of the JAK2 mutation in whole blood samples.
JAK2 mutation tests were undertaken in 70 patients with possible
myeloproliferative disorders attending haematology outpatient
clinics over a 3-month period. Fourteen (20%) were secondary
polycythaemis and were excluded. Of the remaining 56, 31 (55%) were
PV, 21 (38%) were ET, and 4 (7%) were MF. JAK2 mutation was
detected in 25 (81%) PV cases, 11 (52%) ET cases, and in 1 (25%) MF
case. Thrombotic complications were identified in 8 (22%) JAK2-
positive patients, vs 5 (26%) JAK2 negative patients. Haemorrhagic
complications were found in 14 (38%) JAK2 positive patients,
compared to 2 (11%) of those lacking the mutation. The average
maintenance dose of Hydroxycarbamide was lower (554 mg/day vs
861 mg/day) for JAK2-positive patients.
Our data mirrors the findings of the recent studies in terms of the
overall frequency of the JAK2 mutation. Notably, our study indicates
that patients possessing the aberrant form of JAK2 are more sensitive
to hydroxycarbamide. JAK2 mutation testing is a straightforward and
useful diagnostic tool in the myeloproliferative disorders and is
valuable in subsequent management.
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How good is documentation of telephone advice
given by haematologists?
JN Crowe, A Whiteway and J James
Department of Haematology, Frenchay Hospital, Bristol, UK
It is important that medical notes are completed accurately and fully
for patient safety, resource use and medico-legal reasons. Haema-
tological advice is commonly given by telephone. We observed that
this was variably recorded in hospital medical notes and decided to
undertake a formal assessment.
An audit of telephone advice given over a 9-week period was
conducted. The haematologist recorded the advice given and the
medical notes were later reviewed to ascertain whether the advice
given was documented correctly. Advice given to general practi-
tioners was not recorded due to the practical difficulties associated
with reviewing records in the community. A total of 48 episodes were
recorded. The majority of advice was given to general medical teams
(22), followed by neurosurgery (7), neurology (6), orthopaedics (4),
general surgery (3), paediatrics (3), A&E (2), ITU (1). Telephone
consultations were given for the following areas: clotting (20),
general haematology (18), transfusion (8) and malignant haematol-
ogy (5). The commonest questions were regarding thrombocytopenia
(8), and abnormal clotting results (10). Only 27/48 (56%) of
consultations were documented accurately in the medical notes.
Eleven out of forty-eight consultations were not documented at all
and 10/48 consultations were incompletely documented.
These findings indicate that recording of telephone advice is poor.
This means that members of the medical team reviewing a patient at
a later time may not be aware of the advice given and may lead to
inappropriate investigation or intervention. It also creates a potential
medico-legal risk. It is not usual practice for haematologists to keep
their own record of advice given or arrange to write in the notes
themselves. We suggest those giving telephone advice should
consider either specifically requesting that the discussion is
documented in the patient’s medical notes or recording the
consultation themselves.
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Natural history and outcome of amyloidosis in the
elderly
M Offer, AD Wechalekar, JD Gilmore, HJ Lachmann and PN
Hawkins
National Amyloidosis Centre, Royal Free and University
College Hospital, London, UK
The natural history and outcome of elderly patients with systemic
amyloidosis has been little studied. Three hundred and ninty-two
patients over age of 75 years were referred to our centre between 1988
and 2006, amongst whom amyloidosis was confirmed in 292 cases.
One hundred and eighty-three had systemic AL type, 38 had localised
AL, 30 had AA amyloidosis, 21 had a type of hereditary amyloid, 7
had B2 M, and 13 had wild-type ATTR. Median overall survival (OS)
of the cohort was 12 months. OS was 12 months in AA, 9 months in
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AL, 33 months in hereditary types, 22 months in B2 M, and 16 months
in wild-type ATTR. Various chemotherapy regimes were used in AL,
most frequently oral melphalan and prednisolone; OS was signifi-
cantly better among treated patients than those who did not receive
chemotherapy (19 vs 7 months, Po0.0001). The prognosis of AA and
AL amyloidosis is poor in the elderly, but many patients with AL
were able to tolerate chemotherapy and achieve a clonal disease
response that may have improved their outcome. These observations
support trialling newer, more rapidly acting chemotherapy regimes
in the elderly population.
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Implementing an external quality assessment
programme for users of CoaguChek XS and
CoaguChek XS Plus for monitoring INRs
DP Kitchen, S Kitchen, I Jennings, TAL Woods and ID Walker
UK NEQAS Blood Coagulation, Sheffield, UK
Using lyophilised plasma, UK NEQAS Blood Coagulation has
provided External Quality Assessment (EQA) programmes for INR
both in the laboratory and for Point of Care (POC) devices for many
years. Currently the POC INR programme has 930 participants using
CoaguChek or CoaguChek S (the most commonly used POC INR
devices in the UK).
Two new devices – the CoaguChek XS (CUC XS), for patient use,
and the CoaguChek XS Plus (CUC XS Plus), for healthcare
professional use, were launched in 2006. In clinical practice both
measure INR in whole blood samples. Introduction of these devices
has demanded formulation of new material for EQA. In a pilot
exercise, two lyophilised plasma samples (samples 1 and 2) plus
reconstitution and recalcification fluids were distributed to 23
centres routinely using CUC XS or CUC XS Plus. Results showed
good precision; sample 1 – CUC XS median INR5 3.0, CV 8%, CUC
XS Plus median INR5 3.2, CV 6%; sample 2 – CUC XS median
INR5 3.45, CV 4%, CUC XS Plus median INR5 3.4, CV 6%. In this
first exercise, 30% of tests resulted in an error code (no result). In a
second exercise, 2 lyophilised plasmas (samples 3 and 4) prepared
using a modified method were distributed. Precision was again good;
sample 3 – CUC XS median INR5 1.5, CV 4%, CUC XS Plus median
INR5 1.6, CV 18%, sample 4 – CUC XS median INR5 3.05, CV 3%,
CUC XS Plus median INR5 3.0, CV 6%. The error rate (8%) for
samples 3 and 4 was improved. The small differences between
median INRs with CUC XS and XS Plus were not significant. In
conclusion, EQA for CoaguChek XS and CoaguChek XS Plus is
possible. UKNEQAS BC will formally launch an EQA programme for
these devices during 2007.
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Assessment of risk and prophylaxis for deep venous
thrombosis and pulmonary embolism in medicine
wards and ICU in a developing country
N Patni, A Pandey and R Guleria
Department of Medicine, All India Institute of Medical
Sciences, New Delhi, India
Deep vein thrombosis (DVT) and pulmonary thromboembolism
(PE) are important causes of morbidity and mortality in hospitalized
patients. This study was done to assess risk factors and prophylaxis
given for DVT and PE in medically ill patients using risk
stratification score card.
An observational study on 117 patients over 9 months was done in
medicine ICU and wards. Structured proforma was designed using a
standard protocol and effective risk stratification for DVT was done
in low, moderate, high and highest categories. Patient was followed
up for a week to record any changes in the risk categories and
document any signs of PE or DVT if present.
Sixty-eight patients (58.1%) belonged to the wards and 49 (41.9%)
to the ICU. Patients with respiratory illness contributed 37.6% of
sample size. Ninty seven (82.9%) patients had high to highest risk for
DVT and PE, out of which only 11 (9.4%) got DVT prophylaxis and
D-dimer and Doppler were done only in 6 (5.13%) patients. On follow
up over 7 days, 36 (30.8%) patients got discharged and 19 (16.2%)
patients died. Of the remaining 62 patients, 48 (77.4%) belonged to
high to highest risk category. Clinical signs and symptoms of DVT
were present in 19 (30.6%) while that of PE was seen in 6 (11.1%).
Seventy-one per cent of medical ward patients and 100% of ICU
patients observed during the course of study had high to highest risk
for DVT and PE, but only 16.33% in ICU and 4.41% in wards got
prophylaxis. Investigations for confirming DVT and PE were done
only in 5.13% patients. Thus significant risk for DVT and PE exists in
medical patients admitted to wards and ICU but only a small
proportion of the patients are given prophylaxis or investigated. This
study underlines the need to aggressively implement DVT risk
stratification strategy in medical patients and provide prophylaxis
unless contraindicated.
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Observational study of clinically suspected heparin
induced thrombocytopenia (HIT) at the Royal Cornwall
Hospital – the value of pre test probability score and
nature of our patient population
Y Thi and J Blundell
Royal Cornwall Hospital, Truro, UK
Heparin-induced thrombocytopenia (HIT) is an immune-mediated
prothombotic condition caused by the anticoagulant heparin. It is
considered to be a clinicopathological syndrome as the diagnosis is
based on clinical and laboratory findings.
A scoring system known as the 4 Ts (Thrombocytopenia, Timing
of platelet count fall, Thrombosis, other causes of Thrombocytope-
nia) has been devised to estimate the likelihood of HIT.
We retrospectively reviewed 27 cases of clinically suspected HIT.
We looked at the clinical history and assigned a pre test probability
score to each case. The HIT antibody test results were noted.
Sixty-seven per cent of cases were medical patients and only 15%
were surgical patients. This is interesting as published data suggests
that the incidence of HIT is higher in surgical patients.
Forty-eight per cent (13/27) of patients with suspected HIT were
given heparin for thromboprophylaxis whilst 41% (11/27) of patients
were given higher doses of heparin for treatment of venous
thromboembolisms and acute coronary syndrome.
Seven out of twenty-seven suspected HIT patients had confirmed
HIT.
Sixty-seven per cent of those patients were treated with
unfractionated heparin.
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PreTest Probability (PTP) scoring) was found to be strongly
correlated with positive HIT antibody test (ELISA) for clinically
significant HIT.
One hundred per cent of patients with high PTP score and 40% of
patients with intermediate PTP score with none of the patients with
low PTP score were HIT test positive.
Low PTP scoring for HIT seems to be suitable for ruling out HIT
in most clinical situations which means PTP has a high negative
predictive value.
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Inadequate clinical information during the day makes
warfarin dosing perilous by on call medical staff
during the night. Time to change the anticoagulation
prescription chart?
I Sarriegi, K Longman and J Mainwaring
Royal Bournemouth Hospital, Bournemouth, UK
With an increasing elderly population in atrial fibrillation the
numbers of patients taking warfarin continues to rise. Warfarin is
more effective than aspirin in reducing the risks of a thrombotic
stroke in these patients. Warfarin dosing can be difficult in the
elderly related to defective liver metabolism, dietary vitamin K
deficiency and polypharmacy with potentiating drugs. INR results
tend to arrive late in the day hence warfarin dosing for inpatients is
primarily undertaken by the on call medical team rather than the
patient’s normal treating team. This should not be a problem if there
is adequate information relating to the patient’s indication for
warfarin, normal maintenance dose and target INR. Frequently this
information is defective compromising care. To assess the scale of
the problem we undertook an audit of patients receiving warfarin
who were admitted as medical emergencies to this hospital on a
single day and monitored them whilst they remained inpatients. This
group comprised 27 adult patients. Twenty-one were already on
warfarin and six were started on warfarin from scratch. Reviewing
the case notes the clinical indication was available in 44%, usual
warfarin dose available in only 26% and target INR available in 52%.
Not surprisingly with this lack of clinical information there were
significant problems with warfarin prescribing by the on call teams
meaning that non-therapeutic INRs occurred in 58%. One patient in
particular became grossly overanticoagulated because the on call
team restarted warfarin as per the standard anticoagulation protocol
and did not consider the fact that the patient only took 1 mg of
warfarin daily. Thankfully there were no bleeding complications.
Following this audit we have proposed some simple alterations to the
anticoagulation prescription chart improving the available clinical
information that should help to prevent inappropriate warfarin
dosing in the future.
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What is the role for baseline coagulation screens in
acutely ill patients admitted to the medical
assessment unit?
CJ Mainwaring, J Chanaw, J Evansw, A Royw, G Sioftanos and
J Gunasekera
Poole Hospital, Poole, Dorset, UK, wNorth Hampshire
Hospital, Basingstoke, UK
We retrospectively audited the results of baseline coagulation screens
performed on 100 acutely ill patients admitted to the medical
assessment unit during a 2-week period. We wanted to determine
whether this was an appropriate use of resources and how the results
affected clinical care. Coagulation screens were performed on 53/100
patients. The group comprised 35 females and 18 males, with an age
range of 23 to 91 (mean 64). Six out of fifty-three samples were
underfilled or haemolysed and although requests were made directly
to the medical team for further samples none were received.
Indications for the screen were diverse and the commonest was
confusion. Only 9/53 were clinically appropriate based on well
established criteria such as patients with acute bleeding. The
abnormal pickup rate in this group was 5/9 (55%) and all these
results were clinically significant directly affecting patient care. Of
the 44 inappropriate requests the abnormal pickup rate was only 7/44
and clinically significant results only amounted to 2/44 (2.2%). We
were able to highlight a problem with the medical assessment unit
nursing staff performing a range of screening blood tests on the
majority of patients before being seen by the on call medical team.
Apart from the cost a major problem with performing indiscriminant
coagulation screens was the time factor on our haematology
biomedical scientists who are already overstretched with all the
other demands of the on call service. Our audit highlighted the need
for education and the use of protocols to guide investigation. We felt
that with such protocols we could reduce coagulation screen requests
by over 80% on the medical assessment unit and when one considers
that a coagulation screen costs £6.50 this could amount to significant
savings for the trust especially if this change of practice could be
extrapolated to other departments.
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Problems with relying on the PFA100 as a screening
test for platelet function disorders
CJ Mainwaring, S Limw, J Gunasekera, U Perepuw,
G Sioftanos, H Narayanw, R Scottw, J Chackow, J Davies
and G Davies
Poole Hospital, Poole, Dorset, UK, wRoyal Bournemouth
Hospital, Bournemouth, UK
The PFA100 analyser is a useful tool in the initial assessment of
patients with possible von willebrand’s disease or a platelet function
disorder. Invariably these patients are referred to the haematology
department because of a history of abnormal bruising, mucosal
bleeding and immediate bleeding after surgical procedures. They
may also be referred because of family screening. When considering
a possible bleeding diathesis it is paramount to take a detailed
bleeding history beforehand in order to guide investigations. The
PFA100 is thought to have a sensitivity of greater than 95%. Generally
patients with platelet function disorders will have a prolonged
collagen-epinephrine plus collagen-ADP closure times. An isolated
prolonged collagen-epinephrine closure time is normally associated
with the effects of anti-platelet drugs like aspirin. During the past
nine months we have been investigated four patients who had
abnormal mucosal bleeding and an isolated prolonged collagen-
epinephrine time. All avoided aspirin plus non-steroidal anti-
inflammatory drugs. The group comprised two females and two
males. Platelet aggregation tests fitted with a probable platelet release
defect in two and a platelet storage pool disorder in the other two.
During the same time period we have also seen six other patients,
five females and one male, with entirely normal PFA100 results but
probable platelet release defects based on aggregation studies. The
explanation in two probably related to having supranormal levels of
von willebrand’s factor. These cases illustrate the fact that in patients
with a convincing history of mucosal bleeding formal platelet
aggregation studies are appropriate even if the PFA100 results are
normal and an isolated prolonged collagen-epinephrine closure time
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does not necessarily just mean the effects of anti-platelet drugs. With
such variable PFA100 results in patients with mucosal bleeding and
normal von willebrand factor results should we stop doing the
PFA100 and just go straight to aggregation studies?
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An audit of the molecular service for the identification
of mutations in type 2 VWD
C Cooper and D Perry
Addenbrooke’s NHS Trust, Cambridge, UK
In 2003 molecular testing for the detection of mutations in type 2
VWD was set up in our molecular haemostasis laboratory. To date,
38 patients have been investigated. Based on the phenotypic results
and/or the clinical details provided, 29 (76%) had qualitative defects
(13 ?type 2N and 16 type 2A/B/M) and nine (24%) had quantitative
deficiency. The patients with ?2N and quantitative VWD will not be
discussed in this abstract.
In the remaining 16 patients, 15 (94%) had discrepant VWF:Ag
and VWF:Act (VWF:RCo and/or VWF:CB) results with ratios o0.7;
the remaining patient had levels allo5%, so discrepancies were hard
to distinguish. In 10/16 (62.5%) patients VWD mutations were found;
a further patient was later found to have platelet-type pseudo VWD
(p.Gly249Val). Of the ten qualitative mutations found, two were type
2 M (p.Arg1315Cys and p.Arg1426Cys), two were VWD Vincenza
(pArg1205His), three were type two unclassified (p.Arg1374Cys), two
were type 2B (p.Arg1306Trp and p.Val1316Met) and one was type 2A
(p.Ile1628Thr). Seven out of ten had VWF levels measured more than
once before referral; two of the remaining three were related to a
patient tested more than once and in whom a mutation had been
identified. In the five patients where no mutation was identified, all
had only one discrepant VWF activity assay (RCo/Ag5 3 and CB/
Ag5 2) and 3/5 only had their VWF levels measured once suggesting
the discrepant result could be an outlier.
Overall, mutations were found in approximately 70% of cases,
when the platelet-type pseudo VWD case is included. In patients who
had VWF levels tested more than once, a mutation was identified in
80% highlighting the importance of performing phenotypic assays
more than once to confirm the disease and potential subtype before
referral. In conclusion, we believe this audit has shown that the
method developed in our laboratory for detection of mutations in
type 2 VWD is appropriate for investigation of patients with these
qualitative defects.
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Acquired haemophillia in a district general hospital –
18-year lookback
JA Blundell, O Footw and C Robertsw
Department of Haematology, Truro, UK, wPennisula Medical
School, Truro, UK
Current literature on acquired haemophilia A mainly consists of
patients referred to tertiary referral centres. This may result in a
reporting-bias, not accurately reflecting the true features of this
disease. This report looks at a consecutive, unselected cohort of
patients presenting with acquired haemophilia to the Royal Cornwall
Hospital between 1988 and 2006. A total of nine patients were
reported, giving an incidence of 1.43/million/year. Compared to
previously reported cohorts, patients were older (median age 77
years), and more likely to have an underlying diagnosis (67%). The
bleeding phenotype was less severe than in much of the current
literature with 33% of patients not requiring haemostatic treatment
and not a single case of a fatal bleed. Response to immunosuppression
was lower than in some recent reports, with 63% of treated patients
recovering a normal FVIII level and an undetectable inhibitor. Out of
the patients studied 56% died, though in no case was death attributed
to the presence of an inhibitor. There was significant morbidity
associated with immunosuppressive treatment however. This suggests
much of the current literature based on data from referral centre
patients may not be applicable to patients with acquired haemophilia
A presenting to other centres who are likely to be older, have milder
bleeding and be less able to tolerate immunosuppression.
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Source and use of reference ranges in haemostasis:
practice amongst UK NEQAS for Blood Coagulation
participants 2005–6
I Jennings, DP Kitchen, TAL Woods, S Kitchen and ID Walker
UK NEQAS (Blood Coagulation), Sheffield, UK
Some guidelines on interpretation of haemostasis tests and assays
recommend use of locally determined reference ranges to optimise
detection of haemophilic and thrombophilic defects. However, access
to adequate numbers of appropriate donors to allow construction of
local reference ranges is problematic. In two separate questionnaires,
UK NEQAS for Blood Coagulation participants were asked for the
source of their reference ranges for thrombophilia testing (May 2005)
and routine screening tests and factor assays (March 2006). The
findings are summarised below.
For the prothrombin time and APTT, 70% of centres employ a
locally determined reference range. However, only 57/202 construct-
ing local reference ranges include 40 or more individuals in the
reference population. Laboratory staff form the largest group of
donors (85/210). The second largest group (n5 36) is identified as
‘normal patients’. Only 37% of laboratories performing Clauss
fibrinogen assays construct a local reference range, with 37% using
the range suggested in the manufacturers’ literature. For factor
assays the percentage of laboratories determining local reference
ranges falls to an average of 22%. The remainder use either
manufacturers data (42%) or peer-reviewed literature (34%). For
some assays participants using manufacturers data or peer-reviewed
literature quoted clearly inappropriate reference ranges, for example
152 centres reported a lower limit for factor XI:C of 50 U/dl, despite
bleeding episodes reported in subjects with heterozygous deficiency
and levels above this value.
For thrombophilia testing, it is only for PS antigen measurement
that the majority of centres construct a locally determined reference
range; for free PS antigen 23/57 of these centres employ a gender-
specific range. For some assays, centres employing kits from the
same source and quoting the manufacturer as a source of reference
range reported different ranges.
Difficulty in establishing appropriate reference ranges to ensure
accurate diagnosis of haemostatic defects is a challenge to
laboratories; These data confirm the variable practice employed.
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Soluble CD40 ligand and atrial fibrillation: relation-
ship with platelet activation and endothelial damage/
dysfunction
A Blann, A Choudhury, B Freestone, J Patel and G Lip
Department of Medicine, City Hospital, Birmingham, UK
Increased levels of soluble CD40L (sCD40L) in the plasma are
present in many cardiovascular diseases and predict a poor outcome
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in long-term follow-up studies. Levels in atrial fibrillation (AF), a
leading cause of thrombotic stroke, are unknown. The precise source
of this molecule in unclear and although the platelet is frequently
cited as the source of sCD40L, this is not universally recognised. We
hypothesised (a) raised levels of sCD40L in non-rheumatic AF, and
(b) that levels sCD40L correlates with platelet, but not endothelial,
markers, thus suggesting a platelet origin.
sCD40L, platelet marker soluble P selectin and endothelial
markers von Willebrand factor and soluble E selectin were measured
by ELISA in the plasma of 54 AF patients free of diabetes or major
cardiovascular disease, and in 28 age- and sex-matched controls in
sinus.
Median (inter-quartile range) sCD40L in AF was 0.82 (0–4.8) ng/
mL compared to 0.21 (0–5.5 ng/ml) in controls (P5 0.0397). Both von
Willebrand factor and soluble P selectin were also raised (Po0.005)
in AF, but none of the three indices inter-correlated significantly.
Soluble E selectin was not significantly elevated in AF.
sCD40L is marginally raised in AF but the stimulus for this is
unclear. The lack of clear correlation with relevant plasma markers
suggests that the source is unlikely to be the endothelium or platelet
alone.
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Anticardiolipins and pregnancy outcome: a
retrospective audit
JS Laird, E Fergusonw, ID Walker and RC Tait
Department of Haematology, Glasgow Royal Infirmary,
Glasgow, UK, wDepartment of Obstetrics and Gynaecology,
Glasgow Royal Infirmary, Glasgow, UK
Elevated anticardiolipin (ACA) levels are associated with increased
risk of adverse pregnancy outcome. In a retrospective audit we
investigated whether the class and/or titre of ACA (IgG or IgM)
affected pregnancy outcome and examined the effect of treatment
with low-dose aspirin and/or Low Molecular Weight Heparin
(LMWH) on outcome.
From April 2004 to March 2006, 175 pregnancies in 73
women with IgG49 GPL, or IgM ACA411 MPL and no other
thrombophilia were included in this study. Sixty-nine (39%) and 106
(61%) of the pregnancies respectively, occurred in women with
elevated IgG or IgM ACA. Seventy pregnancies were treated with
aspirin and/or LMWH. Main outcome measures were preterm
delivery (PTD), growth restriction (IUGR), recurrent (43 consecu-
tive) first trimester (T1) miscarriages and 2nd (T2) or 3rd (T3)
trimester intrauterine death. Outcomes were compared using chi-
square test.
For both classes of ACA, there were significantly more adverse
outcomes in the untreated groups (Po0.05).There was no significant
difference in total adverse outcomes in the untreated IgG vs IgM
groups, except recurrent 1st trimester miscarriage where elevated IgG
was more significant (P5 0.05). Four patients, nine pregnancies, had
ACA level 440GPL or MPL – 6 untreated miscarried, two were
delivered prematurely after treatment, and one normal delivery was
complicated by maternal thromboembolism.
Pregnancy outcome is significantly worse in untreated ACA-
positive women, even if the levels are lower than the diagnostic
criteria for antiphospholipid syndrome (440 GPL/MPL). Considera-
tion should be given to treating all pregnant women with weakly
positive ACA.
Patient
group
Normal
outcome
Total
adverse
IUGR PTD T1 T2 T3
IgG
treated
12 (48%) 13 (52%) 1 (4%) 3 (12%) 9 (36%) 0 0
IgG
not
treated
10 (23%) 34 (77%) 0 0 29 (66%) 2 (5%) 3 (7%)
IgM
treated
26 (58%) 19 (42%) 7 (16%) 4 (9%) 8 (18%) 0 0
IgM
not
treated
20 (33%) 41 (67%) 4 (7%) 4 (7%) 29 (48%) 3 (5%) 1
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Incorporation of human microvascular endothelial
cells into the whole blood thrombin generation assay
KA Tappenden,w, G Evansw, MJ Gallimorew,z, IJ Mackiey,
HP Wendelz, M Winterw and DW Jones,w
Department of Biosciences, University of Kent, Canterbury,
UK, wHaemophilia Centre, Kent and Canterbury Hospital,
Canterbury, UK, zThe Institite of Surgical Research, Rikshos-
pitalet, Oslo, Norway, yDepartment of Haematology, Univer-
sity College London, London, UK, zDepartment of Thoracic,
Heart and Vascular Surgery, University of Tuebingen,
Germany
There is considerable interest in assays that reflect TG in as near to
physiological conditions as possible. We have developed a whole
blood (WB) thrombin generation (TG) assay that has been adapted
to include human microvascular endothelial cells (HMVEC) in an
attempt to mimic the haemostatic role of the healthy vascular
endothelium. The cellular TG assay was performed on eight healthy
control WB samples in the absence and presence of HMVEC. Whilst
there was no significant difference between peak height (PH) values
in the absence or presence of HMVEC (range 140–328 and 135–
338 nM, respectively), the endogenous thrombin potential (ETP)
values in the absence or presence of HMVEC (range 1586–3541 and
946–3675 nM min, respectively) were significantly lower in the
presence of HMVEC (P5 0.02). Protein C was included in the
cellular TG assay (n5 3) to give final concentrations of zero, 3, 6 and
9mg/ml of WB in the presence and absence of HMVEC. In the absence
of HMVEC the pH remained constant between 0 and 6 ug/ml protein
C (mean5 223 nM, SD7 14.6). At 9mg/ml the PH increased to 258 nM
(SD7 21.2). The ETP values were not affected by increasing protein C
concentrations (mean5 2478 nM min, SD7 174.5). In the presence of
HMVEC there was a reduction in PH and ETP values from 208 to
137 nM and from 2245 to 1452 nM min respectively between 0 and 6mg/
ml protein C. With 9mg/ml protein C, the pH and ETP values then
increased to 162 nM and 1780 nM min respectively. These results show
that the HMVEC influence the TG assay and that incorporation into
the WB assay model may well reflect in vivo changes to a greater
extent than currently available TG assays.
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Whole blood thrombin and thromboelastography
‘thrombus’ generation assays: a comparative study in
healthy control subjects and patients with a history of
venous thromboembolism
KA Tappenden,w, G Evansw, MJ Gallimorew,z, IJ Mackiey,
M Winterw and DW Jones,w
Department of Biosciences, University of Kent, Canterbury,
UK, wHaemophilia Centre, Kent and Canterbury Hospital,
Canterbury, UK, zThe Institite of Surgical Research, Rikshos-
pitalet, Oslo, Norway, yDepartment of Haematology, Univer-
sity College London, London, UK
There is considerable interest in the evaluation of thrombin
generation (TG) as a risk factor for thrombosis. Thrombin
generation assays have historically been performed on platelet poor
and platelet rich plasmas. We have recently developed a TG assay for
whole blood (WB). An alternative approach is the use of WB in
thromboelastography (TEG Haemoscope Corp., USA). A develop-
ment within the manufacturer’s software has enabled the generated
TEG traces to be manipulated to produce ‘thrombus’ generation
curves. A comparison has been made between the two WB models by
testing WB samples from 30 healthy control subjects (HCS) and 49
patients with a history of venous thrombosis (VTE). Reference
ranges (5th to 95th percentile) for the TG assay (peak height [PH] 160
to 304 nM and endogenous thrombin potential [ETP] 1405 to
2323 nMmin) and the ‘thrombus’ generation assay (maximum rate
of ‘thrombus’ generation [MTG] 7.0–10.9 mm 100/second and total
‘thrombus’ generation [TTG] 2505 to 3146 mm 100) were estab-
lished using the WB samples from the 30 HCS. Whilst the PH and
ETP values of the VTE group were significantly higher than the
healthy control group values (P5 0.003, P5 0.003 respectively),
there was no significant difference for the MTG or TTG values
between the groups. Raised PH and/or ETP values were seen in 25
patients and raised MTG and/or TTG were seen in 17 patients. Of the
17 patients with raised MTG and/or TTG, 14 had raised PH and/or
ETP. A significant correlation was observed in the VTE group
between PH and MTG (Po0.001, RS5 0.46) and TTG (Po0.001,
RS5 0.49) as well as between ETP and MTG (Po0.001, RS5 0.48)
and TTG (Po0.0001, RS5 0.54). Both assays detected increased TG
in some patients with a previous history of thrombosis.
44
ABSTRACT WITHDRAWN
Poster Presentations: Lymphoid Malignancy
45
Abnormal AP-1 transcription factor protein expression
in cutaneous large-cell lymphomas
X Mao and G Orchardw
Skin Tumour Unit, St John’s Institute of Dermatology, St
Thomas’ Hospital, London, UK, wDermatopathology Labora-
tory, St John’s Institute of Dermatology, St Thomas’ Hospital,
London, UK
Cutaneous large-cell lymphomas (CLCL) represent a heterogeneous
subgroup of skin lymphomas including primary cutaneous CD301
anaplastic large cell lymphoma (C-ALCL), lymphomatoid papulosis
(LyP), transformed mycosis fungoides (T-MF) and Hodgkin’s
lymphoma (HL) with cutaneous involvement. Despite recent
progress in clinical management of CLCL, the aetiology and
underlying molecular pathogenesis remain elusive. The activator
protein 1 (AP-1) transcription factor consists of JUN (c-JUN, JUNB
and JUND), FOS (c-Fos, FosB, Fra-1 and Fra-2) and other protein
families with diverse biological functions. Recent studies from our
group and others have revealed up-regulation of JUNB in both MF
and C-ALCL and overexpression of JUNB and CD30 in systematic HL
and ALCL. To systematically assess the expression pattern of AP-1
transcription factors in CLCL, we analysed paraffin tissue sections
from 27 cases of LyP, 10 C-ALCL, 8 transformed MF and 2 cutaneous
HL by using immunohistochemistry (IHC) with antibodies against c-
JUN, JUNB, JUND, c-FOS and RAF1. We also stained additonal 7
cases of Sezary syndrome (SS), 10 C-ALCL, 6 T-MF, 3 cutaneous HL,
2 LyP and control samples with total and phosphorated MAPK
antibodies. A definitive positivity (1 1 ) for JUND was seen in 13
LyP (48%), 10 C-ALCL, 6 T-MF (75%) and 2 cutaneous HL cases, and
for JUNB in 4 T-MF (50%), 4 C-ALCL (44%), 3 LyP (11%) and 2
cutaneous HL. While c-JUN, c-FOS, and RAF-1 were rarely
expressed in these CLCL cases. In addition, total (P44/42) Mapkinase
and phosphorylated P44/42 Mapkinase were expressed in 9
C-ALCL (90%), 7 SS (88%), 5 T-MF (89%) and 3 cutaneous HL,
the majority of which were also positive for JUNB. These results
suggest that there is a dysregulation of AP-1 expression in CLCL
mainly due to aberrant JUNB protein expression, which is up-
regulated by MAPK protein, and increased JUND expression may
also be relevant to CLCL.
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Expression of FHIT protein in hodgkin and reed-
sternberg cells from chinese hodgkin lymphoma
P Zhao, YL Lu, M Zhong, LH Chen, XL Pu and X Maow
Department of Pathology, General Hospital of Chinese
People’s Liberation Army, Beijing, China, wSkin Tumour Unit,
St John’s Institute of Dermatology, St Thomas’ Hospital, King’s
College London, UK
Loss of the fragile histidine triad gene (FHIT) has recently been
described in some human malignancies. However, little is known
about the role of FHIT in the pathogenesis of Hodgkin lymphoma
(HL) and the origin of HL tumour cells remains elusive. To address
these issues, we investigated 33 Chinese HL cases by using B- and
T-cell clonality assays and immunohistochemistry (IHC) with
antibodies against FHIT, CD133/1(AC133); CD34, CD20, CD3 and
c-erbB-2. IHC revealed positive staining for FHIT in 30 cases (91%).
FHIT protein expression was mainly located in cytoplasm, nucleus
and membrane of Hodgkin and Reed-Sternberg cells, and associated
atypically spindle cells. In addition, monocytes, histiocytes and
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dendritic histiocytic cells were also positive for FHIT. However,
normal and reactive B and T lymphcytes and their tumour
counterparts were negative for FHIT protein. T- and B-cell clonality
analysis showed that 12 HL cases had TCR-r and TCR-b clones (36%),
of which one case also showed IgH clone in tumour cells. All of the
HL cases analysed were negative for haematopoietic cancer cell
marker CD133/1(AC133), haematopoietic stem cell marker CD34, T-cell
marker CD3 and oncoprotein c-erbB-2. Only 2 cases were positive for
B-cell marker CD20. These results suggest aberrant FHIT protein
expression may be a common feature of HL although the nature of
expressed FHIT protein remain unkown, and HL tumour cells may
originate from histiocytic lineage or its progenitor cells rather
than lymphocyte, haematopoietic stem cells and haematopoietic
cancer cells.
47
Quantitative and qualitative assessment of
constitutive nuclear factor kappa B(NF-kappa B)
expression in CLL cells and its relationship with
in vitro spontaneous apoptosis
S Hewamana, M Clementw, T Lin, C Rowntree, C Fegan,
P Brennanw and C Pepper
Department of Haematology, School of Medicine, Cardiff
University, Cardiff, UK, wDepartment of Medical Biochemistry
and Immunology, School of Medicine, Cardiff University,
Cardiff, UK
NF-kappaB is part of a multi-component signaling pathway that
regulates the expression of hundreds of genes involved in the control
of cell proliferation, cell survival, stress responses, innate immunity
and inflammation. The principal constituents of mammalian NF-
kappaB are p65, p50, p52, c-Rel and Rel-B and in their inactive state
they are bound in the cytoplasm to the inhibitor protein IKB.
Phosphorylation of IKB by IKB kinase leads to the translocation of
NF-kappaB into the nucleus where it can bind to kappaB responsive
elements.
It has been reported that NF-kappaB is constitutively activated in
chronic lymphocytic leukaemia (CLL) cells. However, no
previous studies have prospectively quantified the sub units of NF-
kappaB in CLL cells or examined their relative expression between
patient samples. Therefore, the aim of our study was to quantify the
expression of NF-kappaB in freshly isolated CLL cells and
examine their relationship with in vitro viability. NF-kappaB was
evaluated using EMSA, supershift assays and subunit-specific
ELISA (n5 50). Apoptosis was measured at 24h and 48h using
annexin V/propidium iodide labeling. We demonstrated p50, p65
and C-rel were the predominant NF-kappaB subunits in all
the CLL samples studied. Importantly, we showed a negative
correlation between in vitro apoptosis and nuclear p65 NF-kappaB
expression (r250.34) and a positive correlation (r25 0.65)
with absolute lymphocyte count (ALC). This suggests that high
levels of p65 NF-kappaB are cytoprotective. Furthermore, the
positive correlation with ALC points to a role for p65 in disease
progression.
This study is now being extended to a larger number of patient
samples in order to establish whether p65 expression can be used to
accurately stratify patients according to risk of disease progression
and to investigate the correlation of NF-kappaB level with other
prognostic markers including CD38, ZAP-70, VH mutational status
and clinical staging.
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Development of monoclonal serum paraprotein
following heart or lung transplantation, with a case
report of post-transplant multiple myeloma: a 7-year
study from a UK tertiary centre
R Pitceathly, C Shiach, AM Kellyw and N Yonanz
Department of Haematology, Wythenshawe Hospital, Man-
chester, UK, wDepartment of Biochemistry, Wythenshawe
Hospital, Manchester, UK, zDepartment of Cardiothoracic and
Transplant surgery, Wythenshawe Hospital, Manchester, UK
There is little data published concerning the development of serum
monoclonal paraprotein following heart and lung transplantation. Its
role as a risk factor for the development of subsequent post-
transplant lymphoproliferative disorder is poorly understood.
We reviewed patients receiving heart, single lung and double lung
transplants at a single tertiary centre, and analysed those developing
significant monoclonal paraproteins.
Two hundred and thirty-six patients received organ transplants.
Three developed a significant monoclonal paraprotein. One was
diagnosed with multiple myeloma using criteria applicable to the
non-transplant setting. This case is reported in detail.
There was discrepancy between the rate of monoclonal para-
protein production found in heart and lung transplant patients in
our centre compared with previous reports from patients receiving
lower intensity immunosuppressive therapy following renal trans-
plantation. This challenges the significance of monoclonal para-
protein after organ transplantation as a risk for subsequent
development of post-transplant lymphoproliferative disorder. The
case reported is only the third case of Ebstein–Barr negative post-
transplant multiple myeloma, and it is therefore difficult to draw
significant conclusion from this result. We would encourage further
collection of cases to establish whether intensity of immunosuppres-
sion following solid-organ transplantation is a risk for development
of the disease, and to develop treatment strategies.
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ZAP 70 expression in acute lymphoblastic leukaemia
could have clinical prognostical significance
G Chakupurakal, A Bellw, M Griffithsz, G Begumw, F Wandrooy
and P Mossw
Department of Haematology, Queen Elizabeth Hospital,
Birmingham, UK, wInstitute of Cancer Studies, Birmingham,
UK, zWest Midlands Regional Cytogenetics Laboratory,
Birmingham, UK, ySandwell and West Birmingham
Hospitals, UK
Changes in mRNA expression of three fold may be required for
differential detection by microarray analysis and this technology may
limit the potential information to be derived from the study of ZAP-
70 expression levels. We examined the expression of ZAP-70 in 76
adult patients with ALL (64 B lineage and 12 T lineage) using real-
time quantitative PCR analysis.
RNA was extracted from diagnostic bone marrow specimens
taken from 76 patients aged over 18 years presenting with pre-B ALL.
A wide range of ZAP-70 expression was seen from a ratio of 0.002 to
5.3 with an average of 0.332 and median of 0.185. Expression of ZAP-
70 showed a relatively continuous pattern of expression across the
cohort apart from six samples (8%) with a level of ZAP-70 expression
above that of the Jurkat T-cell line.
Statistical analysis between ZAP-70 expression and cytogenetic
subgroup was performed using either a two-sample test or ANOVA
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and correlation analysis was evaluated using the Pearson coefficient.
No statistically significant association between ZAP-70 expression
and any cytogenetic subgroup were found. All four cases of t(1,19)
with E2A/PBX1 gene fusion in our cohort had ZAP-70 levels above
the median. Observations of interest were (a) high expression in T-
ALL subgroup of patients with 11/12 ratios above the median, and a
mean of 0.26 (b) low expression in the b3a2/b2a2 p210 BCR/ABL
subgroup with 4/5 patients having ratios below the median. Clinical
information on the top 3 patients who expressed ZAP-70, greater
than/equal to 1.3, revealed failure to achieve remission with induction
chemotherapy.
We used quantitative PCR to confirm that ZAP-70 is expressed in
the majority of cases of ALL and demonstrate wide range of
expression between cases. Further studies are required to confirm the
clinical significance of ZAP-70.
50
A phase I/II trial of sirolimus in combination with oral
cyclophosphamide (C-weekly) and dexamethasone
(SCD) in patients with relapsed myeloma
CE Rudin, JL Melhuishw and JC Hallw
Department of Haematology, Royal Devon & Exeter
Hospital, Exeter, UK, wDepartment of Research and
Development, Royal Devon and Exeter Hospital, Exeter, UK
Sirolimus (SRL, rapamycin) is a commercially available oral drug
that acts as an inhibitor of mTOR, a tyrosine kinase that functions as
a cellular integrator of environmental growth signals through its
binding to cytoplasmic FKBP12, and of NF-kappaB through binding
to FKBP51. Early results of a single agent study with temsirolimus, a
prodrug of SRL, showed a response in six out of 14 relapsed/
refractory myeloma patients. SRL has also been shown to sensitize
various myeloid and lymphoid malignancies to conventional
chemotherapy. Since the therapeutic potential of SRL may be
greatest when it is given in combination with conventional
chemotherapy, we set out to perform a dose finding study according
to the 31 3 design of C-weekly at incremental doses in successive
cohorts together with fortnightly 4-day pulses of dexamethasone
20 mg od and SRL 5 mg od, adjusted to achieve whole blood trough
levels of 8–16 ng/ml. So far eight patients have been enrolled (age 49–
77), all with Salmon-Durie stage IIIA disease, five after at least one
autograft earlier in the course of their disease. The starting C-weekly
dose was 200 mg. Two patients, both with significant cytopenias
during earlier courses of chemotherapy, one each in the cohorts
receiving 300 and 400 mg of C-weekly, had to come off study because
of grade 3 thrombocytopenia or neutropenia that took longer than 3
weeks to resolve, but there was no unmanageable haematological or
any significant non-haematological toxicity other than diarrhoea
responsive to loperamide (two patients). All seven patients evaluable
by the Blade´ criteria showed a response (six partial responses,
one minimal response). The study is continuing to enrol at C-weekly
400 mg.We conclude that in relapsed myeloma, SCD is an active
oral chemotherapy combination with manageable haematological
toxicity that warrants evaluation in a randomised controlled
phase II study.
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Stroke-like syndrome secondary to methotrexate
neurotoxicity
WC Gordon, A Sharp, R Shaww, EJ Fitzsimmonsz and
G Loudonz
Department of Haematology, South Glasgow University
Hospitals NHS Trust, Glasgow, UK, wRadiology Department,
South Glasgow University Hospitals NHS Trust, Glasgow, UK,
zDepartment of Haematology, North Glasgow University
Hospitals NHS Trust, Glasgow, UK
Neurological toxicity secondary to intravenous or intrathecal
methotrexate (MTX) is a potentially devastating complication of
therapy for haematological malignancy.
We describe three cases of methotrexate neurotoxicity in young
adult patients. Two of the patients were undergoing phase II
induction as per the current UKALLXII protocol and one as per the
GMALL protocol. Toxicity was manifested by an acute stroke-like
syndrome with characteristic onset and clinical features. The patients
developed a fluctuating neurological deficit characterised by altered
conscious level, expressive dysphasia, dysathria and unilateral
weakness. In each case onset was within ten days of administration
of intrathecal methotrexate. Characteristic multiple bilateral deep
white matter changes were observed on MRI scan in the acute stage
and on follow up. All recovered spontaneously over a period of days
to weeks. The two patients on the UKALLXII protocol were
subsequently re-exposed to intravenous MTX without re-occurrence
of symptoms.
We also describe a fourth case with relapsed ALL who suffered
fatal neurotoxicity secondary to methotrexate during re-induction
with the UKALL2003 protocol. The patient had previously received
cranio-spinal irradiation and we speculate that this led to enhanced
neurotoxicity and a fatal outcome in this case.
A high index of suspicion is required for the diagnosis of MTX-
related neurotoxicity. Recognition of its occurrence is particularly
important given that MTX is a major component of CNS directed
therapy within current therapeutic protocols for ALL. Fortunately
patients normally make a full neurological recovery and importantly
can usually be retreated with MTX without incident. Patients who
have received previous CNS radiotherapy are at higher risk of
significant and potentially irreversible CNS toxicity. Other risk
factors include previous MTX-related neurotoxicity and active CNS
leukaemia. These factors should be taken into consideration when
planning re-induction therapy.
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Impairment of peripheral blood stem cell mobilisation
in patients with mantle cell lymphoma following
primary treatment with fludarabine-based
chemotherapy
HE Eve and SAJ Rule
Department of Haematology, Derriford Hospital, Plymouth,
UK
Fludarabine-based chemotherapy is highly active in newly diagnosed
and pre-treated mantle cell lymphoma (MCL). However, concerns
remain about its potential toxicity to haematopoietic stem cells and
the subsequent difficulty in mobilising sufficient numbers for
transplantation. The National Cancer Research Network is currently
coordinating a phase III randomised study (LY05) comparing
fludarabine and cyclophosphamide (FC)7 rituximab (R) as initial
therapy for previously untreated MCL. We undertook an analysis of
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patients entered within this trial in whom mobilisation had been
attempted to assess the frequency of success.
Thirteen patients (median age 53, range 44–61) were evaluable.
Stem cell collection was attempted after a median of four cycles
(range 3–6) of chemotherapy (FC, n5 7; FCR, n5 6). Twenty-two
leucapheresis procedures were performed after a variety of
mobilisation schedules. Only three patients (23%) achieved an
adequate stem cell yield (greater/equal to 2 106/kg CD341 cells).
This was despite a considerable delay (up to 20 months) between
fludarabine exposure and mobilisation therapy in some patients. In
all three cases, successful harvest followed only one mobilisation
attempt using a combination of cyclophosphamide 1.5 g/m2 (n5 1) or
3 g/m2 (n5 2) plus GCSF 5 mcg/kg/day. Stem cell collection was
unsuccessful in the remaining 10 patients despite one mobilisation
attempt in three cases, two in five cases, and three in two cases.
Our finding is in contrast to other publications reporting higher
frequencies of successful mobilisation post-fludarabine therapy in
indolent lymphoproliferative disorders other than MCL. There is also
good evidence that stem cell mobilisation among patients with MCL
is possible following non-fludarabine-containing therapy such as
CHOP. On the basis of our data, we suggest that patients with MCL
considered candidates for autologous stem cell transplantation
should receive non-purine analogue-containing chemotherapy prior
to mobilisation. If fludarabine-based therapy is preferable, early stem
cell mobilisation after two cycles of treatment should be considered.
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Angiogenesis factors pattern is different in acute
lymphoblastic leukaemia and chronic lymphocytic
leukaemia
S Aref, O Salama, S Shamaa, M El-Refie and H Mourkos
Department of Haematology, Mansoura Faculty of Medicine
Angiogenesis is a crucial event in the survival and progression of
solid tumors. The angiogenic status and the exact role of the
angiogenic cytokines in lymphoid leukemia is not fully clear.
In this context, we have investigated the profile of the systemic
components of angiogenic regulation in B-lineage acute lympho-
blastic leukemia (B-ALL) and B-chronic lymphocytic leukemia (B-
CLL) serum levels of vascular endothelial growth factor (VEGF),
tumor necrosis factor-alpha (TNF-alpha), endostatin and matrix
metalloproteinase-9 (MMP-9) by enzyme–linked immunosorbant
assay (ELISA).
In B-ALL patients, sVEGF, and MMP-9 were significantly lower
than control level at diagnosis (Po0.001, P5 0.004) and increased
near to the control levels in remission (P40.05). Both serum TNF-
alpha and endostatin levels showed no significant difference both at
diagnosis (P40.05) and in remission (P40.05) comparing to control
levels. sVEGF, sTNF-alpha, s-MMP-9 and endostatin level were not
significantly correlated to peripheral white cell count or bone
marrow blast cells count, however, positively correlated to platelets
count.
In B-CLL patients, serum VEGF, sMMP-9 and sTNF-alpha were
significantly higher (Po00.1, P5 0.009, 0.007, respectively) and
decreased near control levels in remission (P40.05 for all). Serum
endostatin levels showed no significant difference at diagnosis and in
remission compared to control levels (P40.05). Significant positive
correlation between sVEGF, sTNF-alpha, sMMP-9 and peripheral
white cell counts and bone marrow lymphocytic count, and platelets
count were detected.
In conclusion our data suggest that the driving forces of
angiogenic factors (VEGF, TNF-alpha, MMP-9) in a adult B-ALL
appears different from that in B-CLL patients. Further investigation
on the biology of angiogenesis in ALL is required.
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Neoplastic plasma cells are demonstrable at bone
marrow sites distant to solitary plasmacytoma of
bone and predict for progression to multiple myeloma
QA Hill, AC Rawstronw, JA Childw, RM de Tutew and RG Owenw
Department of Haematology, Leeds General Infirmary,
Leeds, UK, wHMDS, Leeds Teaching Hospitals, Leeds, UK
Approximately 50% of patient’s with solitary plasmacytoma of bone
(SPB) progress to myeloma. Identification of high-risk patients at the
time of diagnosis would enable risk stratification and more careful
monitoring of patients. Although adjunctive chemotherapy has not
definitively been shown to benefit unselected patients with SPB,
future therapeutic advances might be targeted on patients with a high
risk of progression. We and others have previously demonstrated
that neoplastic bone marrow plasma cells are distinguishable from
their normal counterparts by virtue of their lack of CD19 expression
and/or their aberrant expression of CD56. We developed a multi-
parameter flow cytometry assay, which predicts outcome following
autologous transplantation in myeloma patients and risk of
progression in patients with MGUS. We applied this assay to staging
bone marrow specimens from patients with biopsy proven SPB for
the presence of occult disease at sites distant to the primary lesion.
Fifty-two patients were included (31 male, 21 female, median age 65-
year) and in each case the staging bone marrow was not indicative of
myeloma (o10% plasma cells). Plasma cells comprised a median of
0.6% (0.05–6.2%) of bone marrow leucocytes while distinct
populations with a neoplastic immunophenotype (430% CD19
and/or CD561 as per convention) were demonstrable 35/52 (67%).
Neoplastic plasma cells when present comprised a median of 70%
(35–100%) of bone marrow plasma cells. Twenty-one patients (40%)
developed myeloma with a median time to progression of 476 days
(range 18–1632). Progression occurred in 18 of the 35 (51%) patients
with neoplastic plasma cells in their staging marrows and in 3/17
(18%) patients with a normal phenotypic profile. The difference was
significant using Chi-square analysis with Yates’ correction for
continuity (P5 0.04). We would conclude that neoplastic plasma
cells are frequently found at bone marrow sites distant to SPB and
that their presence predicts for progression to multiple myeloma.
Trials of adjuvant systemic therapy are warranted in this group.
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Cytogenetic classification of T lineage acute
lymphoblastic leukaemia
CJ Harrison, K Barber, Z Broadfield, A Stewart, S Wright,
M Martineau, JC Strefford and AV Moorman
Leukaemia Research Cytogenetics Group, Cancer Sciences
Division, University of Southampton, Southampton, UK
Increasing numbers of genetic changes are being described in T
lineage acute lymphoblastic leukaemia (T ALL), which may be used
to classify patients into subgroups and define multi-step oncogenic
pathways. We have integrated the significant abnormalities into a
comprehensive genetic classification of T ALL, using appropriate
probes for fluorescence in situ hybridization (FISH). This approach
revealed new recurrent translocation partners, as well as determining
the incidence and simultaneous occurrence of the different
abnormalities. The series included 295 patients, children 0–14 years
(n5 206) and adults of 15 years and above (n5 89), with a diagnosis
of T ALL, entered to one of the UK MRC/NCRI ALL treatment trials.
The incidences of the common cryptic abnormalities, SIL-TAL1
fusion and TLX3 were more prevalent in children (20% and 17%,
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respectively) compared to adults (9% each). There was no difference
in event free survival between the childhood patients with SIL-TAL1
fusion and TLX3 rearrangements. CALM-AF10 fusion and MLL
rearrangements accounted for 4% each. A single patient was found
with a BCR-ABL fusion, but the same probe identified nine (3%) with
NUP214-ABL1 amplification. Deletions involving CDKN2A were
present in 49% of patients, in association with all abnormalities.
Concurrent rearrangements were found between the TCR genes, as
well as associations between MYC, IGH and the other oncogenes.
FISH detected several novel, recurrent rearrangements. These
findings demonstrate the valuable role of FISH analysis, with a
panel of carefully selected probes, to classify T ALL patients into
genetic subgroups, including rare variants, and provide information
on the relationship between them. A metaphase FISH approach has
facilitated the identification of potential new target genes. In
particular, multiple partners of TRB@ and BCL11B have emerged,
highlighting the importance of these genes in the pathogenesis of T
ALL.
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Toxicity of fludarabine and cyclophosphamide (FC)7
rituximab (R) as initial therapy for patients with
previously-untreated mantle cell lymphoma: results of
a randomised phase II study
H Eve, P Smithw, W Qianw, L Stevensw and S Rule
Department of Haematology, Derriford Hospital, Plymouth,
UK, wCRUK and UCL Cancer Trials Centre, London, UK
Background: The combination of fludarabine and cyclophosphamide
is well recognized as being significantly immunosuppressive and
there are concerns that the addition of rituximab to this regimen may
increase the frequency of infectious complications. The impact of
rituximab on other markers of toxicity is also unclear.
Methods: The National Cancer Research Network (NCRN) is
currently coordinating a phase III randomized study (LY05)
comparing fludarabine and cyclophosphamide (FC)7 rituximab s
as initial therapy for patients with previously-untreated mantle cell
lymphoma. Prior to the phase III study, the same design phase II
study was conducted. The outcome measures for the phase II study
are response and toxicity.
All toxicity was graded according to the National Cancer Institute
toxicity criteria grading scale.
Results: A total of 139 patients were randomised in the phase II
study. Non-haematological toxicity was similar between the two
treatment arms. The only significant difference in haematological
toxicity was a higher rate of leucopenia with FCR chemotherapy
compared to FC chemotherapy (FCR 58.0% vs FC 41.4%, P5 0.0244).
This was due to lymphopenia rather than neutropenia since the
frequency and severity of the latter was unaffected by the addition of
rituximab (FC 50.0% vs FCR 60.9%, P5 0.2213). Most importantly,
the higher rates of leucopenia with FCR did not translate into a
significantly increased number of febrile episodes (FC 1.6% vs FCR
9.0%, P5 0.5483) or infections (FC 9.7% vs FCR 20.0%, P5 0.2406).
All percentages quoted relate to grade 3 or 4 toxicity only.
Conclusions the addition of rituximab to fludarabine and cyclopho-
sphamide as initial treatment for previously untreated mantle cell
lymphoma has no significant impact on toxicity. The higher rates of
leucopenia produced by FCR chemotherapy are due to lymphopenia
rather than neutropenia and do not result in more frequent febrile
episodes or infections.
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CC-5013 (revlimid, lenalinomide) induces in vitro
PBMC-toxicity against mantle cell lymphoma and this
is enhanced by rituximab
SJ Richardson, JA Copplestone and SAJ Rule
Department of Haematology, Derriford Hospital, Plymouth,
UK
Mantle cell lymphoma (MCL) is an incurable condition in most
patients and with a median presentation in the mid-60s new
treatment modalities are clearly needed. Revlimid, a second
generation immunomodulatory drug (IMiD), which is based on
thalidomide has shown promising results in multiple myeloma and
chronic lymphocytic leukaemia, with a more favourable toxicity
profile.
This study aims to examine in vitro both the direct effects of
Revlimid on patient-derived MCL cells and cell lines (MCL cell
viability) and the indirect effects of Revlimid on the immune system
(PBMC-mediated toxicity, complement-dependent toxicity (CDC)
and antibody-dependent cellular cytotoxicity (ADCC).
Revlimid had no significant direct effect on the viability of MCL
cell lines (Granta 519 and SP53), or on patient-derived MCL cells.
However, in one patient with blast cells, a specific reduction in blast
cells was observed. Rituximab alone and in combination with
Revlimid did not adversely affect viability.
Incubation of Revlimid with both patient derived or healthy
control PBMCs significantly enhanced their toxicity against Granta
519 cells when compared with DMSO control-treated cells (Po0.01).
CC-5013 was also capable of enhancing the toxicity of anti-CD3-
stimulated T cells against Granta 519 when compared to controls (P
o0.01). Pre-treatment of MCL cells with Revlimid did not alter their
susceptibility to CDC, both in the presence or absence of Rituximab.
Co-culture of Revlimid pre-treated PBMCs with rituximab-treated
MCL cells resulted in enhanced ADCC when compared with DMSO
pre-treated PBMCs.
We conclude that Revlimid does not appear to have a significant
direct effect on MCL cell viability or on CDC, but that it is capable of
enhancing PBMC-mediated toxicity both in the presence and absence
of Rituximab.
A NCRN clinical trial using Revlimid in MCL is planned to start
later this year.
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Tropical splenic lymphoma: detailed clinico-
pathological assessment in 19 Ghanaian patients
EA Stephens, I Batesw, G Bedu-Addoz, K Opare Semz, I Ekemy,
Y Deiy, SJM O’Connor, PAS Evans, RA Rollett and RG
Owen
HMDS Laboratory, Leeds, UK, wLiverpool School of Tropical
Medicine, Liverpool, UK, zKomfo Anokye Teaching Hospital,
Kumasi, Ghana, yKorle Bu Teaching Hospital, Accra, Ghana
We have previously described a subgroup of West African patients
with massive splenomegaly who appear to have a clinically
distinctive lymphoproliferative disorder (LPD) termed tropical
splenic lymphoma (TSL). These patients tend to be female, relatively
young and an aetiological link with malaria was postulated. Only
limited phenotypic and genotypic characterization was previously
possible. We have therefore evaluated the clinical and laboratory
features of 19 patients with a clinical diagnosis of TSL to determine
whether TSL represents a distinct entity or should be considered as
splenic marginal zone lymphoma (SMZL). Peripheral blood and bone
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marrow aspirate and trephine biopsies were assessed at the HMDS
laboratory, Leeds. The median age was 63 years, 73% were female and
the median spleen length was 17 cm. Five out of ninteen patients had
lymphadenopathy and seventeen out of ninteen patients had a
lymphocytosis (median 30.1 109/l). Marrow infiltration was evident
in all patients and was frequently extensive. The majority of cases
were characterised by a CD5 CD10 CD201 CD23 CD791
BCL21 BCL6 MUM1/IRF4 cyclin D1- immunophenotype. The
rate of cell proliferation was low in all cases. FISH studies
demonstrated del7q31 in four out of eighteen cases and del6q21 in
one out of ninteen cases but there was no evidence of the t(11;14),
t(9;14) or MALT1 rearrangements. IgH sequence analysis was
performed in 16 cases and demonstrated that nine out of sixteen
cases were germline and seven out of sixteen were mutated. Within
the mutated group the overall mutation load appeared to be
relatively low median 3.3% with most utilising VH3 family genes.
This is the first detailed clinicopathological assessment of TSL. These
patients have some pathological features seen in patients with SMZL
such as CD5 CD10 CD23 immunophenotype, 7q31 deletions and
cases with both germline and mutated Ig genes. Definitive
phenotypic and genotypic features are lacking in SMZL and it
remains uncertain whether TSL represents a distinct clinico-
pathological entity.
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Protein kinase C betaII is overexpressed in B-cell
lymphocytic leukaemia
T Lakum
Department of Haematology, Royal Hallamshire Hospital,
Sheffield, UK, Department of Haematology, University of
Liverpool, Liverpool, UK
B-cell chronic lymphocytic leukaemia (CLL) is an incurable disease
of mature B lymphocytes that becomes malignant in response to
uncharacterised oncogenic events. This response may involve
constitutive signalling within malignant cells resulting in escape
from apoptosis. One such signal could involve constitutively active
Protein kinase C (PKC). PKC is a serine-threonine kinase involved in
an array of biological processes ranging from cellular proliferation to
differentiation and cell survival. Mammalian PKC consists of 12
different isoforms.
Little was known about the relative expression of these isoforms
in CLL cells. The aim of this study was to establish a definite and
quantitative expression pattern of PKC isoforms in CLL cells. The
expression pattern was compared to that of normal B cells and hairy-
cell leukaemia cells. In CLL, PKCs have been identified as therapeutic
targets and PKC modulating agents are already under clinical trials.
It is believed that knowledge of PKC expression pattern would aid in
development of more targeted therapies for CLL patients.
The method involved separation of cellular proteins from CLL,
HCL and normal B cells using sodium dodecyle sulphate-poly-
acrylamide gel electrophoresis and developing Western blots using
anti-PKC antibodies. Purified recombinant PKC proteins were used
as standards. Following densitometry PKC concentrations within the
cell lysates were calculated.
In the present study I established the profile of PKC isoforms in
CLL cells showing that CLL cells express PKC alpha, betaI, betaII,
delta, epsilon, mu, zeta and iota. I also showed, for the first time that
among all isoforms, PKC betaII is over-expressed in these cells.
Further to this it has been shown that overexpression of PKC
betaII is a unique feature of CLL cells and the activity of this enzyme
strongly correlates with CLL-cell response to B-cell receptor
engagement (Abrams ST and Lakum T et al. [2006] Blood Sept 26
Epub ahead of print).
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Profiling of proteasome catalytic activities in chronic
lymphocytic leukaemia
YL Ong, L Crawford and AE Irvine
Department of Haematology, Ulster Hospital Dundonald,
Belfast, UK, Myelopoiesis Research Group, Centre for Cancer
Research and Cell Biology, Queen’s University Belfast, UK
Chronic lymphocytic leukaemia (CLL) is the commonest adult
lymphoid malignancy characterized by peripheral blood lymphocy-
tosis and affecting predominantly the older patients. The proteasome
is a multi-catalytic protease responsible for regulating intracellular
protein degradation. Proteasome inhibition is an emerging novel
therapy in haematological malignancies and bortezomib has already
shown efficacy in the treatment of multiple myeloma. Proteasome
function is mediated by three main enzyme activities, namely,
chymotrypsin-like (CT-L), trypsin-like (T-L) and peptidylglutamyl
peptide hydrolysing (PGPH) activities.
Flurogenic assays were used to investigate the level of the three
activities of the proteasome. Proteasome activity was measured by
monitoring the release of the fluorophore aminomethylcoumarin
(AMC) from peptide substrates specific for each activity (Succ-
LLVY-AMC for CT-L, Z-ARR-AMC for T-L and Z-LLE-AMC for
PGPH). Peripheral blood was collected in an EDTA bottle from newly
diagnosed and known CLL patients. Mononuclear cells were
separated using Ficoll and proteasomes extracted using an ATP/
DTT lysis buffer. Lysates were stored at 801C and batched for
enzyme assay. Results are expressed in arbitrary fluorescence units
(AFU) per 50 mg.
In this group of CLL patients (n5 7, male5 4, female5 3), the
mean CT-L activity was lowest (7.68 AFU, range 2.04–9.08), while the
mean T-L activity was highest (58.58 AFU, range 19.09–169.94).
PGPH activity had an intermediate mean value (36.68 AFU, range
12.24–69.25). In all cases tested, T-L activity was the major
contributor to proteasome function. The proteasome inhibitor
bortezomib has been designed to specifically target the CT-L activity.
It has recently been reported that the IC 50 for CLL cells in vitro is
double that for myeloma cells and that CLL patients have not
responded to bortezomib in vivo. This preliminary study suggests
that lack of response in vivo may reflect the low CT-L activity
detected in vitro. Second generation proteasome inhibitors are
currently being developed to target the T-L and PGPH; these may
show greater efficacy in CLL.
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Rapid infusion rituximab is as clinically effective and
safe as conventional infusion regimes in the
treatment of diffuse large B-cell lymphoma: a
2-year prospective study
GA Pout, SDJ Gibbs and JZ Wimperis
Department of Haematology, Norfolk and Norwich University
Hospital, Norwich, UK
Rituximab is increasingly used in the treatment of CD20 positive B
cell malignancies and other haematological disorders. This has
placed increasing pressure on the capacity of chemotherapy units,
especially given the recommended long infusion times (3–4 hours)for
rituximab. Several studies have suggested that rituximab may be
safely administered by more rapid infusion (90 mins) but none have
examined whether this change of protocol impacts on the efficacy of
the agent.
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We prospectively studied 61 patients with diffuse large B-cell
lymphoma (DLBCL), treated with R-CHOP chemotherapy using a
rapid rituximab infusion protocol from the second treatment
onwards if the initial rituximab infusion administered at the
standard recommended rate, was well tolerated (NCI toxicity grade
0 or 1). Premedication of chlorphenamine 8 mg, prednisolone
100 mg, paracetamol 1 g and tropistetron 5 mg was administered 1
hour before receiving rituximab.
Of the 61 patients, 60 had no reaction with their first standard-rate
infusion, only one patient had a Grade 1 reaction, meaning all could
progress to our rapid infusion protocol for their remaining
treatments. All rapid infusions were well tolerated with no
infusion-related toxicity.
Our study demonstrated that rapid rituximab infusions are both
safe and as clinically effective as those using standard infusion rates.
After follow-up ranging from 7 to 25 months, complete responses
were seen in 69% (42/61) of patients and overall survival was 77%.
This is comparable to the GELA trial (Coiffier et al, 2002) where a
complete response rate of 75% and overall survival of 70% after 2-
years was observed in patients with DLBCL-treated R-CHOP by
standard infusion.
We believe that rapid infusion of rituximab for DLBCL is effective
and safe and should be the standard of care for patients with DLBCL
to allow increased capacity of chemotherapy units and greater
patient satisfaction.
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EBV related transformation events in CLL
HA Sayala, SJ O’Connor, C Patalappa, AS Jack, P Hillmen and
RG Owen
HMDS, Leeds General Infirmary, Leeds, UK
Less than 5% of patients with CLL undergo transformation to diffuse
large B-cell lymphoma. Transformation to Classical Hodgkins
lymphoma (CHL) is also recognised. Such events may reflect genetic
changes in the CLL clone but there is evidence to suggest that at least
some transformation events may be Epstein–Barr virus (EBV) related
neoplasms. We have reviewed the clinical and laboratory features of
15 CLL patients with biopsy proven transformation to DLBL and two
patients who developed CHL. Sections were assessed for the
expression of a range of immunophenotypic markers and EBV
latent membrane protein 1 (LMP-1). Of the 15 patients developing
DLBL five appeared phenotypically related to the underlying CLL
clone. In the remaining patients the tumour cells appeared
phenotypically distinct as they lacked CD5 and CD23 and expressed
germinal centre markers in some instances. LMP1 positivity was
demonstrable in five patients with DLBL (one apparently related and
four unrelated to the underlying CLL). Of the two patients who
developed CHL one was associated with EBV and lacked CD20
expression. All the patients with EBV1 tumours were heavily pre-
treated (median prior therapies 4). The median time from original
diagnosis to histological transformation was 74.5 months. Four
patients presented with nodal disease and two patients presented with
extranodal disease. The outcome of the EBV associated tumors in
these patients was death in two patients, remission with intensive
combination chemotherapy in two patients and spontaneous remis-
sion of nodal disease in one patient. One patient is undergoing
intensive chemotherapy. We conclude that not all transformation
events in CLL occur within the original clone. The majority appear to
be clonally distinct and a significant proportion of these appear to be
EBV associated. This presumably occurs as a result of both the
underlying immune-deficiency seen in CLL as well the potent
immunosuppressive agents given as therapy. At least a minority may
resolve spontaneously. All biopsies demonstrating histological trans-
formation in CLL patients should be assessed for the presence of EBV.
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Dysplastic haematopoiesis in untreated chronic
lymphocytic leukaemia (CLL)
LRJ Eccersley, SP Moulew, G Abrahamson, N Philpott,
S Wagnerw, M Laytonw and F Brito-Babapulle,w
Department of Haematology, Ealing Hospital, London, UK,
wDepartment of Haematology, Hammersmith Hospital,
London, UK
In the MRC CLL-5 pilot study, 8% of patients developed
myelodysplasia/acute myeloid leukaemia (MDS/AML) after treat-
ment. It was not established whether this was an effect of treatment
or due to unmasking of a concomitant dysplastic clone. We therefore
assessed bone marrow aspirates of 28 untreated CLL patients for the
presence of co-existing dysplasia by morphological criteria, evaluat-
ing 100 erythroid cells, 100 myeloid cells and 20 megakaryocytes in
each case. Cytogenetic analysis and trephine biopsy reports (extent
and pattern of lymphoid infiltration) were also reviewed. Abnorm-
alities seen were compared with reported patterns of abnormal
morphological findings in normal volunteer marrows (Bain [1996]
British Journal of Haematology, 94, 206).
Abnormal erythropoiesis (450% cells) was found in 26 (93%) of
cases, abnormal myelopoiesis in 5 (18%) and abnormal megakar-
yopoiesis in 4 (14%). Erythroid abnormalities included irregular/
poorly haemoglobinised/vacuolated cytoplasm (57.8% vs 7.0%, Po
0.0001), cytoplasmic bridging (10.8% vs 6%, P5 0.0498), nuclear
irregularity/fragmentation/lobulation showing a trend to significance
(3.8% vs 2.0%, P5 0.069). Binuclearity was not increased and ring
sideroblasts were not seen. Megakaryocyte abnormalities included
separated nuclei (1–7 cells, in 20 cases), hypolobated/mononuclear
forms (1–5 cells, 14 cases), and occasional micromegakaryocytes.
Myeloid abnormalities included pseudo-Pelger cells (18 cases),
hypogranularity (15), giant metamyelocytes (10), and ring-shaped
nuclei (7). Cytogenetic analysis (conventional and/or FISH) in 17 of
28 patients showed 10 abnormal karyotypes (11q, 13q, trisomy 12,
t(14;18), 17p-, X-, complex). None were diagnostic of MDS. There was
no significant difference in abnormalities seen in those with normal
vs abnormal cytogenetics, high vs low percentage of trephine
infiltration, or diffuse vs non-diffuse marrow infiltration.
We conclude that residual haematopoiesis in untreated CLL
shows significant morphological changes in all lineages, especially
erythroid, as compared to normals. Cytogenetic abnormalities were
not classical of MDS/AML. More sensitive methods than morpho-
logical analysis alone are needed to address whether occurrence of
MDS/AML in CLL is a chemotherapy effect or due to unmasking of
pre-existing MDS.
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CD38 expression in B-CLL is dynamic and influenced
by cell contact in the leukaemic microenvironment
PEM Patten, AGS Buggins, J Richards, A Wotherspoonw,
T Hamblin, G Mufti and S Devereux
Department of Haematological Medicine, King’s College
London, UK, wDepartment of Histopathology, The Royal
Marsden Hospital, London, UK
In order to determine whether microenvironment derived signals
might influence CD38 expression in B-cell chronic lymphocytic
leukaemia (B-CLL), we compared levels of this molecule in
peripheral blood (PB), bone marrow (BM), splenic red pulp (RP)
and splenic white pulp (WP). In 35 paired BM and PB samples,
significantly higher CD38 expression was observed on BM B-CLL
cells compared to PB (27% vs 19%, P5 0.009). Similarly, imaging of
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the splenic tissue by confocal immunofluorescence microscopy
revealed significantly higher CD38 expression by tumour in the WP
compared to RP (Po0.0001), an area also infiltrated with T-
lymphocytes. Cell contact derived signals within the microenviron-
ment might thus be responsible for the level of CD38 expression in B-
CLL.
To test this theory, we examined the effect of contact with
autologous CD3/CD28 activated T lymphocytes using an in vitro
system aimed at mimicking the tumour microenvironment. CD38
expression by B-CLL cells increased significantly in 15/15 cases over
the 6-day culture period and was dependent on cell contact.
Proliferation of tumour cells was also induced and was more marked
in cases with higher initial levels of CD38. A parallel reduction in
apoptosis was also observed. Immunofluorescence microscopy of B-
CLL lymph node and spleen showed that levels of CD38 expression
were higher in areas containing Ki671 tumour and T lymphocytes.
CD381 B-CLL cells were frequently found in areas containing
vascular endothelial cells expressing CD31, a known ligand for CD38.
These results show that CD38 expression in B-CLL is dynamic and
influenced by contact with activated T lymphocytes. Expression of
this molecule in the peripheral blood may thus serve as a surrogate
marker for the extent of survival and proliferation signals provided
by non-malignant cells in the leukaemic microenvironment.
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B-CLL cells secrete factors including IL-6 which inhibit
T cell proliferation and activation and promote Th2
polarisation
AGS Buggins, PEM Patten, J Richards, NSB Thomas, GJ Mufti
and S Devereux
Department of Haematological Medicine, King’s College
London, UK
Immune dysfunction, manifest as susceptibility to infection and
autoimmune disease, is a major clinical feature of B-cell chronic
lymphocytic leukaemia (B-CLL). Although this is in part directly
caused by the tumour load, defective T-cell function is also observed
even in patients with early stage disease.
T cells in B-CLL have an acquired defect in CD40L expression
which we demonstrate is reversible and, contrary to previous work
which suggested it is exclusively due to contact with tumour cells,
demonstrate that soluble mediator(s) found in tumour supernatant
(TSN) are also involved. TSN inhibited 3rd party allogeneic mixed
lymphocyte reactions (MLR), CD40L upregulation and IL-2 secretion
following activation of normal T cells by phorbol ester and
ionomycin. Cell cycle entry and cell division following stimulation
of normal T cells by ligation of CD3 and CD28 were also reduced by
TSN. High levels of IL-6 were detected in B-CLL TSN from all cases
studied. Antibody neutralisation of the IL-6 in TSN demonstrated
restoration of both T-cell IL-2 production and CD40L expression,
whilst addition of recombinant IL-6 to normal T cells inhibited
CD40L upregulation and IL-2 production in a similar fashion to TSN.
When normal T cells were activated in either TSN or IL-6 at similar
concentrations to that found in TSN, Th2 polarisation was induced as
evidenced by a 10 fold increase in the production of IL-4.
In summary, B-CLL cells secrete factor(s) including IL-6, a known
adverse serum biomarker, which inhibit T-cell activation and
proliferation and promote Th2 polarisation. This may in part explain
the susceptibility of B-CLL patients to infection and autoimmunity
and might also promote disease progression through the effects of
Th2 cytokines on the survival of tumour cells. Anti IL-6 therapies are
available and might improve T-cell function, abrogate the suscept-
ibility to autoimmunity and inhibit disease progression.
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Management of Hodgkin lymphoma in the ‘real world’
– analysis of a population based cohort
BD Harrison, M Sheridan, V Dyde, S Jobanputra and CJR Irwin
Departments of Haematology and Oncology, University
Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK
Most data on outcomes in Hodgkin lymphoma (HL) come from
results of clinical trials of therapy in selected groups of patients.
We present data on all patients diagnosed with HL at this hospital,
serving a population of 400 000 in Coventry and Rugby, between
January 2000 and December 2006. Patients referred for treatment
from elsewhere were excluded. There were 57 patients (33 male, 24
female) – an incidence of 2 per 100 000 per year. Median age at
diagnosis was 36 years (range 14–86). Twenty-four patients had Stage
IA/IIA disease; two were HIV positive.
Fifty-five patients have been treated with curative intent. One
patient died before starting treatment. One received only one course
of ABVD before she opted for alternative therapies (alive in partial
response 19 months later). However, 11 patients received attenuated
therapy due to significant comorbidity (3 – cardiomyopathy [1],
multiple sclerosis [1], other active malignancy [1]) or age [8]. Five
patients have not yet completed treatment.
Six patients have relapsed; three have progressed during
treatment (all three died). Eight patients have received salvage
chemotherapy, and six an autologous stem cell transplant. One
patient (relapsed post autograft) also underwent a reduced intensity
allograft. Six patients are alive following salvage chemotherapy (five
post autograft), 28–66 months later. There have been nine deaths,
one prior to treatment, four treatment related, three due to
progressive HL. There was one sudden cardiac death in a 51-year-
old male smoker two years after ABVD and Mantle radiotherapy.
In our cohort, relapse beyond two years is uncommon.
Probability of survival at five years is 0.81, and of disease free
survival is 0.78. These data show early outcomes in an unselected
population of HL patients treated in the ‘real world’. We intend to
observe this cohort as it matures in order to demonstrate the effects
of late toxicities of therapy on survival.
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The t(9;14)(p13;q32)is a rare abnormality in B cell
lymphoma
RJ Kelly, SJM O’Connor, SL Barrans, RJ Johnson and RG Owen
HMDS Laboratory, Leeds Teaching Hospitals NHS Trust, Leeds, UK
The t(9;14)(p13;q32) which deregulates PAX5 as a consequence of its
juxtaposition to the IGH locus was originally described in patients
with lymphoplasmacytic lymphoma. Subsequent studies have failed
to confirm this finding and have demonstrated the translocation in
some patients with splenic marginal zone lymphoma, diffuse large B-
cell lymphoma and post transplant lymphoproliferative disorders. In
order to further clarify this we have evaluated (by interphase FISH)
280 cases of B-cell lymphoma for the t(9;14). Cases of follicular
lymphoma and mantle cell lymphoma were specifically excluded as
they contain disease defining IGH translocations. Samples were
initially screened for IGH rearrangements using a dual colour IGH
breakapart probe set (Vysis 32–191 019) and cases with a split signal
(indicative of an IGH rearrangement) were further evaluated for
rearrangements of PAX5 using another dual colour breakapart probe
set (Dako Y5413). Ninety-six cases of diffuse large B-cell lymphoma
and 45 cases of extranodal marginal zone lymphoma were evaluated
with this strategy but none harbored a t(9;14). A further 139 cases
with CD5– lymphoproliferative disorders were also evaluated and a
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single patient was found to have a t(9;14). This patient had the
clinical and laboratory features typical of splenic marginal zone
lymphoma.
We would therefore conclude that the t(9;14) is a very rare
abnormality in B-cell lymphoma but it may be seen in a minority of
patients with splenic marginal zone lymphoma.
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Effect of cloretazine on acute myeloid leukaemia
blasts in vitro – as a single agent and combined with
cytarabine and daunorubicin
KL Morris, D Wren, JA Adams and JA Liu Yin
University Department of Clinical Haematology, Manchester
Royal Infirmary, Manchester, UK
Current chemotherapy strategies induce remission in the majority of
AML patients; however up to 70% subsequently relapse, highlighting
the need for new therapies. Cloretazine (VNP40101M) is a novel
alkylating agent (Vion Pharmaceuticals Inc., New Haven, CT, USA).
On administration, Cloretazine undergoes activation to form 90CE, a
DNA chloroethylating species which cloroethylates the O6 position
in guanine residues, resulting in inter-strand DNA cross linkage,
cytotoxicity and ultimately cell death.
We have investigated the effect of Cloretazine on cell proliferation,
viability and apoptosis of AML blasts in vitro, both alone and in com-
bination with other chemotherapy agents (Cytarabine/Daunorubicin).
Blast cells were isolated by density centrifugation from 10 patients at
presentation (BM or PB). Cells were cultured in 96-well plates at 1 106
cells/ml in McCoy’s 5A medium supplemented with 15% FCS, GM-CSF
(100 ng/ml), SCF and IL-3 (10 ng/ml). Cloretazine (0, 1, 5, 10 or 20mg/ml)
was added alone or in combination with Cytarabine/Daunorubicin
(10 100 or 500 ng/ml) at establishment of cultures. Cultures were incu-
bated at 371C in 5% CO2, 5% O2, 90% N2 for 72–96 h before cell proli-
feration, viability and apoptosis were measured using tritiated thymi-
dine uptake, WST-1 and Annexin V staining methods, respectively.
All patients studied showed a dose dependent response to
Cloretazine alone. Combination with Cytarabine or Daunorubicin
at a range of concentrations showed increased effects e.g inhibition
of proliferation 50% (24–92) (mean (range) with Cloretazine (5mg/
ml) alone), 71% (32–98) Cytarabine(100 ng/ml) alone increasing to
86% (58–100) when combined, 57% (20–89) Daunorubicin(10 ng/ml)
alone increasing to 73% (28–96) combined. Similarly increases in
cytotoxicity were observed, 28% (0–50) (Cloretazine alone), 43% (0–
86) Cytarabine alone to 52% (15–92) in combination. 22% (1–70)
Daunorubicin alone to 36% (0–78) combined. Apoptosis levels also
showed increases with combinations.
This pilot study indicates Cloretazine is effective on AML blasts in
vitro both alone and in combination with other chemotherapy
agents. Cloretazine is currently undergoing clinical trials.
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Gene expression profiling can identify novel MRD
markers for AML
EL Woodward, AF Gilkes, V Walsh, SJ Austin, S Greenw,
SB Dalyw, JAL Yinw, D Grimwadez, AK Burnett and KI Mills
Department of Haematology, Cardiff University, UK,
wDepartment of Haematology, Manchester Royal Infirmary,
UK, zDepartment of Haematology, University College London
Hospitals, UK
The monitoring of minimal residual disease (MRD) has become an
important issue for the diagnosis and clinical management of
patients with acute myeloid leukaemia (AML). The majority of
patients o60 years of age will enter remission but at least 50% will
subsequently relapse. For those patients presenting with either
t(8;21), t(15;17) or an inv(16) (abnormalities associated with a
favourable risk group) molecular markers have already been
established (AML1-ETO, PML-RARalpha and CBFbeta-MYH11) but
are limited to detection by RT-PCR. As ‘Proof of Principle’, gene
expression data from 350 patients identified several genes that were
specifically, and uniquely, over-expressed for each of the three
favourable risk sub-groups including genes related to the genetic
abnormalities. Quantitative RT-PCR was used to monitor changes in
expression of some of these genes and this was correlated with
monitoring levels using established MRD markers and the clinical
course of the patients. The new MRD markers tracked with the
existing markers.
Unfortunately, the majority of patients, including those with a
normal karyotype (NK), have no leukaemia-specific markers for
MRD monitoring, although a few genes are mutated that have a
noticeable effect upon a patient’s outcome. NPM1 (Nucleophosmin)
mutations occur in about 50% of NK patients and are generally
associated with a good prognosis. The presence of FLT3 (Fms-like
tyrosine kinase 3) mutations is seen as a poorer indicator, even when
present alongside an NPM1 mutation. In the cohort of AML patients
with NK (n5 121) with expression profiles, a similar approach was
taken to identify several specific and unique expressed genes in
patients with a normal karyotype and an NPM1 mutation compared
to those without. These included homeobox proteins, which were
over-expressed by three fold in the NPM1 mutated group. These
genes are being assessed in a series of patients to confirm suitability
for MRD monitoring.
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Mutations of the gene encoding SHIP1 are rare and
SHIP1 expression levels unaltered in caucasian acute
myeloid leukaemia patients
DC Gilby, AC Goodeve, PJM Valkw, PR Winship, R Delwelw
and JT Reilly
Academic Unit of Haematology, University of Sheffield,
Sheffield, UK, wDepartment of Hematology, Erasmus
University Medical Center, Rotterdam, The Netherlands
SHIP1 (SH2-domain-containing inositol 50-phosphatase 1) is pre-
dominantly expressed in haematopoietic cells, and negatively
regulates PI3K-initiated cell signalling. SHIP1/ knockout mice
show increased haematopoietic stem cell numbers and proliferation,
suggesting that SHIP1 acts as a tumour suppressor in haematopoietic
cells. Consistent with this, a recent study identified mutations in the
gene encoding SHIP1 in 22% of Chinese AML patients (Luo et al.
[2004] Journal of Experimental Hematology 12, 420). We aimed to
determine the incidence of SHIP1 mutations and mRNA levels in
Caucasian AML. Group 1: Genomic DNA from 57 adult de novo AML
cases representing all FAB subtypes was studied. PCR amplicons
corresponding to all 27 exons of SHIP1 were analysed for sequence
alterations by DHPLC and potential changes confirmed by DNA
sequencing. Group 2: SHIP1 mRNA expression profile was
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determined in a separate group of 285 AML plus five controls. RNA
from blasts and mononuclear cells was analysed using Affymetrix
U133A GeneChips. Group 1: two missense (one novel; c.466G4A,
R156Q in 1/57 patients (2%), one polymorphic), six synonymous
(four novel) and 34 untranslated sequence alterations (20 novel) were
identified. No changes identified correspond to those present in a
cohort of 32 Chinese AML patients (seven different missense
mutations in seven patients) (Luo et al. [2004] Journal of
Experimental Hematology 12, 420). Furthermore, most sequence
changes identified in our study are polymorphic and therefore
unlikely to elicit any phenotypic effect. Group 2: Compared to
normal subjects, SHIP1 expression level was unaltered in the AML
group overall and following stratification into FAB subtypes or into
16 clusters defined by expression profile. We conclude that SHIP1
mutations and altered expression do not appear to play an important
role in the pathogenesis of AML in the Caucasian population in
contrast to the Chinese study (Luo et al. [2004] Journal of
Experimental Hematology 12, 420). These findings suggest that
therapeutic trials should consider possible ethnic/geographical
differences. However, further investigations are required to exclude
pathogenic SHIP1 post-translational modifications in AML.
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Heterogeneous prognostic impact of derivative
chromosome 9 deletions in chronic myelogenous
leukaemia
S Kreil, M Pfirrmannw, K Waghorn, A Chase, R Hehlmannz,
A Reiterz, A Hochhausz and NCP Cross
WRGL, University of Southampton, Salisbury, UK, wIBE, LMU,
Munich, Germany, zIII. Med. Klinik, University of Heidelberg,
Mannheim, Germany
Der(9) deletions are seen in 10–15% of CML patients and have been
associated with a poor prognosis, however no studies have been
performed in the context of a randomized clinical trial. We
developed a DNA-based deletion screen and investigated 339 chronic
phase patients treated with interferon-alpha (IFN) as first line
therapy in three controlled German studies with a median
observation time of 7 years. Deletions were detected in pretreatment
DNA of 59/339 (17%) patients. Of these, 21 spanned the ABL/BCR
junction and 38 were centromeric (n5 20) or telomeric (n5 18) of
the breakpoint. There was no significant difference in overall survival
between deleted and non-deleted patients. Patients with breakpoint-
spanning deletions had poorer survival compared to patients without
deletions (4.7 vs 7.8 years; P5 0.003) but this was not significant
when censored at allogeneic stem cell transplantation (n5 129) or
imatinib (n5 62) treatment in first chronic phase (P5 0.08).
Unexpectedly, deletions that did not span the breakpoint were
associated with improved survival compared to cases without
deletions (P5 0.001). Multiple Cox regression analysis indicated
that deletion status (P5 0.007), age (P5 0.018) and spleen size (P5
o0.001) were significant independent indicators of survival and
confirmed that only deletions spanning the ABL/BCR breakpoint are
associated with an adverse prognosis (P5 0.039).
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Bone marrow trephine findings in CMML
N Ngo, I Lampert and K Naresh
Department of Histopathology, Hammersmith Hospitals NHS
Trust, London, UK
Objective: To identify characteristic features in bone marrow
trephines of CMML (Chronic Myelomonocytic Leukaemia).
Patients and methods: A retrospective analysis of the bone marrow
trephine features was performed in 22 patients. All patients had a
sustained raise in peripheral blood monocyte count of over 1 109/l.
Results: The average age of the patients is 67.7 year.The mean
peripheral blood monocyte count was 5.84 109/l. All the CMML
patients had hypercellular marrow with an abnormally high M:E
ratio (in excess of 4 in most cases). Fifteen of the cases had
noticeably increased numbers of monocytes on H&E staining, while
in the other seven cases the monocytes were identified by CD68
(PGM-1) staining. The CD34 count was marginally elevated. CMML2
was diagnosed in two cases where the CD34 count was 5% and 10%.
The number of megakaryocytes were increased in 11 cases and
dysmegakaryopoiesis was present in 14 cases. Most (20 cases) had
increased reticulin.
Conclusion: Appreciation of hypercellularity, high M:E ratio, in-
creased proportion of monocytic cells (either on morphology or
aided by CD68 [PGM-1]) and presence of dysmegakaryopoiesis can
aid in the diagnosis of CMML in bone marrow trephine sections.
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Bone marrow trephine findings in AML with
multi-lineage dysplasia
N Ngo, I Lampert and K Naresh
Department of Histopathology, Hammersmith Hospitals NHS
Trust, London, UK
Objective: To identify characteristic features in bone marrow
trephines of acute myeloid leukaemia (AML) with multi-lineage
dysplasia.
Patients and methods: A retrospective analysis of the bone marrow
trephine features was performed in 14 patients. The cases were
subdivided into two groups: (a) AML with background multilineage
dysplasia (AML-MD) (11), (b) Myelodysplastic syndrome which
subsequently transformed to AML (MD-AML) (3).
Results: Nine out of eleven AML-MD patients had hypercellular
marrow and increased proportion of precursor cells could be
identified on morphology and CD34/HLADR/CD117 immunostains.
Four cases showed trilineage dysplasia and five cases showed
bilineage dysplasia. Most had increased reticulin. Megakaryocytes
were increased in number in seven cases and were dysplastic in all
cases but one (marked in seven). The three MD-AML cases show
frank features of AML with increased numbers of precursor cells with
appropriate immunophenotype and all of them showed persistent
dysmegakaryopoiesis, and increased numbers of megakaryocytes,
apoptoses and reticulin.
Conclusion: Assessment of an increased proportion of immature
myeloid cells by their morphology and immunophenotype and
appreciation of dysplastic features in the haemopoeitic lineages
based on morphological features can aid in the diagnosis of AML
with multilineage dysplasia in bone marrow trephine sections.
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Successful treatment of myelodysplasia-associated
Pyoderma Gangrenosum with topical tacrolimus
WW Aye, MW Besser, V Gudiw and MS Young Min
Department of Haematology, West Suffolk Hospital, Bury St
Edmunds, UK, wDepartment of Dermatology, West Suffolk
Hospital, Bury St Edmunds, UK
We report the case of a 71-year old with refractory anaemia with
ringed sideroblasts diagnosed in November 2005 with normal
cytogenetics on a FISH panel (INT-1). As a result of 2–3 weekly
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blood transfusions, his ferritin rose to above 1400 in September
2006. He was started on dexferrioxamine (DF) subcutaneous
infusion. The first needle was left in-situ for 5 days rather than
being replaced every 72 hours as instructed. Shortly after this, he
noticed erythema and induration at the infusion site and over the
next few days, this area ulcerated with purulent discharge. Swabs
grew Staphylococcus aureus, but the ulceration continued to spread
despite adequate antibiotic therapy to a 20 15 mm ulcer in his right
iliac fossa with bluish, undermined margins and copious purulent
discharge. The features were classical for pyoderma gangrenosum
(PG). He was commenced on topical tacrolimus 0.1% ointment once
daily under Mepilex border dressing along with oral flucloxacillin.
The ulcer healed over ten-weeks leaving a depressed scar.
Desferrioxamine was restarted again with care to replace the needle
every 72 hours and PG has not recurred over the last 2 months.
PG is an autoimmune ulcer and is associated with a systemic
disease in about 50% of patients. It is known to be associated with
various haematological disorders including acute myeloid leukaemia,
multiple myeloma, lymphoma or monoclonal gammopathy of
undetermined significance. Trauma is a known precipitant of PG
and it may have played a role in our patient. Therapeutic efficacy of
topical tacrolimus 0.1% (Protopic) in the treatment of PG with
associated myelodysplasia has not been widely reported. Conven-
tional systemic immunosuppressive therapy may be hazardous in
this group of patients who are often elderly.
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High dose cytarabine (HD-AraC) and cerebellar
toxicity – a single centre experience
U Mohite, J Kell, MA Haj, N Evansw, C Rowntree,
K Wilson and AK Burnett
Department of Haematology, University Hospital of Wales,
Cardiff, UK, wDepartment of Pharmacy, University Hospital of
Wales, Cardiff, UK
In acute myeloid leukaemia (AML) standard dose AraC in
combination with an anthracycline is part of induction. A 15–30-
fold AraC dose escalation can elicit a therapeutic response in patients
who failed treatment. Apart from potent myelosuppression, the dose
limiting toxicity of HDAC is cerebellar damage. We report three AML
patients who developed Cerebellar toxicity with use of HDAC at a
single institution between June 2002 and June 2006.
Patient 1: A 37-year woman with AML had second relapse post an
unrelated donor allograft and received HDAC. She developed mild
cerebellar signs on day 5 and cytarabine was stopped. CT and MR of
brain showed only a mild degree of cerebral atrophy and no other
focal lesions. She died of TTP and GVHD with persistent ataxia.
Patient 2: A 62 year man with AML received HDAC for first relapse.
He developed severe cerebellar signs on day 5 of treatment and
required haemodialysis for renal failure. CT scan of brain was
normal. He died of sepsis with persistent cerebellar toxicity.
Patient 3: A 51 year old man with AML received conventional
chemotherapy and consolidation with MidAC and had intermittent
diplopia 2 weeks later. He was admitted 2 months after with
cerebellar signs. CT, MR head were both normal as was CSF. He
continued to detoriate, had status epilepticus and remains in
vegetative state. No cause has been found.
Conclusion: We report two cases of severe neurotoxicity in patients
treated with HDAC for relapsed AML and one patient experienced
severe late neurotoxicity. The main risk factors for neurotoxicity of
HDAC are dose, age of patient and renal impairment. Our experience
suggests that stopping AraC once signs develop may not help to
prevent progression. Therefore, caution needs to be exercised before
using HDAC especially in high-risk patients to prevent this
complication. High dose AraC should not be used in patients with
renal impairment.
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Frequent relapse of acute myeloid leukaemia by
mitotic recombination
M Raghavan, LL Smith, T Chaplin, D Lillington, G Molloy,
I Kakkas, C Chelala, JB Cazier, J Fitzgibbon, TA Lister
and BD Young
CRUK Medical Oncology Unit, Bart’s and the London, Queen
Mary’s School of Medicine and Dentistry, London, UK
Relapse is the commonest cause of death in acute myeloid leukaemia
(AML), but the mechanisms leading to relapse are unclear. Recently,
acquisition of uniparental disomy (UPD) by mitotic recombination
(MR) have been reported in 15–20% of AMLs at diagnosis using
whole genome single-nucleotide polymorphism (SNP) arrays. These
abnormalities are cytogenetically invisible and are associated with
homozygous mutations in several malignancies. Clonal evolution
from heterozygous to homozygous mutations by MR could provide a
mechanism for relapse. DNA from 27 pairs of diagnostic and
relapsed AML samples were analysed using Affymetrix 10K SNP
arrays. Copy number and loss of heterozygosity were analysed using
in-house software. Regions of deletion, amplification and UPD were
documented and compared between diagnosis and relapse. UPDs
were acquired at relapse in eleven AMLs (30%). Six of these were
UPDs of chromosome 13q, which lead to a change from hetero-
zygosity to homozygosity for internal tandem duplication of FLT3
(FLT3 ITD). A further AML acquired UPD of 19q which lead to
homozygosity for a CEBPA mutation 957 C to T. Three more AMLs
had evidence of a subclone with UPD of 13q. One AML acquired UPD
of chromosome 4q, for which a mutation has not been discovered.
Acquisition of UPD by mitotic recombination is a frequent
mechanism for relapse in AML. It is possible that targeting the
associated homozygous mutations could treat or prevent relapses.
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The platelet-derived growth factor receptor beta
fuses to two distinct loci at 3p21 in imatinib
responsive chronic eosinophilic leukaemia
FH Grand, C Curtis, J Score, A Chase and NCP Cross
Wessex Regional Genetics Laboratory, Salisbury and Human
Genetics Division, University of Southampton, UK
We have identified three patients who presented with BCR-ABL
negative myeloproliferative disorders and a t(1;3;5)(p36;p21;q33) or
t(3;5)(p21-25;q31–35). Fluorescence in situ hybridization indicated
that the platelet-derived growth factor receptor beta gene (PDGFRB)
was disrupted in all three cases. 50 rapid amplification of cDNA ends
(5’RACE) for the t(1;3;5) case identified an in-frame mRNA fusion
between WDR48 at 3p21 to PDGFRB. Cases 2 and 3 were negative for
WDR48-PDGFRB but instead harboured an mRNA fusion between
GOLGA4 and PDGFRB. Imatinib, a known inhibitor of PDGFRbeta,
selectively blocked the growth of t(3;5) myeloid colonies and
produced clinically significant responses in all three patients.
Strikingly, both GolginA4 and Wdr48 are involved with endocytic
pathways and protein trafficking within the cell, a functional overlap
with the previously identified Pdgfrb fusion partner rabaptin-5.
Endocytosis is a well-defined mechanism for the attenuation of
proliferative signalling by surface receptors and it is possible that the
transforming ability of these fusions may depend, at least in part,
directly on interference with cellular trafficking.
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CCN3 reduces the clonogenic potential of BCR-ABL1
cells
W Lu, LMR McCallum, S Price, N Planquew, B Perbalw,
AD Whettonz and AE Irvine
Department of Haematology, Queen’s University Belfast,
UK, wLaboratoire d’Oncologie Virale et Moleculaire,
Universite Paris 7D Diderot, Paris, France, zFaculty of
Medical and Human Sciences, University of Manchester,
Manchester, UK
Chronic Myeloid Leukemia (CML) is characterized by expression of
the constitutively active BCR-ABL tyrosine kinase. Previously, we
have identified down-regulation of the negative growth regulator,
CCN3, as a result of BCR-ABL kinase activity and detected reduced
CCN3 expression in human CML cell lines and primary human CML
cells. We now report the growth inhibitory effect of CCN3 expression
in human CML cells.
Colony formation assays were performed over 7 days to determine
clonogenicity of CML cells expressing CCN3 and compared to cells
treated with Imatinib (1mM). Human K562 cells were transfected with
vector alone or vector containing CCN3 using Amaxa nucleofector
technology or treated with Imatinib, for 24 hours prior to plating in
methyl cellulose cultures. Increased CCN3 expression in K562 cells
significantly reduced colony formation by 65.4%7 SD 18.8 when
compared to cells transfected with vector alone (P5 0.027, n5 3).
Treatment with Imatinib also reduced colony formation (75%7 SD
8.2; P5 0.001, n5 3) compared to untreated cells. We next assessed
the clonogenic effects of CCN3 and Imatinib on primary human
CD341 progenitor cells derived from CML peripheral blood samples
at diagnosis (n5 3). Cells were treated with exogenous addition of
CCN3 (1 nM) or Imatinib (1mM) for 24 hours prior to plating in
methyl cellulose. CCN3 reduced clonogenic capacity by 25.5%7 SD
3.9 (P5 0.011) whilst treatment with Imatinib reduced colony
formation by 37.9%7 SD 19.9 (P5 0.010).
CCN3 is known to be a negative growth regulator and increased
expression of CCN3 in BCR-ABL1 cells decreases cell clonogenic
potential. Thus CCN3 down-regulation mediated by BCR-ABL offers
growth advantage to hematopoietic cells.
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Molecular responses to dasatinib reveal multiple
mechanisms of imatinib resistance in patients with
chronic myeloid leukaemia
SE Langabeer, L O’Connorw, J Kellyz, S McCannw,y, M Lawler,w
and E Conneallyy
Cancer Molecular Diagnostics, St James’ Hospital, Dublin,
Republic of Ireland, wInstitute of Molecular Medicine, Trinity
College Dublin, Republic of Ireland, zNational Centre for
Medical Genetics, Our Lady’s Hospital for Children, Dublin,
Republic of Ireland, yDepartment of Haematology, St James’
Hospital, Dublin, Republic of Ireland
Resistance to Imatinib mesylate (IM) can develop in patients with
chronic myeloid leukaemia (CML) through several mechanisms.
Dasatinib, a dual specificity SRC/ABL kinase inhibitor that binds to
the active conformation of ABL enabling in vitro inhibition of most
IM-resistant mutants, can induce haematological and cytogenetic
responses in IM-resistant CML patients. Molecular and cytogenetic
responses to Dasatinib were evaluated in a cohort of IM-refractory or
IM-intolerant CML patients in chronic phase (n5 11) or accelerated
phase/blast crisis (n5 5), initially treated with either 100 or 140 mg
Dasatinib daily. PB BCR-ABL RQ-PCR and BM cytogenetics/FISH
were performed at start of treatment and at three monthly intervals
(follow-up 1–21 months). Mutation screening was performed by
DHPLC followed by allele-specific PCR for the Dasatinib resistant
T315I and sequencing to characterise other mutations. Fourteen
patients had evaluable cytogenetic results. Six had a major
cytogenetic response: four achieved complete cytogenetic response
(CCR); two had partial responses. One patient had a minimal
response. Of those attaining CCR, three had a major molecular
response with one patient achieving a one log depletion of BCR-ABL
transcripts. DHPLC analysis of 6/7 patients with cytogenetic
responses indicated mutations of the ABL kinase domain in five.
One further patient with a G250E achieved a one log reduction in
BCR-ABL transcripts after two months of Dasatinib. Of the nine
patients with no cytogenetic or molecular response to Dasatinib, the
T315I was detected in two, BCR-ABL over-expression with sustained
high BCR-ABL/ABL ratios 4150% detected in three and clonal
evolution with gene amplification due to an extra Ph1 observed in
one. Dasatinib therefore elicited a cytogenetic and/or molecular
response in seven patients by potentially overcoming ABL kinase
domain mutation induced resistance or by inhibition of SRC-
mediated signalling. In those CML patients without a molecular
response, alternative processes causing IM resistance are implicated
that require further elucidation.
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Hypereosinophilic syndrome: challenges in diagnosis
and management
NM Wiles, C Harrison, J van der Waltw, N Crossz
and D Radia
Department of Haematology, St Thomas’ Hospital London,
UK, wDepartment of Histopathology, St Thomas’ Hospital,
London, UK, zDepartment of Cytogenetics, Salisbury District
Hospital, Salisbury, Wiltshire, UK
Hypereosinophilic syndrome is a rare heterogeneous condition.
Recent developments in our understanding of the pathogenesis of
this syndrome has led to diagnostic pathways, prompting potential
subclassification into myeloproliferative and lymphoproliferative
variants. We would like to present three cases of hypereosinophilic
syndrome which demonstrate its complexity, and that management
should be individually tailored. Case 1: A 55-year-old man presented
with a necrotic skin rash and marked eosinophilia unresponsive to
steroids. He developed splenomegaly and multiorgan failure,
requiring months in the intensive care unit. He was unresponsive
to imatinib and required treatment with cytarabine, hydroxycarba-
mide and alpha interferon to control his disease. He made a good
recovery and is currently not on cytotoxics. Case 2: A 55-year-old
woman with progressive severe respiratory compromise associated
with eosinophilia and widespread low volume lymphadenopathy.
This responded to steroids but she developed a desquamative rash
and eosinophilia, which required further steroids. Her symptoms and
blood counts are stable on alpha interferon. Case 3: A 36-year-old
man who presented with severe eosinophilic cellulitis comprising
more than 40% of his body surface area. This responded to steroids
but new skin lesions developed on its cessation. He was unable to
tolerate methotrexate or alpha interferon and is asymptomatic with
normal counts on low dose hydroxycarbamide. All cases had bone
marrow biopsies that were hypercellular with no maturation
abnormalities within the myeloid, lymphoid or eosinophilic lineages.
FIP1L1 PDGRF alpha mutations were not detected and cytogenetics
were normal. We were unable to easily subclassify these patients. The
first case illustrates the need for prompt treatment with cytotoxics in
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some severe cases before a formal diagnosis is made. These cases
highlight the difficulties in the diagnosis and management of such
patients and that treatment modalities used will depend on the
individual patient.
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Analysis of the regulation of angiogenesis in the bone
marrow of myelodysplastic syndrome transforming to
overt leukaemia compared to acute myeloid leukaemia
TJL Keith,w, Y Araki, M Ohyagi, M Hasegawa,
K Yamamoto, M Kurata, Y Nakagawa,z, K Suzukiz
and M Kitagawa
Department of Comprehensive Pathology, Aging and
Developmental Sciences, Graduate School, Tokyo Medical and
Dental University, Tokyo, Japan, wDepartment of Haematol-
ogy, Imperial College, London, UK, zDepartment of Haema-
tology, Japanese Red Cross Medical Center, Tokyo, Japan
Dysregulation of angiogenesis, the formation of new capillaries from
pre-existing vessels, increases bone marrow microvascular density
(MVD) through a similar process as occurs in solid tumours, which
display hypervascularity upon growth, facilitating the proliferation of
the malignant clone.
In order to investigate the regulatory mechanisms controlling
angiogenesis in the development of myelodysplastic syndromes
(MDS) and its progression to overt leukaemia (OL), bone marrow
samples from control, paired samples from MDS patients before and
after transformation to OL (MDS-OL) and de novo AML were
analysed using immunohistochemical staining of vascular associated
antigens, to visualise the microvasculature, to enable measurement of
MVD, and quantitative polymerase chain reaction (PCR) to measure
angiogenic mediator gene expression.
Immunohistochemical staining of the vascular associated antigens
revealed significant increase of MVD in MDS and de novo AML
compared to controls. Surprisingly, the MVD in MDS significantly
decreased upon transformation to OL, which was also significantly
lower than MVD of de novo acute myeloid leukaemia (AML). These
findings were strengthened by the pattern of angiogenic mediator
gene expression evaluated by quantitative polymerase chain reaction,
which correlated with MVD, confirming the importance of various
angiogenic mediators including VEGF, bFGF, TNFalpha, HGF and
the angiopoietin mediators Ang-1 and Ang-2, as well as the
angiogenic mediator receptors VEGFR2 and TIE2. Conversely,
TGFbeta, an angiogenic mediator, exhibited significantly higher
expression in the bone marrow of MDS when OL developed,
indicating the importance of this cytokine as the suppressive factor
of angiogenesis in MDS-OL.
These findings indicate that although morphologically similar, the
bone marrow microenvironment and pathogenic events occurring in
MDS-OL and de novo AML differ remarkably, suggesting that anti-
angiogenic therapy would display differing efficacy between de novo
AML and leukaemia secondary to MDS.
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Effect of selected healthy and psychosocial aspects on
quality of life in adult patients with acute myeloid
leukaemia undergoing autologous progenitor stem
cell transplantation
L Slovacek,w, B Slovackovaz, L Jebavy,w and J Horacek,w
Department of Field Internal Medicine, Faculty of Military
Health Sciences, University of Defence, Hradec Kralove, Czech
Republic, wDepartment of Clinical Haematology, Charles
University Hospital, Hradec Kralove, Czech Republic,
zDepartment of Psychiatry of Charles University Hospital,
Hradec Kralove, Czech Republic
Background: Study analyses the effect of selected healthy and
psychosocial aspects of quality of life in adult patients with acute
myeloid leukemia undergoing autologous progenitor stem cell
transplantation at the Department of Clinical Haematology of the
2nd Internal Clinic of Charles University Hospital in Hradec Kralove,
Czech Republic.
Patients and methods: The total number of respondents with acute
myeloid leukaemia undergoing autologous transplantation from 2001
to 2003 was 19. The return rate of questionnaires was 63% (12
respondents). There were 100% ratable questionnaire. The mean age of
all patients was 47.5 years old (age range 27–68). The males were seven
and the females were five. The Czech version of an international
generic European Quality of Life Questionnaire – Version EQ-5D was
used. The effect of selected aspects (age, sex, level of education, marital
status, number of associated diseases, smoking abuse, religion and time
lapse from autologous transplantation on quality of life in patients was
determined by means of analysis of variance.
Results: The above-mentioned factors proved statistically significant
dependence quality of life (EQ-5D score and EQ-5D VAS) on age (Po
0.01), religion (Po0.05), smoking abuse (Po0.01), education (Po
0.05) and number of associated diseases (Po0.05). EQ-5D score
(dimensions of quality of life) and EQ-5D VAS (a subjective health
condition) significantly decrease with increasing age, religion,
smoking abuse, level of education and number of associated diseases
in patients with acute myeloid leukaemia undergoing autologous
progenitor stem cell transplantation. The effect of other aspects on
quality of life was not proven as statistically significant.
Conclusion: The global quality of life in adult patients with acute
myeloid leukemia undergoing autologous progenitor stem cell
transplantation is on greatly good level (mean EQ-5D score 75.1%,
mean EQ-5D VAS 67.5%) at the Department of Clinical Hematology
of the 2nd Internal Clinic of the Charles University Hospital in
Hradec Kralove, Czech Republic.
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Quality of life in patients with multiple myeloma and
malignant lymphoma after autologous progenitor
stem cell transplantation: an effect of selected
psychosocial and healthy aspects on quality of life: a
retrospective study
L Slovacek,w, B Slovackovaz, L Jebavy,w and M Blazekw
Department of Field Internal Medicine, Faculty of Military
Health Sciences, University of Defence, Hradec Kralove, Czech
Republic, wDepartment of Clinical Haematology, Charles
University Hospital, Hradec Kralove, Czech Republic,
zDepartment of Psychiatry, Charles University Hospital, Hradec
Kralove, Czech Republic
Background: The study analyses the effect of selected psychosocial
and healthy aspects on quality of life in patients with multiple
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myeloma and malignant lymphoma after the autologous progenitor
stem cell transplantation. Patients and Methods: The total number of
respondents after the transplantation from 2001 to 2003 was 80 and
the return rate of questionnaires was 70% (56 respondents: 32
respondents – 18 male and 14 female with multiple myeloma and 24
respondents – 11 male and 13 female with malignant lymphoma). The
average age of patients with multiple myeloma was 60 years and the
average age of patients with malignant lymphoma was 44.5 years. The
Czech version of an international generic European Quality of Life
Questionnaire – Version EQ-5D was used. The effect of selected
aspects (age, sex, level of education, marital status, number of
associated diseases, smoking abuse, religion, type of disease and the
time lapse from the transplantation) on quality of life in patients was
determined by means of analysis of variance. Results: The above-
mentioned aspects proved statistically significant dependence of
quality of life on age, smoking abuse in patients with multiple
myeloma and on type of disease. EQ-5D score (dimensions of quality
of life) and EQ-5D VAS (a subjective health condition) significantly
decrease with increasing age in both groups patients and with
smoking abuse in patients with multiple myeloma, and are
significantly higher in patients with malignant lymphoma. The effect
of other aspectes on quality of life was not proven as statistically
significant. Conclusion: The quality of life in patients with multiple
myeloma after the autologous progenitor stem cell transplantation is
lower (mean EQ-5D score 68.9%, mean EQ-5D VAS 66.6%) than in
patients with malignant lymphoma after the transplantation (mean
EQ-5D score 82.7%, mean EQ-5D VAS 76.7%) at the Department of
Clinical Hematology of the 2nd Internal Clinic of Charles University
Hospital in Hradec Kralove, Czech Republic.
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The role of admission flowcharts in ensuring rapid and
appropriate access to inpatient facilities
H O’Shea, N Lewis and C Loran
Department of Clinical Haematology, University Hospital of
Wales, Cardiff, UK
Advances in treatment for haematological malignancies have resulted
in more patients with increasingly complex health needs requiring
treatment as inpatients. As a level four centre, with referrals from all
over South and Mid wales, demand for beds can often exceed
capacity; however, GP’s and local hospitals can be understandably
nervous to treat Acute Haematology patients.
When patients telephone the ward for advice, they may speak to a
relatively inexperienced nurse who may feel unable to advise them
not to attend for inpatient treatment, even if the problem is not
directly related to their haematological problem.
The senior clinical nurses within the haematology directorate met
to discuss how to manage this problem as well as how to ensure that
nursing staff feel supported in the advice they give. The result of this
meeting was a ‘flowchart’ to help to establish whether a patient
requires immediate admission to the ward or can be reviewed
initially by his GP or local hospital. Accompanying the flowchart was
a list of questions to ask the patient before offering any advice, as
well as who to contact for further advice about the appropriate
management of the patient. This poster gives an overview of the
problem and will demonstrate the flowchart and protocol for
admission.
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An investigation to assess the feasibility of nurse
prescribing of blood components
J Green and ES Piriew
National Blood Service, London, UK, wScottish National
Blood Transfusion Service, Edinburgh, UK
Currently prescribing blood components is viewed as a medical
responsibility. The rationale for this is unclear, as blood components
are not considered to be medicinal products. Lately, there has been
increasing interest by nurses wishing to provide more seamless care
for their patients in undertaking this role. The Department of Health
guidance however, state that this is inappropriate for nurse
precribing. The National Blood Service (NBS) and the Scottish
National Blood Transfusion Service (SNBTS) undertook a collabora-
tive project to explore the feasibility of nurses having the right to
prescribe blood components.
As a first step, a UK-wide survey to identify current practice and
canvass the opinion of nurses and doctors was undertaken. The survey
identified that 60% of respondees were supportive of nurses under-
taking this role, citing it would have a positive impact on the quality of
patient care, less treatment delays with doctors and nurses being able
to use their time more effectively. The remaining 40% of respondees
had reservations; these related to constraints with time, resources and
worries around undermining medical care and responsibility.
In the light of the evidence from the survey and investigation,
three proposals for the future direction of prescribing practice have
been suggested:
Proposal 1: No change to the current situation.
Proposal 2: Determine if blood components could be classified as a
borderline substance and included in the British National Formulary.
Proposal 3: Determine whether blood components could be classified
as a therapy.
The ambiguous situation surrounding the classification of blood
components is an issue, and will influence which proposal is taken for-
ward. Due to positive feedback the investigators will continue to promote
debate and lobby for support. Further development of non-medical
prescribing to include the right for nurses to prescribe blood components
has the potential to deliver a more patient-centred quality service.
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Thalidomide audit
V Murthy, J Neilson and P Harrison
Department of Haematology, Russells Hall Hospital, Dudley, UK
Purpose of this audit was to assess the use of of thalidomide,
response rate to thalidomide, thromboembolic complications and to
identify the regimen that produced the best response in myeloma at
Russells Hall Hospital.
Standard: Thalidomide used as a second or subsequent line unless in
trial.
Expected VTE o5% as single agent, 10–50% in combination
[Jeffrey A Zonder – Haematology 2006].
Response rate as per ASH Education programme book 2005, page
358.
We retrospectively reviewed the case notes of patients between
2000–2005.
We enrolled 46 patients [42 Myeloma, 4 patients MPD/
Myelofibrosis]. Twenty-eight per cent [13/46] received thalidomide
as first line. This included nine myeloma patients of which 7/9 were
in trial (77.7%). 72% (33/46) received thalidomide as Second line.
Twenty-two patients experienced side effects and four stopped
thalidomide. Main side effects were neuropathy and constipation
predominantly grades 1 and 2. DVT was seen in two patients.
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We used EBMT criteria to assess the response. In relapsed/
refractory Myeloma 66.6% (22/33) responded to thalidomide, 68% in
combination as CTD and 32% as single agent. Twenty-one per cent
(7/33) achieved CR, 39% (13/33) achieved PR and good PR. When
used as first line 88% responded (77% CR and good PR [6/9], 11% PR
[1/9]). Response rate was 50% (4/8) in refractory myeloma.
Best response: When thalidomide used as first line response rate was
77.7% (7/9) vs 55.5% (5/9) with VAD regimen. As a second line in
relapsed/ refractory myeloma thalidomide regimen had a response of
42.4% (14/33) vs 33.3% (2/6) with VAD regimen.
Conclusions: Majority of first line treatment are on trial (77.7%).
Peripheral neuropathy and constipation are common side effects
(grade 1–2). Thromboembolic complication is 4%, less than the
expected rate and in combination regimen.
66.6% responded to thalidomide in relapsed/ refractory myeloma.
50% of patients with refractory myeloma have responded to
thalidomide. 88% responded to thalidomide when used as first line.
Thalidomide containing regimen seemed superior to VAD/C-VAD
regimes (77.7% vs 55.5% as first line and 42.4% vs 33.3% as second
line).
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Reduced intensity conditioning transplant as a
succesful treatment for Kostmann‘s syndrome
J Thachil, T Dutt, P Bolton-Maggsw, M Caswell and
R Keenan
Department of Paediatric Haematology, Royal Liverpool
Children‘s Hospital, Liverpool, UK, wCentral Manchester
Healthcare Trust, Manchester, UK
Kostmann syndrome (KS) is a congenital disorder characterized by
severe neutropaenia (o 0.2 109/l) and recurrent bacterial infec-
tions. G-CSF improves neutropaenia in 90% of cases. For those who
do not respond, stem cell transplantation is the only effective
treatment.
We describe a boy with KS presenting with recurrent life
threatening infections including pneumonia and scrotal abscesses.
No response was observed to escalating doses of G-CSF up to 160mg/
kg/day.
We considered his transplant options. Eight patients with KS on
the Severe Chronic Neutropaenia International Registry underwent
transplant between 1976 and 1998, one received a non-myeloablative
regimen with cyclophosphamide alone but rejected the graft. Only
three patients received unrelated donor transplants, two died and the
third, though engrafted, was noted to have severe failure to thrive.
The French Registry reports nine patients between 1993 and 2003, all
but one receiving preparatory myeloablation. The non-myeloablative
regimen consisted of fludarabine and anti-thymocyte globulin before
a second stem cell transplant. The patient failed to engraft and died.
Our patient did not have a sibling and it was decided to proceed
with matched unrelated donor, peripheral blood stem cell transplant.
We opted to employ a novel reduced intensity conditioning regime.
(fludarabine 30 mg/m2 from day 8 to day 5, Campath-1H 0.2 mg/
kg from day 6 to day 2 and thiotepa 250 mg/m2 from day 4
to 2.)
The patient successfully engrafted with a neutrophil count greater
than 0.5 109/l on day 12. Peri-transplant toxicity was low with only
one febrile episode. The patient is now twenty-two months post
transplant with full donor chimaerism, maintains a normal
neutrophil count and has not required hospitalisation post
transplant.
We propose that a reduced intensityconditioning transplant from
a matched unrelated donor is an effective treatment for Kostmann
syndrome, and should be considered for those patients who fail to
respond to G-CSF.
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The impact of infection in early childhood on
intellectual function in adolescence: evidence from
children with sickle cell disease
AM Hogan,z, P Telferw and FJ Kirkhamz
Developmental Brain-Behaviour Unit, University of
Southampton, UK, wDepartment of Haematology,
The Royal London Hospital, UK, zDepartment of
Neurosciences, UCL, Institute of Child Health, UK
Background: Evidence obtained from older adults with neurodegen-
erative disorders suggests that systemic infection promotes an
inflammatory (cytokine) cascade that can lead to an exacerbation of
brain pathology and cognitive decline. Infection as a risk factor for
neurocognitive deficit in sickle cell disease (SCD) has previously
received little attention, although there is some evidence to
hypothesise that a similar pathophysiological pathway may be
activated in these children.
Methods: We retrospectively examined multiple steady-state white
blood cell (WBC) values from 52 children with HbSS SCD (0–16
years) to explore the influence of age, and the association with level
of intellectual function (Wechsler Full Scale IQ). Data were subjected
to mixed-model analysis of repeated measures.
Results: WBC count was chronically high during early to mid
childhood, but decreased thereafter and was maintained at a lower
level through adolescence. In support of our hypothesis, every IQ
point lost in late childhood (9–16 years) was associated with a .14
increase in WBC count during early childhood (0–9 years) (95% CI,
0.26–.02, P5 0.022). While the extent of WBC count variability was
not fully related to later IQ (P5 0.137), approximately 30% of its
variance between children during the ages of 0–9 years was
associated with the level of intellectual function that they demon-
strated in later childhood.
Conclusion: These pilot data suggest that systemic infection may
contribute to intellectual losses in children with SCD. Further
research is required to confirm the possibility that systemic infection
exacerbates underlying brain vulnerability via cytokine activation.
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Changes in brain magnetic resonance imaging
findings in children with sickle cell disease
J Motwani, K Johnson, HK Kanthimathinathan, SE Lawson
and PJ Darbyshire
Birmingham Children’s Hospital, Birmingham, UK
Children with sickle cell disease (SCD) are at high risk for both
neurologically overt cerebral infarcts associated with stroke and
neurologically silent cerebral infarcts (SCI) correlated with neurop-
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sychometric deficit. We performed magnetic resonance imaging
(MRI) & angoigraphy (MRA) on unselected group of 42 children with
SCD aged 2.5–19 years to assess the prevalence of SCI.19 children had
abnormal imaging (45%). Four children had had overt stroke (3
females, 1 male), 2 had SCI with stroke (50%). Fifteen (38%) children
had evidence of SCI (9 females, 6 males) aged o5 years: 2, 5–10: 7,
10–15 3, 415 years: 3.This baseline prevalence is significantly more
than previously reported. Few centres that have looked at this as a
screening tool. Ninty-three pre cent of children with SCI had lesions
in the frontal cortex. Those with overt stroke had lesions of frontal
and parietal cortex. All the patients with overt stroke are on a
transfusion programme. Repeat MRI/MRA did not reveal any new
SCI, suggesting benefit of chronic transfusion. None of our patients
with SCI have developed overt stroke. The investigation has
identified two children with SCI on MRI/A and elevated TCD, who
have been commenced on a prophylactic transfusion programme.
Elevated TCD is known to predict of increased stroke risk and
there is evidence to suggest that SCI are associated with an increased
stroke risk. Studies have shown discordance in MRI and TCD
findings, suggesting that they reveal different aspects of CNS injury
in patients with SCD. More specific indicators of early CNS
pathology, such as neuropsychometric testing may be beneficial.
Chronic transfusion decreases SCI and stroke risk in children with
elevated TCD, further study is required to determine its risk-benefit
ratio in children with SCI detected on MRI/A. We are incorporating
this investigation into our surveillance of children with SCD and will
be prospectively evaluating MRI/A alongside TCD and neuropsycho-
metric testing.
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The use of continuous positive airways pressure in the
management of acute chest syndrome in sickle cell
disease
J Howard, I Gabrielw, S Webster, V Mak and SC Davies
Department of Haematology, Central Middlesex Hospital,
London, UK, wDepartment of Haematology, Hammersmith
Hospital, London, UK
Acute chest syndrome (ACS) is the second most common cause of
hospital admission in patients with Sickle Cell Disease (SCD) and is
the leading cause of mortality in young adults. In our centre we use
early ventilatory support with Continuous Postive Airways Pressure
(CPAP) in patients who are markedly hypoxic or have ACS, in
addition to standard therapy with intravenous fluids and antibiotics.
We report our recent experience here.
Twenty-three episodes of ACS were identified retrospectively over
a two year period and the notes of those patients were reviewed.
Eighteen patients were involved, as three patients had more than one
episode of ACS during the study period. There were 10 female and
eight male patients with an age range of 19–53 years (mean 28 years).
The distribution of phenotype was representative of our clinic
population consisting of 13 patients (72%) with homozygous sickle
cell disease, three patients with HbSC disease and two patients with
HbSBthalassaemia.
Chest pain was a feature in 19 of the episodes (83%), pyrexia was seen
in 21 episodes (91%) and dyspnoea was a feature in 22 episodes (96%).
Five patients did not have changes on their chest radiograph, but had
respiratory symptoms and were markedly hypoxic. In only four episodes
(17%) was a red cell transfusion required because of persistant hypoxia
despite CPAP. No patient required mechanical ventilation and there
were no deaths. These results compare very favorably with similar
studies from the UK and the USA, with reduced requirements for both
transfusion and mechanical ventilation seen in our study.
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Plasma haemoglobin levels in Omani patients with
sickle cell disease
SA Kaaba and SS Al-Kindi
Department of Haematology, College of Medicine and Health
Sciences, Sultan Qaboos University, Muscat, Oman
Intravascular haemolysis is common in sickle cell disease (SCD). The
released Hb in plasma reacts readily with nitric oxide and limits its
bio-availability, and may promote vaso-occlusion as nitric oxide has
potent vaso-dilatory properties. Symptomatic SCD is common in
Oman where the gene frequency is 6%. The plasma Hb levels of 16
adult Omani patients with sickle cell disease, with frequent crises
(more than three vaso-occlusive crises per year requiring hospita-
lization) were compared to 17 patients who were stabilized with
infrequent crisis with or without hydroxyurea treatment. Plasma Hb
levels in patients with frequent crises was 257.97 87.2 mg/l (105.0–
370 mg/l) compared to 190.87 60.7 mg/l (74.0–310.0 mg/l) in stabi-
lized patients without frequent crisis, and this represented a
significantly difference in the two groups (P5 0.041). Although
overall WBC count was high in the frequent crisis group
(11.797 4.82 109/l compared to 8.607 4.32 109/l), however, this
did not represent a significantly difference between the two groups
(P5 0.066). Lower Hb levels, which was statistically insignificant,
were also seen in the frequent crisis group (8.697 1.55 g/dl compared
to 10.137 2.06 g/dl in the infrequent crisis group; P5 0.086). The
neutrophil count was significantly higher (P5 0.012) in the frequent
crisis group compared to those on hydroxyurea and with infrequent
crisis (7.047 3.67 109/l and 4.317 3.02 109/l, respectively). Free-
plasma Hb was positively correlated to the WBC count (rs5 0.451,
P5 0.011) and overall monoctye count (rs5 0.553, P5 0.001). These
findings may be useful in defining the role of haemolysis in the
morbidity of sickle cell disease.
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High definition contrast-enhanced MR imaging in
paroxysmal nocturnal haemoglobinuria (PNH) sug-
gests a high frequency of subclinical thrombosis
A Hill, SA Reidw, RP Rotherz, MT Gladwiny, PO Collinsonz,
DC Gazez, A LoweJ, A GuthrieJ, MU Sivananthanw,J and P
Hillmen
Department of Haematology, Leeds General Infirmary,
Leeds, UK, wLIGHT, University of Leeds, Leeds, UK,
zDepartment of Research, Alexion Pharmaceuticals, Inc.,
Cheshire, USA, yVascular Therapeutics Section, NIH, Bethesda,
USA, zDepartment of Chemical Pathology, St George’s
Hospital, London, UK, JDepartment of Radiology, Leeds
General Infirmary, Leeds, UK
Thrombosis is the most feared complication in PNH and is reported
to occur in 440% of patients. Proposed mechanisms of thrombosis
include depletion of nitric oxide (NO) by intravascular haemolysis
and increased activation of PNH platelets. The occurrence of
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subclinical thrombosis in PNH patients has not been previously
studied using modern imaging techniques. In order to assess for
subclincal thrombosis we evaluated PNH patients with a compre-
hensive state-of-the-art MRI protocol (using both blood pool and
conventional Gadolinium based contrast agents) for the detection of
subclinical thrombosis and its sequelae. The protocol consisted of:
(a) lung perfusion and pulmonary MRA, (b) cardiac MR-including
quantitative studies of both ventricles, right heart flow dynamics and
delayed enhancement for detection of left ventricular damage, (c)
abdominal MR for the assessment of hepatic and portal venous
systems and kidneys. Ten PNH patients (median age 31.5 years) with
large PNH clones but without previous clinical evidence of venous or
arterial thrombosis underwent imaging. Five (50%) patients were on
primary anticoagulant prophylaxis. There was evidence of significant
renal haemosiderosis throughout the cortices in 9/10. Two patients
had small myocardial scars suggestive of previous unsuspected
ischaemic damage. Six patients had sub-segmental perfusion defects
mainly in the peripheries of the lung fields indicative of previous
small pulmonary emboli. No such subclinical thromboses would be
anticipated in an age-matched control population. Eight patients had
reduced right ventricular ejection fractions (mean 42.2%7 1.8%;
normal range 48–63%). The plasma B-type natriuretic peptide (BNP)
level was high in all 10 patients (median 29.4 pmol/l; range 18.7–
373.90; normal subjects 4.897 1.00 pmol/l). BNP has been shown to
increase in proportion to right ventricular dysfunction in pulmonary
hypertension. No intra-abdominal defects were identified with the
current protocol. In summary, we identified abnormalities suggestive
of previous subclinical thromboses in six of 10 haemolytic PNH
patients by high-resolution MR imaging, including in patients on
primary prophylaxis with warfarin. Effective prevention of throm-
bosis is an important aspect of the therapy in PNH.
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The incidence and prevalence of paroxysmal nocturnal
haemoglobinuria (PNH) and survival of patients in
Yorkshire
A Hill, PJ Plattsw, A Smithw, SJ Richards, MJ Cullen,
QA Hill, E Romanw and P Hillmen
HMDS, Leeds General Infirmary, Leeds, UK, wEpidemiology
& Genetics Unit, University of York, UK
PNH is characterised by a population of blood cells deficient in
glycosylphosphatidylinositol-linked proteins resulting in the features
of intravascular haemolysis and thrombosis. PNH is a rare disorder,
but its incidence and prevalence have been poorly defined. In order
to better define the incidence and prevalence, data was collected on
PNH patients in the strategic health authorities of North and East
Yorkshire, Northern Lincolnshire and West Yorkshire between
January 1991 to July 2006. All patients were diagnosed by flow
cytometry at the HMDS laboratory. The population of the study
region is 3 742 835. Seventy-six PNH patients were diagnosed giving
an incidence of 0.13/100 000/year. Based on incidence and survival
rates, the estimated 15-year prevalence of PNH is 1.59 per 100 000
resulting in a predicted prevalence of 59 patients in the study region.
A neutrophil clone size 450% is a predictor of increased thrombotic
risk; this study predicts 25% of patients will have 450% PNH
neutrophil clone size, 43% with 410%, and 82% with 41%. Platelet
count 4100 109//l is used to consider primary prophylactic
anticoagulation if the neutrophil clone size is 450%. In this study,
the platelet count is 4100 109/l in 32% and o30 109//l in 27%.
Levels of LDH were elevated in 82.5% of patients. Of the 59 patients
in the study region, 33% reported haemoglobinuria. Overall survival
was 78% with a median follow-up of 6.25 years (range 0–15 years).
Survival was compared between patients with (a) haemoglobinuria
(89%) vs those without (76%); (b) neutrophil clone size 450% (81%)
vs o50% (80%) and c) platelet counts o30 109/l (61%) vs
430 109/l (86%). Worse survival was predicted by platelet counts
o30 109/l (P5 0.008). With a population of 57 105 375, Britain
should have an estimated 75 new cases of PNH/year and a predicted
prevalence of 908 patients. This study is the first to accurately report
the incidence and prevalence of PNH in a given population in a well-
defined geographical area.
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The use of a text messaging service to improve
attendance at a sickle cell clinic
S Patel, J Howard and K Anie
Haematology and Sickle Cell Clinic, Central Middlesex
Hospital, London, UK
The attendance rates at out-patient clinic appointments tend to be
poor within the sickle cell population. This is partly because patients
forget their appointments which are usually at 6–12-month intervals.
We attempted to decrease the non-attendance rates in our paediatric
and adult clinics using a mobile phone texting service to remind
patients of their routine clinic appointments. This was piloted from
July to December 2006 and a reminder message was texted to
patients or parents of the patients due to attend the clinic that week.
From January to June 2006, 67% of paediatric and 55% of adult
patients attended their clinic appointments. This compares to
attendance rates of 72% in the paediatric clinic and 62% in the
adult clinic from July to December 2006, after the texting service was
introduced. This showed an overall improvement in attendance,
although there was better attendance at the paediatric clinic.
Statistical analyses showed significant improvements in attendance
and non-attendance rates across both clinics. There was a highly
significant improvement in the adult non-attendance rate (Po
0.005), and significant improvements in paediatric attendance (Po
0.01) the paediatric non-attendance rate (Po0.05) and adult
attendance (Po0.05).
We also noted that we did not have up-to-date mobile phone
numbers for all patients; overall 58% of all patients who had clinic
appointments were texted, the remaining 42% were not texted
reminders because we did not have their current mobile numbers.
We are now collecting current mobile numbers from all patients
when they attend clinic and expect to see further improvements in
attendance in the future.
This study shows that the texting service is feasible and is
contributing to improvements in clinic attendance at Central
Middlesex Hospital. Additionally the service has been received
positively by patients, who have reported finding it very helpful in
reminding them of their appointments.
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The use of real-time PCR technique in the
classification of thalassaemias
M Maciag, A Adamowicz-Salachw, A Krawcewiczz,
E Zdebskaz, J Koscielakz and B Burzynska
Institute of Biochemistry and Biophysics, PAS, Warsaw,
Poland, wDepartment of Paediatrics, Haematology and
Oncology, Medical University of Warsaw, Warsaw, Poland,
zInstitute of Haematology and Blood Transfusion, Warsaw,
Poland
The thalassaemias are a diverse group of disorders characterized by
decrease in the amount of normal hemoglobin. Reduced synthesis of
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one or more globin chains leads to imbalanced globin chain
production which influences the severity of thalassaemia. The two
main types of thalassaemias are alpha-thalassaemia caused by
mutations in the gene coding for alpha globin and beta-thalassaemia
resulting from beta globin gene mutations.
The aim of our study was to look for genetic changes in the alpha
and beta globin genes in a group of unrelated Polish patients. We
also discuss the effect of these mutations on the expression level of
the globin genes.
Molecular analysis revealed eight different mutations affecting
transcription and RNA processing (50UTR1 33C4T; IVS-I-15T4C;
IVS-II-745C4G; IVS-I-1G4A; IVS-I-5G4A; IVS-I-64A; 1 and 2
substitutions in 30UTR) and two structural mutations (Val98Met
HbKoln; Phe42 del) in the alpha-globin gene. Multiplex PCR showed
3.7 deletion in alpha-globin gene cluster in patients.
To analyze gene expression we used real-time PCR. Pfaffl model was
employed to estimate the relative changes in alpha-, beta-, gamma- and
delta-globin genes expression of thalassaemia subjects in comparison
with healthy individuals. Data normalization was carried out against
two previously selected reference gene transcripts.
There is a correlation between alpha-globin and beta-globin mRNA
levels and genetic background of the analyzed patients. Most of
thalassaemia patients reveled increased gamma-globin and delta-
globin mRNA levels but there is no correlation between gamma-globin
and delta-globin gene expression levels and HbA2 and HbF levels.
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Hereditary erythrocyte disorders in Poland
E Zdebska, J Spychalska, G Smolenska-Sym,
A Sajkowska, E Golaszewska, A Krawcewicz,
E Mendek-Czajkowska, A Adamowicz-Salachw, B Burzynskaz
and J Koscielak
Institute of Haematology and Transfusion Medicine, War-
saw, Poland, wDepartment of Paediatrics, Haematology and
Oncology, Medical University of Warsaw, Warsaw, Poland,
zInstitute of Biochemistry and Biophysics, PAS, Warsaw,
Poland
In 2003, in response to a need to improve diagnosis of hereditary
disorders of erythrocytes in Poland, we established at the Institute of
Haematology and Transfusion Medicine a specialized diagnostic
centre. Before that date most of those diseases were unrecognized,
and some like thalassaemia were considered very infrequent. The
only exceptions were erythrocyte enzymopathies but the diagnostic
laboratory for those disorders ceased of action in 2002. We started
with setting up modern diagnostic techniques and elaborating some
of our own. The latter applies to developing of the method for
determination of carbohydrate molar composition of membrane
glycoproteins separated by SDS-PAGE, refining SDS-PAGE to
determine major protein bands in terms of copy number per
erythrocyte, and recently, procuring a rapid screening test for
congenital dyserythropoietic anaemia type II. Since 2004 we analyzed
1800 blood samples from patients with anaemia of uncertain
etiology, most of which were sent to us by mail from all over
Poland. We have established correct diagnosis in 182 patients with
spherocytosis, 64 patients with deficiency of erythrocyte enzymes (61
with G6PD, two with PK and one with GPI), 281 patients with beta
thalassaemia minor, at least 27 patients with beta thalassaemia
intermedia (two homozygotes for IVS1–6(T4C) mutation were
identified) and four patients with congenital dyserythropoietic
anaemia type II. In addition we found 11 patients with alpha
thalassaemia (see Maciag et al, this Meeting). Most surprising was the
high number of patients with beta thalassaemia. Of those patients
70% had mutations of the Mediterranean type. The most common
mutations were IVS1–6(T4C) and IVS2–745(C4G). Unfortunately,
in a large percentage of cases we are yet unable to establish a
diagnosis. More advanced techniques for a fast diagnosis of
hereditary disorders of erythrocytes are needed.
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Abnormalities of erythrocyte glycoconjugates are
identical in two CDA-II families with different
chromosomal localization of the disease gene
E Zdebska, A Iolasconw, J Spychalska, S Perrottaz,
C Lanzaraw, G Smolenska-Sym and J Koscielak
Department of Biochemistry, Institute of Haematology and
Transfusion Medicine, Warsaw, Poland, wDepartment of
Biochemistry and Biomedical Technologies, Second University
of Naples, Naples, Italy, zPediatric Department, Second
University of Naples, Naples, Italy
Congenital dyserythropoietic anaemia type-II (CDA-II) is a rare,
recessively inherited disease characterized among others by
abnormalities affecting erythrocyte glycoconjugates. Here we report
the carbohydrate molar composition of erythrocyte anion exchanger
(AE1), glycophorin A, polyglycosylceramides as well as total
carbohydrate contents of erythrocyte oligoglycosylceramides in two
affected siblings and two healthy parents from each of the two CDA-
II families: family 1 with the typical localization of the disease gene
(CDAN2) to chromosome 20q11.2 and family 2 in which this
localization was excluded and a detailed glycoconjugate analysis
was never performed. In spite of the different genetics, the
glycoconjugate abnormalities of erythrocytes in the two families
were identical suggesting a complex inheritance of CDA-II. The
glycoconjugate abnormalities in the parents showed a dosage effect
thus, making possible detection of CDA-II carrier state regardless of
chromosomal localization of CDAN2. We also report for the first
time that erythrocyte AE1 protein is decreased in CDA-II homo-
zygotes and obligate carriers alike.
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Pulmonary arterial hypertension in children with
sickle cell disease: how common is it?
RA Chaudry,w, T Karu, C Hutchinson, S Ball,
G Sutherland, A Bushw, M Rosenthalw and S Crowleyw
St George’s Hospital London, UK, wRoyal Brompton Hospital,
London, UK
The prevalence of Pulmonary Arterial Hypertension (PAH) in adults
with Sickle Cell Disease (SCD) is estimated to be 32% with a 2-year
mortality of 50% from diagnosis. The age of onset is currently
unknown. Echo Tricuspid Regurgitant jet Velocity (TRV) has been
shown to correlate well with catheter measurements of pulmonary
artery pressures and is useful as a non-invasive tool. Hyper-
haemolytic state defined by Haemoglobin (Hb)o 8.5 g/dl and
number of Acute Chest Syndrome (ACS) events may be associated
with an increased risk. Peak incidence of ACS is between 2–5 years.
Aims: To prospectively determine prevalence of PAH in children
with SCD and define associated risk factors.
Methods: Figty (F5 26) patients with SCD, median age 14, range 10–
18 year, and 50 (F5 25) sex-, age-, race-matched healthy controls
were recruited. TRV was measured using 2D-Doppler echo; all
subjects were at baseline state of health. Patients were free of any
vaso-occlusive crisis for 414 days. Hb was measured in all subjects;
detailed medical history was taken with verification from hospital
notes.
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Results: Sixteen out of fifty (32%) of patients had TRV 4 2.5 of m/s.
4/50 (8%) of controls had TRV 42.5 m/s. Age vs TRV 4 2.5 m/s
P5 0.846; Gender vs TRV 4 2.5 m/s P5 0.071; Hbo8.5 g/dl vs TRV
4 2.5 m/s P5 0.108; ACS admission 4 1 vs TRV 4 2.5 m/s P5 0.163.
The youngest patient with TRV 4 2.5 m/s was 10 years. Intra and
inter-observer repeatability/reproducibility studies were robust.
Conclusion: These data suggest a significant number of children with
SCD have echo evidence of PAH. We were unable to identify
association between elevated TRV and hyper-haemolysis, number of
ACS events or increasing age within the patient group. All subjects
with raised TRV will be followed up including the controls. We
suggest all children with SCD be screened for PAH from age 5 years
onwards. Longitudinal studies with therapeutic intervention are
required to enable monitoring of disease progression and response
to treatment.
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A 16.5 kb deletion in the alpha globin cluster
associated with an extremely mild phenotype
MJ Rugless, CA Fisher, J Sloane-Stanley, SA Butler,
H Ayyub, AD Stephensz, RJ Amosy, WG Wood, JM Oldw,
D Garrick, DR Higgs and K Clark
MRC Molecular Haematology Unit, Weatherall Institute of
Molecular Medicine, Oxford, UK, wNational Haemoglobino-
pathy Reference Laboratory, Churchill Hospital, Oxford, UK,
zDepartment of Haematological Medicine, King’s College
Hospital, London, UK, yDepartment of Haematology, Home-
rton Hospital, London, UK
We describe and characterise a de novo deletion in the alpha-globin
cluster identified in a Vietnamese neonate and associated with an
extremely mild alpha-thalassaemia phenotype. The 16.5 kb deletion
removes a significant proportion of the alpha-globin cluster
including pseudo zeta, alpha D, pseudoalpha1 and the alpha2 gene
but importantly leaves the alpha1 gene and associated promoter
completely intact. Located at the breakpoint junction is an insertion
sequence which most likely originates from a repeat element in the
pseudozeta gene. Results from functional analysis of the mutant
chromosome in isolation suggest that this deletion may have an
upregulatory effect on the intact alpha1 gene. This apparent
upregulation could be related to the increased proximity of the
alpha1 gene to cis-acting regulatory elements including HS-40 and/or
reduced competition for them due to the absence of the dominant
alpha2 gene and the minor alphaD gene. The observation that this
novel deletion is associated with such a mild phenotype suggests that
much of the DNA removed by this deletion is functionally redundant.
Furthermore, it is entirely possible that similar types of deletions
could exist that would remain undetected.
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Single centre experience of the efficacy of screening
for proliferative sickle cell retinopathy
V Tindell, S Nimalasena and J Howard
Department of Haematology, Central Middlesex Hospital,
London, UK
Visual loss is common in Sickle Cell Disease, affecting up to 20% of
patients, and is usually due to proliferative sickle retinopathy (PSR).
As the majority of patients with PSR are asymptomatic we provide
yearly ophthalmology screening for all patients with SCD and offer
pan-retinal photocoagulation laser treatment to those with PSR. We
decided to assess the efficacy of this programme by reviewing all
ophthalmic clinic attendances over the previous two years, because
of poor attendance at ophthalmology appointments and also because
over 60% of patients identified with PSR show regression of the
retinopathy over time without intervention.
By using the hospital information system we identified 256
patients who had been referred to the opthalmologists of whom 140
attended their appointment. The notes were available for 71 patients
(51%) and these were reviewed. Thirty-nine patients (55%) had no
sickle retinopathy or non-proliferative retinopathy. No patients had
grade 1, 13 had grade 2, three had grade 3, six had grade 4 and ten had
grade 5 retinopathy. Eight out of the ten patients (80%) with grade 5
and three out of the five patients (60%) with grade 4 retinopathy had
HbSC disease.
Eleven patients were symptomatic, nine with Hb SC and two with
Hb SS and all of these had grade 3 retinopathy or above. Laser
treatment was necessary in nine patients, all were symptomatic and
eight had HbSC.
We have a poor rate of attendance to ophthalmology appoint-
ments in our patient group, leading to a waste of resources. We
found a low incidence of proliferative retinopathy in patients with
HbSS or HbSBthalassaemia. In order to maximize uptake of
ophthalmology screening we should offer this as part of a one stop,
annual clinic review and target the HbSC population for screening.
101
TRIUMPH, a randomized placebo-controlled phase III
trial, demonstrates that the terminal complement
inhibitor eculizumab improves anaemia in PNH
A Hill, J Schubertw, U Duhrsenz, NS Youngy, M Elebutez,
J SzerJ, G Gianfaldoni, G Socieww, P Hillmen, CF Mojcikzz,
RP Rotherzz and P Muusyy
Leeds Teaching Hospitals NHS Trust, Leeds, UK, wSaarland
University, Medical School, Homburg/Saar, Germany,
zUniversity Hospital of Essen, Essen, Germany, yNIH NHLBI,
Bethesda, MD, USA, zSt George’s Hospital, London, UK, JRoyal
Melbourne Hospital, Melbourne, Australia, Azienda Ospe-
daliera Universitaria Careggi, Firenze, Italy, wwHospital Saint
Louis and INSERM, Paris, France, zzAlexion Pharmaceuticals
Inc., Cheshire, CT, USA, yyRadboud University Medical Center,
Nijmegen, the Netherlands
Paroxysmal nocturnal haemoglobinuria (PNH) is a life-threatening
haemolytic anaemia in which red blood cells (RBCs) lacking
complement inhibitory proteins are sensitive to complement-
mediated destruction. Intravascular haemolysis often requires
transfusion with packed RBCs (PRBCs) to maintain tolerable
haemoglobin levels. Eculizumab, a terminal complement inhibitor,
has been shown in a placebo-controlled randomized phase III trial
(TRIUMPH) to reduce haemolysis and transfusion requirements. We
report here a detailed analysis of the effect of eculizumab on various
parameters of anaemia in these study patients. Eculizumab-treated
patients, as compared to placebo, showed an 85.8% decrease in
intravascular haemolysis (as measured by LDH area under the curve,
Po0.001), resulting in a 68% increase in PNH RBC mass from a
mean of 1.1927 0.1 1012 cells/l at baseline to 2.0077
0.13 1012 cells/l at 26 weeks (Po0.001). The PNH RBC mass in
placebo-treated patients was unchanged. Similarly, haemoglobin
levels in eculizumab-treated patients increased relative to placebo (P
o0.001). PRBC units transfused decreased from a median of 10.0/
patient with placebo to 0.0/patient with eculizumab (Po0.001), and
51.2% of eculizumab-treated patients became transfusion indepen-
dent (vs 0.0% of placebo patients, Po0.001). Even patients
who required some transfusions while on eculizumab showed a
marked reduction in transfusion requirement (from a median of
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10.0 U/patient with placebo to 6.0 U/patient with eculizumab; Po
0.001) as well as in intravascular haemolysis (Po0.001). The
reduction in PRBC units transfused with eculizumab was observed
regardless of transfusion requirements prior to treatment (4–14 U/
year; 15–25 U/year; and 425 U/year, Po0.001 for each stratum).
These data demonstrate that control of intravascular haemolysis in
PNH with eculizumab results in a substantial improvement in
anaemia, as evidenced by an increase in endogenous RBC mass and
haemoglobin, and a reduction in transfusion requirements. These
improvements with eculizumab are demonstrated regardless of
historical transfusion requirements or whether patients achieve
transfusion independence during treatment.
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The terminal complement inhibitor eculizumab
reduces thrombosis in patients with paroxysmal
nocturnal haemoglobinuria
P Hillmen, A Hill, P Muusw, U Duhrsenz, AM Risitanoy,
J Schubertz, NS YoungJ, H Schrezenmeier, J Szerww,
RA Brodskyzz, G Socieyy, SA Rollinszz, RP Rotherzz, L Bellzz
and L LuzzattoJJ
Department of Haematology, Leeds Teaching Hospitals NHS
Trust, Leeds, UK, wRadbound University Medical Center,
Nijmegen, the Netherlands, zUniversity Hospital of Essen,
Essen, Germany, yMediche Federico II Univ., Naples, Italy,
zSaarland University Medical School, Homburg/Saar, Ger-
many, JNIH NHLBI, Bethesda, MD, USA, Institut fu¨r Klinische
Transfusionmedizi and Immungenetikn, Helmholtzstr, Ger-
many, wwRoyal Melbourne Hospital, Melbourne, Australia,
zzSidney Kimmel Comprehensive Cancer Center, Johns Hop-
kins University, Baltimore, MD, USA, yyHospital St. Louis and
INSERM, Paris, France, zzAlexion Pharmaceuticals Inc.,
Cheshire, CT, USA, JJIstituto Toscano Tumori, Firenze, Italy
Life-threatening thromboembolism (TE) is the most feared compli-
cation in paroxysmal nocturnal haemoglobinuria (PNH). Approxi-
mately 45% of PNH deaths result from TE. Primary prophylactic
anti-coagulation may reduce the thrombotic risk in PNH patients,
although controlled studies have not been performed and there is a
risk of serious haemorrhage. Three completed studies of the terminal
complement inhibitor eculizumab in PNH recently demonstrated
dramatic reductions in intravascular haemolysis and units of red
cells transfused. We prospectively examined the aggregate TE event
rate in eculizumab-treated patients from these studies and a
subsequent common phase 3 extension study. Before receiving
eculizumab, 124 TE events in 195 patients were identified; 103 patients
were on anti-thrombotics. Eculizumab reduced the TE rate in each
study. The aggregate TE event rate with eculizumab treatment was
1.07 per 100 patient years, compared to 7.37 (Po0.001) in the same
patients before eculizumab treatment, corresponding to a reduction
of 85%. Sensitivity analyses showed the effect to be robust. With
restriction of the pre-treatment observation period to the 12-months
before initiation of the trials, the TE event rate with eculizumab was
reduced 94% from 17.21 to 1.07, respectively (P5 0.002). The TE
event rate was reduced from 21.42 pre-treatment in patients with TE
prior to the trials (n5 63) to 2.27 during eculizumab treatment (Po
0.001). Most TE events prior to eculizumab treatment occurred in
patients receiving anti-coagulants, indicating that this therapy may
be insufficient to prevent thrombosis. Of 103 patients on antic-
oagulants, there were 54 TE events in 30 patients over 385.73 patient
years (14.00/100 patient years) pre-eculizumab compared to one TE
event with eculizumab in 161.8 patient years (0.62/100 patient years;
Po0.001), demonstrating that eculizumab reduces the risk of
thrombosis in anticoagulated PNH patients. These data show that
long-term eculizumab treatment results in a clinically and statisti-
cally significant reduction in thrombosis in patients with PNH.
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Platelet count has no influence on traumatic and
bloody lumbar puncture in children undergoing
intrathecal chemotherapy
JA Ruell, R Karuvattil, R Wynn and A Will
Department of Haematology, Manchester Children’s Hospital,
Manchester, UK
The British Society of Haematology (BSH) produced guidelines in
2002 recommending a platelet count of greater or equal to 50 109/l
was necessary to safely proceed with a lumbar puncture (LP).
Howard et al. (2000) reported a large retrospective analysis of 4309
LPs performed in 959 children including 941 procedures with platelet
count of o50 109/l with no neurological haemorrhagic complica-
tions. This paper recommended to perform routine LP, a platelet
count of 10 109/l or higher would be adequate.
We have retrospectively analysed our institute experience of 54
patients undergoing 713 LP procedures using greater or equal to 30
x109/l as a cut off for a safe lumbar puncture. We have evaluated
complications and determined whether the platelet count has any
significance on the rate of red cell contamination. Of the 713 LPs, 65
(9%) were traumatic and 30 (4%) were bloody, but this was not
dependant on the pre LP platelet count. These results indicate a
significantly lower rate of traumatic and bloody LPs than previously
reported. There were no post LP bleeding or neurological complica-
tions.
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Developing a blood conservation care plan for
Jehovah’s Witness patients with malignant disease
DR Norfolk, P Wadew and R Carterz
NHS Blood and Transplant and Leeds Teaching Hospitals NHS
Trust, Leeds, UK, wHospital Information Services for Jehovah’s
Witnesses, London, UK, zHospital Liaison Committee for
Jehovah’s Witnesses, Leeds, UK
Jehovah’s Witnesses (JWs), like any other patients, seek the most
effective treatments for malignant disease. Successful modern
treatment often involves intensive chemo-radiotherapy or major
surgery supported by blood component therapy. A care plan for JWs
must take into account their informed refusal of the transfusion of
whole blood and its primary components (red cells, platelets,
granulocytes and plasma), accepting the additional risks this refusal
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implies. This may prove challenging to clinical staff. However,
lessons learned from JWs undergoing ‘bloodless surgery’ have been
important in developing modern blood conservation strategies and
there have been recent reports of patients surviving aggressive
therapies such as remission induction for acute leukaemia and
haemopoietic stem cell transplantation.
To help clinical teams develop appropriate care plans a draft
guideline, or aide memoire, has been produced by JW Hospital
Information Services and a number of experienced haematology and
oncology clinicians. This document is presented for discussion and
modification by delegates.
Key elements include understanding that the following may be
acceptable to individuals: blood derivatives (e.g. albumin, cryopre-
cipitate), cell salvage, apheresis and haemopoietic stem cell
procedures.
The guideline emphasises consideration of blood sparing
strategies from the initial MDT meeting and constructive involve-
ment of the local JW Hospital Liaison Committee. Possible surgical
strategies include pre-operative optimisation of Hb, minimising
surgical blood loss, cell salvage technology (with filtration or
irradiation) and minimally invasive tumour embolisation or radio-
frequency ablation. In medical therapies, the management of
profound anaemia and thrombocytopenia are key and the appro-
priate use of growth factors, haemostatic agents and novel treatments
with reduced myelosuppression warrant consideration.
Blood conserving care plans in this difficult area are feasible and
in the light of potential blood shortages certain elements of such
plans could be considered for general application.
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Cryosupernatant and solvent detergent fresh frozen
plasma (octaplas) usage at a single centre in acute
thrombotic thrombocytopenic purpura
M Scully, M Flynnw, J Berrymanw and SJ Machin
Haemostasis Research Unit, University College London, UK,
wUniversity College London Hospitals, London, UK
Thrombotic thrombocytopenic purpura (TTP) is an acute, life
threatening disorder and plasma exchange (PEX) remains the
mainstay of treatment. Plasma therapy remains the mainstay of
treatment in acute TTP episodes and until December 2005, apheresis
was initiated with cryosupernatant unless patients had a previous
severe allergic reaction or refractory disease, so continued with
Solvent-Detergent Fresh Frozen Plasma (S/D FFP), Octaplas. We
reviewed 50 acute TTP episodes involving 33 patients, primarily acute
idiopathic (n5 25). Thirteen episodes used cryosupernatant only and
15 episodes started with cryosupernatant and changed to Octaplas.
Reasons for changing were young age (n5 1), refractory disease,
(n5 2) and allergic reactions to cryosupernatant (n5 22). Once
Octaplas had been used, it was continued on further admissions. In
22 episodes, Octaplas was used exclusively. Cryosupernatant was
used in 27.6% (total volume 508.25 l) and Octaplas in 72.4% (total
volume 1327.6 l) of all episodes. The total number of plasma exchange
proceedures using cryosupernatant were 172 and Octaplas were 512.
The number of citrate reactions and allergic (plasma) reactions were
halved in those receiving Octaplas compared to cryosupernatant
(10% vs 18% and 4.7% vs 9.8% respectiviely). There were 21 line
infections and in approximately 70% of cases the infection was
associated with a reduction in platelet count o150 109/l and was
primarily due to Staphylococcus aureus. In all 50 episodes, the only
documented thrombosis was a superficial non-central vein. In
episodes receiving only cryosupernatant or Octaplas, there was no
significant difference in the median number of PEX to remission, 7
(3–14) and 8.5 (5–30), respectively. Baseline viral screen in all
episodes was negative after discharge following an acute episode. In
conclusion, cryosupernatant and S/D FFP (Octaplas) appear equally
efficacious. However, the risk of allergic/urticarial and citrate
reactions was more common with cryosupernatant. There was no
documented viral transmission with either product or episodes of
TRALI.
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An audit of red cell concentrate, fresh frozen plasma
and cryoprecipitate use within the west of Scotland: a
5-year repeat analysis
JH Laird and RL Soutar
West of Scotland Blood Transfusion Centre, Scottish National
Blood Transfusion Service, Glasgow, UK
The Regional Haematology Audit Group covers a population of 3
million (the area of the regional transfusion centre). An audit was
undertaken in 2000 analysing use of plasma products and was
published: discrepancies in use were identified between hospitals and
the following represents a repeat analysis over the interim 5-year
period.
A questionnaire was distributed to 15 hospitals with an 87%
response rate. This compared April 2004 to March 2005 with the
same period 1999–2000.
The results showed a decline in blood product use during this
period despite a 2.9% increase in bed numbers within the region.
Since 2000, there was a 9.1% reduction in red cell transfusions, but
an even greater reduction in FFP (17%) and cryoprecipitate (20%)
used. Using bed numbers as a surrogate reflection of activity, a mean
of 13.65 red cell units were issued per bed (range 7.68–21.32, SD 4.51)
in 2000, compared to 11.99 in 2005 (range 5.15–17.91, SD 3.34)
P5 0.046.
Repeat analysis identified a substantial change in practice in
previously outlying hospitals in terms of blood product use, with
resultant savings of around £250 000 per annum.
A marked difference in blood product use between the two
cardiac surgery centres was observed, which was thought to be
attributable to regular use of thromboelastography in one.
Interestingly, 15% of centres still continue to take Rhesus D status
into consideration on FFP issue whilst 23% consider it in females of
child-bearing age, contrary to recent guidance from the BCSH.
It was also observed that no standard laboratory procedures were
in place for the issue of methylene blue treated FFP and only 50% of
the hospitals with potential use of this product had it in stock.
The report demonstrates that effective audit can improve and
change clinical practice – something that is often questioned.
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A multi-centre prospective observational study of
platelet transfusion practice in neonates with severe
thrombocytopenia
S Stanworth, S Ballard, A Casbardw, M Murphy, I Robertsz,
N Murrayz and On behalf of PlaNet Study Group
Transfusion Medicine, Oxford, UK, wClinical Studies Unit,
MRC CTU, London, UK, zNeonatal Medicine, Imperial College,
London, UK
Platelet transfusion practice in neonates is not evidence-based and
there is a lack of data relating transfusion to clinical outcome.
Neonates with platelets o60 109/l were studied prospectively at 7
Poster Presentations: Transfusion
r 2007 The Authors
Journal compilation r 2007 Blackwell Publishing Ltd, British Journal of Haematology, 137, (Suppl. 1), 1–88 35
NICUs Mar 05-Sept 06. Daily data were collected on minor (scored
0–7) and major bleeding. Blood counts and reason for transfusion
and its effect on bleeding were prospectively recorded. At the time of
first analysis, 145 of 167 (87%) eligible neonates were enrolled (85%
o37 weeks GA, 61% male). There were 186 episodes of thrombocy-
topenia (1606 study days) and 309 platelet transfusions given to 91
(63%) neonates. Fourteen per cent had major IVH (Grade 3/4) at
study entry. Platelets ( 109/l) at study entry and at platelet nadir,
and duration of counto60 109/l were: 44 (33–54); 31 (19–42); 2 (1–
5) days respectively. In transfused neonates, platelets ( 109/l) pre-
and post-transfusion, and number of transfusions were: 27 (19–36);
84 (46–138); 2 (1–4) respectively. At least one episode of minor
bleeding was recorded on 622/1606 (39%) study days, and scores
recorded for 12 hours pre- and post each transfusion were (median
[IQR]): 1 (0–2) and 0 (0–1) respectively. New or extension of IVH
bleeding to Grade 3/4 occurred in seven neonates and other major
haemorrhage in 11 neonates (four pulmonary, four GI). 14% neonates
died, 13 with major IVH bleeding (of which 10 had Grade 3/4 IVH at
study entry); all received platelet transfusions (total 87; median 3 [2–
7]). In summary, most thrombocytopenia episodes develop after 72
hours of life (median 5 days) and are of short duration (median 2
days). There is a clear distinction between the majority of
thrombocytopenic neonates who receive one or two transfusions as
prophylaxis with a good outcome, and the minority who suffer
adverse outcomes including major haemorrhage (11%) despite
transfusion. These data will be invaluable for planning definitive
trials necessary for rationalising neonatal platelet transfusion.
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PBSC mobilisation with G-CSF alone as opposed to
mobilisation with chemotherapy and G-CSF produces
higher lymphocyte yields followed by faster
lymphocyte recovery after high dose melphalan
chemotherapy and autologous haemopoietic
rescue in myeloma patients
MV Furtado, C Jones, J Coleman, S Walton and C Rudin
Department of Haematology, Royal Devon and Exeter
Hospital, Exeter, UK
In myeloma patients, rapid lymphocyte recovery after high-dose
chemotherapy and autologous haemopoietic rescue has been shown
to be associated with better disease-free and overall survival. Here we
report on a retrospective analysis of the dose of reinfused
lymphocytes in the 30 consecutive myeloma patients who underwent
consolidation chemotherapy with melphalan 200 mg/m2 followed by
a PBSC autograft in our department from March 2004 to March
2006. Whether patients were mobilised with G-CSF alone (10
patients) or intermediate dose cyclophosphamide and G-CSF was
at the discretion of the treating haematologist. The dose of reinfused
lymphocytes was determined with a single platform flow cytometry
technique using a CD45high/SSlow gate that was validated by
comparison with the lymphocyte counts obtained on a Sysmex
XE2100 haematology analyser in a separate batch of 17 peripheral
blood samples with lymphocyte counts between 0.28 and 44.4 109/l
(r5 0.9926). For each patient, the PBSC graft size was chosen such
that the CD341 dose was at least 2.0 106/kg. This resulted in a
median lymphocyte dose in the autografts of 106.7 (range 24.9 to
455.5) 106/kg. Higher lymphocyte doses were significantly asso-
ciated with faster lymphocyte recovery to above 0.5 109/l (Cox
proportional hazards regression, P5 0.0245). Patients mobilised
with G-CSF alone received a graft with a higher lymphocyte content
than those that were mobilised with chemotherapy and G-CSF
(Mann-Whitney U-test P5 0.0062). We conclude that the lympho-
cyte content can easily be incorporated in the routine quality
assessment of PBSC harvests and that mobilisation with G-CSF alone
favours rapid lymphocyte recovery after high dose melphalan
chemotherapy and autografting.
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Fludarabine may enhance the efficacy of DLI post
HSCT for increasing mixed chimerism
G Chakupurakal, L Karnik, G Turnerw, M Griffithsz,
M Velangi, S Lawson and P Darbyshire
Department of Paediatric Haematology and BMT Unit,
Birmingham Children’s Hospital, UK, wNational Blood Service,
Birmingham, UK, zWest Midlands Regional Cytogenetics
Laboratory, Birmingham, UK
The increasing use of donor lymphocyte infusion to improve
increasing mixed chimerism or minimal residual disease post
transplant is well documented. In murine models, addition of
fludarabine to DLI enhances donor chimerism and reduces the
GVHD potential of through effects on a CD4plus CD44 (low)
lymphocyte population. We report seven cases in which DLI was
given with fludarabine for i-MC to enhance its effect.
Two females and five males with mean age of 4 years (range 6
months to 9 years), haematological diagnoses of thalassemia major
(3), osteopetrosis (2), glycogen storage disorder (1) and JMML (1)
were given a range of standard conditioning regimens. Peripheral
blood stem cells were collected from haploidentical (5), unrelated (1)
and sibling donors. The mean CD34 cell dose was 5.96 108/kg
(range 1.18–10 108/kg). Cyclosporin A was given as GvHD
prophylaxis. Neutrophil engraftment occurred 12 days (range 1–21
days) and platelet engraftment 34 days (range 15–86 days) post-
transplant. All patients received DLI for i-MC after a mean 102 days
post-transplant with a mean donor chimerism of 67 (range 25–83).
All had one dose of intravenous fludarabine 25 mg/m2 as further
immunosuppression prior to their second or subsequent DLI. The
second DLI was after a mean 153 days post-transplant. Only three
received a third infusion.
In six cases (86%) stable mixed or full donor chimerism was
achieved. All patients with thalassemia major and osteopetrosis
achieved 490% chimerism. The patient with GSD achieved stable
mixed chimerism. The patient with JMML achieved full autologous
reconstitution with no evidence of disease. Two had grade one skin
GvHD, one self-limiting graft aplasia but none had CMV reactivation,
severe infection or death.
This is the first report in literature of the use of fludarabine to
enhance the effect of DLI in clinical cases. We have demonstrated
that the correction of i-MC with fludarabine and DLI can be achieved
without significant morbidity.
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Donor lymphocyte infusion is an effective manage-
ment of increasing mixed chimerism and high risk
disease with minimal side effects
G Chakupurakal, L Karnik, G Turnerw, M Griffithsz, M
Velangi, S Lawson and P Darbyshire
Paediatric Haematology and BMT Unit, Birmingham Chil-
dren’s Hospital, UK, wNational Blood Service, Birmingham, UK,
zWest Midlands Regional Cytogenetics Laboratory, Birming-
ham, UK
The use of donor lymphocyte infusion has demonstrated its use in
increasing mixed chimerism or minimal residual disease post
transplant. Little data is available on the efficacy of this therapy in
children. We retrospectively analysed 31 patients who received DLI at
Birmingham Children’s Hospital from 1998 to 2006 with a mean age of
5 years; fiftenn female and sixteen male. Seventeen had malignant and
14 non-malignant conditions. Ninteen haploidentical, eight unrelated
and four sibling transplants with mean CD34 cell dose 14 106/kg for
haploidentical and 5.75 106/kg sibling and unrelated transplants.
Indications for DLI in the malignant cohort included (a) relapse
(7) (b) locally determined pre-transplant high-risk features (6), (c) i-
MC (4) (d) MRD (2). Two patients relapsed a year post initial
treatment and were retreated with DLI. Indications for DLI in the
non-malignant cohort (a) i-MC (12), (b) relapse of AA (1) (c)
infection post-transplant (1).
Tweleve out of sixteen had complete donor chimerism post DLI for
i-MC. Four failed to show improvement in chimerism, 2/4 had non
malignant diseases and have stable mixed chimerism and 2/4 had
JMML had full autologous reconstitution with normal haemopoiesis.
Twenty-seven out of thirty-one had Grade 1–2 skin GVHD or no GVHD.
Only 4/31 patients had severe morbidity due to Grade 3–4 GVHD and all
responded to conventional treatment. There were no cases with CMV
reactivation. 2/31 had graft aplasia from which he recovered after
temporary cessation of DLI. There were nine deaths. Six patients died
from relapsed disease. One patient given DLI for i-MC, died of
streptococcal pneumonia due to non-compliance with penicillin V.
Our experience demonstrates that DLI can be delivered safely in
high risk malignant disease post transplant in children but further
work is needed to define efficacy. The correction of i-MC with DLI
can be achieved with minimal morbidity and mortality and to date
22/31 of the group survive disease free.
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Neutrophil engraftment, septic episodes and length of
admission are equivalent in patients who receive
pegfilgrastim after PBSCT compared to those who
receive daily GCSF
IN Novitzky Basso, R Benjamin, K Thomson and K Ardeshna
University College Hospital, London, UK
Patients with lymphoma who receive high dose BEAM chemotherapy
followed by autologous peripheral blood stem cell transplantation
have routinely received daily G-CSF on day1 6 following stem cell
re-infusion to hasten neutrophil engraftment. Pegfilgrastim is a
pegylated form of G-CSF which is released slowly into the circulation
following a single subcutaneous injection. Studies in patients who
have received Pegfilgrastim following chemotherapy in an attempt to
reduce length of neutropenia have shown that 1 dose of Pegfilgrastim
is equivalent to 11 doses of daily G-CSF. We have recently substituted
6 mg Pegfilgrastim administered subcutaneously on day 1 6 instead
of daily GCSF. In this study we have compared the median duration
of neutropenia, number of septic episodes and length of admission
between 16 consecutive patients undergoing PBSCT who received
Pegfilgrastim and 21 consecutive patients who had received daily GCSF.
The median duration of grade 4 neutropenia (neutrophilso0.5) was 8
days in both groups (range: daily GCSF 6–24d; Pegfilgrastim 6–14). The
number of septic episodes and severity was no different (one ITU
admission in daily GCSF group, none for Pegfilgrastim group). In
addition the median length of hospital stay was 22 days in both groups
(range: daily GCSF 16–56 day; Pegfilgrastim 18–35). The daily GCSF
group had 3 patients requiring further doses of GCSF as outpatients;
none in the Pegfilgrastim group required any further GCSF. In the daily
GCSF group, a median of 6 days (range 4–22) GCSF was given to
achieve a neutrophil count of 40.5 for two consecutive days. It thus
appears that a single dose of Pegfilgrastim administered on day 16
following BEAM PBSCT is as effective as daily GCSF. Decisions
regarding the preferred formulation in this setting will need to take
patient convenience and cost into consideration.
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Engraftment of donor langerhans cells following
allogeneic stem cell transplantation with reduced
intensity conditioning (RIC) is delayed compared to
other myeloid lineages
J Richards, L Pearcew, PEM Patten, AY How, A Paliucaw, GJ
Mufti,w and S Devereux,w
Department of Haematological Medicine, King’s College
London, London, UK, wDepartment of Haematological Med-
icine, King’s College Hospital, London, UK
Langerhans cells (LCs) are antigen presenting cells found in the
epidermis. They are thought to originate from bone marrow
precursors although studies in mice suggest they have the ability to
renew in situ. Murine models have also shown that recipient LCs are
required for development of acute graft-versus-host disease (GVHD)
following allogeneic haemopoietic stem cell transplantation (allo-
HSCT). Engraftment of LCs following human allo-HSCT has pre-
viously been assessed using migration from isolated epidermal sheets,
which may be inaccurate because of differential migration capacity of
donor and recipient cells. We therefore studied LC engraftment using
fluorescence immunophenotyping and simultaneous in-situ hybridi-
sation for X/Y chromosomes in sex mismatched transplants. Skin
biopsies were performed at days 28, 56 and 100, 6 months and 1 year
post-transplant on eight patients receiving alemtuzumab based RIC
allo-HSCT regimens. Ten micrometer cryosections were taken, LCs
labelled with anti-CD1a and X/Y chromosomes detected with the CEP
X/Y probe kit. Slides were examined on a Zeiss LSM510 Meta confocal
microscope and Z-stack images were collected. Chimerism of purified
CD151 and CD31 peripheral blood cells was determined in parallel.
Results are tabulated below and show that compared to CD151
myeloid blood cells, donor LC engraftment is markedly delayed (days
28 and 56 paired t-tests give Po0.0001 and P50.0008, respectively).
Of the eight patients studied, three developed biopsy proven GVHD
and in all cases, recipient LCs were still present. These results show
that LC engraftment after RIC-allo-HSCT is markedly delayed with
persistence of recipient cells at up to 1 year.
Cell Type Day 28 Day 56 Day 100 6 Months 1 Year
LC 24.6
(n5 8)
70.5
(n5 7)
86
(n5 7)
92.5
(n5 6)
97.1
(n5 3)
CD31 PB 92.2
(n5 8)
87.3
(n5 6)
72
(n5 6)
83.2
(n5 4)
94.6
(n5 3)
CD151 PB 100
(n5 8)
99.7
(n5 6)
92.5
(n5 6)
100
(n5 4)
100
(n5 2)
% donor chimerism at specific time points following allo-HSCT.
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Induction therapy with high-dose dexamethasone
alone in newly diagnosed myeloma patients produces
a high partial response rate which is predictive of
progression free and overall survival
DA Irvine, MJ Barnett, R Brinkman, DL Forrest, DE Hogge,
J Lavoie, L Lei, SH Nantel, TJ Nevill, J Nitta, J Shepherd,
K Song, CA Smith, C Toze and HJ Sutherland
Division of Haematology, Leukaemia/BMT Program of BC,
Vancouver General Hospital, BC Cancer Agency and University
of British Columbia, Vancouver, Canada
Induction followed by autologous stem cell transplant (ASCT) is
standard treatment for eligible myeloma patients. The strategy in
Vancouver has been to use single agent Dexamethasone as primary
induction therapy. Between January 1998 and June 2005, 406 patients
were referred for treatment of myeloma. We retrospectively reviewed
all patients to determine rate and depth of response to Dexamethasone
and to determine if response predicted survival. One hundred and
twenty-four patients were ineligible due to prior therapy or no
treatment. Analysis was performed on 282 patients. All received single
agent Dexamethasone as primary therapy given at 40 mg days 1–4, 9–
12, 17–20 every 28 days for at least two cycles. Response to
Dexamethasone was as follows; nCR (electrophoresis negative) 4%,
PR1 (490% reduction in paraprotein/involved Ig subtype) 10%, PR2
(450% reduction) 43%, MR (o50% reduction) 20%, NR (within 25%
of baseline) 14% and progression (increase by 425%) 7%. Two
hundred and tweleve patients had ASCT with a melphalan containing
regimen following stem cell mobilisation with cyclophosphamide and
GCSF. Twenty-nine had myeloablative allogeneic transplantation. Mean
follow-up was 35.5 months. In univariate analysis; OS was significantly
influenced by ISS score (Po0.001), beta2microglobulin _3.5 mg/l (Po
0.001), Hgb _10 g/l (P50.006) and Ig subtype (P50.024) while PFS
was affected by beta2microglobulin _3.5 mg/l (Po0.001), Hgb _10 g/l
(P50.006) and depth of response to Dexamethasone (Po0.001).
Achieving MR or better significantly influenced median OS (P50.018)
and PFS (P50.001). Multivariate analysis confirmed depth of response
significantly affected PFS (P50.008). In conclusion, this data suggests
that initial response to Dexamethasone is an important prognostic
factor in patients with myeloma. Whether this relates to reduction of
tumour load or because responsive disease is suggestive of lower risk
tumour biology is unknown however it seems rational to evaluate new
therapies in an attempt to improve depth and frequency of initial
response and assess whether this influences long-term PFS.
114
The ‘MILE’ study achieves 495% prediction accuracy
using gene expression profiling for the diagnosis and
sub-classification of leukaemia
KI Mills,w, A Kohlmannz, M Williamsz, L Wieczorekz and
T Haferlachw,y
Department of Haematology, Cardiff University, Cardiff, UK,
wMILE Study Group on behalf of WP13 European LeukemiaNET
(ELN), zRoche Molecular Systems, Pleasanton, CA, USA, yMunich
Leukaemia Laboratory (MLL), Munich, Germany
The MILE (Microarray Innovations in Leukaemia) study was
initiated in 2005 to assess and compare the clinical accuracy of gene
expression profiling with current routine diagnostic workup using
standardised protocols. Here, data is presented from MILE stage I
where n5 1889 retrospective samples were profiled in 11 individual
laboratories using HG-U133 Plus 2.0 microarrays. In 98.2%, the
generated gene expression profiles passed strict quality acceptance
criteria. These profiles were combined with previous microarray data
from Munich and Memphis to generate a dataset of 2916 patient
samples within 16 subclasses of acute and chronic leukaemia (mature
B-ALL with t(8;14), Pro-B-ALL with t(11q23)/MLL, c-ALL/Pre-B-ALL
with t(9;22), T-ALL, ALL with t(12;21), ALL with t(1;19), ALL with
hyperdiploid karyotype, c-ALL/Pre-B-ALL without t(9;22), AML with
t(8;21), AML with t(15;17), AML with inv(16)/t(16;16), AML with
t(11q23)/MLL, AML with normal karyotype or other abnormalities,
AML complex aberrant karyotype, CML, CLL), MDS, as well as non-
leukaemia and healthy bone marrow as control group.
A linear discriminant classification algorithm was developed with
91.4% prediction accuracy for the 18 classes, and in addition,
highlighting genetic relationships between disease sub-classes. Mis-
calls were mainly between MDS and AML with normal karyotype,
therefore, a separate classification model was generated based on
2647 samples representing 17 classes (excluding MDS) which
increased the prediction accuracy to 95.4% with nine classes
achieving 497.2% accuracy. Based on these results a customized
microarray has been designed and manufactured using 1449 probe
sets for leukaemia classification.
In conclusion, the international multi-centre MILE study research
program has demonstrated a very high accuracy of leukaemia
diagnosis and classification using gene expression profiling and has
built the foundation for an innovative customized microarray
designed for a routine diagnostic application of microarray
technology. The custom AmpliChip Leukemia is currently being
prospectively analysed on an additional 2000 samples in Stage II of
the MILE Study.
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Investigation of HOXA6 as a candidate gene in AML
GJ McGonigle, DPJ Finnegan, MF McMullin, TRJ Lappin
and A Thompson
Haematology Research Group, CCRCB, Queen’s University
Belfast, UK
Molecular profiling in AML has identified several candidate genes
that may define prognosis and response to therapy, including the
Class I homeobox gene HOXA9. The HOX gene network encodes
master regulators of haemopoiesis. To quantify its contribution in
AML, specific RQ-PCR analysis was performed on twenty-four de
novo patient samples using a subset of genes (12 HOX and MEIS1)
selected due to their recently reported expression in AML. HOXA6
was the most highly expressed gene, substantially higher than
HOXA9. Furthermore HOXA6 was highly expressed in CD341 -
enriched primary progenitors. Parallel studies with murine progeni-
tors (c-Kit1 , Lin) and cell lines also showed a preponderance of
Hoxa6 expression over other family members. Hoxa6 regulation
following differentiation or growth factor stimuli was subsequently
investigated in haemopoietic cell lines. Hoxa6 expression decreased
with cell differentiation in EML and FDCP-Mix A4 cells and growth
factor depletion/replenishment studies in 32Dcl3 and Ba/F3 cells
indicated cell-cycle regulation of Hoxa6. Direct evaluation of cell-
cycle status, using Hoechst 33 342 staining and cell sorting, identified
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peak expression of Hoxa6 during S-phase. We overexpressed HOXA6
in Ba/F3 cells to gain functional insights. Ba/F3-A6 cells were
examined on the basis of proliferation, maturation, cell-cycle status,
growth factor-dependence and apoptosis. Ba/F3-A6 cells displayed a
growth advantage over control cells in the presence of IL-3 and
maturation was not impaired. Cell-cycle analysis showed a reduced
number of cells in both G2M and S-phase, associated with
accumulation in the pre G1-phase, indicative of increased apoptosis.
IL-3 depletion studies of Ba/F3-A6 cells indicated substantial factor-
independent growth compared to controls, implying oncogenic
potential for HOXA6. A recent report demonstrated Hoxa6 as a
potential collaborator in a Meis1-induced murine model of AML.
Together these findings suggest Hoxa6 has the capacity to alter
growth and survival of haemopoietic cells and identify Hoxa6 as a
novel candidate gene in AML.
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Use of quantitative PCR approaches to predict relapse
and direct molecularly targeted therapy with arsenic
trioxide (ATO) in acute promyelocytic leukaemia (APL)
D Grimwade, JV Jovanovic, D Diveriow, E Nugent, AY Hoz,
GJ Muftiz, P Harrisony, J Neilsony, E Solomon, RK Hillsz, RE
ClarkJ, F Lo Coco and AK Burnettz
Department of Medical and Molecular Genetics, King’s
College London School of Medicine, UK, wDepartment of
Cellular Biotechnology and Haematology, University La
Sapienza, Rome, Italy, zDepartment of Haematology, King’s
College Hospital, London, UK, yDepartment of Haematology,
Russell’s Hall Hospital, UK, zDepartment of Haematology,
University of Wales, Cardiff, UK, JDepartment of Haematol-
ogy, Royal Liverpool University Hospital, UK, Department of
Biopathology, University Tor Vergata, Rome, Italy
There is increasing emphasis upon de-intensification of treatment
and delivery of pre-emptive therapy for molecular relapse to improve
management of APL, accompanied by greater use of ATO in newly
diagnosed and relapsed disease. However, the optimal ATO dosing
schedule remains unclear; moreover, such strategies depend upon
the development of optimised protocols for minimal residual disease
(MRD) detection using real-time quantitative PCR (RQ-PCR) that
can be applied to all patients. We characterised translocation
breakpoints in diagnostic samples from 144 consecutive cases of
APL, derived largely from the MRC AML15 trial. In 2% breakpoints
were atypical, precluding use of standardised Europe Against Cancer
RQ-PCR assays and necessitating the development of patient-specific
assays. RQ-PCR revealed significant variation (3-log range) in the
relative level of PML-RARA expression in APL blasts, impacting
upon maximal achievable sensitivity for MRD detection (median 1 in
104.2, range 1 in 102.3–5.8). Parallel detection of reciprocal RARA-PML
transcripts improved assay sensitivity in 35% of patients and
enhanced detection of MRD in remission samples. In relapsing
patients, the rate of increase in PML-RARA transcripts varied
between cases (median 0.8 logs/month, range 0.2–1.9), with
molecular conversion occurring in BM ahead of PB. Two ATO
dosing regimens were evaluated in 32 patients failing ATRA1 chem-
otherapy: the conventional regimen (A): 0.15 mg/kg/day (n5 14) or
an alternative regimen (B): 0.3 mg/kg/day 5 day, then 0.25 mg/kg
2 /week (n5 18). ATO regimen B, which is easier to administer,
was comparable to the conventional schedule in terms of toxicity
profile and efficacy, inducing molecular remission in the majority of
patients treated in molecular or frank relapse. Overall survival in
ATO treated patients from time of relapse was 61% at 3 years, which
compared favourably with the survival of patients relapsing following
ATRA1 chemotherapy in the MRC AML10 and 12 trials prior to the
availability of ATO (47% at 3 years). These findings carry implications
for the use of ATO and optimal scheduling of MRD assessment to
realise individualised molecularly directed therapy in APL.
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Outcomes of fully haploidentical hematopoietic stem
cell transplantation compared to unrelated cord
blood transplantation in children with acute
lymphoblastic leukaemia. A retrospective analysis
on behalf of Eurocord, Pediatric disease and Acute
Leukemia Working Party of EBMT
R Hough, M Labopinw, G Michelz, F Locatelliy, T Klingebielz,
W ArceseJ, F Fagioli, L Maderoww, J Cornishzz,
P Darbyshireyy, G Dinizz, E GluckmanJJ, A Vora and V RochaJJ
University College Hospital, London, UK, wEBMT Acute
Leukaemia Working Party, Faculte´ de Me´decine St-Antoine,
France, zHopital d‘Enfants de la Timone, Service d‘Oncologie
Pe´diatrique, France, yIRCCS Policlinico San Matteo, Pavia, Italy,
zKlinikum der Johann-Wolfgang Goethe Universitaet, Klinik
fuer Kinderheilkunde und Jugendmedizin III, Frankfurt,
Germany, JPoliclinico Universitario Tor Vergata, University of
Rome Tor Vergata, Rome, Italy, University of Torino,
Ospedale Regina Margherita, Torino, Italy, wwNin˜o Jesus
Children‘s Hospital, Madrid, Spain, zzDepartment of Paediatric
Oncology/BMT, Bristol Royal Hospital for Children, Bristol, UK,
yyDepartment of Haematology, Birmingham Children’s Hos-
pital, Birmingham, UK, zzInstitute G. Gaslini, JJDepartment
of Haematology/BMT, Hopital St. Louis, Paris, France,
Department of Haematology, Sheffield Children’s Hospi-
tal, Sheffield, UK
Both haploidentical T-cell depleted HSCT (Haplo) and unrelated
umbilical cord blood (UCB) are established alternative stem cell
sources for allogeneic transplantation in the treatment of high-risk
acute lymphoblastic leukaemia (ALL). We have compared the outcome
of these two approaches by performing a retrospective comparison of
paediatric patients with ALL (16 years or younger) receiving a Haplo
(n5 118) or UCBT (n5 341) in EBMT-Eurocord centres between 1998
and 2004. There were no significant differences in white blood cell
count at diagnosis, immunophenotype, remission status at transplant,
history of prior autograft, use of TBI in the conditioning regimen and
year of transplant between groups. However, haplo recipients tended to
be older, had CMV positive serology and t(9;22) more frequently.
Unadjusted outcomes after a median follow-up of 56 months (range
1.3–115) and 24 months (range 2–96) for Haplo-PBSCT and UCBT
patients respectively are summarized in Table 1.
Failure of engraftment was significantly higher following UCBT
23% compared to 11% in Haplo recipients (P5 0.007). In multi-
variate analysis adjusted for differences between the groups and
prognostic factors, relapse incidence was higher in haplo recipients
compared to UCBT (RR5 1.7, P5 0.01), but TRM and LFS were not
significantly different. In conclusion, compared to Haplo, UCBT is
associated with inferior engraftment, a higher incidence of grades II–
IV acute GVHD, lower incidence of relapse but not different in terms
of TRM and LFS, in paediatric patients with ALL. Therefore, in the
absence of an HLA identical donor to treat a high risk ALL, both
strategies are alternative options.
Approach % of grade
II-IV aGVHD
3 year
TRM
3 year
relapse
3 year
LFS
Haplo (n5 118) 21% 507 6% 567 6% 227 4%
UCBT (n5 341) 39% 467 3% 457 4% 297 3%
p value 0.001 0.87 0.04 0.23
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A clinical trial to evaluate peptide immunisation in
chronic myeloid leukaemia (EPIC)
JM Rojas, K Knight, LH Wang and RE Clark
Department of Haematology, University of Liverpool,
Liverpool, UK
Chronic myeloid leukaemia (CML) is characterised by the BCR-ABL
oncoprotein. Vaccination of CML patients with peptides from this
junctional region could elicit/augment immune responses to CML
cells. In our EPIC study, the patient’s entry requirements were: (1)
first chronic phase of CML, (2) expression of e14a2 (b3a2) BCR-ABL
transcript, and (3) prior treatment with imatinib daily (at least
400 mg) at a stable dose for at least 6 months. Each patient received
intradermally a cocktail of 3 BCR-ABL peptides: a 9-mer spanning
the e14a2 region, the same 9-mer linked to PADRE (a helper peptide),
and a 13-mer consensus e14a2 junctional peptide linked to PADRE.
Peptides were administered at either 100 (five patients), 300 (five
patients), 600 (six patients), or 1000 micrograms (four patients) with
sargramostim on six occasions over 2 months. Immune responses to
the vaccine were monitored by IFN-gamma and IL-5 ELISPOT
assays. Molecular responses were assessed by quantitative real-time
PCR of BCR-ABL mRNA. Detectable anti-PADRE CD41 T-cells
responses in all 19 assessable patients showed that the vaccination
protocol could stimulate T-cell responses. Post-vaccination, anti-
BCR-ABL CD41 and CD81 T-cells were detected in 14/19 and 11/19
patients respectively. Serial molecular responses were available for at
least 15 months on 19 cases. In patients where both anti-BCR-ABL
CD81 and CD41 cells were detected, the BCR-ABL transcript
levels were reduced further than in patients showing only partial or
no anti-BCR-ABL immune responses (median reduction from
baseline: 31.4% vs 73.2%, Po0.01 Mann–Whitney two tailed).
Interestingly, in 12/13 patients in at least major cytogenetic response
at baseline, we observed at least a 1 log fall in BCR-ABL transcripts.
Moreover, vaccination improved the fall of BCR-ABL transcripts in
patients who had received imatinib for more than 12 months. These
data suggest that BCR-ABL peptide vaccination may improve control
of CML. Randomised studies are now required.
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ADAMTS 13 in non-thrombotic thrombocytopenic
purpura conditions
M Scully, R Liesnerw, C Burgessw and SJ Machin
Haemostasis Research Unit, University College London, UK,
wHaemophilia Comprehensive Care Centre, Great Ormond
Street Hospital for Children, London, UK
ADAMTS 13 is the primary physiological modulator of the size of
VWF in plasma and its association with thrombus formation in TTP,
led to an investigation in non TTP patients. Normal range for
ADAMTS 13 activity is 66–126%. Ninety two samples from children
attending outpatients, median ADAMTS 13 activity was normal (84%
(13–167%) in cases o12 months, 93% (27–154%) in 1–6-year-olds,
105% (0–201%) in 6–12-years-olds and 78% (50–121%) in chil-
dren412 years). In 26/92 cases, ADAMTS 13 was o66%; 10 cases
with ADAMTS 13 activity o50% – three had a reduced platelet
count (o150 109/l). Median ADAMTS13 activity in, primarily
children, with bleeding disorders pre- (91.1%, range 69.2–176.6%)
and post-factor concentrate replacement (84.8% range 55.4–146.2%)
and Haemolytic Uraemic Syndrome (HUS) cases (62.5% range
33–89%) were within the normal range. Forty-eight children admitted
to intensive care unit (varying medical conditions), 64% had
reduced ADAMTS 13 activity (median 45%, range 0–65%) with
no significant difference in platelet counts (median 261 109/
l-ADAMTS 13 o66% vs 276 109/l-ADAMTS 13466%). VWF:ag
levels were raised (4150 IU/dl) in 28/38 cases (73%) and in those
with VWF:ag levels o150 IU/dl, only 2/38 cases had ADAMTS 13
activityo66%, but in those cases with VWF:ag 4150 IU/dl, 16/38
cases had ADAMTS 13 activityo66%. In 100 unselected adult
inpatients samples, 35 had ADAMTS 13 activity below the normal
range (o66%); 15/35 were ITU patients. In patients with
activityo66%, VWF:ag was significantly higher than patients with
normal ADAMTS 13 activity (297.55 IU/dl v’s 197.8 IU/dl) and
unrelated to platelet count (215 109/l [39–512 109/l]) vs
233 109/l [24–636 109/l] respectively). Ten out of twenty with
ADAMTS 13o66% had IgG antibody levels 44.2%. There were 17
deaths: five had ADAMTS 13o66%. Therefore, the inverse relation-
ship between ADAMTS 13 and VWF may be important in
thrombosis/mullti-organ dysfunction in patients with a prominent
inflammatory component.
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Tissue factor and tissue factor pathway inhibitor
levels in coronary artery disease: correlation with the
severity of atheromatosis
LM Lima, MO Sousa, LM Dusse, MC Lasmar, BA Lwaleedw
and MG Carvalho
Federal University of Minas Gerais, Brazil, wUniversity of
Southampton, UK
Atherosclerosis and its subsequent thrombotic complications are a
major cause of morbidity and mortality in the western world. Tissue
factor (TF) may contribute to atherothrombosis. In vivo TF activity is
restrained by a major physiological inhibitor known as tissue factor
pathway inhibitor (TFPI). Here we determined plasma TF and total
TFPI levels in subjects undergoing coronary angiography. The
relationship between these and the severity of coronary artery
disease (CAD) was also assessed. Using ELISA assays, plasma TF and
total TFPI levels were measured in subjects with normal coronary
arteries (n5 20; controls), mild/moderate atheromatosis (n5 18)
and severe atheromatosis (n5 30). In addition, plasma lipoprotei-
n(a) and D-Dimer (D-D) were analysed using ELFA and turbidimetric
assays. The extent of CAD was assessed using coronary angiography.
The severe atheromatosis group showed significantly high TF levels
compared to controls (Po0.01). Increased TF levels were associated
with coronary stenosis of more than 70% of the luminal diameter.
Plasma lipoprotein(a) levels were also significantly increased in
subjects with severe atheromatosis compared to those with mild/
moderate atheromatosis (Po0.001) or controls (Po0.0001). The
difference in lipoprotein(a) levels between controls and mild/
moderate atheromatosis group was also significant (Po0.0001).
The presence of CAD associated with increased TF (r5 0.42, Po
0.0001) and raised lipoprotein(a) levels (r5 0.63, Po0.0001). For all
groups there was a positive association between TF and TFPI
(r5 0.34; Po0.01), TF and D-D (r5 0.28, Po0.05) and TF and
lipoprotein(a) (r50.33, Po0.01). In conclusion, increased plasma TF
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levels in subjects with coronary artery disease are associated with the
severity of atheromatosis. We observed an association between
increased plasma TF levels and coronary stenosis of more than 70%
of the luminal diameter. The advanced atherosclerotic injuries, the
fatty core of the disrupted plaque and the increase in the
macrophages and smooth muscle cells may have resulted in the
observed rise in plasma TF levels.
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What do elevated D-dimer levels mean in patients
without venous thrombosis (VTE)?
S Bacchuw, S Paneesha, K Frenchw, E Cheynew, A Borg
and P Rose,w
Department of Haematology, University Hospitals Coventry
and Warwickshire Hospitals NHS Trust, Coventry, UK, wDe-
partment of Haematology, Warwick Hospital, Warwick, UK
Use of D-dimer levels with clinical probability scores in the diagnosis
of VTE is well established. High quantitative D-dimer levels have
recently been shown to be predictor for poor survival and underlying
malignancy in patients with VTE. Do quantitative D-dimer levels in
patients without VTE have similar predictive value?
This study included 2263 (F: 1518; M: 745) patient episodes from a
database of patients without VTE at a teaching Hospital, between
2001 and 2005. All patients with suspected VTE underwent a Doppler
ultrasound examination to rule out VTE. D-dimer assays were done
using Bio-Merieux kit. Database was regularly updated using hospital
information systems, questionnaires and clinical review. Statistical
analysis was carried out using SPSS 13.0 for Windows software.
Overall survival (OS) was estimated by the Kaplan-Meier method.
Median age at presentation was 69 years. Median D-dimer level was
1000mg FEU/ml. Fifty-two per cent patients had a D-dimer level of
41000mg and 2% had a D-dimer level of 48000mg. Sixty-five per
cent pateints were aged 460 years. Median follow up was 22 months.
D-dimer level 41000mg, 44000 mg and 48000mg were associated
with decreased OS (Log rank test: P value: 0.002, o0.001 and
o0.001). Age 460 year was also associated with decreased OS
(P value:o0.001). D-dimer 48000mg and age 460 year were an
independent poor prognostic factor for OS on Cox regression
analysis (P value: o0.001). 27.5% patients with a D-dimer level
48000mg had cancer (Fisher’s exact test; P value: 0.003). Seventeen
per cent patients with a D-dimer level 44000mg had cancer (P value:
0.04). 12.4% of patients with a D-dimer level 41000mg had cancer
(P value: 0.02).
This study shows elevated D-dimer levels even in patients without
VTE is a marker for poor survival and a predictor for underlying
malignancy. This suggests heightened fibrinolytic activity in the
absence or presence of established venous thrombosis may be a
marker for underlying malignancy and is associated with poor
prognosis. Further studies are warranted to establish in different
medical conditions the presence or absence of increased fibrinolysis
and impact on clinical outcome.
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Thrombin generation: a comparison of assays using
platelet poor and platelet rich plasma and whole
blood samples from healthy control subjects and
patients with a history of venous thromboembolism
KA Tappenden,w, G Evansw, MJ Gallimorew,z, IJ Mackiey,
M Winterw and DW Jones,w
Department of Biosciences, University of Kent, Canterbury,
UK, wHaemophilia Centre, Kent and Canterbury Hospital,
Canterbury, UK, zThe Institite of Surgical Research,
Rikshospitalet, Oslo, Norway, yDepartment of Haematology,
University College London, London, UK
The monitoring of thrombin generation (TG) using platelet poor
(PPP) and/or platelet rich (PRP) has been proposed as a global assay
to assess coagulability. These assays exclude other cellular compo-
nents of whole blood (WB) that may significantly contribute to the
haemostatic process. We have now developed a fluorogenic WB TG
assay and have compared TG in PPP, PRP and WB samples from 30
healthy control subjects (HCS) and 49 patients with a history of
venous thrombosis (VTE). The platelet count in PRP was adjusted to
the actual platelet count of the subject/patient using autologous PPP.
Reference ranges (5th to 95th percentile) were established for peak
height (PH) and endogenous thrombin potential (ETP) using PPP
(PH 253–361 nM, ETP 1116–1681 nM/min), PRP (PH 131–214 nM, ETP
1170 to 1990 nM/min) and WB (PH 160 to 304 nM, ETP 1405 to
2323 nM/min) in samples from the 30 HCS. The VTE group PH and
ETP values were significantly higher than the healthy control group
in the WB samples (P5 0.003 and 0.003, respectively). Raised PH
and/or ETP values for PPP, PRP and WB were seen in eight, eleven
and twenty-five patients respectively. Peak height and/or ETP values
were not consistently raised between the sample types. Our results
suggest that the WB TG assay may be more sensitive to increases in
TG in patients with a history of VTE than the PPP and PRP TG
assays.
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Sickle cell care pathways – why should we use them?
H O’Shea and M Harness
Department of Clinical Haematology, University Hospital of
Wales, Cardiff, UK
Sickle Cell disorder is the generic term for a group of inherited blood
disorders affecting the red blood cells. There are estimated to be
12 500 sufferers throughout the UK. In the South Wales area the
patient cohort is small with less than 100 affected people which,
historically, meant that care of patients in crisis was variable. The
BSH guidelines for management of these patients, issued in 2003,
were used as the basis for a care pathway for use with all patients in
Crisis within UHW. the pathway was designed to be used by any
member of staff, anywhere in the Trust, regardless of haematological
knowledge. Whilst used effectively with the majority of Sickle Cell
patients, the importance of the pathway was not fully appreciated
until a ‘critical incident’ in 2005. This presentation gives an overview
of the patient involved in the form of a case study. The treatment
history will be outlined and the presenting problems described. The
results of not using the care pathway will be discussed in detail along
with questions raised by this case and implications for future
practice.
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The effect of iron deficiency anaemia on red cell
transfusion in colorectal patients
M Chituku, I Owenw and M Jabbar Al-Obaidi
Department of Haematology, West Middlesex University
Hospital, Middlesex, UK, wDepartment of Pathology, West
Middlesex University Hospital, Middlesex, UK
The purpose of this study was to evaluate the incidence of
preoperative anaemia in patients presenting with colorectal disease,
and the influence of the anaemia on transfusions in the peri-
operative period. Over a 6-month period 121 patients presented at the
hospital colorectal multi-disciplinary meeting (MDT) were identified.
Thirty-nine of these patients were anaemic, and 24 received between
1–19 U of blood. Fourteen of these patients had indices suggestive of
iron deficiency, and they received 59 of the 167 U of blood used by the
patients in this study. The anaemia was diagnosed at a median of 28
days pre-operatively (range 2–120 days), and a median of 26 days
prior to transfusion (range of 2–300 days). The use of parenteral iron
might have prevented half of these transfusions, we are planning to
start an early diagnosis and intravenous iron intervention pathway
for anaemic patients presenting to the colorectal MDT.
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Developing a patient focused service for myeloproli-
ferative disorders – the telephone follow-up clinic
JL Tonkin
Department of Haematology, Essex Rivers Healthcare Trust, UK
Aim: Through service redesign improve the quality of care provided
to patients with chronic haematological disease and create additional
capacity for formal outpatient follow-up.
Background: Each year in the NHS there are 37 million ‘follow-up’
appointments. A significant proportion of these follow-up visits are
clinically unnecessary, create inconvenience and anxiety for patients
and waste valuable resources. Seventy-five per cent of all outpatient
‘Did Not Attends’ (DNA) are for follow-up appointments (DOH,
2004). There are more than four million follow-up DNAs per annum,
which costs the NHS more than £100 million a year.
The nature of haematological disease means that some patients
are followed up on a long term basis as outpatients at varying degrees
of frequency ranging from monthly to annually. These patients often
attend hospital for a review of current blood parameters and are then
advised that their disease is stable and a further follow-up
appointment is scheduled. This frequently means that the patient
has to travel to the hospital, pay to park, wait for a blood test, wait
for the test result and then wait to see the doctor for a very short
consultation.
Method: The development of a Nurse Consultant post gave the
opportunity to remodel services to improve the patient’s experience.
This paper gives account of the development and evaluation of a
nurse led telephone follow up service for patients with stable
haematological disease.
Findings: Responses to a patient satisfaction survey identified that
overall the majority of patients found the system to be effective and
convenient for them with 90% indicating they preferred to be
telephoned. In the first year the telephone clinic has saved 300
outpatient department follow-up appointments.
Conclusions: From this experience it would appear that telephone
follow-up positively impacts on the patient and the service. Patients
receive appropriate and timely care in the right setting and this in
turn has created additional capacity in the outpatient setting for
those that require it.
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Annual consultant review of patients in nurse led
clinics; what does it achieve?
M Taylor, JN Crowe, AJ Sternberg, NE Blesing, AG Gray and ES
Green
Department of Haematology, The Great Western Hospital,
Swindon, UK
We established a nurse led clinic for patients with myeloproliferative
disorders (MPD) in 2004. Stable patients with MPD are reviewed by a
haematology clinical nurse specialist (CNS) either in the outpatient
clinic or by telephone. The patient’s symptoms and blood count are
reviewed and treatment (medication/venesection) adjusted according
to agreed parameters. Medical advice is available from a consultant
or specialist registrar (SpR) in an adjacent haematology clinic if the
patient has new or changed symptoms or unexpected abnormalities
in the blood count.
There are now 107 patients with MPD in the nurse led clinic, with
an average of 14 patients attending weekly in 1.5 clinics. All patients
have an annual clinic appointment with a consultant, or SpR to
review their treatment and progress, and for clinical examination to
assess liver and spleen size. We have prospectively audited this
annual medical review.
To date, 22 patients have been reviewed, 11 by a consultant and 11
by an SpR. Treatment advice by the haematology CNS was deemed
satisfactory in 100% of cases as was documentation in the patients’
notes and letters to the patients’ GP. Clinical examination of the
patients revealed that no patients had splenomegaly, including 2
patients who had previously had a palpable spleen. All patients were
satisfied with their treatment in the nurse led clinic and 94% could
not suggest any changes to improve the service.
This audit demonstrates that patients can be safely managed by a
suitably trained nurse over long time periods. Routine annual
medical review does not alter patient management. We now intend
only to review patients medically if a new problem arises. This will
further reduce medical follow-up, allowing us to increase new patient
capacity. This will facilitate the department meeting outpatient
waiting time targets.
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Improving uptake of patient self-testing in the
anticoagulation clinic
I Longair, MA Pescott, H Erwin, C Gardiner, SJ Machin and
H Cohen
Department of Haematology, University College London
Hospitals, London, UK
Several studies have demonstrated that the quality of oral antic-
oagulation (OAT) may be improved by patient self-testing (PST).
However, these studies used only selected patients who are already
established on warfarin, and the uptake was disappointing, at around
10–25% of those eligible, prompting suggestions that PST is desirable
to only a minority of patients. The aim of this study was to determine
whether patients would accept PST more readily if offered from the
start of treatment, and also to assess the effectiveness of PST in these
patients. Three hundred consecutive patients referred to our
anticoagulation clinic were prospectively assessed for suitability for
PST. Exclusion criteria included: previous OAT, short therapeutic
duration (e.g. pre-cardioversion); known drug/alcohol abuse; atypi-
cal INR target ranges; language barriers; and physical/intellectual
impairment. One hundred and eighty-two out of three hundred
(61%) were suitable of whom 85/182 (47%) consented to PST. Six
patients did not commence self-testing after giving consent. On their
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first visit to clinic 23% of eligible patients were within their target
therapeutic range, with no significant difference between those
electing for PST and those who declined. To date, 69/182 (38% of
those eligible) patients have started PST of whom five have
subsequently withdrawn from the study. The median time between
first clinic visit and commencing PST was 27 days. After 3 months of
treatment, there was no significant difference in the median time in
the target therapeutic range between PST patients and those who
declined PST, 72% and 67%, respectively. The uptake of PST in this
group of patients was superior to that in previous studies performed
in the UK. Our data suggest PST is acceptable to many patients new
to anticoagulation and that they are able to achieve a quality of OAT
which is comparable to that obtained by a specialist hospital
anticoagulation clinic.
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Evaluation of dHPLC in the mutation analysis of type 1
plasminogen deficiency
JS Chong, B Myers, G Dolan and MB Hill
Departments of Clinical Chemistry and Haematology, Queen’s
Medical Centre, Nottingham, UK
Plasminogen (PLG) deficiency is a rare disorder of fibrinolysis. It
may be associated with chronic inflammation of the conjunctiva and
other mucosal surfaces due to the development of ‘ligneous’ fibrin-
rich pseudomembranes. These clinical symptoms are associated with
homozygosity or compound heterozygosity of mutations found
through out the PLG gene.
We have introduced denaturing high-performance liquid chro-
matography (dHPLC) analysis for mutation screening in this
disorder and evaluated its use in comparison with direct sequencing
of control and patient samples.
These techniques were used to provide genetic analysis for a 42-
year-old female patient with ligneous cervicitis, a rare complication
of PLG deficiency. Her PLG residual activity was 24% (nr. 74–104%),
and antigen was 1.44 mg/dl (nr. 6–25 mg/dl).
Oligonucleotide primers were designed for specific amplification
the 19 exons of the PLG gene, avoiding co-amplification of highly
homologous genes. Parallel sequence analysis was carried out on an
ABI 3130 genetic analyser with/without pre-screening using a
Transgenomic WAVE. The patient was found to be a compound-
heterozygote for Lys19Glu (the most common genetic defect
associated with PLG deficiency) and a previously unreported
mutation at the PLG exon 10 donor splice site (c.1256 1 1 G4A);
predicted to lead to a type 1 deficiency due to defective splicing.
Additional polymorphic changes detected in control and patient
samples included Asn91Asn, Cys238Cys, Phe295Phe, Gln342Gln,
Asp453Asn and Gly743Gly. Eight further intronic polymorphisms
were detected. dHPLC detected all changes that were found by
sequencing, although some WAVE pattern changes were subtle.
dHPLC was confirmed as a highly sensitive, rapid and economical
technique for screening mutations. However, the highly polymorphic
nature of the PLG gene should be taken into consideration when
dHPLC is used during the genetic analysis of PLG deficiency.
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Bone marrow microvessel density in chronic lympho-
cytic leukaemia: association with prognostic factors
L Smolej and P Kasparovaw
Department of Clinical Haematology, 2nd Department of
Internal Medicine, University Hospital and Medical School,
Hradec Kralove, Czech Republic, wFingerland Department of
Pathology, University Hospital and Medical School, Hradec
Kralove, Czech Republic
Angiogenesis is considered a prognostic factor in chronic lympho-
cytic leukaemia (CLL). However, there are insufficient data regarding
relationship of bone marrow angiogenesis to prognostic markers in
CLL. Therefore, we assessed microvessel density (MVD) in bone
marrow biopsy specimens from 22 untreated patients with CLL and
17 control biopsies. CLL cohort was further divided into subgroups
according to clinical course (stable, n5 11 vs progressive, n5 11), Rai
stage (0, n5 9 vs I-IV, n5 13), pattern of marrow infiltration (non-
diffuse, n5 11 vs diffuse, n5 11), genetic abnormalities (favourable,
n5 10 vs unfavourable, n5 11), and IgVH mutation status (mutated,
n5 7 vs unmutated, n5 14). Neovascularization was assessed using
immunohistochemical staining of endothelial cells with anti-CD34
monoclonal antibody and quantified using hot spot method. MVD
was significantly elevated in CLL group in comparison to controls
(mean7 standard deviation [SD], 75.67 50.6, 95% confidence
interval [CI], 53.2–98.1/mm2 vs 47.47 21.8, 95% CI, 36.2–58.6/mm2,
P5 0.039). However, there were no significant MVD differences
between CLL subgroups with regard to prognostic factors. Interest-
ingly, when each subgroup was compared to controls, only patients
with diffuse bone marrow infiltration (P5 0.011), Rai stage I–IV
(P5 0.014) and mutated IgVH genes (P5 0.019) had significantly
increased MVD. In conclusion, our study shows that microvessel
density is significantly elevated in CLL. However, this difference is
maintained diffuse pattern of infiltration, mutated IgVH genes and
Rai stage I–IV only. We did not observe significant MVD differences
between CLL subgroups with regard to classical or modern
prognostic factors. Large prospective studies are necessary to
confirm these findings and elucidate the real clinical relevance of
bone marrow angiogenesis in CLL. Supported by grant NR/8373–3
and research project MZO 00179906 from Ministry of Health of
Czech Republic.
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The deltaN isoform of the TP73 gene is produced by
cell cycle-dependent splicing during the G0–G1
transition in primary human T cells to regulate gene
expression
C Chronis, K Raj, AE Smith, SJ Orr, GJ Mufti and NSB Thomas
Department of Haematological and Molecular Medicine,
King’s College London, UK
p73 is a member of the p53-family of transcription factors (p73, p53
and p63). A truncated form of p73 (deltaNp73) also exists that lacks
the transcriptional activation domain and inhibits p53 as well as p73.
However, deltaNp73 transcripts have not been reported in normal
tissues or peripheral blood. We now show for the first time that
deltaNp73 mRNA and protein are not present in quiescent (G0),
primary human T cells but are induced post the G0–G1 cell cycle
commitment point following stimulation with anti-CD3/CD28 or
PMA/ionomycin. The deltaNp73 transcript could be produced either
by activation of a promoter in intron 3 or from the 50 P1 promoter by
alternative splicing. Bisulfite sequencing shows that the intron 3
promoter is hypermethylated in T cells throughout the cell cycle
while the P1 promoter remains largely unmethylated. 50-RACE results
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with quiescent and stimulated T cells verify that deltaNp73
transcripts originate from the P1 promoter. Additionally, RT-PCR
analyses show that the transcript originating from the P1 promoter is
present in G0 and mature deltaNp73 mRNA is produced by cell cycle-
dependent splicing during the G0–G1 transition. We investigated the
function of deltaNp73 during G0–G1 by inhibiting its induction with
two different siRNAs. Microarray analyses show that expression of
the signal transduction proteins ERK1 and two during G0–G1 are
dependent on deltaNp73 and deltaNp73 represses the expression of
the pro-apoptotic protein PUMA, a known p73 target. We conclude
that deltaNp73 is produced in normal, human T cells during entry
into the cell cycle and has a role in regulating normal gene
expression. Moreover, the transcript originates at the P1 promoter
and deltaNp73 is produced by cell cycle-dependent splicing.
Supported by the Leukamia Research Fund.
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‘Excess’ MCM proteins maintain genomic stability in
human cells
SJ Orr, T Gaymes, R Wangw, B Czepulkowski, D Ladon,
C Chronis, GJ Mufti, EM Marcottew and NSB Thomas
Department of Haematological and Molecular Medicine,
King’s College London, UK, wInstitute for Cellular and
Molecular Biology, University of Texas at Austin, TX, USA
Normal DNA replication must be accurate and occur only once per
cell cycle. Sites of DNA replication are specified by binding the origin
recognition complex, which includes minichromosome maintenance
(MCM) proteins. Paradoxically, in higher eukaryotes MCM proteins
are present in 50–100-fold excess of that required for DNA
replication. They are also downregulated by elevated expression of
proteins such as cyclin E that occurs in cancers, including AML and
breast cancer. We investigated why human cells need ‘excess’ MCM
proteins and whether the reduction of MCM protein levels might
contribute to a malignant phenotype. We determined the con-
sequences of reducing the levels of MCM proteins in primary human
T cells in which cell cycle controls and DNA damage responses are
normal. Mass spectrometry sequencing of chromatin/nuclear matrix-
bound proteins and western blotting identified that Mcm7 is not
present in quiescent, normal primary human T cells but is induced in
mid G1 after the G0–G1 commitment point. Reduction of Mcm7 with
siRNA too5% of normal during G0–G1–S-phase reduces chromatin-
binding of each of the MCM proteins that form the DNA helicase.
However, these cells still enter S-phase and replicate DNA, but
exhibit DNA-damage responses involving activation of ATR and
ATM pathways. Misrepair by non-homologous end joining (NHEJ) is
also increased in cells depleted of Mcm7. However, cells depleted of
Mcm7 do not undergo apoptosis, rather reducing MCM levels even
by 50% causes gross non-clonal chromosomal abnormalities
normally found in genomic instability syndromes. M-FISH identified
chromosome translocations, as well as loss and gain of individual
chromosomes. Therefore, ‘excess’ MCM proteins that are present in a
normal, proliferating cell are necessary for preventing DNA damage
and for maintaining genome stability. Our data indicate also that
genomic instability in cancers may result from a decrease in MCM
protein expression.
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Erythropoietin induces expression and phosphoryla-
tion of PI3-kinase p85alpha subunit in the lung
carcinoma cell line H838
ZZ Shi, WM Brown, EA Dunlop, MJ Percyw and TR Lappin
Haematology Research Group, Centre for Cancer Research
and Cell Biology, Queen’s University Belfast, UK, wDepartment
of Haematology, Belfast City Hospital, Belfast, UK
Erythropoietin (Epo) is essential for the survival, proliferation and
differentiation of erythroid progenitor cells. Binding of Epo to its
receptor (EpoR) activates three major signalling pathways, namely
JAK2/STAT5, PI3-kinase/Akt and MAPK. Recently EpoR has been
shown to be expressed by malignant tissue. In contrast to erythroid
cells the EpoR downstream signalling events in malignant cells are
currently unclear. We have shown that the non-small cell lung
carcinoma (NSCLC) cell line H838 expresses cell surface EpoR and
that activation of the JAK2/STAT5, PI3-kinase/Akt and MAPK
pathways occurs upon Epo binding. However, despite the evidence
for downstream signalling in NSCLC cells, no increase in cellular
proliferation was observed. To investigate the downstream signalling
events in H838 cells, a microarray was performed to determine the
effect of Epo stimulation at pharmacological levels. H838 cells were
treated with 10 U/ml of Epo for 3 hours. As a result many genes were
shown to have altered expression and statistical validation high-
lighted three, one of which, the PI3-kinase regulatory subunit
p85alpha, was chosen for further study. This regulatory subunit is
phosphorylated in response to Epo and plays a role in the prevention
of apoptosis in erythroid cells. Real-time quantitative RT-PCR
confirmed it was up-regulated 2 fold in H838 cells when treated with
Epo for 3 hours. In contrast, the erythroleukaemia cell line, UT7,
showed no up-regulation in the presence of Epo. At the protein level
increased phosphorylation of the p85alpha subunit was observed
during treatment with Epo at concentrations of 10 U/ml and 100 U/ml
for between 30 min to 3 hours. Further studies are required to define
the role that PI3-kinase p85alpha plays in Epo induced signalling in
the NSCLC cell line H838 and whether it enhances cell survival in the
absence of proliferation.
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Idiopathic erythrocytosis is associated with a risk of
thrombosis - a retrospective case series review
A Hodson, CN Harrison, M Percyw, F Jonesw and MF
McMullinw,z
Department of Haematology, St Thomas’ Hospital, London,
UK, wDepartment of Haematology, Belfast City Hospital,
Belfast, UK, zQueen’s University Belfast, UK
Idiopathic Erythrocytosis (IE) is a diagnosis given to patients who
have an absolute erythrocytosis (red cell mass 4 25% above mean
predicted value) without a known form of primary or secondary
erythrocytosis. The natural history of IE is not well documented. We
report results of a follow-up study of 80 patients (44 male and 36
female) diagnosed with IE from the UK and the Republic of Ireland
over 10 years. The diagnosis was made on the basis of a raised red
cell mass, absence of Polycythaemia Vera (PV), and the exclusion of
secondary erythrocytosis. Older case studies of patients with ‘IE’
identified a more heterogenous group of patients; more recent
reviews suggest low rates of both transformation to myelofibrosis/
acute leukaemia and thrombosis (1% patient-year). Average age at
diagnosis was 34.5 (2–74 years). Erythropoietin levels were low in 18
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(23%) and normal/high in 59 (74%). Fourteen patients had a family
history of erythrocytosis. Mean follow up is 9.4 years (range 1–39).
Twenty-four are no longer diagnosed with IE, eight have myelopro-
liferative disease; 13 a molecular abnormality likely to account for
erythrocytosis (11 VHL, 1 PHD-2, 1 EPO-receptor mutations); and
three secondary erythrocytosis. Fifty six patients are still classified as
IE; 52/56 are alive (deaths: lung cancer, RTA, sepsis, unknown).
Treatments of IE is venesection (35), hydroxyurea (3), none (11),
unknown (2). Twenty take aspirin, 1 each warfarin/ dipyridamole and
30 neither. Four had thromboembolic complications (3 CVA/TIAs
and 1 recurrent DVT) at/before diagnosis. Subsequently 9 throm-
boses occurred in eight patients –7 arterial (1 CVA, 3 TIAs, 1 MI, 2
PVD); 2 venous (DVT/PE). The rate of thrombosis (1.6% patient-
years) is lower than that in PV and is consistent with other case
series. Molecular defects continue to be identified in this group and
future investigation is likely to reveal further abnormalities.
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Use of free light chain measurements as prediction of
response to induction chemotherapy
S Harding, G Mead, T McSkeaney, C Beardsmorew,
SJ Hattersleyz, P Mossy, G Prattz, A Macwhannalw, A Jacobw,
S Handaw, C Craddocky, M Cooky, AR BradwellJ and S Basuw
The Binding Site, Birmingham, UK, wRoyal Wolverhampton
Hospital, Wolverhampton, UK, zUniversity of Warwick,
Warwick, UK, yUniversity Hospital Birmingham, Birmingham,
UK, zBirmingham Heartlands Hospital, Birmingham, UK,
JUniversity of Birmingham, Birmingham, UK
Aim and Rationale: Over 90% of multiple myeloma patients present
with abnormal serum free light chain (FLC) concentrations. FLC
have shorter serum half lives than intact immunoglobulins making
them attractive candidates to monitor rapidly patient responses to
chemotherapy. In this study, newly diagnosed patients had serum
FLC and intact immunoglobulins monitored at frequent intervals
during induction chemotherapy.
Methods: Serial serum samples were collected from 15 patients with
newly diagnosed multiple myeloma. Where possible, samples were
taken on treatment days 0, 4, 8, 21, 30, and then monthly to a
maximum of three months. Patient characteristics were: age 60–81
(median 71), male to female ratio (2:1) and monoclonal immunoglo-
bulin IgGk(4), IgGg(3), IgAk(4), IgAg(1), LCk(2), LCg(1). Three
treatment regimes were used, namely vincristine, doxorubicin,
dexamethasone (VAD) n5 5, cyclophosphamide thalidomide and
dexamethasone (CTD) n5 5 and melphalan and prednisone (M1P)
n5 5. Clinical response after 3 months was assessed using the Blade
criteria (Blade 1998).
Intact immunoglobulins and FLC were measured nephelometri-
cally using a previously described immunoassay (Bradwell 2002).
Serum FLC concentration was expressed as a percentage of the
concentration at presentation.
Results: At the completion of the study, five out of fifteen patients
had died, eight out of fifteen patients had minimal/partial response
and two out of fifteen patients had complete/very good response.
Assessment of individual patients’ FLC concentrations at days 4 and
8 was not conclusive; however, any increase in concentration above
presentation was indicative of a very poor clinical outcome. A good
serum FLC response after 1 month (range 2–3% (mean 2.5%) of
presenting concentration remaining) or a poor response (range 37–
82% (mean 64%) remaining) corresponded with good and poor 3-
month clinical outcomes respectively. The correlation between serum
FLC response to chemotherapy and outcome could potentially allow
the timely modification of ineffective chemotherapy regimes.
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NT-ProBNP in AL amyloidosis: association with
survival and changes after chemotherapy
AD Wechalekar, JD Gillmore, HJ Lachmann, M Offer and PN
Hawkins
National Amyloidosis Centre, Royal Free and UCL Medical
School, London, UK
Cardiac involvement in AL amyloidosis is one of the most important
determinants of survival and sensitive means of detecting such
involvement remain limited. Cardiac natriuretic peptides are
sensitive markers of cardiac dysfunction and are becoming a routine
part of algorithms for diagnosis of heart failure. Serum NT-ProBNP
is reported to be a promising biomarker of cardiac dysfunction and
response to chemotherapy in AL amyloidosis. However, a number of
patients in such studies had some abnormality of renal function,
confounding interpretation. We studied NT-ProBNP serially in 169
patients with AL amyloidosis diagnosed from 1990–2005, in whom
renal function was preserved. The median NT-ProBNP concentration
was 49 pMol/l (healthy o35). Sixty-six points (41%) with cardiac
involvement by echo had a median NT-ProBNP of 242 pMol/l vs
26 pMol/l for those without. NT-ProBNP o15 pMol/l was an
independent marker of better prognosis, irrespective of septal
thickness on echo and patients with such values had estimated
90% survival at 10 years. No evidence of cardiac involvement was
found by any means in any patient with a NT-ProBNP less than
20 pMol/l, and in only one patient with a value less than 35 pMol/l.
Following chemotherapy, only patients with a complete clonal
response had a significant decrease in the median NT-ProBNP, with
no significant change for those with a partial response and a rise for
the non-responders. However, none of the patients with a decrease in
NT-ProBNP showed echocardiographic improvement. NT-ProBNP is
an independent marker for prognosis in AL amyloidosis but its
behaviour and significance of changes after chemotherapy require
more study.
136
A survey of haematology teaching in UK and Irish
medical schools
MF McMullin and M Boohanw
Department of Haematology, Belfast City Hospital, Belfast,
UK, wDivision of Medical Education, Queen’s University
Belfast, UK
Following the publication of the first edition of Tomorrow’s Doctors
in 1993 by the General Medical Council (GMC) undergraduate
medical education in the UK moved from a discipline based model of
curriculum delivery to an integrated systems based approach. This
transition has resulted in the loss of dedicated courses in a range of
basic science and clinical subjects. The aim of this study is to explore
the current status of teaching about haematology in UK and Irish
Medical Schools.
In May 2006 a twenty item postal questionnaire was sent to 32
Medical Schools in the UK and five Medical Schools in the Republic
of Ireland. Twenty one completed questionnaires were returned
(response rate5 57%).
All of the respondents indicated that haematology is delivered as
part of the core curriculum. Fourteen per cent of respondents offer
Student Selected Components in haematology. Teaching about
haematology is integrated throughout all years of the teaching
programme in three Medical Schools. The majority of respondents
indicated that teaching about this topic is delivered in years two and
three. Ninety five per cent of respondents stated that students are
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assessed in this subject. Fifty two per cent of respondents
recommend a core text book in haematology while ninety five per
cent reported making Study Guides available to students.
The results of this survey suggest that haematology teaching is
integrated into the teaching programmes and is assessed in the
Medical Schools that participated in the study.
All of the questionnaires returned were completed by academic
haematologists. The 43% who did not respond may have minimal
haematology input to the curriculum. The position of haematology
teaching at undergraduate level will influence the doctors’ knowledge
and skills and recruitment into the specialty as teachers act as role
models.
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High rate of renal recovery in patients with cast
nephropathy treated by removal of free light chains
using extended hemodialysis: a phase 1/2 clinical trial
C Hutchison, M Cook, S Basuw, S Hardingz, G Meadz, P
Cockwell and A Bradwelly
Queen Elizabeth Hospital, Birmingham, UK, wRoyal Wolver-
hampton Hospital, Wolverhampton, UK, zThe Binding Site,
Birmingham, UK, yUniversity of Birmingham, Birmingham, UK
Cast nephropathy from excess serum free light chains (FLCs) is the
predominant cause of dialysis-dependent ARF in multiple myeloma.
Only 12–20% of these patients recover renal function. Extended
hemodialysis using a high cut-off protein-permeable dialyser
(Gambro HCO 1100) for rapidly lowering sFLC was assessed for
safety, efficacy and clinical outcomes in patients with multiple
myeloma and dialysis-dependent ARF secondary to biopsy proven
cast nephropathy.
Eight patients were studied: six new onsets; two with refractory/
relapsing disease. The chemotherapy employed was dexamethasone
and thalidomide for new disease; Velcade, doxorubicin and
dexamethasone for refractory/relapsing disease. Extended dialysis
(up to 12 hours/day) was very well tolerated. Consistent reductions in
sFLC concentrations were achieved during each dialysis session (45–
81%). Six patients, including the refractory/relapsing patients,
achieved a sustained reduction in sFLCs of greater than 65% (range
65–95%). These patients subsequently became dialysis independent.
Two patients did not respond to induction chemotherapy, had less
sustained reduction in sFLC concentrations and remained on dialysis.
In conclusion, extended daily dialysis with a high cut-off dialyser
rapidly reduced concentrations of sFLC in patients who were
responsive to chemotherapy. Dialysis independence occurred in
patients who achieved a 460% sustained reduction in sFLCs. Renal
recovery occurred in 75% of patients compared with 10–20% in
published comparative series of patients treated conventionally. This
could have huge impact in the management and outcomes of patients
with renal failure and multiple myeloma, if these results are
replicated in more patients.
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A retrospective correlation study betweenV617F
JAK2 mutation, aetiology of thrombocytosis and
thrombo-embolic events
YL Ong, R Deore and M El-Agnaf
Department of Haematology, Ulster Hospital Dundonald,
Belfast, UK
JAK2, a tyrosinase kinase gene, is located on exon 12. The
substitution of valine to a phenylalanine (V617F) results in JAK2
mutation, which had been associated with myeloproliferative
disorders. JAK2 mutation was recently found to be associated with
higher haemoglobin level and leukocyte count leading to thrombotic
complications (Wolanski et al, 2005). The objective of this study was
to determine if any correlation exists between JAK2 mutation,
aetiology of thrombocytosis, and thrombo-embolic events.
A retrospective study was conducted on all new and review
patients with primary thrombocythaemia, polycythaemia rubra vera,
myelofibrosis and reactive thrombocytosis attending the Haematol-
ogy Department in Ulster hospital Dundonald.
A diagnosis of primary thrombocytosis was made in 22 (36.7%)
patients. JAK2 was positive in 27.3% (6/22) patients. This incidence is
low compared to previous published studies (Pargade et al, 2006). A
history of thromboses was recorded in under a third of patients with
primary thrombocythaemia (27.3%, n5 6/22). Patients with primary
thrombocythaemia and JAK2 mutation showed a 33.3% (2/6) chance
of developing a thrombotic event, compared to 25% in the absence of
JAK2 mutation.
A diagnosis of polycythaemia rubra vera was made in 14 (23.3%)
patients. JAK2 mutation was present in 50% (5/14) patients
(1homozygous and six heterozygous). Thromboses occurred in
35.7% (5/14) of patients with polycythaemia rubra vera. Among
patients with polycythaemia rubra vera as well as the JAK2 mutation,
a 14.3% (1/7) chance of having a thrombotic event was observed; this
risk was higher at 57% in the absence of JAK2 mutation.
In our study population, the incidence of JAK2 mutation in
primary thrombocythaemia and polycythaemia rubra vera is lower
than previously reported. The presence of JAK2 mutation appears to
increase the risk of thrombo-embolic events among patients with
primary thrombocythaemia; the risk was unchanged for myelofi-
brosis and reactive thrombocytosis. Conversely, in polycythaemia
rubra vera, the risk of thrombosis was decreased in the presence of a
JAK2 mutation.
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Presentation and survival of multiple myeloma: six
years survey at Ulster Hospital
R Deore, N Lakshmaiah, M Bowers, YL Ong, C McCoy
and M El-Agnaf
Ulster Hospital, Belfast, UK
We retrospectively reviewed all patients diagnosed with Multiple
Myeloma between 2000 to 2006 from our register. We were able to
retrieve 60 out of 69 patient records.Out of 60 patients that were
diagnosed with Multiple Myeloma 37 were identified as males and 23
as females (M:F5 1.6:1), and median age was 71.5 (36–89). Twenty-
four (40%) patients were asymptomatic and were referred because of
incidental finding of raised paraproteins. Symptoms included bone
pain in thirteen (21.7%), anaemia in nine (15%), acute renal failure
with anaemia three (5%), weight loss in three (5%), pancytopenia in
two (3.3%) patients and hypercalcemia in one (1.7%) patient. Three
(5%) patients progressed from previous MGUS. We also encountered
rare presentation as amyloidosis in one (1.7%) patient, and cord
compression in another one (1.7%). Majority of patients 48 (80%)
were treated at presentation. Other patients were asymptomatic 12
(20%) and were observed. Patients were treated according to their
age at presentation. Twenty-seven (45%) patients with age more than
70 years were treated with Melphalan with or without Prednisolone
as a first line therapy. Patients with age less than 70 years were
treated with VAD regimen four (6.7%) patients, ZDEX 10 (16.7%)
patients, Cyclophosphamide one (1.7%) patient. Additional treatment
such as Radiotherapy was given to 14 (23.4%) patients. Twenty-two
(36.7%) patients needed bisphosphonates. Thalidomide was given to
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7 (11.7%) patients. Eight (13.4%) patients were referred for stem cell
transplant. Five (8.4%) patients had successful stem cell transplant
done. All five patients are still alive and having regular follow up.
Twenty-four (40.1%) deaths were documented. Survival range for
these patients was1 month – 45 months and mean survival age was
37.5 months. Sixty per cent of the patients diagnosed are still under
regular follow-up.
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Platelet alpha granule contents and bone marrow
fibrosis in myeloproliferative disorders
SF Lynch,w, P Dawsonw, D Stirlingw and CA Ludlam,w
College of Medicine and Veterinary Medicine, University of
Edinburgh, Edinburgh, UK, wDepartment of Clinical and
Laboratory Haematology, Royal Infirmary Edinburgh,
Edinburgh, UK
Platelet derived growth factors including transforming growth factor
beta (TGFbeta) have been implicated in the pathogenesis of bone
marrow fibrosis in myeloproliferative disorders (MPD). These
growth factors are contained within platelet alpha granules along
with beta thromboglobulin (betaTG). We measured plasma levels of
TGFbeta and betaTG in 62 patients with MPD including five
myelofibrosis (MF), 16 polycythaemia rubra vera (PRV), 38 primary
thrombocythaemia (PT) and three MPD not otherwise specified, and
compared them to 18 age matched controls. For patients, the degree
of bone marrow fibrosis at diagnosis was obtained from pathology
reports. The means and standard error of the mean (SEM) are shown
in the table; statistically significant results (Po5 0.05) are denoted
with an asterisk. Mean betaTG and TGFbeta levels were elevated in
all MPD patients and each of the MF, PRV and PT groups compared
to control (Po0.01 for all). Additionally, levels were elevated in MF
and PRV compared to PT patients (Po5 0.05 for all). Diagnostic
trephine reports were available for 52 patients; 46 with no, or mild to
moderate reticulin fibrosis (group A/B) and six with fibrosis of grade
3 or greater (group C). Mean betaTG and TGFbeta were elevated in
group C compared to Group A/B (262.0 vs 122.0 IU/ml, Po0.01 and
2959.2 vs 1777.4 pg/ml, P5 0.01).
In conclusion, plasma levels of platelet alpha granule contents
including TGFbeta are elevated in patients with myeloproliferative
disorders, especially MF and PRV, and are associated with greater
degrees of bone marrow fibrosis.
Mean beta TG (IU/ml) Mean TGF beta (pg/ml)
All MPD (62) 121.9 (14.2) 1813.4 (151.5)
MF (5) 246.6 (97.1) 3044.8 (1051.3)
PRV (16) 127.4 (16.8) 2015.2 (337.1)
PT (38) 83.0 (8.1) 150.3 (121.4)
Controls (18) 44.0 (3.8) 744.6 (58.8)
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An audit of the use of recombinant human erythro-
poietin in a haematology department and its sequelae
R Rashid and GM Smith
Department of Haematology, Leeds General Infirmary, Leeds,
UK
Cancer and cancer treatment-related anaemia (CRA) is a common
clinical problem in the management of haematological malignancy.
The mainstay of treatment has historically been red cell transfusions.
More recently, recombinant human erythropoietin (rHuEPO) is
increasingly being used in this setting.
Clinicians today are faced with an expanding choice of
erythropoietic proteins, and a wealth of data regarding appropriate
dosing regimens, approved indications, efficacy and safety. The cost
of rHuEPO is significant, and because not all patients respond to
therapy, it is important that appropriate assessment of patients takes
place pre-therapy, and that monitoring of response is rigid.
We undertook an audit of the use of rHuEPO in our department
to look at these aspects. The findings showed that although red cell
transfusions were avoided in approximately 60% cases of CRA, there
was inappropriate prescription of rHuEPO for the following reasons:
inappropriate trigger haemoglobin level, inadequate baseline checks,
multiple dosing schedules, incorrect monitoring, inappropriate
duration of therapy, and poor documentation of complications.
Critique of existing clinical guidelines led to the introduction of a
departmental policy for rHuEPO prescribing encompassing:
1. Introduction of a specific rHuEPO prescription form which
allowed pharmacy to decline issue of rHuEPO if appropriate baseline
checks were not documented.
2. Review and amendment of the departmental standard operating
procedure for the use of rHuEPO in CRA; recognition of functional
iron deficiency as a cause of inadequate response.
3. Formulation of a departmental algorithm for the management
of CRA.
As a result of these measures, there was significant reduction in
departmental expenditure for rHuEPO equating to a saving of over
£300 000 for the 6-month period following the introduction of the
policy. This audit demonstrates how critical evaluation of depart-
mental practice, with reference to relevant current guidelines, can
lead to better clinical practice and significant financial savings.
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Hyaluronic acid and liver function in myelproliferative
disorders
SF Lynch,w, D Stirlingw, PC Hayesz and CA Ludlam,w
College of Medicine and Veterinary Medicine, University of
Edinburgh, Edinburgh, UK, wDepartment of Clinical and
Laboratory Haematology, Royal Infirmary of Edinburgh,
Edinburgh, UK, zScottish Liver Transplant Unit, Royal
Infirmary of Edinburgh, Edinburgh, UK
Hepatic fibrosis has previously been described in haematological
diseases, in particular the myeloproliferative disorders (MPD).
Serum hyaluronic acid (HA) is used as a marker of hepatic fibrosis
or cirrhosis in a number of liver diseases. We therefore assessed HA
levels and standard liver function tests in patients with MPD. Sixty-
two patients including, five myelofibrosis (MF), 16 polycythaemia
rubra vera (PRV), 38 primary thrombocythaemia (PT) and three
MPD not otherwise specified, were compared to 17 age matched
controls. The mean results and standard errors of the mean (SEM),
are shown in the table; statistically significant results (Pr0.05) are
denoted by an asterisk. HA was greater than the upper limit of
normal (75 ng/ml) in 28 MPD patients (45%) and four controls (24%).
The mean HA for all MPD was elevated compared to controls but this
was not statistically significant (P5 0.19). Subgroup analysis
revealed greater mean HA levels in the MF and PRV patients
compared to PT patients (P5 0.05, 0.02). Mean bilirubin (Bili) and
alanine aminotransferase (ALT) levels were similar in all patient
groups. Mean alkaline phosphatase (ALP) and gamma glutamyl
transferase (GGT) levels were elevated in MF and PRV compared to
PT patients and controls (all Po0.01).
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In conclusion, HA levels are commonly elevated in patients with
MPD and are highest in patients with MF and PRV, who also have
higher ALP and GGT levels compared to PT patients and controls.
HA
(o75 ng/ml)
Bili
(3–16 mg/ l)
ALT
(10–50 U/l)
ALP
(40–125 U/l)
GGT
(10–55 U/l)
All MPD 78.5 9.9 26.5 97.0 57.0
(8.0) (0.6) (2.5) (5.5) (7.7)
MF 104.4 13.0 46.4 158.6 153.4
(32.2) (2.5) (23.7) (41.8) (65.2)
PRV 106.1 9.3 21.8 117.4 67.1
(23.2) (1.1) (2.4) (8.9) (11.7)
PT 61.9 10.1 25.9 76.5 36.5
(6.7) (0.9) (2.3) (3.1) (4.6)
Controls 63.6 8.2 30.7 86.6 38.5
(7.3) (0.6) (4.0) (4.7) (5.4)
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Management of febrile neutropenia: a retrospective
audit in a district general hospital setting
SV Venkatachalapathy, JN Crowe, E Phillips, NE Blesing, AG
Gray, AJ Sternberg and ES Green
Department of Haematology, The Great Western Hospital,
Swindon, UK
Febrile neutropenia (FN) is one of the commonest reasons for
admission following chemotherapy, needing prompt recognition and
treatment. A retrospective audit was undertaken over 1-year of
patients diagnosed with FN and subsequently admitted to the
haematology ward. We assessed whether FN was correctly diagnosed,
according to our local hospital protocol, by the admitting medical
team and and whether it was appropriately investigated and treated
(correct antibiotics given within one hour and appropriate use of
gentamicin).
Forty-three patient episodes were assessed. Thirteen (30%) did
not meet the local criteria for the diagnosis of FN and six of these
patients were treated as FN. Thirty (70%) had FN of which 23 (77%)
were haematology patients, four (13%) oncology patients, and three
(10%) had non malignant conditions with drug related neutropenia.
Of the patients who were diagnosed correctly with FN, 100% were
investigated appropriately (blood and urine culture and chest x-ray)
and received first line antibiotics (piperacillin/tazobactam or
ceftazidime7 gentamicin). However four patients (13.3%) had
significant renal impairment and were given gentamicin without
dose reduction. One patient did not receive gentamicin due to renal
impairment, despite the protocol stating that a reduced dose should
be given. This patient died as a result of overwhelming sepsis.
Only 17% received antibiotics within one hour according to the
local protocol. In 43% there was no documentation about timing of
antibiotics. Forty per cent received antibiotics within 1–5 hours. Of
the patients who had FN, twenty-five were discharged home, four
died of other causes and one died of sepsis.
This audit demonstrates a need for more accurate diagnosis of
FN, more timely antibiotic administration and more cautious use of
gentamicin in renal failure. These findings are useful for the
education and training of front line clinical staff.
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Audit of adult patients with neutropenia referred to
general haematology outpatient clinic
AM Whittle and GM Smith
Department of Haematology, Leeds General Infirmary, Leeds,
UK
Isolated neutropenia of varying severity is a frequent reason for
referral to general outpatient haematology clinics. Local experience
indicated that such patients were rarely found to have a serious
underlying diagnosis. We audited all referrals of patients with
neutropenia to the general haematology outpatient clinic at Leeds
General Infirmary over a 2-year period from January 2003 to 2005.
The neutrophil count of all 477 new patient referrals and the notes of
all 56 patients found to be neutropenic were reviewed. Ethnic
minority groups were over-represented (15% were Afro-Caribbean,
compared with 0.14% of the population). In 48 patients the final
diagnosis was a benign (e.g. chronic idiopathic, ethnic or post viral
neutropenia) or non-haematological one. A distinct group of patients
with mild isolated neutropenia could be identified (defined as those
individuals with neutrophils in the range of 1–2 109/l without other
full blood count abnormalities). Seventy-five per cent of these
patients were female, and their average age was 10 years less than that
of the total group. No patient in this group was found to have a
serious underlying diagnosis. Eight patients were diagnosed as
having a haematological malignancy or aplastic anaemia but all had
other abnormalities in the FBC. These data have been used to
develop a policy for triaging referrals from general practice, with
written advice being given rather than an outpatient appointment
being made. It was recognised that a large proportion of such
referrals could be prevented by appropriate advice being written on
the full blood count report issued by the laboratory. In addition, it is
important to recognise different reference ranges in ethnic
minorities, especially in areas where they do not constitute a large
part of the population. Adoption of these policies may help
haematology services meet new government outpatient waiting time
targets.
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Survival and outcome of blastoid variant myeloma
following treatment with DT-PACE
M Srikanth, MW Jenner, P Wu, P Kaczmarek, S Dines,
RM Saso, M Ethell, M Potter, JG Treleaven, FE Davies and
GJ Morgan
Royal Marsden Hospital, Sutton, Surrey, UK
Blastoid morphology in myeloma is a rare presenting feature
associated with poor outcome, and hence effective treatment
strategies need to be developed. Extramedullary myeloma also often
has this morphology and is known to be associated with a poor
outcome. Cells with these features often respond well to cell cycle
active classic chemotherapy regimens and combination of these
agents with thalidomide offers an interesting new approach, which
may be useful in this setting. We have collected and analysed all such
cases presenting in a 5-year period and evaluated their characteristics
and outcome after treatment with DT-PACE7 autograft. We
analysed the results of 34 patients (median age 51.6 years, range
37–67) of whom 22 (60%) had extramedullary and/or blastoid type
and 12 had relapsed/refractory disease. DT-PACE consists of
dexamethasone 40 mg day 1–4, thalidomide 100–200 mg daily, and
cisplatin 10 mg/m2/day, doxorubicin 10 mg/m2/day, cyclophospha-
mide 400 mg/m2/day, and etoposide 40 mg/m2/day all given on days
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1–4, on a 28-day cycle aiming to deliver two cycles. Twenty patients
received DT-PACE alone, and 14 DT-PACE followed by a melphalan
autograft. The overall response rates (CR/PR) were 59% for the
blastoid group and 27% for the relapsed/refractory group. Despite
these initial good response patients with the blastoid variant had
early disease progression (PFS 5 vs 13 months, P5 0.015) and (OS 10
vs 13 months, P5 0.138). Patients who tolerated the DT-PACE and
were able to go on to the autograft had better PFS and OS when
compared to the group who received the chemotherapy alone
(PFS5 12 vs 4 months, P5 0.023 and OS not reached vs 4 months,
P5 0.006). In conclusion we confirm the poor clinical outcome for
this group of cases even with the intensive regimen DT-PACE,
however, in contrast to previous treatment excellent response rates
are obtained and some long-term survivors are found. This forms the
basis against which future strategies aimed at improving this
regimen utilising novel therapies can be compared.
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Report of the first case of CMV colitis as the
presentation of multiple myeloma
M Micheni, L Eccersley, W Lynnw, S Ashw, M Buckley, Y
Jethava, G Abrahamson, R Morillay, A Aaliz, N Philpott
and F Brito-Babapulle
Department of Haematology, Ealing Hospital, UK, wDepart-
ment of Infectious Diseases, Ealing Hospital, UK, zDepartment
of Microbiology, Ealing Hospital, UK, yDepartment of Hae-
matology, Royal Marsden Hospital, UK
Reactivation of CMV usually occurs in the immunocompromised
patient due to defective T-cell responses. Reactivation has occurred
in solid organ /bone marrow transplant recipients, hemodialysis
patients on immunosuppressive drugs, and in HIV. CMV colitis is
uncommon in patients who are not severely immunocompromised.
Rarely it complicates inflammatory bowel disease- ulcerative colitis
and Crohn’s disease. CMV colitis as a presenting feature of multiple
myeloma (MM) has not been previously documented. We report an
81 year old man who presented with diarrhoea and abdominal pain
due to CMV colitis and was discovered to have multiple myeloma.
The patient presented with 2-month right upper quadrant abdominal
pain, diarrhoea and lower back pain. Abdominal and pelvic CT scans
revealed segmental thickening of the sigmoid colon suggestive of
colitis. Colonic biopsy confirmed CMV colitis with characteristic
scattered enlarged cells staining positive with antibody to CMV.
CMV PCR showed 6400 CMV DNA copies. Thoracolumbar X-rays
and MRI scans demonstrated a crush fracture of D9 spinal region
and cord compression with involvement of D7 and D8 vertebra. A
soft tissue mass extended into the spinal canal. Biopsy of this
revealed plasmacytoid infiltration. Serum electrophoresis revealed an
IgG paraprotein of 20.7 g/l with immuneparesis. Bone marrow
showed 10% plasma cells with light chain restriction. Skeletal survey
did not reveal lytic lesions. Bence-Jones protein levels were 495 per
cent of total urine protein, beta-2 microglobulins of 6.93 g/l, Ig G
26.8, IgA 0.44 (NR0.8-1) IgM 0.49 (NR 0.5-2) corrected calcium of
2.64 mmol/l, creatinine clearance 47 ml/min. HIV 1 and 2 and HTLV1
neg. Treatment with valganciclovir resulted in resolution of
diarrhoea and abdominal pain and two separate negative serum
PCR tests for CMV after treatment. Radiotherapy and cyclopho-
sphamide, thalidomide and dexamethasone were initiated.
CMV colitis has not been reported previously in MM. Since T-cell
dysfunction is known to be abnormal in MM patients CMV colitis
though unusual, should be considered in clinically appropriate
settings. CMV colitis when unexplained should have a serum
electrophoresis performed as investigation of a possible underlying
cause
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An audit of the economic consequences of early JAK2
testing in the investigation of a raised haemoglobin
SP Moule, J Hsuw, L Eccersleyw, C Cotton, S Sandellz, DO
Robinsonz, N Crossz, R Bimolahw, N Kaurw, G Abrahamsonw, N
Philpottw and F Brito-Babapulle,w
Department of Haematology, Hammersmith Hospital NHS
Trust, London, UK, wDepartment of Haematology, Ealing
Hospital NHS Trust, Middlesex, UK, zNational Genetics
Reference Laboratory, Salisbury District Hospital, Salisbury, UK
The myeloproliferative disorders (Dameshek 1951), have until
recently lacked a unifying pathophysiology. In 2005 a single acquired
point mutation in the Janus Kinase 2 (JAK2) gene, at position V617F
was reported. This gene is present in 95% of cases of polycythaemia
vera (PV). Consequently several new diagnostic systems, which rely
on early JAK2 testing, have been proposed (NEJM 2006; 355: 2452–
66). Many centres include JAK2 testing without analysis of cost
implications. We evaluated the health economic value of early JAK2
testing in patients with a raised haemoglobin and haematocrit. We
audited all JAK2 requests generated by our hospital from 10.06.05 to
10.7.06 in patients with high haemoglobins (male Hb417, Hct40.5,
female Hb415, Hct40.46) and correlated it with tests of serum
erythropoietin (EPO), full blood count, urea, creatinine and blood
volume studies. In 47 cases of a raised haemoglobin and haematocrit
four JAK2 mutations occurred. In two of these, the EPO was below
the lower limit of normal. Of 37 JAK2 negative cases,the EPO was
below the lower limit of normal in five. In these five, no explanation
for the low EPO levels could be found but, in one the haemoglobin
normalised without treatment, another is under investigation for a
renal mass, the third had a normocelllular bone marrow and another
had a hypocellular bone marrow with normal blood volume
studies.We therefore do not believe these five cases are in the 5%
of JAK2 negative PV. Our data suggest that JAK2 testing can be
avoided if the serum EPO level is measured first. If testing is reserved
for cases where EPO iso10 mU/ml a cost saving would be made and
the same level of diagnostic precision maintained. In our study £3150
would have been saved. Further analysis of a larger number of JAK
two positive cases would better identify the EPO level below which
JAK2 testing should be performed. We are currently evaluating the
use of a diagnostic algorithm based on these findings. (EPO-£39.90,
Blood volume-£240, JAK2-£150).
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Hyperparathyroidism – associated polycythaemia: an
analysis of 140 cases of hyperparathyroidism
LRJ Eccersley, SP Moule, N Kargathraw, G Abrahamson,
N Philpott, K Baynesz and F Brito-Babapulle
Department of Haematology, Ealing Hospital, London, UK,
wDepartment of Biochemistry, Ealing Hospital, London, UK,
zDepartment of Endocrinology, Ealing Hospital, London, UK
There are several case reports of polycythaemia/erythrocytosis
occurring in association with hyperparathyroidism, due to both
parathyroid adenoma and carcinoma; the mechanism is unclear but
in some cases the polycythaemia disappears on removal of the
tumour. To determine the prevalence of erythrocytosis in hyperpar-
athyroid patients we identified patients with high parathyroid
hormone (PTH) levels attending our hospital between 2001 and
2006. We found 140 patients with elevated PTH and without end-
stage renal failure. Full blood counts were available in 120 patients
(85.6%). Thirteen (10.8%), including one male, had haemoglobin
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and /or haematocrit values above the normal range. The haemoglobin
values in the twelve females ranged from 14.4 to 18.3 g/dl (NR 11.4–15.0)
and the haematocrit from 0.442–0.522 (NR 0.340–0.440), with two
having haematocrit 4 0.48; the one male had a haemoglobin of 16.9 g/
dl (NR 13.5–17.0) and haematocrit 0.503 (0.39–0.50).
The subject with haemoglobin 18.3 g/dl and haematocrit 0.522 was
a 54-year-old female referred for investigation of raised haemoglobin,
who was hypercalcaemic with a persistently raised PTH level. Isotope
studies showed a raised red cell mass with normal plasma volume
and spleen pool, confirming a true polycythaemia. Her erythropoie-
tin level was raised at 35.8 IU/l (NR 5.0–25.0), suggesting a secondary
polycythaemia. She was negative for the JAK2 V617F mutation.
Erythrocytosis, of varying levels of severity, may occur in
association with hyperparathyroidism and may be under-diagnosed.
The case with high erythropoietin suggests that the erythrocytosis is
likely to be secondary, however further work is needed to investigate
the pathogenesis. We conclude that a calcium level should be
included in the initial investigation of an erythrocytosis, and if the
calcium is raised the PTH level should be measured. Conversely, a
full blood count should be performed in the investigative work up of
suspected primary hyperparathyroidism.
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A retrospective audit of a standard protocol for the
rapid reversal of warfarin in patients with intracranial
haemorrhage
R Basavanna, S Dhami, P Kesteven, K Talks and J Hanley
Department of Haematology, Newcastle Hospitals NHS Trust,
Newcastle upon Tyne, UK
Intracranial hemorrhage (ICH) is a major complication of antic-
oagulation. The incidence is approximately 1% per year and
mortality is about 60%. Risk factors include high INR, older age
and cerebrovascular disease. Lower levels of consciousness, large
bleed volume and haematoma expansion are associated with poor
outcome. Early identification of ICH and prompt warfarin reversal
are potentially critical in decreasing mortality and morbidity. To
manage this complication the Northern Region Hematologists Group
designed a protocol to rapidly reverse warfarin in patients with ICH.
The protocol recommends administration of Vitamin K (5 mg IV)
and a Prothrombin complex concentrate (PCC – Beriplex: 30 U/kg).
The protocol was assessed by retrospective audit. 26 patients (14
male; 12 female; median age 71 years (range 39–88) were identified
with warfarin-associated ICH. Persistent headache (54%), decreased
conscious level (38%) and confusion (35%) were the commonest
presenting features. Hypertension (69%) was the commonest risk
factor with INR 44 in only 26%. Good compliance with the
recommended protocol and rapid reversal of warfarin was demon-
strated (Pre PCC administration: INR: median 2.6; range 1.5–10.
15 min post PCC administration: INR median 1.1; range 1.0–1.4). The
median time from hospital admission to vitamin K and PCC
administration was 229 (range 100–460) and 323 (range 150–510) min
respectively. Outcome (at 30 days): Independent (27%); moderate/
severe disability (31%); death (42%).
This retrospective audit shows that a standard protocol for the
reversal of warfarin in patients with ICH is effective and may be
associated with improved outcome. However, in practice, the
administration of both vitamin K and PCC does not occur rapidly
following hospital admission. A prospective study would be required
to assess whether more rapid reversal is associated with an improved
outcome. Patient education is required to ensure persistent headache
is reported as a significant number of patients were symptomatic for
several days prior to presentation.
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Clinical outcomes of point-of-care INR monitoring in
primary care anticoagulation practice
M Mohsin, A Naseem, P Carsonw and MD Creaghw
Peninsula Medical School, Universities of Exeter and
Plymouth, UK, wDepartment of Haematology, Royal Cornwall
Hospitals Trust, Truro, UK
Approximately 500 000 people in the UK receive oral anticoagulant
therapy (OAT), with this figure rising 10% per year and an increasing
workload for laboratories. This workload, together with issues of
patient autonomy and safety of care has resulted in the development
of monitoring of the INR by point-of-care (POC) devices and one
stop primary care clinics. Studies of POC INR testing show
comparable performance to conventional laboratory testing, how-
ever, there is limited information regarding the clinical outcomes
with POC monitoring.
To assess clinical outcomes of POC INR monitoring in primary
care practice, a 12-month retrospective study was undertaken of nine
GP practices with established anticoagulant clinics using POC
monitoring. A postal questionnaire requested the total patient list
size, numbers on warfarin, details of POC testing, the means of
dosing and adverse events for thrombosis, bleeding and deaths.
Nine practices with 101 822 patients reported 1305 subjects on
warfarin monitored by POC devices. All followed manufacturers’
guidance on POC testing, undertook external quality control with the
local Haematology laboratory, with warfarin dosing facilitated by
computerised decisions support software (CDSS). There were three
thrombotic and five haemorrhagic reported episodes with a
respective incidence of 0.23 and 0.38 per 100 000 persons per
annum, with no associated fatalities. Among surgeries reporting
deaths, there were 26 cases amongst 337 warfarinised patients (7.7%),
none due to haemorrhage or thrombosis.
Control of OAT by POC monitoring in primary care is safe and
effective with a low incidence of recorded adverse events, comparable
with patients monitored using conventional laboratory testing
(O’Callaghan S, Laporte S, Camps F, Fuste N, Carrasco P, Tarres V.
(1997) Hemorrhagic complications and Thrombotic Phenomena in
Oral Anticoagulation of Elderly Patients. Revista clı´nica espan˜ola 197,
(5): 323–8.). Further prospective study should be undertaken,
together with a conventionally monitored control group.
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The safety and efficacy of long term low molecular
weight heparin (LMWH) in patients with portal
hypertension
T Dutt, P Sutton, M Gautam, H Smartw and CH Toh
Department of Haematology, Royal Liverpool University
Hospital, Liverpool, UK, wDepartment of Gastroenterology,
Royal Liverpool University Hospital, Liverpool, UK
Portal vein thrombosis (PVT) is responsible for 5–10% of all cases of
portal hypertension in Western countries. The association of PVT
with an underlying pro-thrombotic disorder has been repeatedly
reported and accounts for 10–12% of PVT cases in adults.
There are no prospective studies on the safety and effects of long
term anticoagulation in cases of PVT where an associated pro-
thrombotic history or defect exists. Paradoxically, lack of antic-
oagulation may accelerate GI haemorrhage from oesophageal varices
secondary to further abdominal vessel thromboses.
A retrospective analysis of around 70 patients with PVT, where a
pro-thrombotic state had been demonstrated, reported that these
patients were likely to have recurrent thrombotic events in the portal
venous system, and that recurrent or extensive thrombus was
responsible for as many deaths as GI bleeding. It was concluded that
oral anticoagulation therapy had a favourable benefit risk ratio in
patients with an underlying pro-thrombotic disorder and it has been
proposed that in such patients, or where there is a history of
recurrent thrombosis, long term anticoagulation should be con-
sidered.
We report four patients with PVT, demonstrating an underlying
coagulation defect, and or a recurrent thrombotic history, main-
tained on long term low molecular weight heparin (LMWH). These
patients have been followed for up to 9 years with 3 monthly
endoscopic banding, 6 monthly anti-Xa levels and yearly bone scan
to detect osteopenia. Overall, there have been no episodes of
significant GI haemorrhage, one patient developed a further
thrombotic event, anti-Xa levels have been stable and one patient
has asymptomatic osteopenia of the lumbar spine.
Long term management with LMWH may offer a less labile form
of haemostatic control, in relation to oral anticoagulation. Whilst
being effective and consistent, LMWH is also less problematic in
patients with liver dysfunction.
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Quality of anticoagulation management in primary
care practice
C Allen, M Parkin, M Hicksw, P Carsonw and MD Creaghw
Peninsula Medical School, Universities of Exeter and
Plymouth, UK, wDepartment of Haematology, Royal Cornwall
Hospitals Trust, Truro, UK
Currently an estimated 500 000 people in the United Kingdom
receive oral anticoagulant therapy (OAT). The therapeutic window
for OAT is narrow, with regular monitoring and dose adjustment
required for effective safe treatment. Anticoagulants are one of the
classes of drugs most commonly associated with fatal prescribing
errors, whilst there is limited evidence of the quality of anticoagulant
care delivered in primary care practice. The need for more stringent
safety controls has been identified by the National Patient Safety
Agency, with subsequent guidance in conjunction with the British
Committee for Standards in Haematology (BCSH 2006).
Within Cornwall OAT is mainly managed in the primary care
setting. To assess the delivery of anticoagulation services, a
questionnaire was developed with reference to the BCSH guidance
and sent to the anticoagulant lead in 76 general practices in Cornwall.
Thirty-two (42%) of surgeries responded, most commonly super-
vising anticoagulant care for 80–100 patients (range n5 20–220),
with results as tabulated below.
Among the respondents there was a high level of compliance with
the BCSH guidance, with comprehensive governance programmes,
indicative of good quality care. Ideally, all commissioned services
should be assessed for compliance with current guidance, whilst
systematic collection of outcome data and analysis of cost
effectiveness would be informative.
Percentage
of surgeries
Computerised prescribing 94
Alert for co-prescribed drugs 83
Patient education 100
verbal and leaflet instruction 72
Audit of adverse outcomes 87.5
Audit INR time in range 75
Review of practice at clinical governance meetings 88
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Optimising the use of the clotting screen
AA Johny, DW Cheung, J Ropner and SR Chown
Department of Haematology, Gloucester Royal Hospital, UK
The coagulation profile is often used as a screening test to detect
occult coagulopathies, especially in the pre-operative setting. It is
well known that in the absence of a personal or familial bleeding
history, this test is of low yield and is more likely to raise incidental
laboratory abnormalities of little clinical significance.
In light of recent financial pressures on our laboratory and the
escalating use of the coagulation profile (APTT and PT in our
laboratory), the use of this test over a period of one week was audited
against existing laboratory guidelines. During this period, 642
coagulation profiles were performed (excluding patients on antic-
oagulants); equating to over 32 000 per annum. The audit showed
that 372 (58%) of requests were found to be outside the recognised
criteria for performing the test. During this period, only one
clinically significant bleeding disorder was diagnosed (in a patient
with a significant bleeding history).
Based on these results and after consultation with senior medical
staff, it was decided to allow requesting of the coagulation profile
only if it met appropriate criteria. New guidelines for the appropriate
use of the clotting screen were drawn up and circulated to all medical
staff. The laboratory began vetting all requests and rejecting those
samples not fulfilling the guidelines. The use of clotting screens was
then re-audited after 3 months, again over a 1-week period. There has
been a significant drop in requests (336 requests) with an
improvement in pattern of requesting (97/336 or 29% not indicated).
There have been no reported unexplained bleeding episodes or
attributable clinical mishaps in this 3-month period.
Restricting the use of the coagulation profile has not just resulted
in financial benefits but has also improved medical practice and
decreased unnecessary investigations and undue anxiety to patients.
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Evaluation of the CS-2000i analyser using
coagulation, amidolytic and immuno-turbidometric
assays
AS Lawrie, K Kobayashiw, K Tajimaw, S Hoshikow, N Matsuow,
Y Hamaguchiw, R Liesner,z, SJ Machin,z and IJ Mackie
Haemostasis Research Unit, Department of Haematology,
University College London, UK, wResearch and Development,
Sysmex Corp., Kobe, Japan, zDepartment of Haematology,
University College London Hospitals, London, UK
The CS-2000i, a new coagulation analyser from Sysmex, is capable of
performing coagulation, amidolytic and immuno-turbidometric
assays. Transmitted light can be monitored at multiple wavelengths
(340, 405, 575, 660, 800 nm), allowing more efficient clot detection in
the presence of interfering substances. The CS-2000i also offers a
pre-analytical check and flagging system for haemolysis, icterus and
lipaemia (HIL check). We evaluated this new analyser against the
CA-1500 (light scatter) and STA Compact (mechanical) devices,
using 200 samples from normal subjects and patients with icteric
(bilirubin o489mmol/l), lipaemic (cholesterol o8 mmol/l, triglycer-
ides o7.5 mmol/l), or haemolysed plasmas (plasma Hb 0.4–6.1 g/l),
and high or low fibrinogen content (45 or o0.5 g/l). The CS-2000i
was able to detect excessive icterus and haemolysis at 405 and 575 nm
respectively and potentially flag these sample problems. Biphasic clot
waveforms could be detected in some samples. Between day assay
imprecision (n5 10 replicates on each of 5 days) was assessed using
commercial QC material. Low imprecision was observed for clotting
tests (PT, APTT, Clauss fibrinogen [Fg]) with normal (cv o0.83%)
and abnormal (cv o2.39%) plasmas; chromogenic assays (PC, AT-
III, Plg) with normal (cv o1.49%) and abnormal (cv o3.37%)
plasmas; immuno-turbidometric assays (D-Dimer) with 560mg/l (cv
2.32%) and 2500mg/l (cv 2.24%) plasmas. PT (INR 1.0–5.0), APTT
(27–115s) and Fg (0.5–12.5 g/l) showed good correlations with the CA-
1500 (r5 1.00; 0.99 and 0.99 respectively) and STA Compact
(r5 1.00; 0.97 and 0.98 respectively). PC (15–270 U/dl), AT-III (20–
180 U/dl) and Plg (17–200 U/dl) showed good correlations with the
CA-1500 (r5 1.00; 0.99 and 0.98 respectively). D-Dimer (0–1500mg/l)
showed good correlations with the CA-1500 (r5 0.95). A new clot
detection algorithm avoided early reaction errors and the facility to
switch analysis to different wavelengths avoided interference by
lipaemia, icterus and haemolysis, while fibrinogen sensitivity was
excellent. While chromogenic and immuno-turbidometric assays
exhibited good correlation with the CA-1500 analyser.
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The UK National External Quality Assessment Scheme
(UK NEQAS) for molecular genetic testing in haemo-
philia
DJ Perry, A Goodevew, M Hillz, I Jenningsy, S Kitcheny, ID
Walkery and UK Neqas Blood Coagulationy
Department of Haematology, Addenbrooke’s Hospital,
Cambridge, UK, wAcademic Unit of Haematology, Sir Henry
Wellcome School for Medical Research, Sheffield, UK,
zDepartments of Clinical Chemistry and Haematology, Uni-
versity Hospital, Queen’s Medical Centre, Nottingham, UK,
yUK NEQAS Blood Coagulation, Sheffield, UK
The identification of the causative mutation in individuals with
haemophilia and other inherited bleeding disorders is common
practice. In the UK, participation in a recognised external quality
assurance scheme is a requirement for laboratory accreditation. In
1998, UK NEQAS (Blood Coagulation) established the first pilot
scheme to provide external quality assurance for molecular genetic
testing in haemophilia. Results from three initial surveys highlighted
problems with the quality of DNA and whole blood samples when
used as QA material.
In 2003 the scheme was re-launched and addressed three aspects
of genetic testing: the identification of a mutation, the interpretation
of the mutation in the context of the clinical data and the reporting of
results.
Between 2003 and 2006, five exercises involving whole blood or
DNA (from immortalised cell lines) were circulated to participating
centres in the UK and Iran. Laboratories were asked to undertake
genetic testing, construct a report and return this within 6 weeks of
receipt of samples. Reports were anonymised and scored in three
areas (clerical, genotyping and interpretation) using a standardised
template. Individual laboratory performances together with a
summary of the exercise were returned to participants.
In 2003, a paper exercise highlighted problems with laboratory
reports but following feedback to participants, only a single clerical
error has been made in the five subsequent exercises. No laboratory
has failed to identify the presence of absence of a mutation although
inconsistencies in the interpretation have been noted.
Participating laboratories receive QA material every six months.
Immortalised cell line material was introduced in 2005 and has been
shown to perform well. Feedback from participating laboratories has
been positive and overall the scheme has led to a more uniform
approach for the reporting of genetic data and a more widespread
use of standardised mutation nomenclature.
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Myocardial infarction (MI) in a 28 year old woman
following treatment with DDAVP and tranexamic acid
A Patel,w and M Laffan,w
Department of Haematology, The Hammersmith Hospitals
NHS Trust, London, UK, wDepartment of Haematology,
Division of Investigative Science, Faculty of Medicine, Imperial
College London, UK
DDAVP and tranexamic acid have been safely used in large numbers
of patients with mild bleeding disorders. Large randomised studies
support use of tranexamic acid in cardiac surgery to prevent intra-
and peri-operative myocardial ischaemia and infarction. We report
MI following therapy in a young woman without significant coronary
artery disease.
Case: A 28-year-old woman with a platelet function disorder was
given a single dose of DDAVP (0.3 mcg/kg) to allow an arthroscopy
to be performed. This was followed by seven days therapy with oral
tranexamic acid (1 g tds). The platelet function disorder had been
shown to be responsive to DDAVP and she had received DDAVP
following the birth of her child and also routinely used intranasal
DDAVP for control of epistaxis. 10 days after the operation she
presented with severe central chest pain. ECG and elevated troponin
I (27.81mg/l) confirmed an inferior myocardial infarction. Immediate
angiography revealed occlusion of a branch of the right coronary
artery, too small to stent. The other coronary vessels were normal.
Treatment was with aspirin and clopidogrel, and the patient made an
uneventful recovery.
MI has been reported previously following DDAVP therapy. This
effect is usually immediate and in elderly patients with significant
atheroma. Mannucci (1993) did not find a significant excess of MI in
patients receiving DDAVP during surgery. The timing of MI in our
case makes it unlikely that DDAVP was responsible. Previous reports
of arterial thrombosis associated with tranexamic acid are extremely
rare. Only two cases of MI attributed to its use have been reported,
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one in a 77-year-old and another in a 42-year-old recently initiated
on the combined oral contraceptive. Both women were found to have
coronary stenosis at angiography in the affected territory. Although
the development of the thrombosis in this case is unusually late in
relation to therapy, it seems unlikely that the MI would have
occurred otherwise. These agents should not be regarded as entirely
safe even in patients with low cardiovascular risk.
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Introduction of a biomedical scientist led bleeding
disorder clinic
JM Needham, A Roy and AE Milne
Department of Haematology, North Hampshire Hospital,
Basingstoke, UK
Basingstoke and North Hampshire Foundation Hospital supports a
Haemophilia Comprehensive Care Centre where patients suffering
from abnormal bruising or bleeding are referred for diagnosis and
clinical management of their condition. Traditionally, all patients
were seen in a bleeding disorder clinic by a Consultant Haematol-
ogist.
With the pressures on Consultant Haematologist time and
vacancies, innovative solutions were required to continue to provide
a quality service. With the extensive knowledge of the biomedical
scientists within the haemostasis laboratory it was decided to utilise
this in a new area of clinical activity and introduce a Biomedical
Scientist led Bleeding Disorder Clinic.
With this practice new out-patient referrals are seen by the
Biomedical Scientist were history is taken and appropriate laboratory
investigations performed. All patients are now screened for both
coagulation and platelet function at the first visit and further
investigations instigated by the biomedical scientist according to test
results and history knowledge. Following this the patient is a)
discharged or b) returns to see the biomedical scientist for further
tests. On completion of investigations the Consultant Haematologist
sees either patients with an identified abnormality to discuss
diagnosis or with an impressive history with no specific abnormality
identified.
Over 12 months 60% of patients have been discharged after initial
investigations, with 40% requiring follow-up, of which 50% were
identified with VWD and 20% with a platelet abnormality.
This new model of service has streamlined investigation of
potential bleeding disorders. Patients require less clinic visits to
complete their investigations. It has extended the role of the
biomedical scientist and made effective use of the Consultant
Haematologist clinic caseload for patients with a diagnosed
abnormality or clinically complex cases.
This service development was recognised by the Department of
Health at the Healthcare Science Award 2006, were Dr Needham
received the award for Innovation in Workforce Modernisation
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Management and outcome of pregnancy in patients
with thrombophilia and a poor obstetric history at a
single tertiary referral obstetric unit
CD Arbuthnot, R Kirchmeier and W Lester
Department of Haematology and Foetal Medicine,
Birmingham Womens Healthcare Trust, Birmingham, UK
The management of women with a history of recurrent miscarriage
or late pregnancy loss and thrombophilia remains controversial. We
performed a retrospective study from 1997 to 2005 of women with a
poor obstetric history and a laboratory thrombophilia treated with
low molecular weight heparin (LMWH). The data was collected using
clinical notes and computerized records. Data was available for 159
women between the ages 16 and 44 years: 66 patients had
antiphospholipid syndrome; 24 factor V Leiden; 36 protein C/S
deficiency; four antithrombin deficiency; four PT20210A prothrom-
bin gene mutation and 25 were classified as miscellaneous with
diagnosis including MTHFR variant, borderline APC resistance,
elevated factor VIII, and factor XII deficiency. Overall 73 women were
managed with LMWH only and 85 had both aspirin and LMWH (1
not documented). Of the 159 women, 118 had not had a previous
successful pregnancy and of these 88 (75%) were then successful, 23
unsuccessful and seven not documented. Of 41 women with at least
one previous successful pregnancy, 35 (85%) went on to have a
successful outcome with treatment. The overall success rate for
women with antiphospholipid syndrome and other thrombophilic
disorders was 71% and 82% respectively.
We also studied 103 women with the same obstetric history as the
patient group but with no documented thrombophilic defect and
otherwise normal investigations including cytogenetics, who did not
receive any LMWH. Of 61 women with no previous successful
pregnancies 43 (70%) went on to have a successful outcome and in 42
women with a previous successful pregnancy, 35 (83%) went on to
have a successful outcomes. Most women at our centre with a poor
obstetric history have a successful outcome in subsequent pregnan-
cies whatever the laboratory defect or treatment given. Results from
prospective randomized controlled studies are required to inform
future practice and avoid unnecessary interventions.
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Management of life threatening bleeding in patients
on warfarin – the use of prothrombin complex
concentrate in a district general hospital setting
JN Crowe, SK Allenw and ES Green
Department of Haematology, The Great Western Hospital,
Swindon, UK, wEmergency Department, The Great Western
Hospital, Swindon, UK
Warfarin is the most commonly used oral anticoagulant in the UK.
The main side effect of warfarin is haemorrhage. In major/life
threatening bleeding rapid reversal is necessary. The British
Committee for Standards in Haematology (BCSH) guidelines
recommend reversal of anticoagulation in patients with major
bleeding with a factor concentrate in preference to fresh frozen
plasma, together with 5 mg intravenous vitamin K.
We undertook a retrospective analysis over a 4 year period of the
use of prothrombin complex concentrate (PCC) in the treatment of
patients with life threatening bleeding. A total of 52 patients received
PCC, 29 men and 23 women. Seventeen out of fifty-two patients were
less than 70 years of age. The commonest indication for warfarin was
atrial fibrillation (29), followed by prosthetic heart valves (8) and
venous thromboembolism (7). A total of 19/52 patients had an INR
within the appropriate target range. Eight patients had an INR of
greater than 10. The commonest indication for the use of PCC was
intracranial bleeding (19). The remaining 33 patients had life
threatening bleeding at other sites, or had significant surgical
bleeding. Twelve patients were treated with PCC alone, 33 patients
received vitamin K and PCC. In seven patients it was not possible to
ascertain whether they had received vitamin K. Only 8/52 patients
were treated according to the recent updated BCSH guidelines, the
remainder receiving additional FFP or vitamin K orally and/or in a
different dose. In terms of immediate outcome, 18/52 patients died. In
the longer term, looking specifically at disability, 26/52 patients made
a good recovery, 4/52 patients had a moderate disability. Overall, 13/
17 patients o70 years and 20/35 470 years were alive.
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We intend to use this data to produce local guidelines for the use
of PCC and reversal of oral anticoagulants, and then re-audit
management of warfarin reversal.
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Which patients with venous thrombosis do not require
screening for malignancy? A predictive model to
identify patients with VTE at minimal risk of
malignancy
S Paneesha, W Zhangw, N Parsonsw, P Kestevenz, H Marrz, A
Borg and P Rose
Department of Haematology, Warwick Hospital, Warwick,
UK, wDepartment of Statistics, University of Warwick, Coven-
try, UK, zDepartment of Haematology, The Newcastle upon
Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK
Association between VTE and cancer has been recognised for over a
century. The incidence of occult or overt malignancy in patients with
thrombosis is 7–26%. We propose here a predictive model using age,
quantitative D-dimer level along with site of thrombosis. This study
included 696 (M: 358; F: 338) patients from the prospectively
maintained database of patients with venous thrombosis at a
Teaching Hospital, between 2001 and 2005. All Patients with throm-
bosis received standard treatment with low molecular weight heparin
and warfarin. A logistic multivariate regression model was fitted with
an indicator variable for a subsequent cancer as the response and
age, the natural logarithm of the quantitative D-dimer level and the
site of the thrombosis as explanatory variables. The fitted model was
validated using an additional set of independent data.
The model correctly identified the VTE patients without
malignancy in with 98.5% accuracy. But the model was ineffective
in identifying VTE patients with malignancy (9% accuracy). The area
under the ROC curve was 0.72, indicating that the test developed for
predicting cancer for the model data was reasonably good. Our
model shows that below a predicted probability of 0.10 less than 5%
of the patients actually developed cancer (9/190) whereas for 0.19 less
than 10% of patients actually developed cancer (27/276).
In the validation dataset of 93 patients with VTE, the model
correctly identified the number of patients without malignancy with
98.6% accuracy. There were no significant difference in the number
VTE patients with cancer between the model and the validation
dataset for the predicted probabilities of 0.10 and 0.19 (One-sample
binomial tests; p-values of 0.650 and 0.246, respectively). Our model
is useful for identifying patients at minimal risk of having
malignancy with VTE. This model is reproducible as it has been
validated by an independent dataset. This model will enable a
focused and a cost-effective strategy of screening for malignancy in
patients with VTE.
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Plasma thrombomodulin levels are significantly raised
in pre-eclampsia
LM Dusse, MG Carvalho, D Voegeliw, AJ Cooperz and
BA Lwaleedw
Federal University of Minas Gerais, Brazil, wUniversity of
Southampton, UK, zPortsmouth University, UK
Thrombomodulin (TM) is an endothelial cell membrane glycopro-
tein which functions as a thrombin receptor. The thrombin-
thrombomodulin complex initiates the protein C anticoagulant
pathway. It activates protein C rapidly which together with protein
S inactivate factor Va and factor VIIIa. Pre-eclampsia (P-EC) is a
complex multisystem disorder characterized by hypertension,
proteinuria and edema. It occurs after the 20th week of pregnancy.
P-EC has no cure, except by pregnancy interruption. In more severe
cases, conditions such as eclampsia, HELLP syndrome or dissemi-
nated intravascular coagulation (DIC) may develop. The aim of this
study was to assess plasma TM levels in pre-eclamptic women.
Plasma TM levels were measured using an enzyme-linked immuno-
sorbent assay (ELISA). A total of 57 subjects were studied. These
include non-pregnant women (n5 22), healthy pregnant women
(n5 15), and pre-eclamptic women (n5 20), at the third trimester.
The mean and standard deviation (mean7 SD) for the three groups
were: non-pregnant women (0.60970.311), healthy pregnant women
(0.69270.267) and pre-eclamptic women (0.9177 0.324). Plasma
TM levels showed a statistically significant difference when women
with P-EC were compared to the non-pregnant women group (Po
0.05). However, we observed no significant difference when the pre-
eclamptic women group was compared with the healthy pregnant
women group. In conclusion, plasma TM levels are significantly
elevated in women with P-EC. Endothelial cell injury and/or
inflammatory reaction could have resulted in the increased plasma
TM levels seen in our study. This finding may have a significant clinical
ramification in the management of such patients. Detailed studies are
required to address such an important relationship further.
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Venous thrombosis (VTE) has an adverse impact on the
survival in patients with malignancy
A Lokare, S Paneesha, Z Lesterw, T Nokesw, R Aryaz,
T Farreny, A McManusz, F PressleyJ, N Scriven,
D O’Shaughnessyww and P Rose
Department of Haematology, Warwick Hospital, Warwick,
UK, wDepartment of Haematology, Derriford Hospital, Ply-
mouth Hospitals NHS Trust, Plymouth, UK, zDepartment of
Haematology, King’s College Hospital, London, UK, yDepart-
ment of Haematology, Bart’s and The London Hospital,
London, UK, zThrombosis Research Institute, London, UK,
JRoyal Gwent Hospital, Gwent, UK, The Calderdale Royal
Hospital, Halifax, UK, wwDepartment of Health, London, UK
Association between VTE and cancer has been recognised for over a
century. Data on adverse impact of venous thrombosis on survival in
patients with malignancy is conflicting. Study included 902 (M:463;
F:439) patients from the database of patients from UK venous
thromboembolism registry (VERITY). Counterpart group included
2263 (F: 1518; M: 745) consecutive patients without venous
thrombosis from one site. D-dimer assays were done using Bio-
Merieux kit. Median age at presentation was 66 years. Median D-
dimer level was 2500mg FEU/ml. 17.3% had D-dimer48000mg. Sixty-
one per cent had above knee and 34% had below knee VTE. Five
hundred and twenty-two patients had no malignancy, 89 had bowel,
61 prostate, 56 breast, 41 gynaecological, 29 lung and 102 had
miscellaneous carcinoma. Median follow-up was 21 months. Mean
overall survival(OS) in non-VTE patients without malignancy was 56
months as compared to 54 months in VTE patients with malignancy.
Mean OS in VTE patients with ca breast was 34 months (counterpart
group: 47 m). Median OS in VTE patients with ca bowel was 9
months (counterpart group: 36m). Median OS in VTE patients with
ca prostate was 31 months (counterpart group: 33m). Median OS in
VTE patients with gynaecological ca was 17 months (counterpart
group: 50m). Median OS in VTE patients with miscellaneous
carcinoma was 9 months (counterpart group: 30m). Median OS in
VTE patients with ca lung was 5 months (counterpart group: 4m).
Median D-dimer levels in VTE patients without malignancy, Ca
Breast, Ca bowel, Ca Prostate, Gynaecological Ca, Miscellaneous Ca
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and Ca Lung respectively were 2200, 3650, 4100, 2850, 3140, 3230 and
3400mg FEU/ml. D-dimer48000mg was associated with shorter
survival (Log rank test; p valueo0.001). Our study shows occurrence
of VTE shortens the survival in patients with malignancies. Our
study also shows D-dimer48000mg is associated with significant
shorter survival. More studies are warranted to determine whether
this adverse impact correlates with the thrombogenesity of under-
lying malignancy and also can it be negated by optimum antic-
oagulant therapy.
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Platelet function testing: practice amongst UK NEQAS
for Blood Coagulation participants, 2006
I Jennings, TAL Woods, DP Kitchen, S Kitchen and ID Walker
UK NEQAS (Blood Coagulation), Sheffield, UK
Despite the importance of platelet function testing in investigation of
bleeding tendency, there is little standardisation and no effective
quality control of these tests. A questionnaire distributed in March
2006 sought to establish platelet function testing practice amongst
UK NEQAS Blood Coagulation participants.
One hundred and fifty-eight centres reported use of one or more
tests of platelet function. 27% reported the bleeding time as the only
platelet function test they perform. A variety of bleeding time devices
is employed. Reference ranges, primarily literature derived, ranged
from o6 to o10.5 min. Thirteen per cent perform a combination of
bleeding time (BT), PFA100 analyser and aggregometry tests, 20%
BT1 aggregometry, and 18% PFA1001 aggregometry tests.
Seventy-two centres employ the PFA100; 57/72 may not perform
further investigations if a normal result is obtained. Sixty six out of
seventy centres employ collagen/epinephrine cartridges with each
patient, compared to 48/72 with the collagen/ADP cartridge. Marked
variation in quoted reference ranges were observed, whether locally
determined or literature derived. Fifty centres do not employ
controls for this test.
For platelet aggregometry, variability in preparation of platelet
rich plasma (PRP) and platelet poor plasma (PPP) was accompanied
by adjustment of the PRP platelet count, generally with PPP, in 73/79
centres. Maximum acceptable time for testing samples after
collection ranged from 45 to 240 min. Forty nine out of eighty
centres employed five different agonists in their investigations.
Marked variability in instrumentation and agonist source was
identified; eg 17 different sources of ristocetin were reported.
Variability in agonist final concentrations was compounded by
different units employed. 86/145 centres employed quantitative
aggregation (48/86 reporting maximal aggregation); the remainder
used visual estimation for qualitative assessment. Fewer than 10%
performed other tests of platelet function. In conclusion, there is
marked variability in the laboratory evaluation of platelet function;
updated guidelines and standardisation of methodology are required.
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Endocrine and CNS malignancies are strongly asso-
ciated with symptomatic venous thromboembolism:
findings from the VERITY registry
P Rose, Z Lesterw, P Shankara, A McManusz, T Nokesw,
F Pressleyy, N Scrivenz, T FarrenJ, R Arya and
D O’Shaughnessyww
Department of Haematology, Warwick Hospital, Warwick,
UK, wDepartment of Haematology, Derriford Hospital, Ply-
mouth, UK, zThrombosis Research Institute, London, UK, yDVT
Clinic, Royal Gwent Hospital, Gwent, UK, zMAU, The Calder-
dale Royal Hospital, Halifax, UK, JDepartment of Haematol-
ogy, Bart’s and The London Hospital, London, UK,
Department of Haematology, King’s College Hospital,
London, UK, wwDepartment of Health, London, UK
The association between VTE and cancer is well recognised but VTE
rates in specific cancers and the impact of VTE on mortality are
poorly characterized. VERITY, an ongoing UK prospective VTE
treatment registry, has enrolled more than 60 000 patients with
suspected or confirmed VTE. To further elucidate the relationship
between VTE and cancer, we compared VTE rates in cancer and non-
cancer patients and compared the prevalence of different cancer
types in VTE-positive and VTE-negative cases. This analysis was
undertaken as part of a larger research program to characterize
thrombosis risk and outcome in patients with cancer.
By Dec 2006, VTE diagnosis was known in 52 363 patients (27.1%
[n5 14 199] confirmed with VTE and 72.9% [n5 38 164] with VTE
excluded) and in 3437 patients with cancer. More patients with VTE
had a diagnosis of cancer than VTE-negative patients – 13.7% (1939/
14 199) vs 4% (1498/38 164), respectively. Comparing cancer to non-
cancer patients, VTE was two-fold higher in cancer patients (56%
[1939/3437] vs 25% [12 260/48 926], respectively).
Certain tumour types were more strongly associated with VTE.
The prevalence of endocrine tumours was 16-fold higher in VTE
patients than VTE-negative patients; CNS tumours were 14-fold more
prevalent. Other malignancies were also associated with VTE – head
and neck (10.3-fold higher in VTE patients); pancreatic (9.7); upper
GI (7); lung (5.2); myeloma (4.6); bone (4.4); colorectal (4);
leukaemia (3.5); gynaecological (3). Although breast and prostate
cancer accounted for the highest number of cancer patients with
VTE, these malignancies were only 2.8- and 2.6-fold more prevalent
in VTE patients than VTE-negative patients, respectively. Melanoma,
urological cancers and lymphoma showed a 2-fold higher prevalence
in VTE patients.
These results confirm earlier findings that the overall risk of VTE
in cancer patients is about twice the risk of patients without VTE and
that endocrine and CNS malignancies are strongly associated with
symptomatic VTE.
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B-cells from lymphocytic leukemias are capable of
synthesis of vascular endothelial growth factor (VEGF)
and basic fibroblast growth factor (b-FGF)
S Aref, O Salama, S Shamaa and H Mourkos
Department of Haematology, Mansoura Faculty of Medicine
Angiogenesis is a crucial event in the survival and progression of
solid as well as hemopoietic malignancies. To determine whether
angiogenesis in lymphocytic leukemias is an intrinsic property of
leukemic cells, Bone marrow mononuclear B-cell lineage were
separated from 25 acute lymphoblastic leukemia (ALL) and 15
Chronic lymphocytic leukemia (CLL) and cultured for 24 hour.
Culture supernatant were assayed for the secretion of VEGF and b-
FGF using enzyme linked immunosorbent assay. These data
demonstrated that leukemic B-cells isolated from CLL and ALL
patients at diagnosis spontaneously secrete both VEGF and b-FGF
(55.1;7.0–295, 68.2,5.0–400.0, respectively) in CLL and (70.4; 20.4–130;
99.137.4–172.0, respectively) in ALL. The pretreatment bFGF and
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VEGF levels were significantly higher as compared to that in
remission both in ALL and CLL. The level of the secretion at
diagnosis was higher in CLL-cells separated from advanced Ria
stages as compared to those with favorable Ria stage (Po0.05 for
both). On the other hand their levels did not differ in ALL FAB
subtypes (P40.05 for both).
In summery, these data collectively indicate that angiogenesis in
lymphocytic leukemias likely to represent an intrinsic property and
that the level of angiogenic factor secretion is correlated with
advanced CLL disease.
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Incidence and significance of the t(14;19)(q32;p13) in
B-cell lymphoproliferative disorders
RJ Kelly, SL Barrans, SJM O’Connor, K Turner, AS Jack and RG
Owen
HMDS Laboratory, Leeds Teaching Hospitals, Leeds, UK
The t(14;19)(q32;p13) which deregulates BCL3 as a consequence of its
juxtaposition to the IGH locus is a rare abnormality in B-cell
lymphoproliferative disorders (LPD). It is said to occur primarily in
CLL where it is associated with an atypical immunophenotype,
typically the lack of CD23 expression and possibly a poor outcome. It
has however been described in a number of other lymphoma
subtypes. In order to clarify this we have evaluated a large series of
B-cell lymphomas with interphase FISH. Samples were initially
screened for IGH rearrangements using a dual colour IGH break-
apart probe set (Vysis, 32–191 019) and cases with a split signal were
further evaluated with a BCL3 dual colour breakapart probe set
(Dako, Y5411). Cases of follicular lymphoma and mantle cell
lymphoma were specifically excluded as they contain disease
defining IGH translocations. Ninty-seven cases of diffuse large B
cell lymphoma were evaluated and a t(14;19) was demonstrable in two
patients both of whom had a preceding history of CLL. Interestingly
in one of these patients the translocation was not demonstrable in
the CLL cells prior to histological transformation. Forty-seven
patients with extranodal marginal zone lymphoma (ENMZL) were
also evaluated and a t(14;19) was demonstrated in a single patient
with gastric MZL (overall incidence 2.1%). The translocation was not
however demonstrable in CD5 LPD (n5 136) but was seen in 2/76
(2.6%) patients with CD51 CD23 LPD. The majority of these
patients were considered to have atypical CLL on the basis of their
clinical features, immunophenotype and lack of a t(11;14).
We would therefore conclude that the t(14;19) is indeed a rare
abnormality. It is seen in a minority of patients with atypical (CD51
CD23) CLL and may be associated with large cell transformation. It
is also demonstrable in a minority of patients with ENMZL.
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Rearrangements of MALT1, IGH, FOXP1, BCL3 and
PAX5 are rare events in extranodal marginal zone
lymphoma in the UK
SL Barrans, K Turner, SJM O’Connor, AS Jack and RG Owen
HMDS Laboratory, Leeds Teaching Hospitals NHS Trust, Leeds,
UK
A number of balanced translocations have been described in
extranodal marginal zone lymphoma (ENMZL). The t(11;18) and
variant t(14;18) which deregulate MALT1 are the commonest reported
occurring in up to 40% of patients. The t(3;14), t(1;14) and t(14;19)
which deregulate FOXP1, BCL10 and BCL3 respectively have been
described in a variable proportion of patients. The purpose of this
study was to evaluate the incidence of such abnormalities in the
routine diagnostic setting in a geographically defined region of the
UK. We therefore reviewed a series of 64 cases presenting between 11/
03 and 12/06 in the Yorkshire and Humberside Haematology
Networks. All cases were investigated for MALT1 rearrangements
with an alpha satellite 18 control (Vysis 32-190055/ D18Z1) and cases
with available biopsy material were further investigated for
rearrangements of IGH (Vysis 32-191019), PAX5 (Dako Y5413),
BCL3 (Dako Y5411) and FOXP1 (in-house probe). Seven out of sixty
four (11%) cases demonstrated rearrangement of MALT1, 5/7 were of
gastric origin. 16/64 (28%) cases demonstrated trisomy 18. Ten of
fifty-six (18%) cases showed rearrangement of IgH which was
attributed to a t(3;14)(p14;q32) in one case and a t(14;19)(q32;p13) in
another. No cases (0/45) were demonstrated to have rearrangement
of PAX5, but 11/45 (24%) showed three copies of PAX5 and similarly
16/42 (38%) had extra copies of FOXP1, consistent with complete or
partial trisomy of chromosomes nine and 3 respectively.
The incidence of MALT1 rearrangements in this study is lower
than most published series. We similarly failed to demonstrate
rearrangements of PAX5. The t(14;19) and t(3;14) were both
demonstrated but at low frequency (2.1% and 2.4% overall). It is
clear that although significant advances have been made in our
understanding of the pathobiology of ENMZL the underlying
cytogenetic defect remains unknown in the majority of patients.
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Bone marrow fibrosis is a negative predictor for
osteolytic lesions in patients with myeloma
S Paneesha, R Pol, N Chachalani, G Prattw, P Rose
and A Borg
Department of Haematology, Warwick Hospital, Warwick,
UK, wDepartment of Haematology, Birmingham Heartlands
Hospital, Birmingham, UK
Myeloma is associated with an unbalanced bone remodelling leading
to osteolytic lesions. Marrow interstitial fibrosis is common in
myeloma. Correlation of marrow fibrosis with clinical parameters
and survival is conflicting. We have analysed the impact of marrow
fibrosis in 83 (F: 45; M: 38) patients with median age 67 years on
osteolytic lesions and survival. Reticulin silver impregnation is
employed as standard matrix stain. H & E slides were reviewed for
degree and pattern of plasma cell infiltration. Marrow reticulin was
quantified from Grade 0–4. Forty-two per cent had increased marrow
reticulin (4 grade 2). Haemoglobino10 gms/dl was in 47% patients.
Thirty-three per cent had hypercalcaemia. Fifty-one per cent had 42
osteolytic lesions at diagnosis. Fifty-five per cent had a2-micro-
globulin 44 mg/l and 22% had renal failure at diagnosis. Forty-seven
per cent needed 41 line of therapy. Marrow reticulin was a negative
predictor for osteolytic lesions (p 0.001). Marrow reticulin did not
correlate with other laboratory parameters. Marrow reticulin, sex,
BJP and number of osteolytic lesions at diagnosis did not impact on
OS (Log Rank test p values: 0.6, 0.07, 0.6 and 0.4). Known poor
prognostic markers Hbo10 gm/dl, hypercalcaemia, renal failure and
elevated a2-microglobulin were associated with poor OS (p values:
0.02, 0.04, 0.004 and 0.002) with median follow-up 27 months.
Number of osteolytic lesions and anaemia at diagnosis had impact on
progression free survival (p values: 0.01 and 0.02) where as raised a2-
microglobulin, marrow reticulin, hypercalcaemia and renal failure (p
values: 0.07, 0.7, 0.9 and 0.35) had no impact. Marrow reticulin had
no effect on requirement for 41 line of therapy (p value: 0.17).
Marrow reticulin is a negative predictor for osteolytic lesions, even
though it does not appear to impact on survival in patients with
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myeloma. Our study also confirms the poor prognostic role of
anaemia, hypercalcaemia, renal failure and raised a2-microglobulin
in patients with myeloma. Further study of the hgf/c-Met interaction
may identify the negative correlation between marrow fibrosis and
osteolytic lesions. This may enhance understanding of skeletal
prophylaxis in patients with myeloma.
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Ultra low dose thalidomide in myeloma
L Yates, A Minchom, MM Ryali and SJ Bowcock
Department of Haematology, Queen Mary’s Sidcup NHS Trust,
Sidcup, Kent, UK
Thalidomide is effective alone or in combination with chemotherapy
for myeloma. The optimal dose is unclear. Thalidomide has a
significant side-effect profile that may be dose related. Where
patients could not tolerate thalidomide 50 mg daily, we tried an ultra-
low dose(ULT) of 25 mg daily, alone or in combination with
dexamethasone and/or cyclophosphamide.
Records were analysed of all patients who had received ULT for at
least 2months. Six patients were identified, median age 74.
Three of the six patients showed a marked reduction in
biochemical markers of myeloma on ULT (decrease in paraprotein
of 53%, 47%, serum-free light chains (FLC) of 98%). One of these
patients was on ULT alone, while the other two were also on
cyclophosphamide1 dexamethasone.
One patient had already achieved a 90% reduction in FLC on
50 mg thalidomide1 cyclophosphamide1 dexamethasone over 6
weeks, and this response was maintained on ULT1 cyclopho-
sphamide1 dexamethasone.
Two patients showed marginal biochemical responses to ULT
1 cyclophosphamide or1 cyclophosphamide1 dexamethasone (fall
in paraprotein 26%, fall in FLC 27%) but neither had improved
responses to Thalidomide 50 mg with cyclophosphamide7dexa-
methasone.
WHO performance status (PS) improved in our cohort from a
median PS of 2.5 at onset of treatment to 1.5 at assessment date. No
patients reported progression of neuropathy or unmanageable side
effects when receiving ULT.
In summary, one patient had a 50% fall in paraprotein on ULT
alone, suggesting that ULT may have activity in myeloma. The other
5 patients all had dexamethasone and/or cyclophosphamide with
ULT, so it is not possible to claim that the anti-myeloma activity was
due to ULT. However, two of these five patients had a good response
and one continued in plateau, suggesting that the regime of ULT with
dexamethasone and/or cyclophosphamide is active in elderly
patients. This is important as some patients are unable to tolerate
higher doses of thalidomide.
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Genome complexity in patients with B-lineage acute
lymphoblastic leukaemia revealed by array-based
comparative genomic hybridization
JC Strefford, H Worley, K Barber, ARM Stewart, Q An,
HM Robinson, AV Moorman and CJ Harrison
Leukaemia Research Cytogenetics Group, Cancer Sciences
Division, University of Southampton, Southampton, UK
Array-based comparative genomic hybridization (aCGH) allows the
entire genome to be scanned for DNA copy number alterations
(CNA) at high resolution and mapped onto the human genome
sequence. Here, we report the analysis of CNA in ALL patients
(n5 140). We have targeted three distinct patient groups: those with
no established chromosomal abnormality (group A, n5 80); those
positive for the ETV6-RUNX1 fusion (group B, n5 40) intrachro-
mosomal amplification of 21q (iAMP21, group C, n5 30). To confirm
and further refine abnormalities detected by aCGH, molecular copy
number counting (MCC), and breakpoint cloning were carried out.
CNA were common in all sub-groups, with group A patients showing
recurrent involvement of chromosomes 6, 9, 12, 15 and 21. Deletions
of 6q were heterogeneous, ranging from 34.5 to 91.1 Mb. They shared
a common deleted region (CRD) of 1.8 Mb, including the GRIK2
gene. Deletions involving 9p ranged from 0.7 to 36.7 Mb in size and
showed considerable heterogeneity in both the extent and location of
the deletion. Deletions of 12p, ranging from 0.7 to 20.9 Mb, all with a
CRD between 10.9 and 11.6 Mb, encompassing the ETV6 gene. Group
2 patients showed deletions of 11q and gain of Xq, in addition to
recurrent imbalancesof 12p and 21q. In Group 3, it was possible to
accurately map chromosome 21 CNA showing considerable hetero-
geneity. This is the first report of genome wide detection of CNA in
ALL patients using aCGH. It has provided further insight into the
size, genomic position, gene content and high-resolution character-
ization of the breakpoints involved in these abnormalities, demon-
strating that these changes are often more complex than anticipated.
Such precise descriptions of the genetic alterations in ALL may lead
to improved molecular diagnosis and prediction of outcome.
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CD381 sub-clones exhibit increased proliferative
activity but similar proliferative histories when
compared with CD38 sub-clones derived from the
same CLL patient
TT Lin, R Hambly, S Hewamana, G Prattw, D Bairdz,
C Fegan and C Pepper
Department of Haematology, Cardiff University, Cardiff, UK,
wBirmingham Heartlands Hospital, Birmingham, UK,
zDepartment of Medical Biochemistry and Immunology,
Cardiff University, Cardiff, UK
CD38 expression is a marker of poor prognosis in B-cell chronic
lymphocytic leukemia (CLL) but the biological rationale for this
remains obscure. We recently showed that CD381 and CD38 sub-
clones derived from the same patient have distinct gene expression
profiles despite their monoclonality. Furthermore, we also demon-
strated that CD381 sub-clones have an increased proliferative
activity when compared with their CD38 counter-parts, as
evidenced by elevated Ki-67 expression (n5 19; Po0.0001). This
finding raised the possibility that the CD381 fraction of individual
patients may have different proliferative histories. Therefore, we
measured telomere lengths and telomerase expression (hTERT) in
cell-sorted CLL cells. hTERT expression was significantly higher in
CD381 sub-clones when compared to CD38- sub-clones derived
from the same patient (P5 0.03) and the increased expression of
hTERT was confirmed at the protein level by flow cytometry.
However, the telomeres of CD381 and CD38 sub-clones were not
significantly different from one another implying that they had
undergone a similar number of cell divisions. Importantly, the
telomere lengths of both sub-clonal populations were consistently
short (approximately 3 Kb) indicating very active proliferative
histories. Taken together, our data suggest that CD38 is not stably
expressed on individual CLL cells but is more likely expressed in a
dynamic fashion with higher expression found on those cells most
recently exposed to activation stimuli. The fact that both CD381 and
CD38 sub-clones have similarly short telomeres implies that CD38
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sub-clones have probably repeatedly expressed CD38 in their past
(and may do so again). If this were not the case then CD38 sub-
clones would have a permanently reduced capacity for proliferation
their telomeres would be longer than those of CD381 sub-clones.
Therefore, the poor prognosis associated with CD38 expression in
CLL is probably caused by an enhanced proliferative capacity and the
subsequent elevated risk of clonal evolution.
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Tissue samples involved by multicentric Castleman’s
disease among HIV-positive individuals is often
involved by microscopic foci of Kaposi’s sarcoma
K Naresh, Al Ricew and M Bowerz
Department of Histopathology, Hammersmith Hospital,
London, UK, wDepartment of Histopathology, St Mary’s
Hospital, London, UKUK., zDepartment of Medical Oncology,
Chelsea Westminster Hospital, London, UK
Multicentric Castleman’s Disease (MCD), a lymphoproliferative
disorder and Kaposi’s sarcoma (KS), a vascular tumour, both occur
at a higher frequency among patients with human immunodeficiency
virus (HIV) infection. Furthermore, the virus human herpes virus 8
(HHV8), with an ability to persist in a latent form in both B-
lymphoid cells and endothelial cells, is causally associated with both
MCD and KS. The co-existence of these two HHV-8-associated
malignancies in same tissue samples has hitherto not been system-
atically investigated.
In this report, we compile the histological and immunohisto-
chemical findings in seventeen consecutive cases of MCD seen
during 2004 to Jan 2007, which included 15 lymph node (LN) and two
spleen samples. All but two patients were men. The age range was 34–
70 years. Values of plasma HHV-8 viral load was available in 10
cases; it ranged from 0 to 400 000 viral copies per mm3 (median:
550). In addition to MCD, 11 of 17 (65%) samples showed evidence of
co-existing KS. The foci of KS were typically ‘microscopic’ involving
the LN capsule, trabeculae or the hilum. In all cases, presence of
HHV-8 was documented in the so-called ‘plasmablasts’ by immu-
nostaining with HHV-8 latent nuclear antigen-1 (LANA1). In cases
involved by KS, the spindle cells showed expression of HHV-8-
LANA-1 and of the endothelial markers CD34/CD31. Additional
clinical information was available in 12 cases. Six of them had KS
elsewhere; four of these six had microscopic evidence of KS in lymph
nodes.
Co-existence of MCD and KS in the same tissue sample is a
common phenomenon that has not been previously appreciated.
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Marginal zone B-cell lymphoma with prominent
follicular colonisation - difficulties in diagnosis; a
study of 15 cases
K Naresh
Department of Histopathology, Hammersmith Hospital,
London, UK
While colonisation of reactive follicles is well described in MALT
lymphoma, this is not fully appreciated among nodal marginal zone
B-cell lymphomas (NMZL). In this case series, histological features
and immunohistochemical findings of fifteen NMZLs with promi-
nent follicular colonisation is described.
Fourteen of the cases were referrals from other hospitals. All 15
cases had showed a follicular pattern, which was prominent in six
cases. Cytologically, the cells were small-cleaved cells with moderate
to abundant cytoplasm. There was a prominent plasmacytoid
differentiation in six cases.
A feature common to all cases was prominent ‘follicular
colonisation’. The process of colonisation varied in its extent
between cases and between follicles. In many follicles the colonisa-
tion was partial and follicles were composed of a reactive germinal
centre component as well. Follicular pattern was highlighted with
CD21 and CD23 stains. Follicular colonisation was accentuated with
the help of immunostains – CD20, CD10, Bcl-2, Bcl-6 and MUM1. The
benign/reactive follicle centre cells expressed CD20, CD10 and Bcl-6
and were negative for Bcl-2 and MUM1. On the other hand, the
colonising marginal zone lymphoma cells expressed CD20, Bcl-2 and
often MUM1, and they were negative for Bcl-6 and CD10. Follicles,
which were partially colonised, showed a typical ‘moth-eaten’
appearance on CD10, Bcl-2, Bcl-6 and MUM1 immunostains.
In none, excepting one of the referred cases a diagnosis of NMZL
was made at the time of initial diagnosis. Initial diagnoses included
follicular lymphoma, chronic lymphocytic leukaemia with prolifera-
tion centres, progressively transforming germinal centres, suspect
low-grade lymphoma and reactive lymph node.
Recognising and appreciating that a subset of NMZLs present
with a prominent follicular pattern where these structures represent
follicles colonised by marginal zone lymphoma cells is necessary in
reaching the correct diagnosis. Appropriate use immunohistochem-
istry and knowledge of immunohistology features can aid in the
correct diagnosis.
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FDG-PET is highly sensitive for Burkitt’s lymphoma
and may predict relapse risk
R Weinkove, M Hoffmanw, NG Mikhaeelz, T Nunanw, R Carr
and PA Fields
Department of Haematology, Guy’s and St Thomas’ NHS
Foundation Trust, London, UK, wClinical PET Centre, St
Thomas’ Hospital, London, UK, zDepartment of Clinical
Oncology, Guy’s and St Thomas’ NHS Foundation Trust,
London, UK
Interim fluorodeoxyglucose (FDG) positron emission tomography
(PET) scanning is highly predictive of relapse risk in both Hodgkins
and non-Hodgkins lymphoma. We report the results of PET scans
prior to and during intensive chemotherapy in patients treated for
Burkitt’s lymphoma at our centre.
Ten patients were identified. Median age was 34 years (range 15–
49). Six patients (60%) were male. Two patients were HIV positive;
two were on immunosuppressive medications post-renal transplant.
All patients had histological evidence of typical Burkitt’s
lymphoma. All patients were treated with intensive chemotherapy
according to the French Society of Pediatric Oncology LMB89
protocol apart from one patient with completely resected stage 1
disease who received three cycles of CODOX-M chemotherapy.
The patient with complete surgical resection of disease had a
negative pre-chemotherapy PET scan. All remaining patients had
positive PET scans. Of these nine patients, the frequency of PET
uptake at specific sites was: bone/marrow 78%, nodal 67%, liver 44%,
gut 44%, spleen 22%, retroperitoneum 22%, renal 11%, breasts 11%,
adrenals 11%. Presentation Ann Arbor stage was: stage IV in 80%,
stage II in 10%, stage I in 10%.
Seven patients had interim PET scans within the first three
months of chemotherapy. Six out of seven patients (86%) had a
complete response on interim PET scan; one patient had minimal
residual uptake. At a median follow-up of 39 months (range 8–144),
Poster Presentations: Lymphoid Malignancy
58
r 2007 The Authors
Journal compilation r 2007 Blackwell Publishing Ltd, British Journal of Haematology, 137, (Suppl. 1), 1–88
all six patients who had achieved complete response on interim PET
are in complete remission. The patient who had minimal residual
disease on interim PET subsequently progressed and died.
FDG-PET is highly sensitive for Burkitt’s lymphoma and is of
particular value in confirming early stage disease. Evidence from this
small series suggests that early interim PET can differentiate between
patients who are destined to be cured and those who will fail therapy.
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Clinical significance of plasma endostatin in patients
with chronic lymphocytic leukaemia
L Smolej, C Andrysw and M Hrudkova
Department of Clinical Haematology, University Hospital
and Medical School, Hradec Kralove, Czech Republic, wInsti-
tute of Clinical Immunology and Allergology, University
Hospital and Medical School, Hradec Kralove, Czech Republic
Several studies have pointed to angiogenesis as a new potential
prognostic factor in chronic lymphocytic leukaemia (CLL). Many
papers have investigated the role of angiogenic activators in CLL.
However, there is insufficient data regarding inhibitors of angiogen-
esis in this disease. Endostatin is a is a naturally-occurring 20-kDa C-
terminal fragment of collagen XVIII and has a potent antiangiogenic
and antiproliferative effects in vitro and in vivo. To assess potential
prognostic role of this cytokine in CLL, we quantified plasma
concentrations of endostatin using sandwich ELISA (RD Systems) in
peripheral blood plasma of 44 patients with never-treated CLL and 26
healthy blood donors. Endostatin concentrations were significantly
increased in CLL patients when compared to controls (mean7 SD
[standard deviation], 226.97 69.0 vs 171.07 9.1 pg/ml, 95% con-
fidence interval of mean [CI], 205.9–247.8 vs 152.2–189.8, P5 0.0003).
There was no difference in endostatin levels between patients with
stable (n5 18) and progressive (n5 25) disease. Similarly, no
difference was found between patients with early vs intermediate
vs advanced disease (Rai modified staging). In ten patients with
serial endostatin measurements before and after intensive therapy
using fludarabine-based treatment, there was a trend towards
endostatin increase after therapy; however, the difference was not
significant (P5 0.13). We conclude that plasma endostatin might be
useful as a part of complex assessment of angiogenesis in CLL.
Furhter studies with regard to clinical significance and correlation to
other angiogenic markers and modern prognostic factors (IgVH
mutation status, genetic abnormalities) are necessary. Supported by
grant NR/8373-3 from Ministry of Health of Czech Republic.
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Relationship of ZAP-70 expression and circulating
angiogenic cytokines in chronic lymphocytic
leukaemia
L Smolej, C Andrysw, V Vroblovaw, J Novosadw and J Krejsekw
Department of Clinical Haematology, University Hospital
and Medical School, Hradec Kralove, Czech Republic, wInsti-
tute of Clinical Immunology and Allergology, University
Hospital and Medical School, Hradec Kralove, Czech Republic
Chronic lymphocytic leukaemia (CLL) is a disease with an extremely
variable clinical course. Several studies have shown that angiogenesis
is increased in CLL and may potentially serve as a new prognostic
factor. Zeta-associated protein of 70 kDa (ZAP-70) is an intracellular
tyrosin kinase belonging to modern powerful prognostic markers in
CLL with significant impact on clinical course. In our study, we
analyzed ZAP-70 expression using flow cytometry in CLL cells from
peripheral blood of 32 patients. Furthemore, we quantified plasma
concentrations of angiogenic activators (vascular endothelial growth
factor – VEGF, basic fibroblast growth factor – bFGF) in peripheral
blood plasma of the same CLL patient group and 80 healthy donors.
Commercially available sandwich ELISA kits (RD Systems, MN,
USA) were used for bFGF and VEGF measurement. ZAP-70
expression was quantified using PE-conjugated ZAP-70 monoclonal
antibody (Caltag); cut-off level of 20% positivity was used as
recommended by literature. Both angiogenic cytokines were
significantly increased in CLL patients when compared to controls
(bFGF, Po0.0001; VEGF, P5 0.0004). Twenty patients were ZAP-70
negative and eleven ZAP-positive. Interestingly, bFGF and VEGF
correlated inversely with percentage of ZAP-positive cells (bFGF,
r50.43, P5 0.014; VEGF, r50.39, P5 0.025) and were sig-
nificantly elevated in ZAP-negative patients (bFGF, P5 0.021; VEGF,
P5 0.035). In conclusion, our findings underline the importance of
angiogenic signaling in CLL and point to possible association with
ZAP-70 expression. Further investigation in terms of impact on
clinical course and survival is clearly warranted. Supported by grant
NR/8373-3 and research project MZO 00179 906 from Ministry of
Health of Czech Republic.
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Use of bone marrow flow cytometry in multiple
myeloma – an audit
S Bhandari, E Hodgesw, A Maniw and AG Smith
Department of Haematology, Southampton University
Hospital NHS Trust, Southampton, UK, wDepartment of
Immunology, Southampton University Hospital NHS Trust,
Southampton, UK
Bone marrow plasma cell assessment is a key component of myeloma
diagnosis and treatment monitoring. Light microscopy, fluorescence-
activated cell sorter (FACS) analysis and trephine histology are the
established methods used to assess marrow plasmacytosis. Generally,
sampling variation and techniques give differing estimations of
marrow plasma cell involvement. Published studies indicate that
FACS underestimates the degree of marrow plasmacytosis. This
study has assessed the role of FACS in myeloma diagnosis and
follow-up.
Aims: (1) Investigate the number of requests for FACS in marrow
aspirate samples in diagnostic, follow-up and day 100 post-autograft
cases (2) Determine if FACS results affect management decisions. (3)
Compare the aspirate morphology results with FACS results.
Methods: A Cohort of patients attending the Southampton myeloma
clinic over a 3-month period, who had marrow aspirates during the
twelve months prior to 30 Sep 2006, was included. CD19, CD45,
CD38, CD56 antibodies were used in two combinations for plasma
cell FACS analysis. Aspirate morphology reports, FACS reports and
documentation in patient records were reviewed.
Results: Sixty aspirates from 53 patients were analysed (number of
FACS requests in brackets) as follows: diagnostic 11 (11); non-
transplant follow-up 39 (34); day 100 post-autograft samples 10 (8).
Results from FACS confirmed neoplastic plasma cells but did not
influence patient management decisions from any of the 60 samples.
In general, the percentage of plasma cells counted by FACS was lower
than that counted by light microscopy in the majority of samples.
The total estimated local cost of FACS analysis using primary screen
and myeloma antibodies was £4835.
Recommendations: FACS did not affect management in both
autograft and non-transplant follow-up samples. FACS screen in
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diagnostic samples assists exclusion of other pathology and confirms
neoplastic phenotype of the plasma cells.
Conclusion: Routine use of bone marrow FACS in myeloma follow-
up is not indicated.
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VH3-48 and VH3-53 gene rearrangements represent
unique subgroups in CLL and are associated with
biased lambda light chain restriction, homogenous
LCDR3 sequences and poor prognosis
MA Catherwood, L Galligan, D Gonzalezw, TCMMorris and
HD Alexander,z
Department of Haemato-Oncology, Department of Haema-
tology, Belfast City Hospital Trust, Belfast, UK, wDepartment of
Haemato-Oncology, BLB, Institute of Cancer Research, Surrey,
UK, zSchool of Biomedical Sciences, University of Ulster,
Coleraine, UK
Background: In recent years IgVH mutational status, VH gene usage,
and the potential role of antigens in the leukomogenesis of chronic
lymphocytic leukaemia (CLL), have been studied extensively. In
particular, the identification of VH3-21 gene usage as a unique subset
of CLL has lead to questioning of the prognostic limitations of IgVH
mutational status, as VH3-21 usage is associated with poor prognosis,
irrespective of the fact that two thirds of such patients have mutated
IgVH genes. Furthermore, specific gene usage has been linked with
highly homogeneous heavy and light complementarity determining
regions (CDR3), indicating that these patients possess virtually
identical BCR binding sites and thus suggesting a common antigenic
progenitor.
Aims: The aims of this study were to verify these findings in a larger
cohort of CLL patients.
Methods: Three hundred patients were recruited from Belfast City
Hospital Haematology Outpatient Clinic and surrounding regional
hospitals. Clinical staging (Rai and Binet), immunophenotyping,
lymphocyte doubling time (LDT) and time to treatment (TTT) were
available on all patients. IgVH and IgVL mutational status, gene
usage and CDR3 sequences were determined using multiplex
BIOMED-2 primers and protocol and sequence analysis. FISH
analysis was performed on all patients.
Results: VH3-48 (n5 14) and VH3-53 (n5 6) gene rearrangements
showed biased lambda light chain restriction (12e¨: 2eˆ, 4e¨: 2eˆ,
respectively). Further analysis revealed overuse of VL3-21 (Ve¨2-14)
gene (7/8) and highly homogenous LCDR3 sequence
(QVWDSSSDHPWV) in VH3-48 patients. Both VH3-48 and VH3-53
categories showed a preponderance of females, short LDT (o1–
21 mths) and an absence of any poor prognosis chromosomal
aberrations.
Conclusions: This study has confirmed earlier findings that VH3-48
rearrangements and VH3-53, represent unique subgroups in CLL
associated with poor prognosis, irrespective of mutational status.
The recurrent use of specific VL genes and homogenous LCDR3
sequences in these patients suggests a common aetiological factor.
179
Associations between gender, age at presentation,
IgVH mutational status, gene usage, clinical stage and
cytogenetic aberrations in B-CLL
L Galligan, MA Catherwood, C Hodkinson, C Matthews,
TCM Morris and HD Alexander,w
Department of Haematology, Belfast City Hospital, Belfast,
UK, wSchool of Biomedical Sciences, University of Ulster,
Coleraine, UK
B-cell chronic lymphocytic leukaemia (B-CLL) is a heterogenous
disorder with a highly variable clinical course and median survival of
approximately 10 years. It affects mainly older individuals and shows
a male preponderance. The aims of this study were to determine if
age at presentation, or gender, showed an association with IgVH
mutational status and/or gene usage, clinical stage or cytogenetic
aberrations. Three hundred and three B-CLL patients were recruited
from Belfast City Hospital Haematology Outpatient Clinic and
surrounding regional hospitals. Clinical staging (Rai and Binet),
immunophenotyping, lymphocyte doubling time and time to
treatment were available on most patients. IgVH mutational status,
gene usage and CDR3 sequences were determined using multiplex
BIOMED-2 primers and protocol and sequence analysis. FISH
analysis was performed on all patients. Eighteen patients were o50
years of age and 285 450 years of age upon presentation. There were
no significant differences in the male:female ratio, IgVH mutational
status, or poor prognostis cytogenetic aberrations between the two
age groups. However, there was a significant increase in the number
of Binet stage B and C patients in the older age category. In addition,
IgVH4-34 gene usage was more prevalent in the younger age group
(23.5% compared to 11.0% in the older group). Overall, the total CLL
cohort consisted of 61.4% males and Binet stage B and C disease, and
unmutated IgVH gene status, were significantly more frequent in
males than females. Interestingly, IgVH3-30 and IgVH4-34 gene
rearrangements were significantly more common in females than
males. Females were also more likely to have no detectable poor
prognosis cytogenetic aberrations, whilst trisomy 12 was significantly
more prevalent in the male sub-group. In conclusion, our findings
confirm that male CLL patients have biomarkers associated with
poorer prognosis, a factor accentuated with advancing age at
diagnosis. The associated molecular basis for this phenomenon
remains to be elucidated. Ongoing studies are being carried out to
investigate the biased IgVH gene usage and proportion of somatic
hypermutation in the female sub-group.
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Bortezomib, low dose intravenous melphalan and
dexamethasone for patients with relapsed multiple
myeloma: results of a phase I/II clinical trial
R Popat, C Williamsw, M Cookz, C Craddockz, S Basuy,
C Singerz, T Gumbleton, N Foot, H Oakervee and
J Cavenagh
Department of Haematology, St Bartholomew’s Hospital,
London, UK, wDepartment of Haematology, Nottingham
University Hospitals, Nottingham, UK, zDepartment of
Haematology, University of Birmingham, Birmingham, UK,
yDepartment of Haematology, Royal Wolverhampton
Hospitals, Wolverhampton, UK, zDepartment of
Haematology, Royal United Hospital, Bath, UK
Bortezomib is an effective treatment for patients with relapsed
multiple myeloma (MM) with an overall response rate
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(MR1PR1CR) of 46% and time to progression of 6.2 months
(APEX study).
In this multi-centre, non-randomised Phase I/II clinical trial,
patients with relapsed MM received bortezomib 1.3 mg/m2 on Days 1,
4, 8 and 11 of a 28 day cycle, and intravenous melphalan on Day 2 for
a maximum of 8 cycles. The maximum tolerated dose (MTD) of
bortezomib was 7.5 mg/m2 as defined in the Phase I component.
Dexamethasone 20 mg on the day of and the day after each dose of
bortezomib was permitted for progressive or stable disease.
Fifty-three patients were enrolled (median age 61 years) with a
median of three lines of prior therapy of which 39 (74%) have had
one previous autologous stem cell procedure, five (9%) have had two,
34 (64%) have had prior exposure to thalidomide and five (9%) to
bortezomib. The overall response rate (CR1PR1MR) was 76%
rising to 80% (CR 10%; nCR 2%; VGPR 8%; PR 39%; MR 20%) with
the addition of dexamethasone in 14 cases. Rapid responses were
seen (median time to response 1 month) and the median time to
progression was 10 months (median overall survival not yet been
reached). Of the patients that had disease progression eight (30%)
had responses of longer duration than their previous therapy.
Toxicities were acceptable with 22 SAEs reported (15 hospitalisa-
tions due to infection). The most common grade 3–4 adverse events
were: thrombocytopenia (53%), neutropenia (49%), infections (17%)
and neuropathy (11%) and 13 patients were withdrawn from study
due to toxicity. Of note 11 patients (28%) had pre-existing grade 1
neuropathy prior to starting therapy.
This combination of bortezomib, low dose intravenous melphalan
and dexamethasone is highly effective (ORR 80% 12% nCR/CR) and
tolerable in patients with relapsed multiple myeloma.
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An audit of presenting features, treatment and
outcome in nodular lymphocyte predominant
hodgkin’s disease. A 10 year experience in the
West of Scotland
VJ Lynch, MTJ Leach and P McKayw
Department of Haematology, Stobhill Hospital, Glasgow,
UK, wDepartment of Haematology, Western Infirmary/Gart-
navel General Hospital, Glasgow, UK
Retrospective data was collected from an audit of forty-two patients
with a diagnosis of nodular lymphocyte predominant Hodgkin’s
disease (nLPHD) over a 10-year period (1997–2006) in the west of
Scotland. This region has a population of 2.5 million. Detailing
patient characteristics, presentation, treatment and outcome of
nLPHD in comparison to national data for patients with classical
Hodgkins disease. It confirms that the majority of patients present
with Stage I or II disease, no B symptoms and with a median
duration of lymphadenopathy prior to presentation of 6 months (1
month–18 months). The patients have a median age of 39years with
minimal co-morbidity. Overall survival is excellent with only one
death which was unrelated to disease at a median follow-up of
55months (1 month–204 months). Most patients were treated by
radiotherapy alone, followed by chemotherapy alone. Three patients
had combined modality therapy. Two patients had excision biopsy
followed by simple observation. Two of the 42 patients are currently
undergoing treatment. Of the 40 treated, 38 (95%) reached complete
remission (CR). The remaining two patients remain in partial
remissions that have lasted for 18 months and 36 months. Four (10%)
patients relapsed and two (5%) developed DLBC NHL. Of the four
patients that relapsed, two have gone into second CR and the other
two are currently undergoing treatment. The main complication, so
far, of radiotherapy was endocrine related and of chemotherapy was
infection.
Conclusion: Nodular lymphocyte predominant Hodgkins disease is a
clinically separate entity to classical Hodgkins disease often
presenting at early stage, without B symptoms and has a good
prognosis. No disease related deaths were identified in our patient
population. It may therefore require less intensive treatment than
classic Hodgkin’s disease in order to reduce the potential late
complications of therapy.
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Haematological malignancies and palliative care
P Ansell, D Howell, A Garryz, S Kitez, J Munroy, E Roman
and M Howardw
Epidemiology and Genetics Unit, University of York, UK,
wYork Hospitals NHS Trust, UK, zLeeds Teaching Hospitals NHS
Trust, UK, yMarie Curie Cancer Care and Bradford Community
Health NHS Trust, UK, zNorth Yorkshire and York PCT, UK
Haematological malignancies are a diverse group of diseases which
vary in terms of aggressiveness, symptoms, illness course and
outcomes yet little is known about provision of palliative care for this
group of patients. We report a 12-month pilot project whose primary
aim was to describe the frequency and characteristics of patients with
haematological malignancies who are (and are not) referred to
palliative care, and the determinants of these processes. The project
utilised the resources of the Haematological Malignancy Research
Network (http://www.bloodcancers.info/) a collaborative venture
between NHS clinical and diagnostic services and the Epidemiology
and Genetics Unit at the University of York.
Data were abstracted from hospital records of 108 patients who
died during the study period: 27 diagnosed with leukaemia (23 AML);
48 lymphoma (30 DLBCL); 22 myeloma; and 11 with myelodysplastic
syndromes. Ninty-three patients (86.1%) were over 60 years of age,
with 33 aged 80 years or older. The co-existence of one or more other
illnesses increased with age from 20.0% in the group aged o60
years, to 25.0% at 60–79 years, and 39.4% in patients aged 80 years or
over. Thirty-three patients (30.6%) were referred to specialist
palliative care services. There was little difference by age or
diagnostic group in patients referred, although those aged o60
years were less likely to be referred than older age groups. 25.4% of
patients (17/67) dying on a hospital ward received specialist palliative
care compared with 85.7% (6/7) dying at home and, unsurprisingly,
all patients dying in a hospice (8/8). Time between diagnosis and
death influenced referral: 46.2% (24/52) of those dying 30 days or
more after diagnosis were referred to specialist palliative care
compared with only 19.1% (8/42) of those dying within 30 days. In 14
patients diagnosis was made after death.
A 3-year project investigating patient needs has now commenced.
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T-lymphocyte subsets in treated and untreated
patients with B-CLL. Effect of treatment on T-cell
subsets and correlation with infections
M El-Karim, S Moule, L Eccersley, G Abrahamson,
N Philpott, A Prenticew, W Stewartw, F Wrightw and
F Brito-Babapulle
Department of Haematology, Ealing Hospital, UK, wDepart-
ment of Haematology, Royal Free Hospital, London, UK
T-cell dysfunction occurs in B-cell chronic lymphocytic leukaemia
(B-CLL) and may contribute to the protean manifestations of
the disease. CD81 lymphocytosis correlates with CLL disease
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progression and low expression of CD4 and CD8 is seen when
autoimmune disease coexists. B-CLL patients at diagnosis with small
tumour loads do not show signs of immune deficiency and some,
treated with fludarabine-containing regimens have decreased in-
hibitory function of T-cells. We therefore analysed T-lymphocyte
subsets by FACS Calibur flow cytometer (Becton Dickinson) and
correlated this with clinical data in 20 patients with either untreated
but known (N5 11) or treated B-CLL (N5 9) to evaluate the impact
of treatment on T-cell subsets. B-CLL patients were studied on a
single occasion in the period from May to July 2006 and correlations
were made with clinical data. Analysis of the percentage and absolute
numbers of total lymphocytes, total T-cells and T-cell subsets (pan T-
cells (CD3), helper cell (CD4), suppressor cell (CD8), CD4/CD8 ratio,
natural killer cells (CD56), total B cells (CD19), and pre B-cell (CD10)
were performed and correlated with clinical data. The relationship of
each antigen with lymphocyte count, age, treatment status (treated or
untreated), drug regime and infection rate was tabulated against
increasing numbers of each T-cell subset.
Results-A variation in absolute CD4 lymphocyte counts in both
treated and untreated B-CLL patients was seen with an increase in
absolute CD4 count in untreated patients even with small amounts of
disease (absolute lymphocyte count 8–89 109/l). Patients treated
with intensive chemotherapy protocols revealed significant T-cell
depletion with a more profound reduction in CD4 count than CD8
resulting in a significantly reduced/reversed CD4/CD8 ratio com-
pared to untreated. In our study chemotherapy was found to be the
primary contributor to the T-cell depletion observed in patients with
BCLL. This is primarily overall T-cell subset depletion, with CD4
depletion being generally more severe than CD8 depletion. A
probable correlation between T-lymphocyte subsets, numbers and
the type of infection and number of infections was noted.
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Spontaneous remissions and relapses of chronic
lymphocytic leukaemia
HI Atrah
Bronglais Hospital, Aberystwyth, UK
Chronic lymphocytic leukaemia (CLL) is characterised by the
presence of clonal malignant lymphocytes in peripheral blood, tissue
and organ infiltration and relentless albeit variable rate of
progression. Isolated reports have described rare spontaneous
remission of CLL. The purpose of this contribution is to report
further cases of documented spontaneous remission and relapse of
genuine CLL verified by immunophenotyping.
Five patients three males and two females with an age range of 65–
77 years (at diagnosis) were identified with history of spontaneous
remission(s) with or without relapse(s) during routine haematolo-
gical follow up of 3–12 years from diagnosis in a small district general
hospital serving a population of just under 100 000 population.
Spontaneous remission was defined as reduction of lymphocytosis to
below 4 109/l and resolution of lymphadenopathy without the use
of cytoreductive therapy. The maximum lymphocyte counts prior to
spontaneous remission were 22.7, 6.2, 7.3, 5.6 and 30.7 and the lowest
lymphocyte counts following spontaneous remission were 1.5, 1, 2, 3.3
and 1.4 109/l (respectively). At diagnosis four patients were at Binet
Stage A whereas the fifth patient was at Binet Stage B due to
widespread lymphadenopathy. Three patients had lymphadenopathy
at some stage of their illness. However, the most interesting case was
that of a patient who had no lymphadenopathy at diagnosis but he
developed bilateral cervical and inguinal lymphadenopathy 1 year
later. Lymphadenopathy disappeared within a few months when he
achieved spontaneous remission of CLL. However, lymphadenopathy
reappeared with profuse sweating when his CLL relapsed after just
over a year of complete spontaneous remission.
In conclusion, spontaneous remissions and relapses of CLL are
not as rare as commonly thought. Further studies are needed to
identify and understand the factors responsible, if these are to be
exploited therapeutically in CLL and possibly in other malignancies.
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Is JAK2 V617F negative ET due to clonal lymphoid
proliferations? A report of three cases of JAK2
negative sustained thrombocytosis in
lymhoproliferative disorders mimicking co-existing
essential thrombocythaemia
F Brito-Babapulle,w, I Clarkez, K Nareshz, I Gabrielw, K Taylorw
and E Kanferw
Department of Haematology, Ealing Hospital, UK,
wDepartment of Haematology, Hammersmith Hospital, UK,
zDepartmentt of Histopathology, Hammersmith Hospital, UK
Essential thrombocythaemia (ET) is a chronic myeloproliferative
disorder (CMPD) of the stem cell however some patients with ET
show polyclonal haematopoiesis. Only 50% of patients with ET show
the JAK2 V617F mutation supporting the observation that ET is
pathologically heterogeneous. Distinguishing clonal and reactive
megakaryocytic proliferation has problems. A diagnosis of ET
requires the absence of a reactive cause, characteristic bone marrow
(BM) morphological features, degree and duration of thrombocy-
tosis, and now JAK2 V617F positivity. ET megakaryocytes as defined
by Thiele (2002) are thought to be characteristic with presence of
increased numbers of giant to large megakaryocytes in loose clusters
with mature, multilobulated staghorn-like nuclei, in a normocellular
or mildly hypocellular marrow. Pajor et al in 2004 reported varying
lymphoid populations in up to 32% of trephine biopsies of 106
patients with CMPD including 28 patients with ET. In 5% (four of 81)
including one case of CML and three cases of CMPD (non specified)
PCR analysis revealed clonal B-cell populations. We describe three
female patients with lymphoproliferative disorders, two with
documented CD5 positive clonal B-cells in the marrow with sustained
thrombocytosis. Bone marrow trephines showed megakaryocytes
akin to ET but absent JAK2 V617F. Hence a firm diagnosis of ET
could not be established but in case 2 and 3 sustained rises in
platelets to 41000 109/l necessitated Hydroxyurea therapy which
controlled platelets but had no effect on lymphoid cells. In case 1
however treatment with chlorambucil lead to reduction of platelets to
normal levels. As ET and other lymphoproliferative disorders like
CLL are ‘common’, by chance they may co-exist. Also megakar-
yocytic proliferations akin to ET may occur in the background of an
established lymphoproliferative disorder. In such cases the mega-
karyocytes may be driven by the lymphoid neoplasm through a
paracrine mechanism but mimick ET. Diagnosis of ET should be
made carefully in the presence of JAK 2 negativity. Some cases may
have indolent low grade clonal lymphoid populations not detectable
by conventional means.
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Childhood ALL minimal residual disease analysis by
proteomics
EC Burt, F Hussain, G Wright, M Corbo, U Johansson, S
Medahunsi and FE Cotter
Department of Haematology, Institute of Cell and Molecular
Science, Bart’s and The London, Queen Mary School of
Medicine, London, UK
Acute lymphoblastic leukaemia (ALL) is the commonest childhood
malignancy, accounting for approximately one-third of all childhood
cancers. Treatment for the disease has substantially improved with
long-term survival in nearly 80% of cases. However, current therapy
is associated with significant side effects and 20% of patients are not
cured despite intensified treatment.
The molecular measurement of minimal residual disease (MRD)
can assist in the early evaluation of treatment, potentially leading to
improved clinical outcome. The most specific and sensitive method
for monitoring MRD is the polymerase chain reaction-based analysis
of rearranged immunoglobulin and antigen-receptor genes. This
method permits stratification of patients to different risk groups
according to MRD level. However, the method cannot be applied to
all samples, and is labour-intensive and costly. Patients could benefit
from improved or additional methods of MRD detection. Liquid
proteomics may be a means of identifying novel ‘biomarkers’
associated with risk groups.
A proteomic study of childhood ALL samples using the Ciphergen
ProteinChip system was initiated. The system is ideal for protein
profiling, with disease and control samples processed on the same
chip surfaces and analysed under the same conditions. Subsequent
spectra comparison can identify patterns of protein expression, to be
used as ‘fingerprint’ profiles for the diagnosis, follow up and
biomarker discovery for patients.
Plasma samples taken from pre-B cell ALL patients and age-
matched controls were analysed, having been divided into high- and
low- risk groups according to MRD level. They were assessed prior to
treatment (day 0) and after the first round of induction therapy (day
28). Markers capable of discriminating between high- and low-risk
groups were identified, including a 6 kDa marker with differential
levels of expression between risk groups at day 0 and 28. These
findings may provide an alternative MRD approach for ALL.
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Dynamic assessment of apoptosis for in vitro design
of bortezomib combination therapies for lymphoid
malignancies
LC Wallis, MJ Streetly, R Auer, J Gribben, D Zhangw, WD
Hankinsz, S Mehdi Zadehw and FE Cotter
Centre for Haematology, Institute for Cell and Molecular
Science, Bart’s and The London, Queen Mary’s School of
Medicine and Dentistry, London, UK, wBio-Kinetic Profiling
Ltd, London, UK, zJohns Hopkins University, Baltimore, MD,
USA
Conventional techniques for assessing drug response and apoptosis
induction rely on static assessment of cellular changes at predeter-
mined time points (e.g. detection of exposed membrane phospholi-
pids by Annexin V). The Kinetics of Optical Response assay (KOR) is
a new technique that detects induction of apoptosis dynamically. It
detects changes in optical density associated with membrane blebbing
related to growth and death, allowing detection of apoptosis in real
time. This study uses the KOR assay in lymphoid malignancy and
shows sensitivity to apoptosis induction by conventional and novel
agents including bortezomib. The lymphoma cell line DOHH2
(t(14;18)), U266 (myeloma), K562 (CML) and primary CLL cells were
used in this study with HL60 (AML) as a control. Cells were seeded in
96 well plates and treated with a variety of drugs alone or in
combination (cytarabine, fludarabine, doxorubicin, daunorubicin,
etoposide, melphalan, bortezomib) at multiple concentrations.
Measurements were taken at 5-min intervals for up to 48 hours and
analysed using KORsoft software to generate apoptotic response
curves, which were compared to conventional techniques. The KOR
assay can show maximum sensitivity (Smax) to cytotoxics. DOHH2
was found to be dose responsive to four of the drugs used. There was
no effect from fludarabine, but the addition of bortezomib increased
Smax when in combination with etoposide. Parallel flow cytometric
analysis using Annexin V and PI showed similar results to those from
the KOR assay, confirming the assessment of apoptosis to be valid.
Primary CLL samples were cultured with and without IL4 and run in
the KOR assay with cytotoxics including bortezomib. Culture with IL4
alone gave good growth characteristics and revealed the combination
of etoposide and bortezomib to provide the best induction of
apoptosis. The combination of bortezomib and etoposide appears
effective for lymphoma. Such approaches can accelerate the develop-
ment of clinical trials.
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Prognostic relevence of circulating matrix metallo-
proteinase-2 in acute myeloid leukemia
S Aref, E Osmanw, S Mansyw, N Omerw, E Azmyz and T Goday
Department of Haematology, Mansoura Faculty of Medicine,
wMansour Faculty of Science, Mansoura University,
zHaematology-Oncology Unit, Mansoura Faculty of Medicine,
yDepartment of Internal Medicine, Mansoura Faculty of
Medicine
matrix metalloproteinase (MMPs) were postulated to have important
implication in progression and invasiveness of many malignant
disorders. On the other hand the biological role of MMP-2 in acute
myeloid leukemia is not fully clear.
Serum MMP-2 concentration levels was determined in 37 AML
patients pretreatment and for 20 AML patients after induction
chemotherapy using enzyme linked immuno-sorbent assay and were
compared to thier levels in normal healthy control group (n5 10).
The pretreatment sMMP-2 levels were significantly lower as
compared to post induction level (P5 0.000) and control levels
(P5 0.007). Pretreatment sMMP-2 levels were not significantly
correlated to FAB subtypes, Peripheral blood blast cell couts,
Peripheral WBCs counts, BM blast cell counts, and blast cell
distribution ratio. Patients who had high pretreatment levels of
sMMP-2 had particulary poor outcome. High sMMP-2 had an
independent adverves influence on survival, it was entered as a factor
into multivariate analysis together with other prognostic factors
(relative risk 9.0, confidence interval 0.94–86.0, P5 0.01).
Conclusion: High pretreatment levels of sMMP-2 are associated with
poor survival in patients with AML
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Rapid screening for gene mutations in AML patients
using pyrosequencing
M Lazenby, AF Gilkes, V Walsh, AK Burnett and KI Mills
Department of Haematology, Cardiff University, Cardiff, UK
Multiple genetic alterations are usually required for the development
of acute myeloid leukaemia. In addition to the major cytogenetic
abnormalities such as translocations t(15;17), t(8;21) and inv(16)
several genes are commonly mutated including FLT3, NPM, MLL and
c-kit. Some of these secondary mutations have been shown to add
prognostic significance to the cytogenetic based risk groups.
Therefore, identification of these mutations at diagnosis is important
not only for assigning possible prognostic groups, but also for use as
a means of monitoring minimal residual disease. The development of
novel therapeutic agents, such as FLT3 inhibitors, further reinforces
the need for early identification of mutation status to allow the
inhibitors to be used on the appropriate patient group.
We have developed pyrosequencing assays for the rapid detection
of FLT3-TKD, npm1,and c-KIT mutations. Pyrosequencing assays
have advantages over standard PCR/restriction digest techniques in
that they are faster, allow different mutations within a region on the
target gene to be analysed from a single PCR, and give the precise
sequence of the mutation without the need for further analysis. An
estimate of the size of clone with the mutation may also be obtained.
Ninety-six wells can be processed post-PCR within 90 min producing
multiple gene mutation information for multiple patient samples.
These assays have been used prospectively to analyse RNA
isolated from AML patient diagnostic samples for the presence of
FLT-TKD, NPM and c-kit mutations. Pyrosequencing is unsuitable
for detection of FLT3-ITD mutations as the start site and length of
the duplication is highly variable. FLT3-ITD results were obtained
using a different technique. To date, 130 AML samples have been
prospectively analysed; 22% have FLT3-ITD mutations with pyrose-
quencing detecting 3.1% with FLT-TKD, 16.9% with NPM1 and 3.1%
with c-kit mutations.
The rapid and versatile methodology of pyrosequencing will add
to a leukaemia diagnosis repertoire.
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A molecular classification of leukaemia reveals MDS
as a disease continuum with non-leukaemia and AML
sub groups
KI Mills,J, T Haferlachw,J, JM Hernandezz,J, W-K Hofmanny,J,
A Kohlmannz, M Williamsz and L Wieczorekz
Department of Haematology, Cardiff University, Cardiff, UK,
wMLL, Munich, Germany, zHematologia, Salamanca, Spain,
yCharite, Berlin, Germany, zRoche Molecular Systems,
Pleasanton, CA, USA, JMILE Study on behalf of European
LeukemiaNET (ELN)
Recently, the MILE (Microarray Innovations in LEukemia) study has
analysed B2000 expression profiles of 16 acute and chronic
leukaemia subclasses, MDS, and non-leukaemia as control group in
11 centres (ELN: seven, USA: three, Singapore: one) and compared
the microarray classification accuracy, to routine diagnostic workup.
The overall cross-validation accuracy was very high for the
leukaemia subclasses: B96%.
However, only 49.1% of the 173 MDS samples included in the
study were correctly called as MDS from their underlying gene
expression profiles. The remainder were approximately equally split
between a call of ‘non-leukaemia’ (24%) and ‘AML’ (24.6%). Our
analysis showed that neither study centre nor age were a factor in
differentiating between ‘MDS’, ‘MDS with an AML-like signature’ or
‘MDS with a non-leukaemia like signature’. WHO classification was
highly correlated with the microarray classification result; specifi-
cally RAEB (I or II) was associated with ‘AML’ call (Po0.0001)
whilst, RA/RARS was highly correlated with ‘MDS’ or ‘non-
leukaemia’ calls. Furthermore, IPSS was significantly correlated with
call (P40.0001): 65% of patients with an IPSS score of Int-2 or above
were classified as ‘AML’. Individually, the blast, karyotype and
cytopenia contributions were highly significant (Po0.0001, o0.013
and o0.0001 respectively) when comparing ‘MDS like AML’, ‘MDS’
and ‘MDS like non-leukaemia’ samples. Survival data (available for
122 of the diagnosed MDS patients) showed that MDS patients called
‘MDS like AML’ had a trend towards shorter survival (2P5 0.2) than
those called ‘MDS’ or ‘MDS like non-leukaemia’. The mapped
molecular pathways and functions between these sub-groups may
give an indication of the molecular steps involved in disease
evolution and lead to a molecular redefinition of MDS.
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Embryonic gene (Oct-4) expression in normal adult
bone marrow CD1331 CD341 stem cells
X Zhai, JA Goodacre and HT Hassan
Lancashire School of Postgraduate Medicine, University of
Central Lancashire, Preston, UK
Human CD133 stem cell antigen is expressed in several normal adult
stem cells including endothelial, basal epidermal, prostate epithelial,
haematopoietic, mesenchymal and neural cells. In adult bone
marrow, 90% of human haematopoietic stem cells co-express
CD133 and CD34 and are mostly in quiescent phase of cell cycle.
Recently, the expression of binding transcription factor Oct-4, a
marker of embryonic pluripotent stem cells was reported in several
adult human non-haematopoietic stem cells including epithelial and
basal epidermal cells ([2005] Carcinogenesis 26: 495–502). The
present study was performed to evaluate similar Oct-4 expression in
normal adult haematopoietic stem cells. Immune-fluorescence
staining using Anti-Oct-4 monoclonal antibodies of isolated bone
marrow CD1331CD341 stem cells from healthy adults revealed the
expression of Oct-4 in two thirds of these haematopoietic marrow
stem cells as shown in the table.
The present results demonstrate substantial expression of
embryonic stem cell marker Oct-4 in human haematopoietic stem
cells in adult bone marrow. We recently reported similar expression
of Oct-4 in human CD1331CD341 AML cells ([2006] Haematolo-
gica 91(s1): 426). Oct-4 expression in both normal and leukaemia
CD1331CD341 stem cells in adult human bone marrow suggests
their embryonic stemness renders them the most likely target for
development of AML. Immunophenotyping of marrow samples from
de novo AML patients revealed strong presence of CD1331CD341
stem cells (420%) in two thirds of AML cases ([2001] Haematolo-
gica 86:154–161) and their capability of forming leukaemic CFU in
vitro ([2001] Cytotherapy 3: 449–459) further supporting the role of
these stem cells in the propagation of AML.
Oct-4 Expression
in Human Adult Bone
Marrow CD1331CD341
Stem Cells
Percentage Bright Dim Negative
Median 33.1% 37.9% 29.0%
Range 19.5–45.4 25.0–46.5 16.7–43.5
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Are we NICE to chronic myeloid leukaemia patients in
the northern cancer network?
KE Hodgson, WL Osborne, FN Macleanw and AL Lennard
Department of Haematology, Newcastle upon Tyne NHS
Hospitals Foundation Trust, Newcastle upon Tyne, UK,
wUniversity of Newcastle upon Tyne, Newcastle upon Tyne, UK
Targeted therapy has significantly altered the prognosis for patients
with CML. Technology Appraisal Guidance documents published by
NICE in September 2002 and October 2003 recommended the use of
imatinib mesylate for chronic phase CML patients intolerant of/
resistant to interferon, and for newly diagnosed patients respectively.
Patient groups have questioned the access of CML patients to
imatinib and specialist haematology care. A retrospective study of all
patients in the Northern Cancer Network diagnosed with CML has
allowed us to review epidemiology of the disease, local adherence to
these national guidelines and quality of care.
All new Philadelphia chromosome positive/Philadelphia chromo-
some negative bcr/abl positive patients were identified for the period
January 1996–December 2005 from records held at the single regional
cytogenetics laboratory. pH 1 ve ALL patients were excluded.
Available case notes were reviewed. 166 new patients with CML were
diagnosed giving a crude annual incidence of 0.8 per 100,000 in our
population of 2.1 million. 148 case notes were available for further
evaluation.
146 patients were managed by consultant haematologists. One
elderly patient is monitored by FBC sent from her nursing home.
One patient declines treatment. 56 patients have died. Of the
surviving 92, two have changed areas and current treatment details
are unavailable. 84 were treated in accordance with NICE guidelines.
Six are not currently treated according to NICE guidelines (4 of these
were imatinib intolerant). Details of imatinib response will be
presented. In the five year period 1996–2000, 12 allogeneic
transplants were performed compared to 2 in the period 2001–5.
This population based study confirms a lower incidence of CML
in the Northern Cancer Network compared to published data. We
find no evidence of restricted access to specialist care or imatinib.
Our practice reflects the global decrease in transplantation in the
post imatinib era.
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Serum selenium at presentation may predict disease
outcome in acute myeloid leukaemia (AML)
JM Stevens, RA Watersw, C Sieniawskaz, F McDougall,
S Juliger, SP Joel, J Fitzgibbon and TA Lister
Centre for Medical Oncology, Bart’s and the London School
of Medicine and Dentistry, London, UK, wCentre for Statistics
in Medicine, University of Oxford, Oxford, UK, zTrace Metals
Laboratory, Southampton University Hospital Trust,
Southampton, UK
We have previously shown that patients with aggressive lymphoma
and low serum selenium at presentation have a less favourable
response rate and overall survival. We have extended these
observations to AML.
Inductively coupled mass spectrometry was used to measure
serum selenium concentration from 163 adults, 16–60 years, with
newly diagnosed AML. Mean serum selenium was 68.2?g/l. Selenium
concentration showed a negative association with white cell count
(r50.28, P5 0.0003) and positive association with albumin
(r5 0.33, Po0.0001); no relationship was seen with gender, age or
karyotype.
Patients were divided by their serum selenium into ‘normal’
(within UK reference range, 70.2 – 58 ?g/l) or ‘low’ (below range),
with 80(49%) and 83(51%) patients in each group respectively. Of
those evaluable, remission after induction therapy was achieved in 57
(71%) patients in the normal group and 48 (58%) in the low group.
Thirteen (16%) and 19 (23%) patients in each respective group were
refractory to treatment, with 6 (8%) and 13 (16%) deaths. A chi-
squared test on induction data showed a better outcome for patients
with normal selenium (P5 0.04). Overall survival was better in the
group with normal selenium (P5 0.08). Univariate Cox analysis gave
a hazard ratio of 1.43 (95% CI 0.96–2.13) for patients in the low
selenium group. There was no similar relationship between selenium
at presentation and progression free survival.
In multivariate Cox analysis, selenium was not predictive of
survival once the more significant factors of albumin and karyotype
were added to the model. However, an interaction term between
selenium and albumin was added (P5 0.05), suggesting that changes
in albumin level have a larger effect on survival for patients with
normal selenium. The longest survival was predicted for patients
with both high albumin and normal selenium at presentation.
These data support the hypothesis that serum selenium at
presentation may predict outcome in AML patients.
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Safety and feasibility of home delivery of low dose
cytarabine by continuous subcutaneous infusion in
acute myeloid leukaemia
J Chakrabartty, Y Noble, M Evans, SM Ward, M Mangi and
SJ Bowcock
Department of Haematology, Queen Mary’s Sidcup NHS Trust,
Sidcup, Kent, UK
It is reported that administration of Cytarabine by continuous
intravenous infusion is more effective than giving bolus doses
(intravenously or subcutaneously) since Cytarabine is quickly de-
aminated in the liver to Uracil Arabinoside, which is non active. The
Baxter infusion balloon-pump is ideal for home treatment, but there
is no experience of continuous subcutaneous delivery of Cytarabine
by this system, keeping the pump close to the body. Cytarabine is
stable in this infusor at 25degC, but there are no stability data when
Cytarabine is maintained at near-body temperatures.
We prepared 2 Baxter 7-day Infusors with Cytarabine 140 mg in
95 ml of 0.9% normal saline (1.47 mg/ml). One was tested at time 0
and then discarded, and the other was incubated at 351C and tested
after 7 days. Samples were analysed using High Powered Liquid
Chromatography (HPLC) (Applied Analysis Ltd). Once the stability
of the Cytarabine was established, patients with AML wanting non-
intensive chemotherapy were offered Cytarabine 20 mg daily by
continuous pump subcutaneously as an outpatient for 7 to 21 days.
The concentration of Cytarabine in the infusor fell from 95% at
time 0 to 93% at 7 days and the pH fell from 7 to 5.6. HPLC showed
the only degradation product was Uracil Arabinoside. There was no
solution discolouration nor crystal deposition.
Six patients were treated with 26, 7-day Baxter-infusors. All
patients found the portable pump acceptable. A subcutaneous lump
formed under the needle after 4–5 days causing slight discomfort in
some. Most patients chose to have the needle re-sited, but some
continued for 7 days without discomfort. One patient with
thrombocytopenia experienced local bleeding, and one developed
local infection when neutropenic.
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Our results show that Cytarabine is stable for 7 days in the Baxter
balloon infusor even at close to body temperature. Patient
acceptability was good with few practical difficulties and few hospital
attendances.
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Poor response to imatinib therapy in chronic myeloid
leukaemia expressing variant BCR-ABL transcripts
T Dutt, CM Lucas, L Wang and RE Clark
Department of Haematology, University of Liverpool, UK
In CML, imatinib produces complete cytogenetic remission (CCR) in
approximately 80% of newly diagnosed cases, in about 50% of
chronic phase patients who have failed interferon, and in 10–20% of
patients with more advanced disease. At least 98% of CML patients
express either one or both of e13a2 (b2a2) or e14a2 (b3a2) BCR-ABL
fusion transcripts arising from breakpoints in the major breakpoint
cluster region of BCR. Variant transcripts arising from outside the
major breakpoint cluster region are rare. These variant transcripts
are increasingly being reported, however, their associated disease
phenotype remains unclear. There are no data currently available on
the efficacy of imatinib in patients with variant transcripts.
From October 2000, 221 cases of CML have been molecularly
screened at our institution. 217 expressed one or both of the major
breakpoint cluster region transcripts e13a2 or e14a2.
Here, we report the effect of imatinib in the remaining four cases,
each expressing a variant transcript: e13a3, e19a2 (two patients) and
e6a2. Two of the patients presented in chronic phase, (treated with
400 mg daily), one in blast crisis and the other in accelerated phase
(each treated with 600 mg daily). Three cases died within 6 months
of commencing imatinib therapy without achieving CCR, and the
remaining case died after 4 years of therapy, again without achieving
CCR. All patients died of disease progression.
As a result of varying breakpoints, the three dimensional
structure of the BCR-ABL fusion protein may differ from that of
‘classic’ transcripts. This may alter the capacity for tyrosine kinase
drug interaction. To our knowledge, this is the first report of the
effects of imatinib in patients with variant BCR-ABL transcripts. At
present, we suggest caution in extrapolating the excellent results of
imatinib therapy in major breakpoint CML to patients with variant
transcripts.
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Empirically diagnosed Aspergillus infection and the
curtailment of chemotherapy for AML. Five years
experience in a single Institution
S Griffith, T Seale, A Thomas and J Seale
Alaw Unit, Ysbyty Gwynedd, Bangor, UK
To assess the impact of Aspergillus infection on treatment for AML,
we studied the records of patients treated with intensive chemother-
apy over a 5-year period. Diagnosing fungal infection according to
the EORTC/IFICG (2002) stratification is impractical in a District
General Hospital. We therefore classified our patients with suspected
Aspergillus infection into three groups: refractory fever only,
refractory fever1 radiological evidence of lung infiltration and
refractory fever1microbiological evidence. All patients assessed
(26) were treated with curative intent in NCRI protocols. Their ages
ranged from seventeen to 79. Seventeen patients (65%) failed to
complete the specified number of chemotherapy cycles. In three this
was due to refractory disease and in two due to patient choice. The
remainder had their treatment curtailed due to complications that
were considered life-threatening. One of these had isolated
chemotherapy toxicity, four had severe microbiologically proven
bacterial septcaemias, one had severe candida septicaemia and six
(23% of our total group) had suspected Aspergillus infection. Of these
six, microbiological evidence was only available in two. One patient
had radiological evidence and three had refractory fever only. All six
had received intensive anti-microbial therapy with liposome-
encapsulated amphotericin but were considered too frail to receive
further consolidation chemotherapy. Twelve of the 17 patients who
failed to complete their treatment have died, five survive in remission
with a median follow up of 3 years. Nine patients completed all cycles
of their scheduled treatment, six of these have died and three are in
remission. In this group, four were suspected of having aspergillus,
three on radiological evidence and one because of refractory fever
only. In this small series, empirically diagnosed Aspergillus infections
were more common than is quoted in the literature. They resulted in
curtailment of treatment in almost a quarter of the patients but this
does not seem to have had an adverse impact on outcomes.
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Successful cytogenetic remission following the use of
dasatinib in a patient with BCR-ABL positive chronic
myeloid leukemia who relapsed following nilotinib
therapy
FA Wandroo, J Araziw, M Griffithsz, S Akikiz, J Kaeday
and C Craddockw
Department of Haematology, Sandwell and West Birming-
ham Hospital, University of Birmingham, West Bromwich, UK,
wCentre for Haematology, University Hospital Birmingham,
Birmingham, UK, zWest Midlands Regional Genetics Labora-
tory, Birmingham Women’s Hospital, Birmingham, UK,
yDepartment of Haematology, Hammersmith Hospital,
London, UK
A 57 year old female with chronic myeloid leukaemia went into blast
crisis at 10 months after achieving complete cytogenetic remission
with glivec 400 mg. At the time of relapse her BCR-ABL: ABL ratio
increased to 155% from a residual level of 11% with reappearance of
original cytogenetic rearrangement between chromosome 9q, 12q
and 22q together with monosomy seven indicating cytogenetic clonal
evolution. She showed a brief response to two courses of
daunorubicin and cytosine arabinoside but soon relapsed. She was
now commenced on nilotinib ( AMN107) at a dose of 400 mg twice
daily and achieved major cytogenetic response (2% abnormal
metaphase cells), and with a significant reduction in the BCR-
ABL:ABL ratio (31%) that was sustained for only six months. She was
now commenced on dasatinib 50 mgs twice daily and achieved
complete cytogenetic and major molecular response (43 log
reduction in BCR-ABL transcripts) that is maintained at six months.
Mutation analysis detected two mutations at the time of first blast
crisis (F359V and H396P) and a new mutation was found (Y253H)
following a loss of response to nilotinib. As her responses to
treatment were not sustained it is likely that she developed mutations
at the time of each relapses (further samples under analysis),
however it is also possible that other additional genetic changes were
driving some of the relapses, e.g. related to the monosomy 7. Her
current molecular response to dasatinib suggests effectiveness of this
drug against her nilotinib resistant clones. More follow up is however
needed to see how long this response is sustained. This case
highlights the fact that Dasatinib is a highly potent tyrosine kinase
inhibitor, which can be effective against imatinib and nilotinib
resistant clones. The response to 1st and 2nd generation tyrosine
kinase inhibitors in sequence may suggest using these agents in
combination after detailed mutational analysis.
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Artificial neural network analysis identifies novel
patterns of HOX gene expression in prognostic
subgroups of acute myeloid leukaemia
DPJ Finnegan, MF Quinnw, M Humphreysz, TRJ Lappin,
MF McMullin,w, A Thompson and GR Bally
Department of Haematology, Queen’s University Belfast,
Belfast, UK, wDepartment of Haematology, Belfast City
Hospital, Belfast, UK, zRegional Genetics Department, Belfast
City Hospital, Belfast, UK, ySchool of Biomedical and Natural
Sciences, Nottingham Trent University, Nottingham, UK
The acute myeloid leukaemias (AMLs) are a heterogeneous group of
haematological malignancies with diverse clinical outcomes. Pre-
treatment karyotype analysis identifies biologically distinct sub-
groups and is currently used as a predictor of response to induction
chemotherapy and risk of relapse. Cases may be stratified into
relatively favourable, intermediate and adverse prognostic sub-
groups. HOX genes encode master transcription factors which
regulate key developmental processes. Humans have 39 HOX genes
and multiple lines of evidence implicate their deregulated expression
in the pathogenesis of AML. Drabkin et al. (Leukemia 2002; 16: 186–
95) have reported that AMLs with a relatively favourable prognostic
karyotype are associated with low levels of HOX gene expression
whereas AMLs with an adverse prognostic karyotype have higher
levels of expression. To further characterise HOX gene expression in
cytogenetic prognostic subgroups we determined the expression
profiles of 26 HOX genes by real-time quantitative PCR (Q-PCR) in
diagnostic samples, representative of the three prognostic subgroups,
from 25 patients with de novo AML. Profiles were then analyzed
using Artificial Neural Network based computational approaches to
identify a subset of HOX genes which could discriminate between
prognostic subgroups in a predictive fashion. The relatively
favourable prognosis subgroup was primarily defined by down-
regulation of HOXA5 and up-regulation of HOXC4. The expression of
six and eleven HOX genes were required to define membership of the
intermediate prognosis and adverse prognosis subgroups respec-
tively, reflecting both the molecular complexity of these subgroups
and the small sample size. The results show that Artificial Neural
Network based computational approaches are capable of further
characterising HOX gene expression within AML prognostic
subgroups as determined by presenting karyotype and that
measuring the expression levels of a small number of HOX genes
at diagnosis can provide useful clinical information in cases where
karyotype analysis has been unsuccessful.
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The quality and utility of stem cells cryopreserved in
chronic phase chronic myeloid leukaemia (CML): is
routine leucopheresis still cost effective?
A Masurekar, M Guttridgew, A Tothamw, D Potokw,
S Robinson, D Pamphilonw, DI Marks and EJ Massey,w
Avon Haematology Unit, Bristol, UK, wNational Blood
Service, Bristol, UK
As a result of successful targetted therapy such as Imatinib and
improvements in the outcome of allogenic transplantion in CML the
practice of autologous SCT is declining.
We performed a retrospective audit of patients with chronic phase
CML who underwent leucodepletion and/or stem cell storage in
Bristol over an eight year period from 1998 to 2006. The aims of the
audit were to assess the criteria for referral and the quality of stem
cells collected with respect to CD341 cell count and engraftment.
A total of 56 patients (19 women, 37 men) with chronic phase CML
were referred for apheresis procedures. Fifty-four patients also
required stem cell collection and storage. Two patients underwent
cytoreduction without stem cell storage because one patient was not
a candidate for transplantation and the other had imatinib resistant
CML.
The mean WBC count of the whole group was 225.32 (range 3.7 –
814) 109/l. Eight patients had symptoms of leukostasis with a mean
WBC 403 (range 216–814) 109/l, and required between one and five
procedures for effective cytoreduction. There were no reported
significant complications. The first apheresis procedure led to an
average reduction in white cell count of 30%. The mean dose of
CD341 cells cryopreserved was 66.95 106/kg (range 4.92–210.62).
None of the stored autologous stem cells were infused. Twelve
patients received allogeneic stem cell transplants.
This audit demonstrated that adequate stem cell doses were
collected at presentation but that in eight years none of these
collections were actually used. This calls into question the cost
effectiveness of the common practice of cryopreservation of stem
cells at presentation. Designing the audit also highlighted the lack of
guidelines for cytoreduction in chronic phase CML. All patients with
symptoms of leucostasis had a WBC greater than 200 109/l.
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Central nervous system lymphoid blast crisis in a
patient with haematological remission of chronic
myeloid leukaemia (CML) on dasatinib
LRJ Eccersley, G Abrahamson, N Philpott, L Mitchellw,
T Holyoakew, T Szatrowskiz and F Brito-Babapulle
Department of Haematology, Ealing Hospital, London, UK,
wBone Marrow Transplant Unit, Glasgow Royal Infirmary,
Glasgow, UK, zGlobal Medical Affairs, Bristol-Myers Squibb,
Princeton, NJ, USA
Dasatinib(BMS-354 825) is now available to treat imatinib-resistant
CML. A preliminary study of K562 CML cell lines implanted
intracranially in SCID–beige mice showed growth stasis of these
cells during dasatinib therapy and increased lifespan compared to
controls, suggesting that dasatinib may have therapeutic advantages
over imatinib in management of intracranial CML(Wild et al, [2004]
Blood, 104 11). We report CNS lymphoid blast crisis developing in a
patient with haematological response on dasatinib.
A 20-year-old male with chronic phase (CP) CML received
hydroxyurea, interferon, then imatinib three years later. Haemato-
logical response, without cytogenetic response, occurred on imatinib
doses to 600 mg/day. Tibial biopsy for tibial pain developing after
two years on imatinib revealed lymphoid blasts (CD10 1 , TdT1 ),
also present in bone marrow (BM430% lymphoblasts); at this time
CNS was clear. After two courses of fludarabine/cytarabine/G-CSF/
idarubicin (FLAG-Ida), second CP occurred. Due to cytopenias and
gastrointestinal disturbance methotrexate/6-mercaptopurinemainte-
nance was stopped. White cell and platelet counts increased rapidly,
with 7% blasts by BM immunophenotyping. He then commenced
dasatinib 140 mg/day without CNS prophylaxis. Three months later,
on dasatinib, he developed headaches, ataxia and burning foot pains.
CT brain was normal. CSF showed 95% B-ALL blasts. The blood
count was normal, and BM showed CML in CP, with 0.5%
TdT1 cells. Thus CNS blast crisis developed despite haematological
response to dasatinib.
In a phase II trial of dasatinib, one lymphoid blast phase CML and
five Ph1ALL with documented CNS leukaemia were treated with
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dasatinib; 4/6 attained complete cytogenetic response, five had
documented CSF resolution of CNS leukaemia with dasatinib
monotherapy, and one had CNS disease resolution with dasatinib/
intrathecal cytarabine. In our case CNS disease appeared or was not
suppressed by dasatinib; this may have been due to development of
resistant mutations. CNS prophylaxis appears necessary in CML
lymphoid blast crisis treated with dasatinib. Whether concomitant
dasatinib with CNS prophylaxis increases CNS toxicity will be
determined by more extensive usage of dasatinib.
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A visual guide to the administration of blood
components
N Lewis, M Roberts and A Hughes
Department of Clinical Haematology, University Hospital of
Wales, Cardiff, UK
The administration of blood components can be a potentially risky if
not fatal process. These risks can be present in areas where
administration of blood components are given frequently as staff
can become blase´ or complacent about the procedure. In areas where
blood products are seldom given staff will arguably need extra
support. To address all areas where these components are given a
simple flow chart indicating best practice as recommended by the
British Committee for Standards in Haematology has been estab-
lished.
This algorithm is in a simple format and clearly shows how
different components should be administered. It is user friendly and
as appropriate to senior haematology nursing staff as it is to junior/
student nurses and those unfamiliar to haematology.
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Role of the haematology specialist nurse in the
management of patients with suspected
myeloproliferative disorders
L Wallis, D Oscier and J Chacko
Department of Haematology, Royal Bournemouth Hospital,
Bournemouth, UK
The Royal Bournemouth Hospital is a general hospital serving a
population of 350 000 people. An audit was carried out of patients
who were referred by their GPs for the investigation of a raised
haemoglobin, haematocrit or platelet count between August 2002
and March 2006.
Over a 3-year 7-month period 322 patients underwent extensive
investigations including ultrasonography, erythropoeitin levels, JAK
testing, bone marrow analysis and red cell masses. Two hundred and
sixty-four patients were diagnosed as having a non-myeloprolifera-
tive condition. One hundred and five of these patients with non-
primary haematological conditions are still being seen regularly in
the haematology department.
From these 322 referrals:
Ninteen patients were diagnosed as polycythaemia vera,
Thrity-nine were diagnosed as essential thrombocythaemia.
Seventy-seven were transient polycythaemia/thrombocythaemia
Eighty-five were secondary/reactive polycythaemia/thrombo-
cythaemia
Seventy-one were idiopathic polycythaemia/thrombocythaemia
From this audit it could be seen that Consultant Haematologists
are spending a proportion of their clinic appointment slots dealing
with the investigation of potential myeloproliferative disorders. Once
diagnosed patients continue to return to clinic for management or
treatment of their condition.
Funding was made available for the post of a Haematology Nurse
Specialist for the out-patient department and her role consists of the
following:
 Regular management of stable MPD patients treated with
hydroxycarbamide/venesection with emphasis on good patient
information at diagnosis and self care strategies in order to manage
side effects of treatment.
 Streamlining of investigations for referred polycythaemia/
thrombocythaemia patients. This includes ensuring results of basic
investigations are available to the haematologist at the first visit.
 Management of secondary polycythaemia with emphasis on
encouraging and giving information about lifestyle changes.
It is hoped that this new service will provide a cost-effective
alternative for the Trust that will allow Consultant Haematologists to
deal with more complex cases. Patients will receive a timely and
quality service with emphasis on helping them to cope with their
condition by giving information and in some cases trying to reduce
it’s severity by encouraging a change to lifestyle.
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Sickle cell vaso-occlusive attack and intergrated care
pathways
ME Harness
Haematology Directorate, University Hospital of Wales,
Cardiff, UK
There is a population of less than 30 people suffering with sickle cell
disorder in the South Wales area. Many weeks or months may elapse
before the medical team in the Cardiff and Vale trust care for a
patient suffering with a vaso occlusive attack. Consequently the care
for this client group has been inconsistent.
In early 2004 a mulidisciplinary team was assembled to develop
an intergrated care pathway based on the British Society of
Heamatologists guidelines for the patient with a vaso occlusive
attack. The document was implemented in August 2004 and an Audit
performed 24 months later.
The purpose of the Audit was to ascertain if the pathway was used
and if it was used properly, also to see if the goals set out (such as
pain relief given within 30 min) in the pathway where met.
The findings where that out of 18 admissions the pathway was
used 14 times, with only 10 of the documents being completed
adequately. Two patients received pain control within 30 min but 10
having pain assessments performed. It was found that only nurses
filled out the care pathway after the 1st day. In conclusion it was
found staff need to be consulted as to why the document is not being
widely used and that more education is needed with medical and
nursing staff.
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Audit of the appropriateness of referrals to the nurse/
pharmacist-led hydroxycarbamide service at the RUH
T Peters and V Clarke
Royal United Hospital, Bath, UK
Hydroxycarbamide is used to treat patients with essential thrombo-
cythaemia, polycythaemia rubra vera and other myeloproliferative
disorders. Historically, all patients attended the RUH Haematology
Clinic to have their FBC checked and Hydroxycarbamide prescribed,
with little or no dosage change. The patients often travelled long
distances, waited in clinic to be seen, and then had a brief
appointment with a clinician. A Nurse/Pharmacist-led service has
been set up at the RUH so that patients who are stable on
Hydroxycarbamide are referred to the service by the clinician and
have blood testa at their GP surgery at specified time intervals. The
results are reviewed by the Specialist Nurse or Pharmacist and the
patient told by phone whether they need to change thier Hydro-
xycarbamide dose. The aim of the audit was to ascertain whether
patients were being appropriately referred to the service. Enrolling as
many patients as possible onto the Nurse/Pharmacist-led service may
result in a reduction in an over-booked Haematology clinic.
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Childhood extramedullary acute lymphoblastic
leukaemia: how should it be managed?
AD Fletcher, SE Kinsey, EM Richards and GA Shenton
Department of Paediatric Haematology, Leeds Teaching
Hospitals Trust, Leeds, UK
Extramedullary acute lymphoblastic leukaemia (ALL) with no bone
marrow disease is extremely rare at first presentation of disease. It
can occur in many different sites and is referred most frequently to
surgeons. Incorrect diagnosis of lymphoma can be made if thorough
investigation is not carried out. There are no established guidelines
for its treatment. Intensive multi-agent therapy is recommended
despite the frequent small amount of localised disease. Treatment is
successful in the majority of patients with overall survival similar to
ALL presenting with bone marrow disease.
We present four cases of precursor B-cell ALL that have presented
to our institution over a period of six years. Ages at presentation
ranged from 3 to 12 years. Sites of involvement include skin,
subcutaneous soft tissue and a lymph node. Morphology in each case
revealed the presence of intermediate or large lymphoblasts with
irregular nuclei and several nucleoli. Immunohistochemistry showed
cells of B-cell lineage and Tdt positivity consistent with precursor B-
cell ALL. In all cases further investigation revealed no other sites of
disease and no bone marrow involvement.
Each patient was treated with multi-agent chemotherapy using the
current national ALL treatment protocol at time of diagnosis.
Response to therapy in each case was assessed clinically and wider
leukaemia burden assessed as directed in their treatment protocol.
Two patients continue on treatment. In all cases response,
determined clinically because of their localised disease, has been
complete.
Extramedullary ALL is rare and presentation pattern is variable.
Diagnosis can be difficult but it can be successfully treated with
different regimens and these are discussed. The expectation is that
success of therapy will give overall survival similar to patients with
disease only affecting bone marrow. There are no specific guidelines
for management of extramedullary ALL in children. Consensus for
management and data collection for this rare group of patients is
needed.
206
Recombinant activated factor VII as treatment for
children with severe congenital platelet disorders.
Experience of a single paediatric haemophilia centre
GH Stiefel, D Marshall, M Bradbury and M Williams
Department of Haematology, Birmingham Children’s
Hospital, Birmingham, UK
Bleeding episodes in children with severe congenital platelet
disorders are associated with significant morbidity and mortality.
Historically, platelet transfusions have been used to achieve
haemostasis but recent concerns about transfusion transmitted
infection and the risk of platelet alloimmunisation have led to the
proposed use of recombinant activated factor VII (rFVIIa) (Novo-
Seven; Novo Nordisk) as an alternative treatment.
We assessed the treatment of 63 episodes of bleeding in two
children with Bernard Soulier Syndrome (BSS) and three children
with Glanzmann’s Thrombasthenia (GT) treated between 2000 and
2006. Bleeds were classified as mild (57) or severe (6) depending on
whether the patients were haemodynamically compromised and/or
had a drop in haemoglobin 42 g/l from their baseline. In all bleeding
episodes rFVIIa was given as first line therapy in a dose of 90mg/kg,
repeated after 2 hours if no initial response had been obtained.
Efficacy of rFVIIa in achieving haemostasis was effective if bleeding
had stopped at less than or equal to 6 hours from presentation.
Overall, 73% of bleeding episodes responded to rVIIa. rVIIa
treatment was ineffective in patients presenting with severe bleeding
episodes, all of whom required platelet transfusions to achieve
haemostasis. Twenty-seven out of thirty-six (75%) of mild bleeding
episodes in GT patients responded to rFVIIa. Of these, 78%
responded to a single dose. Ninteen out of twenty-one (90%) of
mild bleeding episodes in BSS patients responded to rFVIIa; 79% of
these responding to a single dose.
This study confirms that rFVIIa is a useful alternative to platelet
transfusion as a treatment for mild bleeding in children with BSS or
GT. Perhaps surprisingly, it would appear to be more effective
patients with BSS rather than GT, though this observation will
require further evaluation. Our experience would suggest platelet
transfusions should remain first line treatment for all severe bleeding
episodes in BSS and GT.
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Nocturnal hypoxemia and intracranial vessel
turbulence on magnetic resonance angiography in
children with sickle cell disease
N Dlamini, DK Hewesw, M Byneveltz, JPM Evansw, TC Coxz,
A Connellyz, R Liesnerz and FJ Kirkhamw
Evelina Childrens’ Hospital, London, UK, wInstitute of Child
Health, UCL, London, UK, zGreat Ormond Street Hospital,
London, UK
Nocturnal hypoxemia predicts CNS events in sickle cell disease
(SCD). Underlying mechanisms are poorly understood but may
include hypoxemia-mediated activation of inflammatory cells
resulting in increased cellular adhesion or an interaction with
haemolysis. In patients, the severity of hypoxemia might be
associated with the degree of increased turbulence in the terminal
internal carotid, middle and anterior cerebral arteries, which has
been shown to correlate with the degree of distal MR perfusion
abnormality. Time-of-flight magnetic resonance angiography (MRA)
was performed in 56 patients with SCD (30 boys; median age 8 years,
range 2–16 years). Each prospectively had a sleep study, MRA and
reticulocytes count. Turbulence on MRA was graded as 0 (none), or
as increasing severity grades 1–3 by two radiologists blinded to the
data.
There was a significant difference in mean overnight SpO2 for
those with different degrees of turbulence (P5 0.003, Kruskal–
Wallis). Post-hoc analysis revealed a significantly lower mean SpO2
in patients with grade 2 (n5 13; median 94.7%, range 85–97.8%) and
grade 3 (n5 14; median 93.6%, range 87–97.5%) turbulence than in
those with no vascular disease (n5 21; median 96.5%, range 90.2–
99.5%) (P5 0.008 and 0.021 respectively). There was no difference
between the mean overnight SpO2 in those with grade 1 turbulence
(n5 8; median 96.1%, range 92.4–98.3%) and any of the other groups
or between those with grade 2 and 3 turbulence. Reticulocyte count
was significantly higher in those with grade 3 turbulence than in
those with no turbulence. In a binary logistic model (grades 0 or 1
turbulence vs grade 2 or 3), mean overnight SpO2 (P5 0.0001) and
reticulocyte count (P5 0.01) were independently associated with
turbulence.
Our results suggest an association between the degree of
nocturnal hypoxemia and severity of intracranial vasculopathy in
children with SCD. Correcting potential causes of hypoxemia may
substantially reduce the risk of stroke in this population.
208
Transition services in sickle cell disease: patients’
fears and expectations
HE Jones, C Turner, H Appleby and B Inusa
Evelina Children’s Hospital, Guy’s and St Thomas’ Foundation
Trust, London, UK
Sickle cell is due a single amino acid substitution of the beta-chain of
haemoglobin of valine for glutamic acid in position six. The central
phenomenon is the tendency for paracrystal formation of deoxyge-
nated haemoglobin and subsequent vaso-occlusion and is respon-
sible for pain, end-organ damage such as stroke, renal disorders,
delayed puberty and psychosocial development.
The provision of transition services presents particular challenges
in relation to the development of self independence, adaptation, and
self-determination. These issues are more profound sickle cell
disease as a chronic condition and the unpredictable nature of the
pain with the feeling of loss of control.
We set out to determine the views of teenagers on their
expectation for service provision and their fears for the future. A
semi-structured questionnaire jointly developed by doctors, psychol-
ogists, nurses and teenagers was initially piloted on a variety of
children and then administered to 41 adolescent sickle cell patients
attending Evelina Children Hospital.
The following suggestions for service improvement were made:
teenage books and magazines and computers games, social and IT
information areas. A significant portion (55%) of the patients wanted
to talk about personal issues such as sex, alcohol and drugs. Up to
41% suggested setting up of a social group or camp so they can meet
with their peers with chronic illness and just over 50% wish to be
seen alone without their parents in clinic.
Their biggest fear was ‘fear of death’ or dying at a young age
(30%) and pain (15%), stroke (7%), or passing the sickle cell gene to
their children.
Conclusions: This highlights the need for confidentiality, devel-
opment of independence for patients to be seen on their own in
clinic. The main cause of anxiety is the fear of death and dying at
young age, or passing sickle cell to their children.
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Circulating DNA as a biomarker in sickle cell disease
P Ulug, N Vasavda, S Menzel, K Ramasamyw, T Sugaiw,
G Cheungw, S Kondaveeti, M Awogbadew, S Bannisterw,
J Cunninghamw, D Reesw and SL Thein,w
Division of Gene and Cell-Based Therapy, King’s College
London School of Medicine, London, UK, wDepartment of
Haematological Medicine, King’s College Hospital, London,
UK
Free circulating DNA has been shown to be present in the plasma of
healthy subjects and elevated in conditions characterised by
increased cell death, such as cancer and physical trauma. In sickle
cell disease (SCD) an increased cell turnover can be expected through
recurrent episodes of vaso-occlusion and inflammation, leading to
cell death and organ damage. We proposed that circulating DNA
levels would be higher in patients with SCD, that these elevations
would increase with acute crises and that the extent of increase may
serve as a marker of disease severity. Plasma samples were collected
from patients with SCD attending the specialist clinic at King’s
College Hospital. Over a 2-year period, 154 patients (105 HbSS, 46
HbSC, 3 HbS/beta0 thalassaemia) provided samples at each visit to
the specialist clinic and also during an acute crisis, as defined by
hospital admission for sickle-related pain, giving a total of 418
samples. The ethnically-matched control population consisted of 53
non-SCD individuals. Plasma DNA concentration was measured by
real-time quantitative PCR using a probe specific for the beta-globin
gene. There was no significant difference in plasma DNA levels
between controls and SCD patients during steady state. However,
mean plasma DNA levels for sickle patients during steady state, and
those in crisis were highly significantly different (Po0.0001).
Circulating DNA levels correlated with CRP levels in the SS/Sbeta0
(r5 0.24, Po0.005) and SC groups (r5 0.31, po0.05) but not in the
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controls. DNA levels correlated with WBC in the SS/Sbeta0 group
only (r5 0.25, Po0.05). Our preliminary studies showed that,
unexpectedly, circulating DNA levels were not elevated in steady
state SCD despite the ongoing inflammatory state. However, DNA
concentration may be a reliable biomarker in SCD crisis. We are
currently carrying out longitudinal studies to explore the value of
serial measurement of plasma DNA levels and their association with
organ damage in SCD.
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The interaction of UGT1A, HO1 and alpha-
thalassaemia variants with bilirubin levels and
gallstones in sickle cell disease
N Vasavda, S Menzel, S Kondaveeti, E Maytham, M
Awogbadew, S Bannisterw, J Cunninghamw, Y Danielz, A
Eichholtzz, I Okpalaz, T Fulfordy and SL Thein,w
Department of Molecular Haematology, Division of Gene
and Cell Based Therapy, King’s College London School of
Medicine, London, UK, wDepartment of Haematological
Medicine, King’s College Hospital, London, UK, zDepartment
of Haematology, St Thomas’ and Guy’s Hospital, London, UK,
yMRC International Nutrition Group, London School of
Hygiene and Tropical Medicine, London, UK
Chronic hyperbilirubinaemia is common in patients with sickle cell
disease (SCD), frequently resulting in gallstone formation. It is
attributed to haemolysis that exceeds the conjugating capacity of the
hepatic UDP-glucuronosyltransferase (UGT1A) enzyme. Previous
studies have shown that genetic variants ([TA]n repeats) in the
UGT1A gene promoter region have a major influence on bilirubin
levels and gallstone formation. Alpha-thalassaemia, which is
associated with reduced haemolysis, has also been shown to affect
bilirubin levels. Another potential modulating factor is heme-
oxygenase, a rate-limiting enzyme in the heme catabolic pathway
that results in bilirubin production. While the severity of jaundice
and cholelithiasis in SCD patients is predisposed by the inheritance
of certain UGT1A genetic variants, inconsistencies have been
observed. We investigated whether the modulating effects of HO1
and alpha-thalassaemia variants may explain these inconsistencies.
Two hundred and sixty-three SCD patients attending specialist
clinics in two hospitals were studied: King s 116 SS, 5 Sbeta0, 59 SC; St
Thomas 83 SS. Eighty-one ethnically matched subjects were recruited
as controls (HbAA). Cholelithiasis data ascertained by liver
ultrasound was available for a subset of patients (76 SS, four SC).
Samples were genotyped for variants of UGT1A, HO1 and alpha-
thalassaemia. Data was analysed according to the sum of (TA)
repeats on both alleles for the UGT1A and HO1 genes. Regression
analysis showed that serum bilirubin levels were strongly associated
with UGT1A repeat length in all subjects (Po0.0001). Furthermore,
the mean increase in serum bilirubin (21.3% for SS/ Sbeta0, 20.5% for
SC) and cholelithiasis risk (86.5% for SS/ Sbeta0, 67.6% for SC) could
be quantified per (TA) repeat. HO1 genotype did not affect serum
bilirubin in patients or controls. Co-existing alpha-thalassaemia
correlated negatively with serum bilirubin in SCD patients (Po
0.0001) but not controls. This is the first time the relationship
between UGT1A (TA) repeat length, serum bilirubin and cholelithia-
sis, and its moderation by co-existing alpha-thalassaemia has been
quantified.
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Levels of haptoglobin and haemopexin in patients
with sickle and other haemolytic diseases, and
haptoglobin genotype frequency
AHB Podmore, J Dalton, JS Henthornw and SC Daviesw
Department of Research and Development, Bio Products
Laboratory, Elstree, UK, wDepartment of Haematology, Cen-
tral Middlesex Hospital, London, UK
Several studies have reported anhaptoglobinaemia in sickle patients
that disappears after crisis. They demonstrated low levels of
haptoglobin in steady state, with low or undetectable haemopexin
in crisis that recovered to a moderate level in steady state. Other
studies of haptoglobin phenotype have suggested an increase
prevalence of Hp1 in Sickle Cell disease.
Haptoglobin levels were determined for 24 patients with
haemolytic disease, including 15 sickle patients, by measuring
peroxidase activity in complex with haemoglobin at low pH using
colorimetry. Haemopexin concentration was determined using radial
immunodiffusion. Haemoglobin was measured using a Hemocue
system. PCR haptoglobin genotyping was done for 46 sickle
patients.
Haptoglobin was detectable in 7 of 24 patients (less than 0.2 g/l),
including 3 of 15 Sickle patients (LOD less than 0.1 g/l). The normal
plasma range is 0.5 to 2 g/l. The mean haemopexin level for Sickle
patients was 0.26 g/l7 0.18 (SD), average maximum levels were 0.4
to 0.5 g/l. Normal plasma range is 0.7 to 0.8 g/l. Free haemoglobin
levels did not always inversely correlate with haemopexin concen-
tration in these patients. All of the four SC patients had haemopexin
levels of greater than 0.44 g/l (Mean 0.56 g/l). SB0 and SBpositive
together had a mean of 0.313 g/l7 0.16 (SD). It was not possible to
correlate haemopexin level to crisis recovery.
Numbers of haptoglobin genotypes in Sickle patients were 16, 24
and 6 for Hp1, Hp2/1 and Hp2 respectively. These frequencies are
similar to those reported in African populations and do not suggest
an increased frequency of a specific genotype.
We suggest haemopexin might be a useful marker for measuring
success of therapeutic interventions in haemolytic disease as it is
unaffected by in vitro haemolysis. Possible therapeutic interventions
might include trying to increase Hp concentration to achieve benefits
from its antioxidative and anti-inflammatory properties that may
help to stabilise and prevent pain episodes.
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Meeting standards for the clinical care of children and
adults with sickle cell and thalassaemia disorders in
Wales
P Palmer, T Liburd,w, S Patel,z, D Deew, L Kingz, M Bashiy,
L Jaderz and A MayJ
Cardiff Sickle Cell and Thalassaemia Centre, Cardiff and Vale
NHS Trust, UK, wUniversity of Glamorgan, UK,
zHaemoglobinopathy Laboratory, Cardiff Vale and NHS Trust,
UK, yDepartment of Haematology, Cardiff Vale and NHS Trust,
UK, zDepartment of Public Health Medicine, Cardiff, UK,
JUniversity of Wales College of Medicine, UK
Wales is an area of low prevalence for the haemoglobin disorders
with one city of high prevalence. The Cardiff and Vale Thalassaemia
and Sickle Cell Anaemia Professional Advisory Group (PAG) met for
the first time in January 2004. The remit was to improve, rationalise
and consolidate the work of the core team, clarify each member’s role
and responsibility, identify gaps in quality standards and find
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solutions as an informal network with colleagues around Wales.
Barriers to service commissioning were the ill-defined nature of
service need and the lack of acceptable benchmarks for quality
control. By October 2006 clinical standards of care for adults and
children with thalassaemia and for children with Sickle Cell
Disorders had been published.
To discover the challenges faced by Health Care Professionals in
meeting the standards. A meeting was arranged to discuss these with
the authors of the guidelines and patient representatives. PAG also
analysed hospital admission data undertook a questionnaire survey
of Consultant Haematologists and Paediatricians regarding patient
numbers and the level of service provided.
Attendance was multidisciplinary and involved Health Profes-
sionals from different parts of Wales. More than 60 patients had
received regular treatment in the area over the last three years. The
standards of care for these patients in Wales are uneven with little or
no organisation outside South Wales. Significant numbers of Health
Professionals reported challenges relating to the lack of a Paediatric
Haematologist, the complexity of the disorders encountered, and the
lack of adequate and appropriate genetic counselling, local guidelines
and clinical support in managing these disorders.
Feedback endorsed the idea of an informal network with the
delegates providing the initial framework. There is an urgent need
for the implementation of the standards, with local centres and links
to specialist centres, clinical networks, audit and monitoring in
Wales.
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A pilot study to investigate the relationship between
symmetric dimethylarginine and glomerular filtration
rate in children with sickle cell disease
PDB Inusa, CJ Booth, C Turner, H Appleby, HE Jones,
CN Ugochukwu and RN Daltonw
Evelina Children’s Hospital, London, UK, wKing’s College
London, UK
Sickle cell disease (SCD) is an inherited disorder of beta-globin
synthesis of haemoglobin, resulting in a tendency for haemoglobin
polymerisation and consequent vaso-occlusion, tissue hypoxia, and
ensuing organ damage. The kidney is particularly sensitive to
hypoxia and renal failure is a major cause of morbidity and mortality
in SCD.
In SCD there is initial hyperfiltration followed by progressive
decline in glomerular filtration rate (GFR). Routine estimation of
GFR in children is primarily based on plasma creatinine measure-
ments. Problems associated with plasma creatinine in SCD children
include increase in concentration with body size, changes in tubular
secretion, and the use of inappropriate normal ranges. Estimated
GFR (eGFR), kheight (cm)/plasma creatinine (mmol/l), where k is a
constant dependent on the creatinine analytical method, compen-
sates for changes in body size. However, the formula has never been
validated in hyperfiltration or children with SCD. Recently, new GFR
markers have been proposed, including symmetric dimethylarginine
(SDMA), that may be independent of body size. In this pilot study we
have tested the hypothesis that eGFR and/or SDMA allow reliable
estimation of GFR in SCD.
Thirteen HbSS patients, x male, age range 10–20 years (mean age
15 years) attending the Evelina Children’s Hospital were studied. The
patients were on regular blood transfusion for stroke management
and were referred to the paediatric nephrology service for renal
investigation, including formal GFR measurement using plasma
clearance of Inutest. The plasma samples were also used for the
measurement of creatinine and SDMA by stable isotope dilution
mass spectrometry. eGFR was calculated using k5 35.
Inutest GFR ranged from 70–175 ml/min/1.73 m2. There was a
significant inverse correlation between SDMA and Inutest GFR (Po
0.01). There was no significant correlation between either plasma
creatinine or eGFR and Inutest GFR.
These early data suggest that SDMA might prove valuable in
monitoring GFR in children with SCD.
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Prenatal diagnosis of Hb H hydrops fetalis due to
compound heterozygosity for the Filipino alpha-0
thalassaemia deletion and Hb Adana, alpha 2 codon
59 GGC-GAC
SJ Henderson, M Pitmanw, J McCarthy, AT Molyneux,
D Styles and JM Old
National Haemoglobinopathy Reference Laboratory, Oxford
University, UK, wFetal Medicine, Royal Hampshire County
Hospital, Winchester, UK
Here we describe the first prenatal diagnosis by molecular genetic
analysis for Hb H hydrops fetalis due to compound heterozygosity
for the Filipino alpha 0-thalassaemia mutation (–FIL) and the highly
unstable alpha 2-chain variant Hb Adana.
Until recently Hb H disease was thought of as a generally mild
disorder. However it is now recognised that Hb H disease,
particularly forms involving non-deletion mutations can result in a
critical reduction in alpha globin chain synthesis, producing severe
phenotypes requiring transfusions or even death.
The couple originated from the Philippines and were referred for
genetic testing when routine antenatal haemoglobinopathy screening
identified the mother as having haematological parameters consis-
tent with alpha 0-thalassaemia trait and the father as having
parameters consistent with alpha1 thalassaemia trait. Gap-PCR
showed that the mother was heterozygous for the Filipino alpha 0-
thalassaemia deletion (–FIL) and alpha globin gene sequencing
showed that the father was heterozygous for the alpha 2 codon 59
GGC-GAC mutation (Hb Adana). Only one case involving alpha 2 Hb
Adana and the –FIL deletion has been described in the literature and
this resulted in the phenotype of Hb H hydrops fetalis. Therefore the
couple were offered prenatal diagnosis for two pregnancies, both
unfortunately resulting in an affected fetus and subsequent termina-
tion.
The incidence of Hb Adana and other potentially severe non-
deletional alpha1 thalassaemia mutations is presently unknown in
most populations but needs to be elucidated, so that their
significance to public health can be evaluated.
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Mild haemolytic anaemia due to homozygosity for Hb
Icaria, alpha 2 stop codon TAA-AAA
SJ Henderson, H Sykesw, J McCarthy, AT Molyneux,
A Gallienne and JM Old
National Haemoglobinopathy Reference Laboratory, Oxford
University, UK, wDepartment of Haematology, Kingston
Hospital, Kingston upon Thames, UK
We present a case of homozygosity for the alpha 2 stop codon
mutation TAA-AAA (Hb Icaria). Homozygous Hb Icaria is
previously unreported.
The patient was a 51 year old female of Italian ancestry with a long
history of being investigated for unexplained mild haemolytic
anaemia. Her red cell indices were; Hb 95 g/l, RBC 3.74 1012, MCV
88 fl, MCH 25.4 pg and her A2 and F levels were 1.7% and 1.8%
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respectively. Initial investigations of her alpha thalassaemia status by
Gap-PCR and Southern Blotting were normal indicating the absence
of any of the common deletional forms of alpha thalassaemia.
However recent further investigations by alpha-globin gene sequen-
cing and MLPA revealed that she is homozygous for Hb Icaria. Like
the other alpha 2 stop codon mutations (e.g. Hb Constant Spring and
Hb Koya Dora), Hb Icaria is unstable and gives rise to the phenotype
of alpha1 thalassaemia trait.
Unlike Hb Icaria, the homozygous states for Hbs Constant Spring
and Koya Dora have been described previously. Both give rise to a
phenotype which is very unusual for homozygous alpha1 thalassae-
mia. They are characterised by Hb levels from 90 to 110 The red cell
count is relatively low with a mean of 3.9, the MCV tends to be
normal (mean 88), while the MCH is only slightly reduced (mean
26pg). They also have mild haemolytic anaemia. Homozygous Hb
Icaria seems to produce a similar atypical phenotype.
The reasons for the unusual phenotype associated with homo-
zygosity for the alpha 2 stop codon mutations are incompletely
understood. However the normal MCV may be related to over-
hydration of the red cells due to abnormal volume control, which
results from membrane damage caused by the oxidised abnormal
alpha chains.
As homozygosity for an alpha 2 stop codon mutation does not
produce a typical alpha thalassaemia phenotype it may not
considered as a possible cause of a patient’s haemolytic anaemia,
therefore cases of homozygous Hb Icaria (and the other stop codon
mutations) may be under-reported.
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Avascular necrosis of the femoral head in HbSS
children taking hydroxyurea
AK Anderson, A Simmons, H Newell, N Fofana,
M Patersonw and P Telfer
Department of Paediatric Haematology, Royal London
Hospital, UK, wDepartment of Paediatric Orthopaedics, Royal
London Hospital, UK
Avascular necrosis (AVN) of the hip is a recognised complication of
sickle cell disease during childhood, and a significant cause of
morbidity. The natural history and risk factors are better defined in
adults, where advanced AVN is irreversible and may require hip
replacement. In children, early stages of the condition may be
reversible, particularly prior to fusion of the femoral epiphysis.
Hydroxyurea (OH-urea) has been used in this clinic since 1999 for
children with frequent and severe vaso-occlusive crises. During this
time period, thirty one children under the age of 16 have been treated
(median age 12.1 years, 18 males). The median (IQ range) of
treatment duration at censorship (treatment terminated or 31/12/06)
was 3.3 years (2.1–4.4). Concurrently, between 1999 and the end of
2005, 227 children under 16 years of age with HbSS, born between
1983 and 1999 have been followed in this clinic (104 patient years with
hydroxyurea, and 1485 patient years without hydroxyurea). There
were three cases with symptomatic AVN of the hip (stage 3 or 4) in
children not taking OU-urea (incidence 0.2 per 100 patient years
follow-up) compared with the 5 cases while on OH-urea (incidence
4.8 per 100 pt years follow-up. AVN was diagnosed after a median of
2.7 years on therapy. The risk by Kaplan Meier analysis, after 5 years
of therapy was 17.4%. In all cases, the femoral epiphyses had not
fused at the time of diagnosis. OH-urea was stopped, and two have
been started on regular transfusion therapy with symptomatic and
radiological improvement.
These observations suggest that hydroxyurea therapy in children
may increase the risk of AVN, perhaps by increasing blood viscosity
and reducing blood supply to the femoral head. Children on
hydroxyurea should be observed carefully and considered for
alternative therapy if this complication occurs.
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Extracranial carotid artery occlusion in children with
sickle cell disease
A Bhattacharya, H Newell, J Evansonw, F Kirkhamz and
P Telfer
Department of Paediatric Haematology, Royal London
Hospital, UK, wDepartment of Neuroradiology, Royal London
Hospital, UK, zInstitute of Child Health, University College
London, UK
Cerebral artery stenosis and occlusion is observed in 10–20 per cent
of children with HbSS, and predisposes to ischaemic infarct. The
lesions are usually seen in the intracranial portions of the internal
carotid artery (ICA) as well as the proximal middle cerebral artery
(MCA) and anterior cerebral artery (ACA), and are identifiable by
transcranial doppler ultrasound (TCD) and magnetic resonance
angiogram (MRA). We are aware of only two patients reported in the
literature with stenotic lesions in the neck vessels, one case involving
the common carotid, the other involving the vertebral artery. This
paucity of reports may be due to the rarity of these lesions, or
because recommended neuro-imaging in HbSS children does not
routinely include the neck vessels.
We have now observed four such children, three presenting with
acute infarctive stroke with internal carotid artery occlusion and one
found incidentally on MRA, during investigation of increased TCD
velocities. The diagnoses were made by magnetic resonance
angiography of the neck and head. Their clinical features and
radiographic findings will be presented.
The children with stroke were initially anti-coagulated, as it was
not possible to exclude carotid dissection. All four are now on long-
term transfusion. Follow-up scans have been done on two and both
show persisting extracranial occlusion. There have been no further
episodes of cerebral infarction in the affected children.
We suggest that internal carotid artery occlusion or dissection
should be considered in children with sickle cell anaemia presenting
with stroke, and they should have imaging of the neck vessels as well
as cranial MRI and MRA. Consideration should be given to anti-
coagulation in those with extracranial carotid occlusion. Further-
more, children with high velocities on TCD should also have doppler
ultrasound of the neck vessels.
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Risk factors for stroke recurrence in sickle cell disease
PDB Inusa, M Prenglerz, K Pohl, D Saundersz, M Byneveltz,
T Coxz, K Chongz, O Wilkeyy, A Yardumiany, P Telferz,
Jo HowardJ, W Jan, M Dickw, D Reesw, S Whitmarsh
and F Kirkhamz
Evelina Children’s Hospital, Guy’s and St Thomas NHS
Foundation Trust, UK, wKing’s College Hospital, London, UK,
zInstitute of Child Health, London, UK, yNorth Middlesex
Hospital, London, UK, zThe Royal London Hospital, London,
UK, JCentral Middlesex Hospital, London, UK, Whipps Cross
Hospital, London, UK
Introduction: Regular blood transfusion to maintain haemoglobin S
below 30% reduces the risk of recurrent ischaemic stroke in sickle
cell disease (SCD) from 70% to 10%. Risk factors for recurrence
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despite transfusion include absence of a prodromal illness before the
first stroke and presence of occlusion or severe stenosis of the basal
cerebral vessels with moyamoya collaterals, but it is not clear
whether these are independent.
Methods: Medical records were retrieved for London patients with
SCD with ischaemic stroke (acute neurological event with infarction
on neuroimaging) between 1981 and 2001 and had been on a regular
transfusion program to prevent recurrence. Survival analysis was
used to examine the effects on recurrence risk of the presence of
moyamoya on angiography (magnetic resonance or conventional)
soon after the first stroke and a prodrome at the time of the first
stroke.
Results: Of 96 patients (92 HbSS; 46 male) with a first stroke at a
median age of 5.9 (range 1.1–19.7) years, 44 had had a prodrome (10
chest crisis, nine pain, eight fever, four parvovirus associated aplastic
anaemia, four meningitis, two dehydration and one head injury)
beginning 1–10 days previously. Twenty-one had moyamoya
collateral on initial angiography. After median follow-up of 3.89
years (range 1 day to 20 years), forty-five had a further event (23
transient ischaemic attack, 22 stroke), and four died. In multivariable
Cox regression, risk of recurrence was less for those with a
prodromal illness before the first stroke (hazard ratio, [HR] 0.45,
95% confidence intervals [CI] 0.23, 0.89) and indepedently greater
for those with moyamoya collateral (HR 2.12, 95% CI 1.14, 4.11).
Discussion: Moyamoya collateral on angiography and absence of a
prodrome are independent risk factors for recurrence in children
with SCD and stroke. In selected patients, revascularisation surgery
might reduce the risk of further neurological events.
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Auto-immune haemolytic anaemia and intracranial
vasculopathy in Down syndrome
MJ Morgan, T Birch, M Gawne-Caine, A Whitney, G Connett
and FJ Kirkham
Southampton General Hospital, Southampton, UK
Haemolysis appears to be a risk factor for pulmonary hypertension
in haemolytic anaemias. Cerebral vasculopathy might also be
associated.
A 4-year-old girl with Down syndrome presented with a right-
sided hemiparesis and expressive dysphasia a few days after
developing an upper respiratory tract infection (URTI). Aortic
coarctation and an atrio-ventricular septal defect had been repaired
in infancy. She had had idiopathic thrombocytopaenic purpura (ITP)
at the age of 2 and a history of mild asthma and recurrent URTIs
associated with pallor but not jaundice.
Haemoglobin was 80 g/l with slightly elevated reticulocytes
(112 109, normal 10–100 109). Lactate dehydrogenase (LDH) was
elevated (962 IU/l, normalo500 IU/l). Warm IgG and C3d antibodies
were detected, haptoglobin was 0.0583 and DAT test was positive.
The bone marrow was hypercellular and showed a left shift in
granulopoiesis. A polyclonal B-cell population raised the suspicion of
autoimmune lymphoproliferative syndrome but T-cell subsets were
normal double and negative T cells were absent.
Echocardiography demonstrated elevated right ventricular pres-
sures (55 mmHg). Transcranial Doppler showed right and left
internal carotid/middle cerebral artery (ICA/MCA) velocities of 250
and 180 cm/s respectively (normal o140 cm/s).
She was commenced on prednisolone but 2 weeks after weaning,
she had a further episode of slurred speech and unsteadiness. Her
TCD velocities remained high and she had further episodes of
haemolysis treated with steroids at 8 and 10 months after initial
presentation; during the second, she had a further stroke and
received a blood transfusion. Angiography confirmed occlusive
vasculopathy and she underwent right-sided external–internal
carotid artery revascularisation. Fifteen months later, she had no
further episodes, and was making development progress along her
previous trajectory, with Prednisolone cover for URTIs.
Stroke has been reported in several haemolytic anaemias. Once
haptoglobin is saturated, nitric oxide is scavenged by oxyhaemoglo-
bin, leading to vasoconstriction and eventually to irreversible
vasculopathy and ischaemia.
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Transcranial doppler in sickle cell disease in Africa
T Ajala-Agbo,w, A Kombaw, J Makaniw, CR Newtonw,z, TR
Williamsw, K Marshw and FJ Kirkham,z
Southampton General Hospital, Southampton, UK,
wKEMRI-Wellcome Unit, Kilifi District Hospital, Kilifi, Kenya,
zUniversity College Institute of Child Health, London, UK
Background: Although sickle cell anaemia (SCA) is one of the
commonest genetic disorders in the world, there has been limited
clinical research in Africa. Measuring cerebral blood flow velocity by
Transcranial Doppler (TCD) is a sensitive and specific tool in stroke
prediction.
Methods: TCD was performed in patients recruited from the
outpatient clinic in Kilifi, Kenya.
Results: In 140 patients with SCA, ages 3 months to 16 years, the
median time averaged mean velocity (Vmean) was 116 cm/s (SD 38,
range 0–219 cm/s) compared with 97 (SD 24, range 46–190) cm/s in
142 controls aged two months to 14 years (P5 0.0001). Twenty-eight
SCA patients (20%) had Vmean greater than and 16 (11%) had
Vmean less than two standard deviations from the mean for controls
in one or both ICA/MCAs, but only seven (5%) had a velocity above
170 cm/s (one 4200 cm/s), with the highest proportion aged between
5–9 years (P5 0.02). Forty-five (32%) SCA patients had a second
TCD, two 14 years later and the remainder 2 years later. Of the 21
restudied who had high Vmean at baseline, 14 remained high and 2
became low. Of 15 restudied who had low Vmean at baseline, 14
remained low and none became high. Patients with abnormal
velocity had lower oxygen saturation (P5 0.01) and haematocrit
(P5 0.05). Although abnormal Vmean was also associated with lower
haemoglobin level, red blood cell count and high white cell count,
this was not statistically significant. Neurology included history of
convulsions in 25 (14%) and of CVA in 4 (2%). There was a trend for
a greater increase in Vmean (P5 0.06) in three patients with
convulsions in the interim.
Conclusion: A relatively small proportion of African SCA patients
have conditional or abnormal velocities or stroke, although
convulsions are common. Low velocities, perhaps secondary to
moyamoya, are common.
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Nocturnal autoCPAP for sleep-disordered breathing in
sickle cell disease: pilot data
FJ Kirkham, MJ Marshall, J Legge, AM Hogan and MJ Morgan
Southampton General Hospital, Southampton, UK
Young people with sickle cell disease at high risk of sleep disordered
breathing and there is some evidence for an effect on severity.
However, surgery has long waiting lists and may not work.
Conventional CPAP has proved difficult to use in children, but
autoCPAP, which only triggers when the patient obstructs, might
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have advantages. We report the use of and compliance with auto
CPAP in a child with sickle cell anaemia over a one year period and
the development of a protocol for a pilot study.
The patient is 13 and arrived in England at the age of 10. There
were symptoms of upper airways obstruction, with loud snoring
every night and mouth breathing. Overnight pulse oximetry showed
a mean overnight oxyhaemoglobin saturation of 93% with frequent
dips. A trial of autoCPAP was instituted with a clinical endpoint of an
improvement in pain frequency. The patient hoped Mathematics
scores might improve.
The patient tolerated seven nights a week initially but then asked
to use the autoCPAP for schoolnights only, with compliance for one
year despite some discomfort from the mask. Exercise tolerance,
concentration and daily pain improved and Mathematics improved
by one grade.
Based on this experience, the pilot phase of a randomised
controlled trial has commenced at Kings College hospital (PI Dr
David Rees). The primary hypothesis is that nocturnal desaturation
is associated with low Processing Speed Index and that this
morbidity can be reduced with auto CPAP and/or overnight oxygen
supplementation. Secondary endpoints are sleep quality, assessed
with the Chervin sleep questionnaire, internal carotid/middle
cerebral artery velocity measured using transcranial Doppler and
attention using Connor Continuous Performance Test. This pilot
phase will also explore feasibility, acceptability, compliance, dosage,
safety, particularly with respect to the potential toxicity of oxygen,
and the use of texting to document pain frequency.
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Fresh frozen plasma (FFP) from male donors – the
impact on reported incidence of transfusion related
acute lung injury (TRALI) in the UK reported to the
Serious Hazards of Transfusion (SHOT) scheme
CE Chapman, LM Williamsonw, H Jones, H Cohen and
D Stainsby
Serious Hazards of Transfusion, Manchester, UK, wNational
Blood Service, Cambridge, UK
From 1996 to 2005, 185 cases of suspected TRALI were reported to
SHOT; 38 fatal, 110 causing major morbidity. Case definition is ‘acute
dyspnoea with hypoxia and bilateral pulmonary infiltrates during or
in the 24 hours after transfusion, with no other apparent cause’. All
cases should be discussed with the Blood Service, to ensure that
patients and donors are investigated for leucocyte antibodies and
antigens, with the aim of identifying the implicated component and
determining imputability.
There were 49 cases assessed as highly likely or probable TRALI
where FFP or platelets were implicated, compared with 11 for
implicated red cells; an incidence of 1:76 000 for FFP/platelet units
and 1:1 440 000 for red cell units issued from UK Blood Services.
In 2003, the English National Blood Service, which provides
480% of UK blood supplies, implemented a policy of using plasma
from male donors, as far as processing restrictions allow, to produce
FFP and for suspension of buffy coat derived platelet pools. This has
been achieved for 490% FFP units and 485% of platelet pools.
Female plasma in stock was not withdrawn.
TRALI cases reported to SHOT since 1996 are analysed to assess
the impact of this strategy. The number of reports of TRALI graded
as possible or higher has fallen in 2004 and 2005, as have TRALI
related deaths. This decrease is entirely due to a reduction in cases
associated with FFP and platelets. Female donors still accounted for
all cases in 2004 and 2005 where a significant matching antibody was
found.
Year 96/
97
97/
98
98/
99
99/
00
00/
01
01/
02
2003 2004 2005
Number of reports
Total all causes 190 244 292 282 480 454 540 609
TRALI reports
meeting case
definition
9 14 16 18 13 33 36 23 23
Highly likely/
probable
N/A N/A N/A 6 8 18 22 13 6
Possible N/A N/A N/A 9 2 14 6 4 4
Implicated components in highly likely/probable TRALI
FFP N/A N/a N/a 3 4 8 8 6 1
Platelets N/A N/a N/a 1 1 3 8 4 2
RBC N/A N/a N/a 1 3 1 1 3 2
FFP1 other N/A N/a N/a 1 0 6 3 0 0
Cryoprecipitate N/A N/a N/a 0 0 0 2 0 1
Deaths at least
possibly due to
TRALI:
2 2 4 4 3 7 7 3 3
15 months data due to change in reporting yearN/A not assessed
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A retrospective study on transfusion practice in
myelodysplasia and myelofibrosis: includes effect of
age of blood and type (BAT v TT)
S Ackroyd and S MacLennan
National Blood Service, Leeds, UK
Little is published on transfusion practice in myelodysplasia. This is
a retrospective study at a single institution including 23 patients with
myelodysplasia and examining 185 transfusion episodes. Results
showed that the average transfusion ‘trigger’ Hb was 9.5 (7.2–11.8,95%
CI). Patients with symptoms of anaemia had significantly lower Hb
(9.1 vs 9.8, F5 5.3, P5 0.002). The age of blood transfused had no
significant effect on the transfusion interval or change in HB.
However most blood was 415 days old and younger blood tended to
be used on patients with antibodies which may confound results. The
type of blood transfused (BAT vs TT) had no measurable effect on
transfusion interval or change in Hb. However the number of
patients is small and this does not exclude an effect but does suggest
any effect would not be clinically significant.
In conclusion increasing the transfusion trigger Hb for patients
may alleviate symptoms. A further study is needed to ascertain if this
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would also increase the number of transfusions or just involve more
intensive transfusions initialy to raise the Hb threshold.
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Haemolytic disease of the fetus and newborn due
to anti-Fya: further evidence of severely affected
pregnancies
AK Morris, P Reagan, S Search, R Leiblingw and E Massey
National Blood Service, Bristol, UK, wFetal Medicine Unit,
Bristol, UK
Maternal alloimmunisation against Duffy (Fy) red cell antigens,
usually Fya, has rarely been reported to cause severe haemolytic
disease of the fetus and newborn (HDFN). Two recent cases of severe
HDFN associated with anti-Fya prompted us to review all cases
monitored by the South-West regional Fetal Medicine Unit and Red
Cell Reference Laboratory between 2000 and 2006.
Sixty-one pregnancies were identified. Forty-five of these had
anti-Fya titres rising above 32, the threshold for referral for specialist
assessment and counseling. Two cases were referred for intra-uterine
transfusions(IUT). The first case was blood group O R1R2 and in her
fourth pregnancy. Anti-Fya titre rose to 2000 at 20-weeks gestation
and evidence of fetal anaemia was seen on scan at 28-weeks. The fetal
haemoglobin prior to transfusion was 5.3 g/dl and rose to 16 g/dl after
60 mm of packed red cells. She had an emergency section at 32 weeks.
The cord direct antiglobulin test was strongly positive and the baby
required a top-up transfusion. The second case was maternal group
O R1R1. She was in her sixth pregnancy having had a baby previously
affected by HDFN due to anti-Fya who required a top-up transfusion.
Evidence of fetal anaemia and reduced fetal movements were seen at
a 35-week scan with anti-Fya titre 256. Fetal blood sampling showed
the fetal haemoglobin to be 13.5 /g/dl which is on the 10th centile for
gestational age. The baby was delivered by caesarian section the
following week, had a strongly positive direct antiglobulin test and
required phototherapy.
These cases show that severe HDFN can be associted with anti-Fya
and our data suggest that 1% of affetced cases may require IUT.
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In vitro assessment of a novel pooled granulocyte
component produced from whole blood donations: an
improved component for clinical use
R Cardigan, S Bashir, S Thomas, DI Marksw, S Robinsonw,
S Stanworth and EJ Massey,w
National Blood Service, UK, wBristol Children’s Hospital
BMTU, UK
The number of granulocyte concentates transfused in England is
increasing. Whole blood derived granulocytes (buffy coats) may be
issued as an alternative to apheresis donations. Buffy coats are
however not only heavily contaminated with red cells and platelets
but there is also minimal data describing their funtionality. We
developed a method to produce a purer pooled granulocyte
component (PGC) from whole blood donations and assessed its cell
content, neutrophil viability and function. The PGC was prepared by
pooling 400 ml of SSP1 platelet additive solution and 10 ABO-
matched buffy coats. Following centrifugation, the leucocyte-rich
layer was removed, 160 ml ABO-matched plasma was added and the
PGC irradiated (25–50 Gy). Neutrophil viability, chemotaxis, phago-
cytosis and oxidative killing activity were determined by flow
cytometry. Results from 13 PGC 16–18 hours following donation were
compared with those obtained from 20 standard individual buffy
coats 12–18 hours following donation, and with fresh whole blood.
The PGC contains similar numbers of neutrophils with a reduced
volume and haemoglobin content when compared to 10 individual
buffy coats. Neutrophils in the PGC maintain 490% viability,
oxidative burst and phagocytic activity and their ability to migrate
towards a chemoattractant 16–18 hours following donation. This
compares well with neutrophil function in fresh whole blood and
standard buffy coats. Six PGC have been transfused to three patients
without adverse clinical sequelae. Clinical studies assessing the safety
and dose of the PGC are in progress.
Fresh CPD
whole blood
(n5 18)
Buffy coat
@ 12–18
hours (n5 20)
PGC @ 16–18
hours (n5 13)
Viability (%) 495 96.9
(88.3 to 99.2)
98.8
(97.7 to 99.2)
pH – 7.08
(7.02 to 7.22)
7.06
(7.02 to 7.11)
Volume (ml) – 58
(55 to 65)
250
(232 to 272)
Haemoglobin
(g/unit)
– 7.93
(5.88 to 10.15)
15.25
(12.53 to 19.58)
Granulocyte con-
tent ( 1010)
– 0.11
(0.043 to 0.20)
0.88
(0.70 to 1.17)
Phagocytosis
(% PMN positive)
93.3
(82.5 to 98.6)
64.6
(82.1 to 97.0)
94.3
(86.0 to 98.7)
Oxidative burst
(% PMN positive)
87.1
(73.2 to 98.9)
88.7
(77.4 to 95.2)
89.6
(35.2 to 96.1)
Chemotaxis
(% PMN
migrated)
Control
0.6
(0.4 to 0.9)
Control
0.08
(0.3 to 2.7)
Control
1.8
(0.5 to 4.2)
fMLP
6.8
(1.7 to 17.7)
fMLP
4.1
(1.5 to 14.3)
fMLP
7.8
(1.9 to 14.4)
Date5Median (range)
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The effect of the Sugarbaker procedure on
haemostasis
WK Leversuch, JM Needham, A Roy, AE Milne, BJ Moran
and G Knightw
Department of Haematology, North Hampshire Hospital,
Basingstoke, UK, wDepartment of Applied Sciences, University
of Portsmouth, Portsmouth, UK
Pseudomyxoma peritonei is a progressive disease of the peritoneum,
characterised by the gradual accumulation of mucinous fluid in the
peritoneum. Left untreated it is ultimately fatal. Although no cure
exists, the Sugarbaker procedure combining complete cytoreduction,
intra-operative hyperthermic intra-peritoneal chemotherapy and
post-operative intra-peritoneal chemotherapy, has shown promising
results.
The aim of this study was to assess haemostatic function in this
group of patients pre-operatively and the effect of the Sugarbaker
procedure on haemostasis.
Citrated plasma was collected from 40 patients, pre- and post-
operatively, and pre and 30 min post any blood components during
surgery. Coagulation screening tests and whole blood global assay for
haemostasis were performed. The prothrombin time (PT), activated
partial thromboplastin time (APTT), fibrinogen (Fib) were per-
formed on the MDA II (Trinity Bioscience). Thromboelastometry
tests (Ex-TEM, In-TEM and Fib-TEM) were performed on the
ROTEM (Biodis).
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Pre-operatively patients had normal PT (mean5 13.5 s) and APTT
(mean5 30.6 s) and raised Fib (mean5 4.7 g/l), suggesting the
possibility of a hypercoagulable state.
The PT (mean pre-op5 13.5 s, post-op5 15.9 s), APTT (mean pre-
op5 30.7 s post-op5 36.6 s), and fibrinogen (mean pre-op5 4.7 g/l
post-op5 1.6 g/l) all displayed significant differences with p values of
o0.001. Thromboelastography demonstrated deterioration in clot
quality as measured by the MCF (maximum clot firmness).
The PT, APTT and Fib pre and post FFP (fresh frozen plasma)
showed no significant difference.
Results indicate that this procedure has a detrimental effect on
haemostasis, identified by a reduction in fibrinogen and loss in clot
quality as indicated by thromboelastography. This suggests that
cryoprecipitate, rich in fibrinogen, may be a more appropriate blood
component for use in association with this surgery.
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Use of the haemonetics OrthoPats orthopaedic
perioperative autotransfusion system reduces both
blood usage and overall transfusion costs in patients
undergoing revision hip arthroplasty (RHA)
D Watson, J Jones, NJ Shaw, R Rogers and A Iqbal
Department of Haematology, University Hospital of North
Durham, Durham, UK
In response to HSC2002/009 ‘Better Blood Transfusion’ in May 2005
our institution introduced the use of the Haemonetics OrthoPats
Orthopaedic Perioperative Autotranfusion System for patients
undergoing RHA. There was an initial period of staff training
however no additional theatre staff were required to operate the
OrthoPats system.
In the first quarter (May-July 2005) the OrthoPats was only used
in 12% (2/17) of cases resulting in total blood usage of 64 units and
mean transfusion cost per case (including costs of the OrthoPats) of
£533. By the fourth quarter (Feb-April 2006) the OrthoPats had been
used in 50% (7/14) of cases with a total blood usage of 22 units and a
mean transfusion cost per case (including the cost of the OrthoPats)
of £334. There was an overall mean reduction in blood usage of 58%
and mean reduction in transfusion cost per case of 37%. The mean
volume of blood salvaged was 234 mls (haematocrit 0.75–0.80) with a
range ofo50 mls to 600 mls. Both the use of the OrthoPats and the
volumes of blood salvaged increased during the study period and the
technology is currently being use in 75% of cases.
Our results show that the use of the OrthoPats can reduce both
the overall blood usage and mean transfusion costs in patients
undergoing RHA. In our experience there was a gradual increase in
the use of the OrthoPats and a significant period of time following
its introduction before we were able to demonstrate its potential
benefits.
We also found the overall reduction in blood usage was greater
than would have been expected from the volumes of blood salvaged
alone suggesting the introduction of such technology may result in
additional benefits such as a greater awareness of good blood
transfusion practices within the orthopaedic directorate.
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Risk factors, management and consequences of
rhodoturula infections in immunocompromised
haematology patients
P Gallipoli, B Jonesw, IG McQuaker and A Parker
Department of Haematology, Glasgow Royal Infirmary,
Glasgow, UK, wDepartment of Microbiology, Glasgow Royal
Infirmary, Glasgow, UK
Rhodotorula species are saprophytic yeasts belonging to the family
Cryptococcaceae. They have been isolated from human skin,
environmental sources and seem to have strong affinity for plastics.
Rhodotorula species show low virulence but have been reported
causing serious infections in immunocompromised patients, parti-
cularly in the presence of indwelling catheters.
Between August 2003 and September 2006, 12 episodes of
rhodotorula fungaemia (defined as at least one positive blood
culture) in 10 patients were documented within our Unit. All positive
blood cultures were from Hickman lines. 50% of episodes were in
patients who had been neutropenic for a prolonged time (10 days to
12 months), 58% in patients within 6 months of an allogenic bone
marrow transplant (all conditioned with MabCampath), 34% in
patients who had undergone intensive chemotherapy before the
infection, and 8% in patients who had received immunosuppressive
medications during the 6 months before the infection.
In 11 of 12 episodes the line was removed when results of cultures
were available. In one episode the line was not removed but infection
recurred within 60 days requiring line removal. In 9 of 12 episodes,
patients were started on intravenous antifungals. In the remaining 3
episodes, patients were kept on oral azoles. All patients survived the
septic episode without major clinical consequences.
Most Rhodotorula infections are of low virulence. Presence of an
indwelling catheter and immunosuppression are the main risk
factors. Treatment with MabCampath appeared to be a possible risk
factor. In 50% of the episodes, patients had a normal neutrophil
count but they were significantly immunocompromised either
because of concomitant treatment or underlying disease. Line
removal is probably the most valuable therapeutic intervention and
is sometimes sufficient to treat the septic episodes but, in some
instances, the introduction of intravenous antifungals may be needed
on the basis of the clinical picture.
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Echocardiographic findings in long term survivors of
allogeneic stem cell transplantation for chronic
myeloid leukemia
R Ayto, B Garfield, J Toddw, E Kanfer, E Olavaria, A
Rahemtulla, D Marin, J Apperley and N Salooja
Department of Haematology, Hammersmith Hospital,
London, UK, wDepartment of Endocrinology, Hammersmith
Hospital, UK
Long term cardiac complications following allogeneic stem cell
transplantation include cardiomyopathy, impaired left ventricular
function, cardiac dysrhythmias, valvular dysfunction and pericardial
disease. Cardiac dysfunction may result from pre-transplantation
toxicity due to induction chemotherapy (e.g. alkylating agents,
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anthracyclines) the transplant conditioning regimen (chemotherapy
and/or radiotherapy) or co-morbidities.
We have evaluated transthoracic echocardiography data from 22
patients (12 male) who had received myeloablative allografts for CML
more than 10 years previously. All patients received cyclopho-
sphamide and total body irradiaion (TBI) as their conditioning
regimen. Two patients received a second allograft procedure with
chemotherapy only conditioning. The median age at the time of
assessment was 48.5 years (range 34–70) and the median transplant
to assessment time was 14 years (range 12–26 years).
The median fractional shortening in this group of patients was
35% (normal 29–37%) with a range of 26–42%. Four patients had
mild impairment of their fractional shortening. One of these patients
also had moderate mitral regurgitation and a history of hypertension.
Three patients with normal fractional shortening were noted to have
mild diastolic dysfunction.
Among the patients transplanted for CML described in this study,
the prevalence of observed echocardiographic abnormalities was low
and contrasts with patients transplanted for acute leukemia where a
significant reduction in fractional shortening has been reported
(Liesner et al, [1994] Journal of Clinical Oncology, 12, 916–24). This
difference may be a reflection of the more intensive pre-transplant
chemotherapy given to patients with acute leukaemia.
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Confirmation that ideal body weight is a safe method
for calculating CD341 stem cell dose for PBSC
autograft in haematological malignancy
PS Maclean, AN Parkerw, IG McQuakerw, AD Clarkw, E Farrellw
and KW Douglas
Department of Clinical Apheresis, Scottish National Blood
Transfusion Service, Glasgow Royal Infirmary, UK, wBone
Marrow Transplant Unit, Glasgow Royal Infirmary, UK
CD341 dose is an important factor in determining rate of
engraftment following stem cell reinfusion in PBSCT autograft.
Recent reports have suggested that there is a closer correlation
between CD341 cells/kg and haematopoietic reconstitution when
the stem cell dose is calculated using ideal body weight (IBW) rather
that actual body weight (ABW). We confirm these findings in 218
consecutive patients receiving PBSCT autograft for haematological
malignancy at a single centre. The median ABW was 74 kg compared
to 62 kg when IBW was calculated, a 21% difference. Thus the
recorded median CD341 dose of 5.0 106/kg (ABW) rose to
6.1 106/kg when calculated by IBW. Neutrophils reached 0.5 109/l
in 8–21 days (median 11) while platelets reached 20 109/l
unsupported in 7–38 days (median 12). For both neutrophil and
platelet engraftment a greater inverse correlation was seen when IBW
rather than ABW was used to calculate stem cell dose (r25 0.104 vs
r25 0.082 for neutrophils and r25 0.135 vs r25 0.085 for platelets).
Those patients who did not achieve a CD341 dose of 4 106 cells/kg
by ABW but did by IBW were show to achieve almost equivalent
neutrophil and platelet engraftment (z50.1 P5 0.018) as those
who achieved the target stem cell dose by both methods. In those
patients treated for myeloma this finding was not confirmed due to
the difficulty in accurately calculating IBW in patients who have lost
skeletal height. Our study confirms that calculation of CD341 cell
dose by IBW safely predicts engraftment in PBSC autograft but we
would suggest that pre-morbid height be used in its calculation in
patients with myeloma. The major benefit of this method of
calculation is that it reduces the absolute stem cell dose required
for approximately 80% of patients and therefore allows some to
avoid additional apheresis procedures or even courses of condition-
ing chemotherapy.
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The first case of optic neuritis preceding progressive
outer retinal necrosis (PORN) after bone marrow
transplantation (BMT): a severe manifestation of
varicella-zoster virus (VZV) infection
A Patel,w, S Narat, E Grahamz,y and E Olavarria,w
Department of Haematology, Hammersmith Hospitals NHS
Trust, London, UK, wDepartment of Haematology, Division of
Investigative Sciences, Faculty of Medicine, Imperial College
London, UK, zGuy’s and St Thomas’ NHS Foundation Trust, St
Thomas’ Hospital, London, UK, yUniversity College London
Hospitals NHS Foundation Trust, The National Hospital for
Neurology and Neurosurgery, London, UK
Severe VZV infection causes PORN, resulting in devastating
unilateral and bilateral visual loss, and occurs with immune
suppression. It was first described in HIV patients, where regression
is commoner. However, only three reported cases in BMT exist,
where presentation, treatment and prognosis vary, being more
severe, with refractory disease outside the orbit, causing permanent
disability.
CASE: An 18-year-old woman with Philadelphia chromosome
positive acute lymphoblastic leukaemia underwent allogeneic stem
cell transplantation from an haplo-identical donor. Five months
post-engraftment, VZV was isolated from left groin shingles, which
resolved with intravenous aciclovir, and then valaciclovir. Three
months later, the patient was admitted with two weeks of headaches
and blurred vision in the right eye, with central visual loss over four
days. Examination revealed no light perception, relative afferent
papillary defect, Snellen 6/6 vision in the left eye and normal
fundoscopy. Optic neuritis was diagnosed and treated with three
days of intravenous methylprednisolone and oral prednisolone. Five
days after treatment, blurred vision in the left eye developed. Repeat
fundoscopic and slit-lamp appearances were initially confused for
leukaemic infiltration. However, subsequent appearances were
consistent with PORN. Orbital MRI confirmed optic neuritis and
VZV DNA was detected by PCR from the CSF and vitreous humour.
Visual deterioration continued despite the combination of
ganciclovir and foscarnet. Intravenous cidofovir and intra-vitreous
foscarnet were added without success. Cerebellar signs and
oscillopsia developed after four weeks, with disease extension. Other
late complications included recurrent retinal detachment requiring
multiple surgical interventions. The patient is now registered blind,
reading Braille and studying literature.
This is the first case of optic neuritis preceding PORN in BMT,
where treatment is particularly challenging. Optimal therapy is
undefined. Distinction from acute retinal necrosis, CMV retinitis,
and leukaemic retinal infiltration may prove difficult without
vitreous and CSF VZV PCR.
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A standardized potency assay for stem cell products
prior to transplantation
IN Rich, KM Hall, LH Gebruw and JA Reemsw
HemoGenix, Inc., Colorado Springs, CO, USA, wPuget Sound
Blood Center, Seattle, WA, USA
The potency or quality of a stem cell product for clinical
transplantation is usually determined by total nucleated cell counts
(TNC), viability, CD34 cell numbers and growth in the colony-
forming assay (CFA). Results from the latter are subjective, cannot be
standardized and require 14 days to be obtained. In contrast, an
instrument-based, ATP proliferation assay (HALO) can produce
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results in 5–7days and is fully standardized so that intra- and inter-
laboratory results can be directly compared. As lympho-haemopoie-
tic cells proliferate in response to growth factors, the intracellular
ATP (iATP) increases proportionately. After incubation in 96-well
plates, the iATP is released and acts as a limiting substrate for a
luciferin/luciferase reaction producing bioluminescence that is
measured in a plate luminometer. In this study, two groups (HG
and PSBC) performed TNC, viability, CFA and HALO on similar
aliquots from 12 erythrocyte-depleted cord blood samples on the
same day. CD34 was performed only at PBSC. The results were the
following. A correlation existed for TNC between sites (r5 0.98, Po
0.001). A correlation (r5 0.79, P5 0.02) also existed between sites
for the CFA despite using different methodologies, but a good
correlation between CFA and CD341 cells was only found at PSBC
(r5 0.87, Po0.001). A significant correlation (r5 0.82, Po0.001)
was observed at HG between CFA and HALO. The lack of correlation
observed for the CFA with CD34 and HALO was due to differences in
colony counting practices, thereby illustrating the how subjectivity
can lead to inconsistent results. In contrast, when the results from
HALO were compared, a significant correlation (r5 0.94, Po0.001)
was found between both sites. Despite the small number of samples,
the results clearly demonstrate that measurement of proliferation
potential using HALO is an alternative to measuring differentiation
potential using the CFA technique.
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A novel application of digital single nucleotide
polymorphism (dSNP) technology to the identification
of chromosome 13q deletions in multiple myeloma
and chronic lymphocytic leukaemia
K Hanlon,w,z, LW Harriesw, S Ellard,w and CE Rudinw,z
Department of Molecular Genetics, Royal Devon and Exeter
NHS Trust, Exeter, UK, wInstitute of Biomedical and Clinical
Science, Peninsula Medical School, Exeter, UK, zDepartment of
Haematology, Royal Devon and Exeter NHS Trust, Exeter, UK
Deletions of 13q14 are common in Chronic Lymphocytic Leukaemia
(CLL) and Multiple Myeloma (MM). Such deletions are commonly
identified using interphase Fluorescence In Situ Hybridization
(FISH), but this technique may have limited application when
applied to archival tissue or samples with heterogeneous cell
populations such as MM. Consequently, there remains a need to
develop a sensitive technique for accurate detection of 13q14
deletions in both fresh and archival tissue.
We report here the novel application of digital Single Nucleotide
Polymorphism (dSNP) technology to detect and characterise 13q
deletions in MM and CLL. We tested paraffin-embedded bone
marrow biopsies and whole blood samples from 12 MM and 15 CLL
patients respectively. We analysed heterozygous SNPs across the
13q14.2 to 13q32 region for the presence of skewed allelic ratios and
tested results for statistical significance by sequential probability
ratio analysis. Where possible, deletion analysis was also performed
by FISH.
We identified 13q14 deletions in 6/12 (50%) MM and 12/14 (80%)
CLL cases, demonstrating the utility of dSNP technology. FISH and
dSNP data proved concordant in 4/6 MM and 10/14 CLL cases. With
most discrepancies (5/6), 13q14 deletions detected by dSNP analysis
may not have extended to the region covered by the FISH probes.
dSNP analysis in MM allowed detection of 13q deletions in
archival tissue with minimal neoplastic cell infiltration without the
need for prior plasma cell enrichment. Deletion analysis in this
cohort indicated that the minimal deleted region (MDR) may localise
to a 331,000bp region of chromosome 13q14.3.
Our results indicate that dSNP is a useful technique that can be
applied to both fresh and archival tissues and has particular utility
where numbers of neoplastic cells are limited. Using this approach, it
may be possible to narrow the MDR for MM and CLL, potentially
enabling identification of candidate tumour suppressor genes.
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The telomerase-associated protein NOP10 is mutated
in autosomal recessive dyskeratosis congenita
AJ Walne, TJ Vulliamy, A Marrone, R Beswick, MJ
Kirwan, Y Masunari, F Al-Qurashiw, M Aljurfw and I Dokal
Academic Unit of Paediatrics, Queen Mary School of
Medicine and Dentistry, London, UK, wKing Faisal Specialist
Hospital and Research Centre, Riyadh, Saudi Arabia
Dyskeratosis congenita (DC) is a bone marrow failure syndrome
associated with multiple somatic abnormalities and an increased risk
of malignancy. Identification of the genes involved in of this disease
suggests that it may arise through a defect in the maintenance of
telomeres. To date, mutations have been identified in the RNA
component and the reverse transcriptase component of telomerase in
autosomal dominant DC, and in the protein dyskerin in X-linked DC,
which is a core component of H/ACA small nucleolar RNPs as well as
the telomerase complex. Through homozygosity mapping in
consanguineous families we have previously shown that the
autosomal recessive form of the disease is genetically heterogeneous.
In one large consanguineous family, we have mapped the disease
locus to chromosome 15q14. The gene encoding NOP10, a small core
component of H/ACA small nucleolar RNPs and the telomerase
complex, maps to this region and was therefore an ideal candidate.
We find that three affected individuals in this family, who present
with classical mucocutaneous features of DC, are homozygous for a
mutation causing an R34W substitution in NOP10; consistent with
autosomal recessive inheritance, their asymptomatic parents are
heterozygous for this mutation. This amino acid is highly conserved
and lies at the site of protein-protein and protein-RNA interaction in
the RNP complex. We show that affected individuals have very short
telomeres and significantly reduced levels of TERC in peripheral
blood, while heterozygotes for this NOP10 mutation (parents and
three normal sibs) have intermediate telomere lengths and TERC
levels. Using small interference RNAs, we demonstrate that a
reduction of NOP10 transcript levels brings about a subsequent
reduction in the amount telomerase RNA. In conclusion, these
findings suggest that this unusual family represents the first
description of autosomal recessive DC, due to mutation in another
component of the snoRNP and telomerase complex.
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Utility of early screening for JAK2 V617F mutation in
patients with erythrocytosis or thrombocytosis in a
District General Hospital
J Chacko, L Wallis, A Jonesw, NCP Crossw and DG Oscier
Department of Haematology, Royal Bournemouth Hospital,
Bournemouth, UK, wWessex Regional Genetics Laboratory,
University of Southampton, Salisbury, UK
We retrospectively analysed the diagnostic utility of testing for the
V617F JAK2 mutation in 322 consecutive patients referred to the
Royal Bournemouth Hospital, for either raised red cell indices
(n5 247) or raised platelet count (n5 65), over a 43-month period
during which red cell mass measurement was not routinely available.
Based on a preliminary assessment consisting of history and
physical examination, full blood count, ESR, blood film, Pa02,
abdominal ultrasound (159 cases) serum Epo (126 cases) and bone
marrow biopsy (58 cases), polycythaemia was considered to be
transient (71 cases), secondary (89 cases), P Vera (19 cases) or to have
no apparent cause (68 cases). Essential thrombocythaemia (ET) was
diagnosed in 39/64 patients with persistent thrombocytosis.
Most patients with secondary polycythaemia had a history of
heavy smoking and/or alcohol consumption. Only two abdominal
ultrasound scans yielded a clinically significant diagnosis (hyperne-
phroma). Low serum erythropoietin levels (17/126) were found in all
four groups of polycythaemic patients whilst high levels (4/126)
occurred only in non-PV group. Bone marrow histology consistent
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with PV and ET were observed in 13/13 and 10/28 respectively. All ET
patients had a normal ESR.
V617F JAK2 mutation was detected in DNA extracted from
leucocytes using a tetra primer ARMS PCR assay and quantitated by
pyrosequencing. Results are available for 136 patients with erythro-
cytosis and 44 patients with thrombocytosis and showed presence of
mutation in 16/17 with suspected PV, 0/34 with secondary
polycythaemia, and 24/39 with suspected ET. A low-level mutation
was seen in 5 polycythaemic patients not initally suspected of having
a myeloproliferative disorder.
In summary our data would support testing for the JAK2 V617F
mutation in patients suspected of having PV and ET based on clinical
criteria, blood count and blood film. Recent data suggest that JAK2
negative PV patients and those with a low Epo level should be
screened for exon 12 JAK2 mutations.
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HOX genes are a major target for epigenetic
mis-regulation in adult and childhood leukaemia
G Strathdee,w, TL Holyoakez, A Simw, A Parkery, DG Osciery,
JV Meloz, S MeyerJ, T EdenJ, AM Dickinson, R Soutarww and
R Brownw
Crucible Laboratory, University of Newcastle, Newcastle-
upon-Tyne, UK, wCentre for Oncology and Applied Pharma-
cology, University of Glasgow, UK, zDivision of Cancer
Sciences and Molecular Pathology, University of Glasgow, UK,
yDepartment of Haematology, Royal Bournemouth Hospital,
UK, zDepartment of Haematology, Imperial College London,
UK, JDepartment of Paediatric Haematology and Oncology,
Central Manchester and Manchester Children’s University
Hospitals, UK, Department of Haematological Sciences, The
Medical School, Newcastle upon Tyne, UK, wwDepartment of
Haematology, Western Infirmary, Glasgow, UK
Altered expression of key transcription factors plays a pivotal role in
the development of leukaemia. To begin to assess epigenetic
mechanisms responsible for such aberrant regulation we have
analysed the role of DNA methylation in altered expression of
members of the HOX gene family, which are key regulators of
embryonic development and differentiation and have been impli-
cated in normal and malignant haematopoiesis. In both adult
myeloid and lymphoid leukaemia two members of the HOXA cluster
(HOXA4 and A5) were found to be frequently inactivated by
promoter hypermethylation (between 26–64% of cases). A further 12
HOXA, B and C cluster genes were, in contrast, found to be
essentially devoid of increased methylation (except HOXA6 in CLL,
where 34% of samples exhibited hypermethylation). HOXA4 and A5
were also frequently inactivated in childhood ALL and AML (39–79%
of samples). However, in contrast to the adult leukaemias, all but one
of the additional HOX genes analysed were also found to be common
targets for hypermethylation in both ALL and AML (4–26%),
suggesting that HOX genes are differentially regulated in childhood
vs adult leukaemia.
Interestingly HOXA4 hypermethylation exhibits frequent correla-
tions with poor prognosis in patients. Hypermethylation of HOXA4
correlates with progression to blast crisis (P5 0.007) and poor
response to imatinib in CML (P5 0.04), with cytogenetic status in
AML (38%, 78% (P5 0.002 vs good), 100%(P5 0.0002 vs good,
P5 0.04 vs intermediate) samples hypermethylated in good,
intermediate and poor prognostic subtypes respectively) and
correlates with IgVh mutational status (P5 0.003) and poor survival
in CLL (median survival 159 vs 199 months in hypermethylated and
non hypermethylated patients, respectively). Furthermore re-expres-
sion of HOXA4 in a CML blast crisis cell line results in re-expression
of markers of myeloid differentiation. These results suggest that
aberrant epigenetic regulation of HOXA4 may play a key role in the
development of multiple types of leukaemia.
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The novel protein JUNE-1 binds histone H3
VM Hodges, S Rainey, V Smyth, TRJ Lappin and
AP Maxwellw
Haematology Research Group, Centre for Cancer Research
and Cell Biology, Queen’s University Belfast, UK, wRegional
Nephrology Unit, Belfast City Hospital, Belfast, UK
Erythropoietin (EPO) is the principal regulator of terminal erythroid
differentiation. Recently expression of EPO and its receptor has been
demonstrated in non-erythroid cells with a potentially controversial
role in tumour development. To increase understanding of EPO
downstream signalling events, differential display PCR was used to
isolate EPO responsive genes in a murine model of terminal
erythroid differentiation. June-1, a novel gene upregulated in
response to EPO, was identified. JUNE-1 has significant identity
with only one other human protein SPOC1/PHF13, also of unknown
function but which demonstrates an association with residual disease
and survival in ovarian cancer. The gene is widely expressed
suggesting a role beyond erythropoiesis and although highly
conserved across vertebrate species the function of JUNE-1 remains
to be elucidated. A splice variant, missing a 201 bp section of exon 4,
has also been identified. In silico sequence analysis reveals a nuclear
localization signal (NLS) and a PHD motif (plant homeodomain).
PHD domains act as zinc fingers and many PHD containing proteins
have a role in chromatin regulation. Cellular localisation studies
using GFP tagged JUNE-1 indicates that the protein is located almost
exclusively in the nucleus. The splice variant which retains both the
PHD domain and the NLS is also nuclear. Western blot analysis of
immunoprecipitated JUNE-1 from transient over-expression in 293T
cells reveals both tyrosine and serine phosphorylation suggesting
additional regulation at the post-translational level. Some PHD
fingers recognise modified histone residues which promote activa-
tion and/or repression of gene expression. JUNE-1 demonstrates an
association with histone H3 suggesting it may function as a novel
effector protein involved in regulating transcription.
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Systems biology analysis of the G0-G1 cell cycle
transition of human primary T cells
SJ Orr, R Wangw, NC Lea, C Chronis, AK Ramaniw,
GJ Mufti, EM Marcottew and NSB Thomas
Department of Haematological and Molecular Medicine,
King’s College London, UK, wInstitute for Cellular and
Molecular Biology, University of Texas at Austin, TX, USA
We identified a G0-G1 commitment point in primary human T cells
that controls entry into the cell cycle from quiescence. We
demonstrated proof of principle that cellular pathways coupled
during CD3/CD28 stimulation can be uncoupled experimentally. We
have now used systems biology approaches to identify nuclear
protein networks in primary human T cells that are regulated during
the transition from quiescence into the cell cycle (G0-G1-S-phase).
First we sequenced chromatin and nuclear matrix proteins that
became bound in G1 but were not bound in G0 and vice versa by
mass spectrometry. Bioinformatic analysis identified 76 proteins
specifically bound in G0 not G1 and 254 bound in G1 not G0. 179 of
the 254 proteins bound in G1 not G0 (i.e. dynamic protein changes)
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were mapped to the 55,000 human protein interaction dataset. These
are involved in numerous cellular functions, including epigenetics,
transcription, RNA splicing and transport, and others. Cell cycle
regulated chromatin/matrix binding of a subset was verified by
western blotting (2/2 bound in G0 not G1 and 22/23 bound in G1 not
G0).
One of the proteins induced and bound in G1 was SAP145 (SF3B2).
This is a component of the ubiquitous SF3b RNA splicing complex,
involved in both major (U2-type) and minor (U12-type) spliceo
somes. Since SAP145 is induced during G1 we investigated whether
there was a role for SAP145 in regulating cell cycle progression. T cells
depleted of SAP145 by siRNA enter G1 from G0 but progress poorly
through S phase and die, probably by apoptosis. Proteins normally
induced during G1, e.g. cyclin D3, Cdc6 and cdc2 are produced,
suggesting that their pre-mRNAs are spliced normally. In contrast, the
expression of p107 and cyclin A were reduced. Therefore, a systems
biology approach to analysing cell cycle transitions identifies SAP145 as
rate-limiting for the G1-S phase cell cycle transition.
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Management of over-anticoagulation in children
HK Kanthimathinathan, GC Taylor, J Motwani and
MD Williams
Birmingham Children’s Hospital, Birmingham, UK
Recent BCSH guidelines have addressed the management of adults
over-anticoagulated with warfarin. However, despite increasing
numbers of children taking long term warfarin there is a lack of
data on the incidence and management of over-anticoagulation in
this population. We have carried out a retrospective review of
anticoagulation practices in our hospital and describe the manage-
ment of children with INRs 45.0.
Data was collected retrospectively for 86 children on long-term
warfarin between September 2001- September 2006. 53 children had
undergone a Fontan’s procedure and 19 had prosthetic heart valves.
Two hundred and thirty-six of one thousand and ten INRs done in
the five year period (2.3%) were 45.0 (INR 5–8: 211, 8–10: 12, 410:
13). These episodes were managed by: a) warfarin dose reduction
(n5 98), b) dose omission (n5 116), c) oral Vitamin K (n5 14) and
d) IV Vitamin K (n5 8). Mean INR values for these 4 groups were
5.5, 6.3, 9.5 and 9.4. Therapeutic INRs were achieved within 24 hours
in 39%, 33%, 20% and 25% respectively. Six per cent of INRs were
sub-therapeutic following dose reduction or omission, 75% following
IV Vitamin K and 50% following oral Vitamin K. Vitamin K was
usually one tenth of the dose of warfarin previously administered
though the range varied between 0.1 and 3.0 mg.
Minor bleeding complications occurred in 3 patients only.
High INRs occur infrequently in children and most can be safely
treated in the absence of bleeding by a reduction or omission of the
dose of warfarin. We have noted variability in management of high
INRs, with less experienced clinicians more inclined to stop warfarin
or administer vitamin K. This has led to subtherapeutic INRs which
can be hazardous for children with prosthetic heart valves. As a
result of this study, a more standardised approach to the manage-
ment of over coagulated children has been introduced in our
hospital.
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Use of alternate stem cell sources for allografting in
malignant infantile osteopetrosis: single centre
experience
L Karnik, G Chakupurakal, M Velangi, S Lawson and
P Darbyshire
Bone Marrow Transplant Unit, Birmingham Children’s
Hospital, Birmingham, UK
Malignant infantile osteopetrosis (MIOP) is a lethal disorder of
osteoclast dysfunction. Haematopoietic stem transplantation is the
only curative treatment currently available. The best results are seen
with matched sibling donors; however the use of alternate donors is
being explored. Early allografting is essential in order to minimise
permanent neurosensory deficit. We studied 5 children with MIOP
who underwent 8 allograft procedures in our unit in 3 years. The
mean age was 18 months (2–53 months). Donors were matched
sibling (n5 1), unrelated cord (n5 2) and haploidentical parent
(n5 5). The mean CD34 dose was 8.4X106/kg and a dose of 10 106/
kg was achieved with all haploidentical grafts. Haploidentical grafts
were T cell depleted and patients received serotherapy (ALG in four
and OKT3 in one). Common conditioning regimes were used.
Cyclosporine was used for graft-versus-host disease (GvHD)
prophylaxis. Neutrophil and platelet engraftment was seen at a
mean of 15 days (range 11–20 days) and 49 days (range 12–60 days)
respectively. Three episodes of primary graft rejection occurred in
two patients who then engrafted successfully after a haploidentical
graft. Three patients showed complete chimerism (CC) at day 28 and
this has persisted. Two patients that showed increasing mixed
chimerism (i-MC) were treated with escalating donor lymphocyte
infusions (DLI) with fludarabine resulting in CC in one patient and
stable mixed chimerism in the other. Four patients developed grade
two acute skin GvHD (2 post-DLI), one patient developed chronic
skin GvHD. Clinical improvement or stabilisation was seen in four
patients. Disease progression occurred in one patient in spite of CC.
There was no transplant related mortality. One patient developed
acute immune thrombocytopenic purpura needing immunoglobulin
therapy. Hypercalcemia needing pamidronate was seen in one
patient. Both have resolved. We have shown that the use of alternate
stem cell donors, especially haploidentical parents, in the absence of
a fully matched sibling donor, is a safe, readily available and effective
transplant option that is likely to improve the outcome in children
with malignant osteopetrosis.
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Evaluation of analgesia regime with intranasal
diamorphine and oral morphine for acute painful
sickle crises in children
C Lahoz, K Aliw, J Challandsz, I Morrisonw, K Newell, Y John
and P Telfer
Department of Paediatric Haematology, Royal London
Hospital, UK, wDepartment of General Paediatrics, Royal
London Hospital, UK, zDepartment of Anaesthetics, Royal
London Hospital, UK
Pain control for children with SCD is often inadequate and delayed.
Use of injected opiates is frequent but uncomfortable, and may lead
to increasing reliance on large injected doses later in life. We have
designed a protocol for immediate and sustained analgesia avoiding
injected opiates, relying on rapid assessment and treatment by the
paediatric casualty nurse.
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On arrival, intranasal diamorphine (0.1 mg/kg) is given with
oramorph (0.4 mg/kg). Oramorph is repeated at 1,3,6 hours and 3
hourly prn thereafter. MST 1 mg/kg bd is added at 6 hours if pain is
inadequately controlled. Treatment failures are given iv PCA
morphine. We have evaluated the protocol by auditing our
admissions between September 2004 and August 2005. We have
also undertaken a questionnaire survey to assess subjective
perception by patients/parents.
There were 96 admissions in 38 children. 13 did not require
morphine. Average age was 11 years (4–16). There were 23 males and
15 females, 36 with HbSS and 2 HbSC. Time to intranasal
diamorphine was: immediate in 44 (53%), and within 10 min in 21
(25%). There were deviations of the protocol in 24 admissions.
Average dose of oramorph was 127.36 mgs (6–946 mgs). MST was
required in 25 episodes (29%). Average dose was 267.4 mgs (40–
760 mgs). On eight admissions in four patients PCA was required. In
72 evaluable episodes, median time to pain relief (mild or no pain)
was 20 hours (IQ range 12–70). Median duration of admission was 3
days (IQ range 2–6). The regime was well tolerated, side effects
included constipation, 15 (17.4%); vomiting, 7 (8%); pruritus, 13
(15%); and drowsiness: 1 (1.2%). Four episodes were complicated by
chest crises.
In conclusion, this is an effective and practical protocol, which
circumvents the need for injected analgesia. It could be compared
with standard use of parenteral morphine in a randomized controlled
study.
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Acute chest syndrome in children with sickle cell
disease: an inner London experience
MR Fine-Goulden, R Ahmad and PDB Inusa
Department of Paediatrics, Guy’s and St Thomas’ Hospital,
London, UK
Acute Chest Syndrome (ACS) is diagnosed in a child with Sickle Cell
Disease (SCD) when a new infiltrate on chest radiograph is
accompanied by acute respiratory symptoms. It is the leading cause
of death and the second most common cause of hospitalisation in
children with SCD. ACS accounts for 20–30% of all sickle cell
admissions in children and up to 15% of those are reported to require
intensive management and mechanical ventilation. Most reports
come from large, multi-centre studies from the USA and there is
limited data on the pattern of illness and its management in the UK.
We set out to describe the pattern of ACS in children by reviewing
retrospective data from a Central London teaching hospital with over
400 children with SCD who account for 110 acute admissions per
year. A total of 29 episodes of ACS in 24 children were identified,
four with pre-existing asthma and three with severe gastro-
oesophageal reflux disease.
The age range was one to 15 years (median five years); 20 (69%)
were female. Length of stay was from one to 27 days (median four
days). Eighteen (62%) were admitted with a diagnosis of ACS. The
remaining cases were intially admitted for acute painful crises or
surgery, but developed acute chest syndrome while in hospital.
The most common clinical features were fever (median 39 degC)
and low oxygen saturation (median 92%). Eight cases (28%) received
blood transfusion. Only three (10%) patients were transferred to the
Intensive Care Unit for further managment. There were no reported
deaths.
ACS is a significant cause of hospital admission and morbidity in
children with SCD, and a third of cases developed ACS after being
admitted for a different conditon. A less severe pattern is observed
than has been reported previously.
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The Shwachman–Diamond protein is required for
translational activation of ribosomes
TF Menne,w, B Goyenechea,w, N Sa´nchez-Puig,w,
CC Wong,w, LM Tonkin,w, PJ Ancliffey, RL Brostz,
M Costanzoz, C Boonez and AJ Warren,w
MRC Laboratory of Molecular Biology, Cambridge, UK,
wDepartment of Haematology, University of Cambridge,
Cambridge, UK, zBanting and Best Department of Medical
Research and Department of Molecular Genetics and Micro-
biology, Terrence Donnelly Center for Cellular and Biomole-
cular Research, University of Toronto, Canada, yCamelia
Botnar Laboratories, Great Ormond Street Hospital, London,
UK
Shwachman–Diamond syndrome (SDS) is an inherited bone marrow
failure disorder associated with pancreatic exocrine insufficiency,
metaphyseal chondrodysplasia and leukaemia predisposition. As the
cumulative risk of MDS/leukaemia is around 36% by 30 years, SDS
represents an important paradigm for understanding the genetic
determinants underlying the multi-step progression to leukaemia.
The majority of SDS patients carry mutations in the SBDSgene that
encodes a highly conserved 250 amino acid protein of unknown
function. Indirect evidence suggested that SBDS might function in
ribosome biogenesis. In particular, X-ray crystallographic studies
revealed structural homology between an archaeal SBDS orthologue
and two yeast ribosome-associated proteins, Yhr087w (which co-
precipitates with 60S ribosome biogenesis factors), and elongation
factor 2 (the eukaryotic homologue of the bacterial GTPase
elongation factor G). By taking advantage of the powerful genetic
tools afforded by the model organism Saccharomyces cerevisiae, we
have elucidated the conserved function of the yeast SBDS orthologue
Sdo1. We demonstrate that Sdo1 is critical for the release and
recycling of the nucleolar shuttling factor Tif6 from cytoplasmic pre-
60S ribosomes. This is the final step in the maturation of 60S
subunits and is required for the translational activation of
ribosomes. Through the application of genome-wide synthetic
genetic array mapping technology, we identified multiple TIF6
gain-of-function alleles that suppressed pre-60S nuclear export
defects and cytoplasmic mislocalisation of Tif6 in SDO1 null cells.
We show that Sdo1 functions together with the GTPase elongation
factor-like 1, in a pathway that controls the translational activation of
ribosomes. Our data link defective late 60S ribosomal subunit
maturation to an inherited bone marrow failure syndrome associated
with leukaemia predisposition. As ribosome dysfunction has also
been described in Diamond–Blackfan anaemia, dyskeratosis con-
genita and cartilage hair hypoplasia, our data suggest that common
molecular mechanisms may underlie the pathogenesis of these
inherited bone marrow failure syndromes.
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UK validation and initial testing of an ITP quality of
life instrument
JD Grainger, C Beane, PHB Bolton-Maggsw, C Wakefieldz,
C Curtisz, VS Balnchettez, NL Youngy and R Klaassenz
Royal Manchester Children’s Hospital, UK, wManchester
Royal Infirmary, UK, zThe Hospital for Sick Children, Toronto,
Canada, yLaurentian University, Sudbury, Canada, zChildren’s
Hospital of Eastern Ontario, Ottawa, Canada
Children with ITP need to adapt their lifestyle to minimise bleeds
whilst awaiting spontaneous remission or curative therapy. Little is
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known about how ITP affects the quality of life (QoL) of the child or
family. Successful treatment my improve QoL or conversely may
worsen QoL if excessive side effects develop.
We describe the ‘translation’ of an ITP-specific QoL tool (KIT),
developed in Canada, into use for children from the UK. The KIT
consists of 26 questions. A version is completed by children of seven
years or older. Parents complete a proxy version and a parent
impact KIT. The KIT produces scores with a range of 0 (worst) to 100
(best).
We have tested the KIT on 10 children with ITP. Prior to the final
version all the children and 86% of the parents reported
misunderstandings with the original version. Eight changes were
made from the original Child/Proxy KIT and five changes in the
Parent Impact.
Worrying about the ITP getting worse, concerns about appear-
ance, constitutional symptoms and changes in mood were high-
lighted as particular problems. Children with a platelet count below
20 had a significantly worse QoL than children over 20 (67 vs 85, Po
0.05).
Cross-cultural testing of a North American measure in the UK
resulted in important changes to the measure. We plan to
incorporate the KIT into the UK registry www.uk-itp.org. Ultimately
the KIT will be an essential outcome measure in clinical trials and
may aid in making decisions on whether or not to treat.
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Incidence of bleeding and thrombotic events and
pregnancy complications in cohort of families with
dysfibrinogenemia secondary to Arg-16-His mutation
EK Nicholson, M Hillsw, G Dolanw and RC Tait
Department of Haematology, Royal Infirmary, Glasgow, UK,
wDepartments of Clinical Chemistry and Haematology,
Queen’s Medical Centre, Nottingham, UK
The dysfibrinogenemias are a group of inherited disorders
characterized by fibrinogen molecules that are abnormal in structure
and function. As a group these disorders exhibit heterogeneous
clinical behaviour. The most common reported mutation is the
substitution of histidine for an arginyl residue at position 16 (Arg-16-
His) which is associated with a mild clinical phenotype. Published
data suggests that 25% of affected patients have haemorrhagic
symptoms, 5% have thrombosis (with known risk factors) and 3%
have thrombosis without other known risk factors. Rates of
spontaneous abortion and postpartum haemorrhage are also
increased. However the apparent clinical significance may be
overestimated due to case finding bias. We have identified 17
families with the Arg-16-His mutation, many incidentally through
routine pre-surgical coagulation screening. We undertook a compar-
ison of incidence of thrombotic and haemorrhagic events and
pregnancy complications in these individuals and unaffected
relatives.
Thirty-five individuals (27 affected; 8 unaffected) were assessed
from the 17 families. Bleeding scores [Tosetto et al, Journal of
Thrombosis and Haemostasis 2006; 4:766–733] in affected indivi-
duals ranged from 2 to 18 (mean 5, median 3) and in unaffected
individuals from 3 to 4 (mean 1, median 0). An abnormal bleeding
score (43) was more common (55% vs 12.5%) in the affected
individuals (P5 0.05). Venous thromboembolism occurred in 11% of
affected individuals and 12.5% of unaffected relatives. Of the affected
females, there were a total of 43 successful pregnancies and 7
miscarriages giving an incidence of miscarriage of 14%; similar to the
overall population miscarriage rate of 0–15%. There were a total of 10
successful pregnancies in the unaffected females and 3 miscarriages
(incidence of miscarriage 23%).
This study of 17 families demonstrates a small increase in bleeding
manifestations in patients affected with Arg-16-His mutation as
compared to unaffected relatives but no increase in thrombotic or
pregnancy complications.
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In vivo recovery of ristocetin co-factor and in patients
with von Willebrand disease undergoing procedures
requiring treatment with Haemate P
SG Watt, M Walsh, M Nash, P Bolton-Maggs, L Birtwistle and
CRM Hay
Department of Haematology, Manchester Royal Infirmary,
Manchester, UK
It is important to ensure that the dose of clotting factor concentrate
patients receive is within the therapeutic range to minimise risk of
bleeding or thrombosis in patients undergoing invasive procedures.
This study looked at the data in patients with von Willebrand
disease (VWD) who underwent procedures requiring Haemate P
treatment between 2002–2006. We obtained a minimum dataset of
weight, dose of factor concentrate, age, sex, pre and post first dose of
concentrate levels for factor VIII and ristocetin cofactor (VWF:RCo)
and type of VWD on 30 patients for 33 episodes.
There were 23 episodes with females and 10 with males. Twenty-
one had type 1 VWD, 10 type 2 and 2 type 3. Median age was 45
(range 21–84). Mean dose of Haemate P was 37.6 units of factor VIII
per kilogram (range 22.5–54.5) equivalent to 90.2 VWF:RCo units.
Data showed a wide range of results with a mean recovery of
1.50IU/dl per IU/kg of VWF:RCO administered (standard devia-
tion5 0.55, range 0.56 to 2.43). There was no significant difference in
recovery between the mean of males (1.48) and females (1.50). There
was an inverse correlation (0.55) between increasing doses per
kilogram and recovery. There was some correlation (0.36) between
increasing weight and recovery. There was no correlation with age.
Our study showed that recovery cannot be predicted for
individuals. There is poor correlation between recovery and age or
sex of the patient. There was a fall in recovery with larger doses of
concentrate per kilogram and there appears to be greater recovery in
larger patients. The mean recovery of 1.50 iu/dl per iu/kg of
VWF:RCO administered is the same as stated in the Haemate P
summary of product characteristics.
The study shows the importance of dosing based on VWF:RCo
levels in pre and post operative patients.
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Managing peri-delivery anticoagulation in women on
therapeutic dose low-molecular weight heparin: a role
for unfractionated heparin
J Lambert, S Austinw, D Peeblesz and H Cohen
Department of Haematology, University College London
Hospitals NHS Foundation Trust, London, UK, wDepartment of
Haematology, University College London, London, UK,
zDepartment of Obstetrics and Gynaecology, University
College London, London, UK
There is no evidence based approach for the optimal management of
peri-delivery anticoagulation in women receiving therapeutic dose
low molecular weight heparin (LMWH) during pregnancy, although
maintenance of anticoagulation for the maximal period peri-delivery
appears appropriate in these women considered to be at high risk of
venous or arterial thromboembolism. We developed a simple,
flexible regimen based on fixed prophylactic dose unfractionated
heparin (UFH) peri-delivery and audited the outcomes. The study
population comprised 33 consecutive women who received ther-
apeutic dose LMWH during pregnancy, with the indications: venous
thromboembolism (VTE) in index pregnancy/high risk of VTE (26)
and cardiac: mitral stenosis/prosthetic valves (7). On the evening
prior to planned delivery (induction of labour or elective caesarian
section (CS)), fixed prophylactic dose UFH by continuous intrave-
nous infusion (15,000units/24 hours) was commenced, starting 12
hours after the last dose of 12 hourly LMWH. UFH was stopped
between 1–6 (typically 4) hours pre-delivery and restarted 2–6 hours
post-delivery. LMWH (75% of therapeutic dose) (7warfarin) was
reinstituted 24–48 hours post-delivery, and UFH stopped. Nineteen
patients were delivered by CS (9 elective), of which 6 received
epidural/spinal anaesthesia without complication. In 28/33 patients
managed according to the specified regimen, there were no cases of
PPH (blood loss 4500 ml or 41000 ml within 24 hours of vaginal
delivery or CS respectively) and no thrombosis. In the remainder (5/
33), there was one case of PPH and one line-associated thrombosis
immediately after post-natal emergency mitral valve replacement. In
conclusion, the peri-delivery anticoagulation regimen based on fixed
prophylactic dose UFH enabled maintenance of anticoagulation
except for a matter of hours, and, was simple, flexible and acceptable
to staff and patients.
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Off-label use of rFVIIa and its clinical effectiveness:
results from a Scottish national audit
P Gallipoli, M Robertsonw and RC Tait
Department of Haematology, Glasgow Royal Infirmary,
Glasgow, UK, wDepartment of Haematology, Royal Alexandra
Hospital, Paisley, UK
Recombinant FactorVIIa (rFVIIa; Novoseven) is licensed to treat
bleeding in haemophiliac patients with inhibitors. Anecdotal reports
and randomised studies indicate its potential value in intracerebral
haemorrhage (ICH) and massive haemorrhage. During 6 months in
2006, the Scottish Haematology Audit Network audited patterns for
off-label use of rFVIIa in 27 acute Hospitals. Results were compared
with a previous audit from 2003.
Ninty-two per cent of the hospitals keep a stock of rFVIIa on site,
48% having a written protocol for its release. In 88%, Consultant
Haematologist authorisation is required. Off-label use has increased
since 2003 (48 vs 38 episodes/year) especially in non-Haemophilia
Centre Hospitals. Other than increasing use for ICH, indications have
changed little over time. Immediate response rate [RR; defined by
either major reduction or cessation of haemorrhage according to
subjective clinical assessment], 24-hour survival rate [24SR] and 28-
day survival rate [28SR] have not changed – combined data showing
68% RR, 79% 24SR and 52% 28SR. A high coagulopathy score [CS;
scoring one point for each of plateleto50, fibrinogeno1.0, and INR
or APTTr 4 1.5] is associated with non-significant lower RR and
24SR. Combining data from both audits, comparing CS 2–3 vs CS 0–1
by Chi-squared test gives RR of 58% vs 78% and 24SR of 62% vs 84%
(Po0.1 for both). Platelet count o50, alone, is associated with
significantly worse RR and 24SR – 45% vs 83% (Po0.01) and 60% vs
85% (Po0.05) respectively.
In conclusion, off-label use of rFVIIa has increased in District
General Hospitals, reflecting its wider availability. It has also started
to be used for ICH. rFVIIa appears less effective in patients who are
more coagulopathic, particularly if platelets are o50 at time of
administration. Overall, despite a high subjective clinical RR of 68%,
28-day survival is poor at about 50%.
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Reports to the Serious Hazards of Transfusion (SHOT)
scheme of post-transfusion purpura (PTP) and
transfusion-associated graft-versus-host disease
(TA-GvHD) before and after implementation of
universal leucocyte depletion in the UK
LM Williamsonw, D Stainsby, H Jones, EM Love,
CE Chapman, A Casbardw and H Cohen
SHOT Steering Group, Manchester, UK, wNational Blood
Service
To establish whether universal leucodepletion in the UK has reduced
the observed incidence of PTP and TA-GvHD, all reports to SHOT
from 1996–2005 meeting these case definitions were reviewed. For
TA-GvHD, the case numbers transfused with LD vs non-LD
components were compared. Since the LD status of components
transfused to PTP cases was unknown, we compared case numbers
before and during implementation of universal LD (1996–1999), with
2000–2005.
From 1996–2005, 6.2 million non-LD and 19.6 million LD red cells
and platelets were issued. There were 13 reports of TA-GvHD, all
fatal. Ten patients had at least one risk factor:- undiagnosed
immunodeficiency (2), B cell lymphoproliferative disease (6),
steroids (1), transfusion of fresh blood (1) and donor/recipient
HLA haplotype share (4). Eleven cases received non-LD red cells
and/or platelets and 2 LD (Po0.001). No TA-GvHD cases have been
reported to SHOT from 2002–2005.
There were 46 reports of PTP; 45 in parous females, one in a
previously transfused male. Two patients died. Alloantibodies to the
Human Platelet Antigen-1a (HPA-1a) were found in 34 cases (78%),
either alone (29), or in combination with other HPA antibodies (2),
heparin-induced antibodies (2), or a glycoprotein Ia/IIa autoanti-
body (1). Nine cases had antibodies to other HPA specificities, either
singly or in combination. From 1996–1999, there were 31 PTP cases
(10.3/ year), which fell to 15 (2.5/year) from 2000–2005 (Po0.001).
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Before universal LD, only 1/31 (3%) PTP cases had received platelets
as well as red cells, in contrast to 8/15 (51%) afterwards (Po0.001).
Prior to LD, 11/31cases (32%) had antibodies to HPA specificities
other than HPA-1a, compared to 1/15 (6.5%) after LD (P5 0.07).
These findings suggest that universal LD has markedly reduced
but not eliminated the risk of TA-GvHD, and has both reduced and
altered the profile of PTP cases.
250
Selection criteria and consent for granulocyte
donation
G Cherian, H Sethiw, A Tothamw, D Potokw, N Som, A Greenw,
GF Lucasw, K El-Gharianiz, S Robinson, DI Marks and
EJ Massey,w
Bristol Children’s Hospital, Bristol, UK, wNational Blood
Service, Bristol, UK, zNational Blood Service, Sheffield, UK
The use of Granuocyte Colony Stimulating Factor (G-CSF) has
revived interest in granulocyte transfusion as a strategy to protect
against bacterial or fungal infection in neutropenic patients.
Local and national guidelines were used as standards to audit
donor selection when volunteer donors (relatives and friends) were
referred for G-CSF, Dexamethasone and apheresis granulocyte
donation. The donation program was coordinated between the
Bristol BMT unit and a blood establishment.
All donors must answer a screening questionnaire and undergo a
medical assessment by a doctor other than the physician treating the
potential recipient. Donors should be ABO, RhD and CMV
compatible with the patient (and in SCT to the stem cell donor).
All donors must undergo mandatory microbiology screening.
National guidelines also suggest that all recipients be screened for
HLA antibodies.
Ninty-five potential donors (age range 20 to 68 years) were
referred. Ten failed screening criteria because they were either
underweight, too old, had high titre anti-A, a raised aspartate
transaminase, were HLA incompatible with a refractory recipient or
in four cases they were CMV IgG1 . Therefore 85 donors donated
169 donations for 38 recipients.
The average dose of granulocytes obtained was 58.1 109/pack
(range 2–134). Only 3 doses were less than 10 109/pack, one dose
being less than UK specification of 5 109/pack. One donation was
ABO incompatible (donor O1 with high titre anti-A, recipient
A1 ). This donation was plasma depleted. All apparently CMV
incompatible donations were justified by the clinical scenario (CMV
negative recipient ineligible for allogeneic transplantation or CMV
/ graft in whom the risk of mortality from sepsis outweighed the
risk of CMV transmission).
Adherence with guidelines was confirmed in over 90% of
donations the apparent exceptions were clinically justified. Accep-
table doses of granulocytes can be obtained for most recipients
following the implementation of a robust program for donor
selection.
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Type I recessive congenital methaemoglobinaemia
associated with a triple mutation of NADH-
cytochrome b5 reductase
MJ Percy, LJ Crowleyw, D Roperz, DM Laytonz, TRJ Lappiny and
MJ Barberw
Department of Haematology, Belfast City Hospital, Belfast,
UK, wDepartment of Molecular Medicine,
University of South Florida College of Medicine, Tampa, FL,
USA, zDepartment of Haematology, Imperial College, London,
UK, yDepartment of Haematology, Queen’s University Belfast,
UK
Recessive congenital methaemoglobinaemia (RCM) is caused by
NADH-cytochrome b5 reductase (cb5r) deficiency. Two distinct
clinical forms have been recognised. In both types I and II cyanosis is
present, but patients with type II also exhibit neurological
impairment. The enzyme is composed of one FAD and one NADH
binding domain linked by a hinge region. It is encoded by the DIA1
gene and more than 40 mutations have been described, some of
which are common to both types of RCM. Mutations associated with
type II tend to cause incorrect splicing, disruption of the active site
or truncation of the protein. To investigate the contribution of
specific mutations to the two clinical phenotypes a heterologous
expression system has been developed. We have used this to
investigate a child aged 7 years with type I RCM with two different
mutations, the novel Pro92His on both alleles and the previously
described Glu255del on one allele. To assess the impact of the
Pro92His and the Pro92His/Glu255del double mutation on the
function of cb5r both variants were generated using the expression
system and characterised for enzyme activity and thermostability.
The Pro92His mutation, located in the FAD binding domain,
moderately impaired enzymatic activity of cb5r without causing
dramatic changes in affinity for NADH. The Glu255del mutation,
located in the NADH binding domain, strongly reduced enzymatic
activity. Moreover, the thermostability of the Pro92His variant was
substantially decreased as indicated by reduction of the T50 by 111C
compared to wild type enzyme. The Pro92His/Glu255del double
mutant exhibited substantial loss of enzymatic activity, lowered
affinity for NADH and decreased thermostability. These experi-
mental data are consistent with the apparent type I clinical
phenotype of the child and suggest that further studies using this
model system will help to define the characteristics of the enzyme
variants which determine the clinical phenotype.
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Blockade of intravascular haemolysis in paroxysmal
nocturnal haemoglobinuria (PNH) with the terminal
complement inhibitor eculizumab unmasks low-level
haemolysis potentially occurring through C3 opsoni-
sation
A Hill, RP Rotherw, AM Risitanoz, DS Coley, MJ Cullen,
SJ Richards, C Selleriz, P Ricciz, B Rotoliz, L Luzzattoz and
P Hillmen
Department of Haematology, Leeds General Infirmary,
Leeds, UK, wDepartment of Research, Alexion Pharmaceuti-
cals, Inc., Cheshire, USA, zDivision of Haematology, Federico II
University of Naples, Naples, Italy, yDepartment of Medical
Biochemistry and Immunology, University Hospital of Wales,
Cardiff, UK
PNH is an acquired haemolytic anaemia characterised by intravas-
cular haemolysis. PNH red blood cells (RBCs) lack two complement
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regulatory molecules, CD59 and CD55. Eculizumab, a monoclonal
antibody that inhibits terminal complement by binding C5,
effectively controls intravascular haemolysis determined by a
dramatic reduction in lactate dehydrogenase (LDH). Control of
intravascular haemolysis in these patients led to a reduction or
cessation of transfusions. During eculizumab treatment, most
patients demonstrate residual, low-level haemolysis with slightly
elevated LDH levels, low/undetectable haptoglobin levels, and above
normal bilirubin levels. This low-level residual haemolysis may be
due to C3b-mediated clearance of PNH RBCs. We investigated C3
deposition on RBCs in PNH patients before and on eculizumab. A
direct antiglobulin test (DAT) using monoclonal anti-C3d was
positive in 29/39 PNH patients on eculizumab. Of these 29 DAT-
positive patients, who were all receiving transfusions prior to
eculizumab, 25 had DAT testing before therapy and only one was
positive. Using flow cytometry with anti-CD59 and anti-C3, most
patients on eculizumab demonstrated three RBC populations:
(i)CD591 /C3- (normal RBCs); (ii)CD59-/C3- (PNH RBCs without
C3 coating); (iii)CD59-/C31 (PNH RBCs coated by C3). No CD591 /
C31 RBCs were observed. Of 21 DAT-positive eculizumab treated
patients tested, the median proportion of total RBCs that were C3b
positive was 17.6%. 18/29 (62%) DAT-positive eculizumab patients
received at least one transfusion during eculizumab therapy
compared with 1/10 (10%) for DAT-negative patients (P5 0.01).
The median haemoglobin value for the 29 DAT-positive eculizumab
patients was 9.8 g/dl compared with 11.3 g/dl in the 10 DAT-negative
eculizumab patients (P5 0.08). It is proposed that resolution of
intravascular haemolysis in PNH patients on eculizumab results in
deposition of C3b on the surface of PNH RBCs which may explain, at
least partly, the residual low-level haemolysis occurring in some
patients. This is a previously undescribed mechanism of RBC
clearance in PNH, most likely obscured by the rapidity of
intravascular haemolysis in the absence of eculizumab therapy.
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The first ALAS2 alternate splice variant associated
with X-linked sideroblastic anaemia (XLSA)
B Kerr, G Birgegardw, H Bostromz and A Mayy
Department of Haematology, University Hospital of Wales,
Cardiff, UK, wDepartment of Haematology, Uppsala University
Hosptial, Sweden, zDepartment of Genetics, Uppsala Univer-
sity Hosptial, Sweden, yDepartment of Haematology, Cardiff
University School of Medicine, Cardiff, UK
A 24 year old Swedish male with no declared family history of
anaemia presented with fatigue and was found to have a pyridoxine-
refractory microcytic, hypochromic anaemia with iron overload (Hb
8g/dl, MCV 55fl, MCH 16pg, serum ferritin 1000m/l) and ringed
sideroblasts. Sequence analysis demonstrated ALAS2 variation
hemizygosity at codon 190 in exon 5 (GAT4TAT, c.G620T), absent
in 184 control alleles, predicting both the Asp190Tyr substitution on
the protein outer surface and the insertion of a new splice donor site.
The proband’s reticulocytes expressed RNA utilising either the
normal exon 5 splice donor site or the alternate site removing 72
bases from the 30 end of exon 5. The deletion was in frame and
predicted the loss of 24 amino acids (a.a.190–213) comprising a beta
sheet, loop and helix sequence linking the ALAS2 N-terminal and
catalytic domains and including at least one invariant residue. A
previously-reported mutation (c.A621T; Asp190Val) was shown to
inhibit both interaction of ALAS2 with succinyl-CoA synthase and its
correct mitochondrial processing, but should not result in the splice
variant observed with Asp190Tyr. The proband’s haematologically-
normal mother was confirmed to be a c.G620T heterozygote,
however, expression of the variant allele was not detected in her
peripheral blood reticulocytes and markedly-skewed X-chromosome
inactivation of the abnormal allele was found. Family study on the
maternal side has so far revealed four haematologically normal
people (3M,1F) without this mutation, one additional female carrier
and, in particular, one distantly-related, iron-loaded hemizygote with
microcytic, hypochromic anaemia (Hb 7 g/dl, MCV 64fl, MCH 18pg,
ferritin 767m/l) providing strong evidence for a causal link with
XLSA. Investigation of the respective roles of the two ALAS2 variants
in SA is underway, nevertheless this is the first ALAS2 variant shown
to alter RNA splicing that is associated with, and likely to be the
cause of, XLSA.
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Non-invasive prenatal diagnosis for HbSC disease
A Gerovassili, BE Clarkw, S Colellaz, KH Nicolaidesy,
J Ragoussisz, SL Thein,w and DC Rees,w
Division of Gene and Cell Based Therapy, King’s College
London School of Medicine/King’s College Hospital, London,
UK, wDepartment of Haematological Medicine, King’s College
Hospital, London, UK, zGenomics Laboratory, Wellcome Trust
Centre for Human Genetics, University of Oxford, Oxford, UK,
yHarris Birthright Research Centre for Fetal Medicine, King’s
College Hospital, London, UK
HbSC is a genotype causing sickle cell disease (SCD). Prenatal
diagnosis (PND) of fetuses at risk is normally carried out by
chorionic villus sampling (CVS) which has a 1% risk of miscarriage.
The detection of foetal cell-free (cf) DNA in the circulation of
pregnant women opened up the possibility for non-invasive prenatal
diagnosis and prognosis of many clinical conditions.
A method was developed based on genotyping of cfDNA using
matrix assisted laser desorption/ionisation time of flight mass
spectrometry (MALDI-TOF MS). The approach was applied to
exclude the foetal inheritance of the paternally derived diseased
allele. Absence of the paternally diseased allele would reassure the
parents while its presence could mean that the fetus is a carrier for
the parental mutation or a compound heterozygote for both parental
disease alleles.
Eight carrier women (HbAC or AS) at risk of having a fetus
affected with HbSC were blood sampled in the first trimester of
pregnancy and cfDNA was extracted from their plasma. They
subsequently delivered and the genotypes of the babies were
confirmed by DNA analysis.
The paternal diseased allele was not detected in cfDNA of five
cases (two of these babies were normal and three heterozygous for
the mother’s diseased allele). The paternal diseased allele was
detected in cfDNA of three cases (two babies were HbSC and 1
heterozygous for the paternal diseased allele). These results suggest
that in the 5 cases where the paternal diseased allele was not detected
the CVS could have been avoided.
This is the first non-invasive prenatal diagnosis approach for
exclusion of fetuses at risk of sickle cell HbSC disease.
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Nocturnal hypoxaemia is associated with conditional
and high risk transcranial doppler velocities in
children with sickle cell disease
P Telfer, A Franklinw, S Carrw, S McKenziew, H Newell and
F Kirkhamz
Department of Paediatric Haematology, Royal London
Hospital, Centre for Haematology, Queen Mary University of
London, UK, wDepartment of Paediatric Respiratory Medicine,
Royal London Hospital, UK, zWolfson Centre, Institute of
Child Health, University College London, UK
Background: Snoring appears to be associated with high internal
carotid/middle cerebral artery velocities on transcranial Doppler
(TCD) in the general paediatric population but there are few data
comparing overnight oximetry in those with normal or abnormal
TCD. Snoring and low oxyhaemoglobin saturation (SpO2) are
common in sickle cell anaemia (SCA) but any association with
abnormal TCD has received little attention.
Methods: Children with SCA in East London had overnight pulse
oximetry and regular TCD scans. 45 had sleep studies as part of an
unselected cohort studied between 1991 and 1993 (only 5 of whom
had no history of snoring) and the remainder were undertaken as
part of clinical care. Mean and minimum SpO2 were compared in
those with standard risk, conditional (4170o200 cm/s) or abnormal
(4200 cm/s) TCD.
Results: One hundred and forty-three children (86 boys; median
[range] age 6.8 [1–23] years) had TCD and a sleep study. 121 TCDs
were standard risk, 15 were conditional and seven were abnormal. In
multivariable binary logistic regression, lower mean and minimum
overnight SpO2 were independently associated with conditional or
abnormal TCD (for mean SpO2, odds 0.9 (95% confidence intervals
[CI] 0.7, 0.9), P5 0.001; for minimum SpO2, odds 0.97 (95% CI 0.95,
0.99), P5 0.0001) but age was not. In the 64 patients in whom
haematocrit was available, low values were not commoner in those
with abnormal TCD (P5 0.4).
Discussion: TCD velocity 4170 cm/s, an intermediate endpoint
which predicts a high risk of stroke in SCA, is commoner in snoring
children with SCA and sustained and intermittent overnight
oxyhaemoglobin desaturation, probably independently of haemato-
crit. Early management of sleep disordered breathing might prevent
the development of cerebrovascular disease in SCA.
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